Pharmacotherapy and weight management: efficacy and clinical effectiveness in patients with obesity and type 2 diabetes by Aldekhail, Nasser Mohammed N.
 
 
 
 
 
 
 
 
 
Aldekhail, Nasser Mohammed N. (2018) Pharmacotherapy and weight 
management: efficacy and clinical effectiveness in patients with obesity and 
type 2 diabetes. PhD thesis. 
 
 
 
http://theses.gla.ac.uk/8659/ 
 
Supplied for personal use only to Michael Benskin. 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
  
 
 
 
Pharmacotherapy and weight management: 
efficacy and clinical effectiveness in patients with 
obesity and type 2 diabetes 
 
 
Nasser Mohammed N Aldekhail 
BSc., MSc. 
 
 
Thesis is submitted in fulfilment of the requirements for the degree 
of Doctor of Philosophy (PhD) in Clinical Pharmacology and 
Therapeutics 
 
 
Institute of Cardiovascular and Medical Sciences 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
December 2017 
 
 
 
2 
Abstract 
The prevalence of obesity worldwide has more than doubled since 1980. The World Health 
Organisation (WHO) estimates that more than one in ten adults in the global population is 
obese. Cardiovascular and metabolic health can be improved with moderate weight loss; 
losses of 5%–10% have been found to improve conditions such as diabetes, hypertension 
and cholesterol and low-density lipoprotein (LDL) levels. Within the UK, a number of 
weight management programmes that depend on lifestyle intervention (tier 2) and others 
that supplement this with drug therapy (tier 3) and surgery (tier 4) are available. 
 
The guidelines produced by the Scottish Intercollegiate Guideline Network (SIGN) 
advocate that weight management programmes address changes to diet, physical activity 
and behaviour. For patients with a body mass index (BMI) ≥30 kg/m2 or ≥28 kg/m2 in 
patients with comorbidities, orlistat can be considered as a drug intervention on a case-by-
case basis following a full risk and benefit assessment. The objective of the Glasgow and 
Clyde Weight Management Service (GCWMS), a specialist weight-loss programme, is for 
patients to lose at least 5 kg.  
 
There are a number of metabolic disorders that are associated with obesity. One such 
disorder is type 2 diabetes mellitus, where weight loss is a standard recommendation to 
improve blood glucose control. Randomised controlled trials (RCTs) of orlistat indicate 
that the drug is effective in promoting weight loss and improving metabolic control for 
those patients with the comorbidity of type 2 diabetes and obesity. There are several 
different groups of anti-diabetic drugs that can be used to manage diabetes. The effects of 
the different medications on body weight are considerable. Some, such as biguanides 
(metformin), dipeptidyl peptidase-4 inhibitors (DPP-IV), Glucagon-like peptide-1 agonist 
(GLP-1) and sodium-glucose co-transporter-2 inhibitors (SGLT2), either have no effect on 
weight or can cause weight loss. Others, such as sulfonylureas (SUs) and 
thiazolidinediones (TZDs) can lead to weight gain. 
 
This thesis explores the impact of lifestyle interventions in weight management services, 
and the impact of drug interventions, on weight loss and glycaemic control. It is supported 
by the results of five complementary studies that reviewed the effect of orlistat on type 2 
diabetes and assessed the impact of the prescription patterns of anti-diabetic drugs in 
addition to the effects of these pharmacological interventions on weight change in 
comorbid patients. 
3 
The first aim of this thesis is to review the evidence of the effects of orlistat on diabetic 
outcomes. The second aim is to evaluate the lifestyle interventions, and phase 2 of the 
GCWMS. Finally, the third aim is to determine the prescribing patterns of anti-diabetic 
drugs, and to observe the association between anti-diabetic medications and weight 
change. This thesis addresses the following objectives: 
 
1. To undertake a systematic review and meta-analysis of published studies in order to 
review the evidence of the effects of orlistat on weight loss, specifically concerning 
glycosylated haemoglobin (HbA1c) and fasting plasma glucose (FPG), using the Cochrane 
review methodology; 
2. To investigate the proportion of patients losing 5 kg of weight, commencing from their 
entry into the GCWMS programme, until the end of the lifestyle phase of treatment, for 
individuals of different ages, genders, and socioeconomic groups; 
3. To study the proportion of patients losing 5 kg of weight, commencing from their entry 
into the GCWMS programme, until the end of phase 2, with the three different 
interventions of orlistat, low-calorie diet (LDL), and further weight loss (FWL); 
4. To investigate the proportion of patients referred to the GCWMS on weight-neutral, 
mixed, and weight-gaining anti-diabetic medications; 
5. To investigate the effect of baseline anti-diabetic medications on weight change for 
patients within a weight management programme. 
 
Chapter 2 presents the first study, which was a systemic review that considered the 
evidence collected in RCTs on the efficacy of orlistat for type 2 diabetes and weight loss. 
The effects were considered at the biochemical level and included the levels of 
glycosylated haemoglobin (HbA1c) and fasting plasma glucose (FPG) in people with 
overweight and obesity. The results, collected from 2,802 participants in 12 trials, were 
combined into a meta-analysis. The overall finding was that a combination of orlistat and 
lifestyle intervention yielded superior results. When the results were compared, it was 
evident that patients who are overweight or obese who were subjected to combined 
lifestyle and drug intervention lost more weight and had better glycaemic control than 
patients who were subjected to lifestyle interventions only. 
 
Chapter 3 presents the second study which appraised the effectiveness of a real-life NHS 
lifestyle weight management intervention in reducing body weight by ≥5 kg. The study 
followed 23,650 patients referred to the GCWMS, of whom 7,329 attended at least two 
lifestyle intervention sessions. Those individuals had either a BMI of ≥30 kg/m2, with 
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obesity-related comorbidities, or a BMI of ≥35 kg/m2 and were aged ≥18 years. The 
lifestyle interventions included a combination of a 600 kcal deficit diet, exercise, and 
behavioural changes. 30% of the overall group succeeded in losing ≥5 kg. Out of those 
who completed the programme, however, a considerably higher number (46%) lost ≥5 kg. 
The greatest losers were men, those aged ≥40 years, those with a BMI ≥50 kg/m2, and 
those from areas that are more affluent. 
 
Chapter 4 presents the third study which focused on patients who lost ≥5 kg in phase 2 of 
the treatment provided by GCWMS which comprised a low-calorie diet (LCD), orlistat 
120 mg, three times a day, or further weight loss (FWL). Participants on LCD were 
prescribed a 1,200 or 1,500 calorie plan; however, those on FWL repeated the lifestyle 
phase. There were 3,262 participants who attended at least two sessions in phase 2; these 
were divided into three categories: 536 who took orlistat, 1,043 who followed a LCD and 
1,683 who were selected FWL. By the end of phase 2, the levels of success in terms of 
weight loss across the groups varied from 31% of participants in the orlistat group to 22% 
of participants in the LCD group and 83% of participants in the FWL group who lost ≥5 
kg.  
 
Chapter 5 presents the fourth study, which evaluated the pattern of anti-diabetic drug 
prescriptions for comorbid patients referred to the GCWMS. The study also looked at the 
proportion of patients who were referred prior to and after the publication of updated SIGN 
guidelines for the prescription of anti-diabetic medication. In total, the study enrolled 3,063 
participants who received anti-diabetic medications, of whom 47.8% received weight-
neutral medications, 39.4% had mixed-effect medications and 12.7% took weight-gaining 
drugs. Prior to the publication of the SIGN guidelines, 11.6% of participants were on 
weight-gaining drugs, a proportion that did not change significantly one year after the 
release of the guidelines. Weight-neutral drugs were more commonly prescribed to 
women, those with a higher BMI and young people. No relationship was observed between 
the Scottish Index of Multiple Deprivation (SIMD) and anti-diabetic drug prescriptions. 
Weight-gaining drugs such as SUs and TZDs were more commonly prescribed to older 
patients and those with lower BMIs.  
 
Chapter 6 presents the fifth and final study, which investigated the effect on body weight 
of anti-diabetic medications in 998 participants following the lifestyle phase of the 
GCWMS. By the end of the programme, patients who were on weight-neutral anti-diabetic 
drugs achieved a mean weight change of -3.3 kg (95% confidence interval [CI]: -3.8 to -2.9 
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kg) and those on weight-gaining drugs achieved a mean weight change of -2.5 kg (95% CI: 
-3.2 to -1.8 kg), p =0.05. Among those who completed the programme, the difference was 
statistically significant (p =0.005). The association between weight change and anti-
diabetic drug type was not explained by differences in sex, initial BMI or age. 
 
To conclude, there was a clinically and statistically significant change in weight, HbA1c 
and FPG in patients with obesity and type 2 diabetes who used orlistat. Of the patients 
following the GCWMS lifestyle phase, less than 50% succeeded in losing at least 5 kg, 
with patients who completed the programme being more successful. Participants who lost 
weight in the lifestyle phase were selected for FWL and experienced the greatest weight 
loss by the end of phase 2. Those who were unsuccessful in losing 5 kg through the 
lifestyle programme, were offered orlistat and LCD. The large sample size increased the 
precision of the results, while the stratification for potential confounding factors increased 
the study’s validity. A higher proportion of patients were prescribed weight-neutral 
medications, compared with mixed and weight-gaining anti-diabetic medications. The 
proportion of patients on weight-gaining diabetes drugs referred to the GCWMS did not 
alter appreciably following the release of the SIGN guidelines. By the end of the lifestyle 
treatment phase, patients receiving weight-neutral drugs (metformin, DPP-IV, GLP-1, and 
SGLT2) were more successful in losing weight than those receiving weight-gaining drugs 
(SUs, TZDs, and any combination including insulin). The main recommendation from this 
research are, that further studies are carried out to better establish the best timing of use of 
orlistat within a weight management programme, that the intensity of phase 2 of the 
GCWMS is increased, and that prescribers take account of a patient’s current BMI prior 
when prescribing anti-diabetic medication, especially when recommending weight loss and 
referring to a weight management programme. 
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Introduction 
 
1.1 Epidemiology of obesity  
1.1.1 Definition of obesity 
Obesity has been defined by the World Health Organisation (WHO) (2000, 2013) as a 
medical condition in which the health of the individual is put at risk and/or the likelihood 
of mortality is enhanced due to the excessive increase in the body’s fat storage capacity. To 
put it differently, obesity represents accumulation of fat beyond levels that are considered 
healthy. It is caused by the fact that the energy absorbed in the form of calories is greater 
than the energy consumed, with the unconsumed energy being deposited in different parts 
of the body as fat.  
 
The risks to health depend on the manner in which the body fat is distributed. For example, 
as indicated by Jensen (2008), upper body or abdominal obesity is associated with greater 
health risks when compared to lower body or gluteal-femoral obesity, because in the 
former case the fat is mainly intra-abdominal or visceral, while in the latter case the fat is 
subcutaneous (Harvard Health Publications, 2006) and therefore is less dangerous to health 
as it accumulates under the skin rather than around the organs. Although a clear 
understanding of the heightened risks related to visceral fat is yet to be achieved, there is 
extensive evidence that visceral fat can contribute to metabolic disorders, cardiovascular 
disease and type 2 diabetes (Despres, 2012; Jensen, 2008). The Body Mass Index (BMI), 
which is determined based on an individual’s weight and height, represents the standard 
tool of obesity measurement. 
 
1.1.2 Incidence and prevalence 
Using a BMI of 30 kg/m2 and 25-29.9 kg/m2 as the reference point to define ‘obesity’ and 
‘overweight’, respectively, the WHO has estimated that, at global level, the number of 
individuals who are overweight has reached 1 billion; 300 million of who are classified as 
obese (WHO, 2014a). From 1995 to 2002, the total number of individuals with obesity 
rose by 100 million (Formiguera and Canton, 2004). By 2014, the number of individuals 
with overweight reached almost 1.9 billion with 600 million being classified as obese 
(WHO, 2014a). In percentages, this means that 39% of individuals older than 18 years of 
age are overweight and 13% are obese. Obesity is not restricted to certain countries or 
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areas but has become a global trend, with many countries, including China, having high 
numbers of individuals suffering from obesity. However, because obesity is the outcome of 
lifestyle and cultural choices as well as genetic factors, there are differences among 
countries in terms of how prevalent obesity is and how it occurs.   
 
The countries with the highest obesity rate in 2011 were identified by the Organisation for 
Economic Cooperation and Development (OECD) as being the US (33.8%), Mexico (30%) 
and New Zealand (26.5%); while India (2.1%), Indonesia (2.4%) and China (2.9%) were 
listed as the countries with the lowest obesity rate in the same year (NHS Information 
Centre, Lifestyle Statistics, 2012). 25% each of male individuals of black Caribbean and 
Irish descent were found to be obese. Similarly, there were more female individuals of 
black Caribbean (32%), Pakistani (28%) and black African (38%) descent that were found 
to be obese than the percentage of people with obesity found in the general population, but 
fewer Chinese female individuals were found to be obese (8%) (NHS Information Centre, 
Health Survey, 2004). Initially, it was found in affluent countries that obesity was most 
prevalent and most likely to occur, but due to changing trends, obesity has now also 
become much more prevalent in moderately rich and poor countries. A direct correlation 
between a BMI ≥30 kg/m2 and age was highlighted by the Scottish Health Survey (The 
Scottish Government, 2011). No significant difference relating to age was found in the 
proportions of male and female individuals having a BMI ≥30 kg/m2 apart from 
individuals falling within the 16-24 year age group where it was found that 16.9% of the 
females and only 9.2% of the males had a BMI ≥30 kg/m2. 
 
1.1.3 Obesity in the male and female populations 
Worldwide, the annual mortality rate among people who are overweight or obese is 2.8 
million (WHO, 2014b). Obesity has become more prevalent throughout the world, having 
increased two-fold from 1980 to 2008. 35% of adult individuals were classified as 
overweight in 2008, with male and female individuals accounting for 34% and 35% of the 
whole population, respectively (WHO, 2014b). Furthermore, based on a BMI ≥30 kg/m2, 
10% of the global male population and 14% of the global female population were 
classified as being obese, which represents a two-fold increase compared to 1980, when 
there were fewer individuals with obesity on a global level (5% male and 8% female), 
although in affluent countries men’s BMI exceeded that of women’s. According to the 
Foresight Report, in the UK there are more male individuals who are overweight or obese 
than female individuals; 47% and 36% of male and female individuals are expected to 
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become obese by 2025 (Robertson et al., 2014). By contrast, in Scotland, more female 
individuals are obese than male individuals (29.3% vs. 24.9%) (The Scottish Parliament, 
2015). 
 
According to data reported by WHO (2014 b), the majority of overweight (62%) and obese 
(26%) adult individuals are in the Americas, whereas the fewest overweight (14%) and 
obese (3%) people are in Southeast Asia (Ogden et al., 2007). The WHO further indicated 
that over half of the female population of the Eastern Mediterranean, Europe and the 
Americas was overweight, while the female obesity proportions for these same regions 
were calculated to be 24%, 23% and 29%, respectively. Indeed, obesity levels were higher 
among female individuals than male individuals in every region covered by the WHO. 
Moreover, the obesity levels among females in Africa, the Eastern Mediterranean and 
Southeast Asia were almost double the levels among males (Figure 1-1). 
 
The WHO (2014b) has concluded that there is a greater predilection towards obesity 
among females than males. However, irrespective of gender, the likelihood of a BMI 
≥30kg/m2 is increased by factors such as lack of physical activity, living in a deprived area, 
not being fit for work, poor level of education, smoking, alcohol consumption, married 
status, having poor general health and suffering from a protracted illness. Social and 
economic factors (e.g. income level and occupation) have been found to increase the 
likelihood of obesity among females more than they did among males. A comparison 
between the two quintiles with the highest and lowest level of deprivation revealed that 
33% of individuals in the former and 19% of individuals in the latter had a BMI ≥30 kg/m2 
(The Scottish Government, 2011). This could be because a person’s economic status has an 
impact on their diet.  
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Figure 1-1 A graphical representation of the prevalence of obesity (WHO, 
2014b) (AFR: Africa; AMR: Americas; SEAR: South-East Asia; EUR: 
Europe; EMR: Eastern Mediterranean; WPR = Western Pacific).  
 
1.1.4 Obesity in the UK 
There is increasing awareness in the UK about the serious health implications of obesity 
which, according to health authorities, is a major cause of mortality, but which is 
preventable. It has been estimated that by 2020 around 33% of the UK population could be 
obese (Seidell, 2006). The proportion of adults who are obese in the UK has reached 
23.1%, which is greater than the average obesity rate of 15.5% in the rest of the European 
Union states (Freeman, 2010). Since 2009, about 25% of the adult population of the UK 
has been considered obese, with male and female individuals accounting for 22% and 24%, 
respectively. In 2010, 26% of the adult population of England was obese, with more men 
(42%) being overweight than women (32%) (NHS, Lifestyle Statistics, 2012). 
Furthermore, according to the Scottish Parliament Information Centre, the numbers of 
female adults who are overweight and obese are higher in Scotland than in England, Wales 
and Northern Ireland respectively (SPICe, 2015). On the other hand, the number of male 
adults with obesity is greater in both Northern Ireland and England than in Scotland. 
 
1.1.5 Obesity in Scotland 
Statistics regarding the rate of obesity in Scotland show a gradual rise in the number of 
individuals with obesity over the years. Since 1995, obesity levels have increased markedly 
among individuals in the 16-64 age range. An obesity rate of 17.2% in 1995 rose to 26.1% 
in 2012 and 27.1% in 2013, with 65% of adult individuals being considered overweight or 
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obese (The Scottish Government, 2014a). However, as observed by Keenan et al. (2011), 
this rate has not changed significantly since 2008. Over the same period, the proportion of 
individuals who are overweight or obese reached 61.9% in 2013, in contrast to 52.4% in 
1995. Scotland is the fifth country in the world with the highest number of individuals with 
overweight or obesity and the sixth country with the highest rate of obesity. An overview 
of obesity trends and the numbers of overweight individuals in Scotland during the period 
from 1995 to 2013 is provided in Figure 1-2 below (SPICe, 2015). 
 
 
Figure 1-2 Number of Scottish adults with overweight and obesity (aged 16 to 64 
years) from 1995 to 2010 and from 2003 to 2013 (aged ≥16 years). Source: SPICe.  
http://www.parliament.scot/ResearchBriefingsAndFactsheets/S4/SB_15-
01_Obesity_in_Scotland.pdf. 
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1.2 Causes of obesity 
1.2.1 Genetic history 
As high calorie foods have become increasingly available and the opportunities for 
physical activity have decreased, a growing number of people at global level have become 
obese in recent years (Formiguera and Canto´n, 2004). This trend is to some extent rooted 
in genetic factors, despite the fact that the extremely slow occurrence of variation in 
populations’ genetic composition means that such factors are not wholly accountable for 
the increasing obesity rate (Walley et al., 2009). There is some consensus among scientists 
that genes play a role in the regulation of food-derived energy assimilation, storage and 
consumption by the human body. Out of the various genes considered to make an 
individual prone to becoming obese (O’Rahilly and Farooqi, 2006), the major one is the fat 
mass and obesity-associated gene (FTO), which has been the focus of extensive research 
since its identification in 2007 (Frayling et al., 2007). Shinozaki and Okuda (2012) 
reported that, within the general population, FTO variations have been associated with a 
0.39 kg/m2 body mass increase, while variations in the areas proximal to MCR4 genes 
have been related to an increase in body mass of 0.23 kg/m2 to 0.25 kg/m2 (Zobel et al., 
2009). Furthermore, according to Herrera et al. (2011), genetics can help shed light on 40-
70% of variability in proneness to obesity. 
 
Environmental and genetic factors must be afforded equal importance in any investigation 
of the increase in the rate of obesity throughout the world. From a genetic perspective, a 
frequently invoked explanation is the development of an imbalance between the 
environment and the internal structure of the body. Fawcett and Barroso (2010) have 
suggested that significant environmental transformations have led to modifications in the 
functions of the so-called thrifty genes, which enabled early people to withstand periods of 
food shortages. 
 
Different studies have supplied scientific proof suggesting an indirect correlation between 
obesity and genetics (Gregg et al., 2003). Such proof is usually the outcome of research 
into similarities and discrepancies between family members, adopted individuals and 
twins. Research has also focused on certain genes that are found more extensively in 
people with obesity. Although this kind of research identifies genetic factors as the most 
likely cause of many of the weight variations observed in adult individuals, the exact 
nature of such factors is not yet known (McCarthy, 2010; Barry et al., 2009). Genes have 
been identified as being the direct determinants of an individual’s weight in research 
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conducted on identical twins (Silventoine et al., 2010). Thus, an individual who is 
overweight or obese is likely to be so due to genes inherited from parents who are 
overweight or obese. In addition, the body’s capacity for fat storage and the distribution of 
fat are significantly influenced by genes. Furthermore, since physical activities and dietary 
patterns are shared within families, genes are closely correlated with the environment.  
 
1.2.2 Lifestyle factors 
1.2.2.1 Diet and eating habits 
Lifestyle choices and dietary patterns are generally considered to be the major reasons why 
individuals become overweight or obese. Throughout the world, obesity is mostly due to 
excessive eating and the eating of unhealthy food, such as processed food or food with a 
high fat content (Perez-Cueto et al., 2010) as opposed to vegetables, fruit and unrefined 
carbohydrates. Alcoholic drinks and soft drinks containing large quantities of sugar also 
cause an increase in body weight (Powers and Bruty, 2009; Ludwig et al., 2001) and 
therefore their consumption should be avoided (Ebbeling et al., 2006). 
 
McNeill and Cummings (2004) suggest decreasing the amount of calories consumed per 
day by 600 calories, that is, 20-25% of the energy intake, to achieve what is considered to 
be an appropriate weight loss of 0.5 kg weekly. Ordering a starter and dessert in addition to 
the main course in a restaurant is considered excessive eating which can lead to obesity, 
especially if the amount of fat in the consumed foods is high. Bes-Rastrollo et al. (2013) 
systematically reviewed studies on the correlation between weight increase and drinks with 
high sugar levels and found that ten out of twelve (83.3%) reviews with no specified 
conflict of interest confirmed that weight increase was indeed related to consumption of 
sugary drinks. Furthermore, the family plays an important role in an individual’s 
development of unhealthy dietary patterns. 
 
1.2.2.2. Physical activity 
Any movement of the body determined by the activation of skeletal muscles and leading to 
energy consumption can be considered to be physical activity (Caspersen et al., 1985). The 
implications of both physical activity and of the lack of physical activity have come into 
sharper focus due to research conducted in the last ten years. A direct correlation has been 
established between the lack of physical activity (i.e. sedentariness) and heightened risks of 
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chronic health conditions such as obesity, diabetes and cardiovascular disease (Van der 
ploeg et al., 2012). The reason for this is that energy intake is greater than energy release. 
The physical activity levels of the majority of adult individuals are insufficient to ensure 
fitness and prevent obesity, contributing to the elevated rate of obesity at a global level. 
According to Wright and Aronne (2012), the lack of physical activity is due to the fact that 
technological innovations have diminished the necessity for people to engage in physical 
tasks. 
 
1.2.2.3. Other factors 
Ex-smokers are likely to gain weight both because the smell and taste of food improves 
when one stops smoking (Sahlin et al., 2009) and also because the body metabolism does 
not function as fast as it does when there is nicotine in the system, resulting in reduced 
energy consumption (Chiolero et al., 2008). Although the majority of studies have argued 
that smoking and adipose levels are negatively correlated, the manner in which fat is 
distributed in smokers is more harmful to the metabolism and the rise in BMI is directly 
proportional to smoking frequency (Kim et al., 2012). In comparison to individuals who do 
not smoke and have a normal BMI, those who do smoke and have a high BMI are 6 to 8 
times more likely to die from obesity-related conditions. Furthermore, in comparison with 
individuals who do not smoke and have a normal waist circumference (WC), smokers who 
have a high WC are more than five times more likely to die than non-smokers with a 
normal WC. 
 
The increasing rate of obesity throughout the world is also tied to the fact that people are 
living longer. Loss of muscle mass is a common consequence of age advancement, 
particularly in the case of sedentary individuals. This in turn reduces energy consumption, 
which increases the probability of weight gain, especially if the energy intake is higher 
(Sahlin et al., 2009). As indicated by the findings of cross-sectional studies, the rise in 
obesity levels is directly proportional to age increase, accelerating between the ages of 20 
and 30 and continuing until the late 50s (Rolland-Cachera et al., 1991). Meanwhile, an 
important determinant of obesity prevalence is income, which reflects socioeconomic 
standing. In England, the BMI of female individuals with a lower income is higher than 
that of female individuals with a higher income (average BMI 27.7 kg/m2 vs. 26.5 kg/m2), 
but no correlation has so far been established between income and BMI in the case of male 
individuals (NHS, 2013). By contrast, a general association has been established between 
lower socioeconomic standing and higher obesity rates in Scotland (SPICe, 2015). 
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The caloric content of alcohol is considerable and therefore drinking alcohol directly leads 
to weight gain. In addition, it has been demonstrated that weight gain is also triggered by 
alcohol consumption indirectly because it enhances appetite and the sensation of being 
hungry in the short-term (Sahlin et al., 2009). Pregnant women are more predisposed to 
weight gain, due to the fact that foetus’ development demands higher amounts of energy 
and nutrients. However, many women struggle to return to their normal weight after they 
give birth (Sahlin et al., 2009), thus increasing the likelihood of becoming overweight or 
obese, particularly if they have been through more than one pregnancy (multiparity). 
 
Another factor that can heighten the likelihood of obesity is lack of sleep. During sleep, the 
hormones ghrelin and leptin, which are respectively linked to the sensation of hunger and 
satiety, are regulated by the body. However, the ghrelin levels increase and the leptin 
levels decrease when an individual has not slept sufficiently (Sahlin et al., 2009), making 
them feel hungry. Furthermore, Wright and Aronne (2012) have suggested that a negative 
correlation exists between the number of hours slept per night and BMI, with fewer hours 
of sleep stimulating cravings for carbohydrate- and calorie-rich foods and excessive eating, 
resulting in weight gain. 
 
1.2.3. Use of medication 
Evidence exists that a range of prescription medication intended for health and wellbeing 
causes body fat levels to rise, thus leading to weight gain. It is still unclear how 
prescription medication determines weight gain exactly, but it has been demonstrated that 
some medication, such as medication for diabetes, depression, inflammation, and 
convulsion, is accompanied by side-effects such as an increased sense of hunger or water 
retention (Malone, 2005), as well as a reduction of the metabolic rate, leading to increased 
sedentariness. Table 1-1 lists a number of agents that may cause weight gain or are weight 
neutral. The sensation of hunger is enhanced by some medication which acts on the brain 
and triggers modifications in the centre concerned with satiety. There are a number of 
considerable dangers related to weight gain and higher BMI caused by prescription 
medication, including an increased level of cholesterol, hypertension, and risk of diabetes. 
Some medication may induce weight gain in a short period of time, resulting in adverse 
cardiac effects and leading to hypertension, which requires immediate medical attention. 
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Prescription medication alternatives may be suggested in certain cases, although these may 
also have secondary effects and may therefore not provide a viable solution. Furthermore, 
as noted by Seagle et al. (2009), not all people respond in the same way to particular 
medications, so the effects may vary. For example, a certain type of medication may cause 
some individuals to lose weight and have no effect on others.  
 
 
Drug groups Example of weight gain drugs Example of weight 
neutral/loss drugs 
Anti-diabetic agents Insulin, SUs and TZDs. GLP-1, metformin, SGLT2 
 
Psychiatric agents 
 
Fluoxetine, citalopram 
amitriptyline, olanzapine, 
risperidone 
 
Bupropion, Tranylcypromine 
 
β-adrenergic blockers 
 
Propranolol, atenolol 
 
- 
 
Neurologic agents 
 
Valproic acid, carbamazepine 
 
Lamotrigine, topiramate 
Table 1-1 List of medications that may cause weight gain or are weight neutral. 
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1.3 Body composition measurement 
Epidemiological studies have highlighted the fact that to determine how the reflective body 
adipose tissues are distributed, there is no need for complicated densitometry or imaging 
methods, as anthropometric measurements (i.e. body dimensions and weight 
measurements) are sufficient. These measurements provide an indication of an individual’s 
predisposition towards obesity based on the determination of adipose tissue levels. The 
statistical correlations between the weight and size of the body have enabled the 
formulation of accurate limits for overall body fat volume (Heim et al., 2010). 
 
In the UK, threshold values associated with morbidity and mortality, especially in the case 
of non-transmittable conditions such as type 2 diabetes and cardiovascular disease (CVD), 
have been established (National Obesity Observatory, 2009). Apart from BMI, there are 
two additional fundamental anthropometric measurements for adults, namely, WC and 
waist to hip ratio (WHR). 
 
1.3.1 Body Mass Index (BMI) 
Calculated as the body weight divided by the square of the body height (kg/m2), the BMI 
indicates the overall body fat volume, but does not reflect how the fat is distributed. Its 
measurement is straightforward and accurate and most individuals have no trouble 
understanding it (WHO, 2013). A BMI that exceeds 25 kg/m2 is considered to be a clear 
indicator of all-cause mortality (Calle et al., 1999). However, the fact that it cannot 
differentiate fat mass from lean mass is a major drawback of the BMI, because it can lead 
to errors of categorisation of younger and older people. On the other hand, evidence 
gathered by previous studies suggests that patients who are overweight have a lower risk of 
suffering from cardiovascular disease and have better survival rates than those with a BMI 
within the normal range (Romero-Corral et al., 2006; Oreopoulos et al., 2008). 
 
Pischon et al. (2008) argued that, in the case of young adults, obesity is overestimated by 
the BMI measure. Young individuals can be classified as overweight even though what 
causes high BMI values may be lean mass rather than fat mass, which means that their risk 
of morbidity is reduced because they are fitter (Pischon et al., 2008). On the other hand, 
obesity may be underestimated by the BMI measure in the case of individuals who are 
older or who are not of white ethnicity, due to the fact that the level of body fat of these 
individuals is greater than that of younger individuals. Additionally, the degenerative 
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processes that accompany age advancement cause a reduction in the height of older 
individuals. 
 
The National Institute of Clinical Excellence (NICE) (National Obesity Observatory, 2009) 
states that optimum cut-off values have not yet been clearly defined in the case of older 
individuals. In the case of individuals of Asian origin, the issue is further complicated 
because they seem to be more at risk of health conditions associated with obesity even if 
they have a normal BMI (Pischon et al., 2008). Therefore, the intermediate cut-off values 
of 23 kg/m2 (“increased risk”) and 27.5 kg/m2 (“higher risk”) have been introduced for this 
population (WHO Expert Consultation, 2004). Compared to individuals with overweight or 
those of normal weight, individuals who are obese are more likely to develop diseases. 
Nevertheless, as stressed by Mei et al. (2002), BMI cannot be used to diagnose obesity but 
only to screen for obesity. The classification of body weight and the risk of health 
complications can be seen in Table 1-2. 
 
 
1.3.2 Waist Circumference (WC) 
 WC is a surrogate measure for visceral fat and provides a cheap, accessible, simple 
measure. Abdominal adipose tissue can be measured by computed tomography (CT) and 
magnetic resonance imaging (MRI), and these techniques are able to differentiate between 
subcutaneous abdominal adipose tissue (SAAT) and visceral adipose tissue (VAT). The 
advantage of the two techniques is that they provide accurate results; however, the services 
they provide are expensive so their use is limited to hospitals and research centres. The 
processes also take a long time and therefore these techniques are unsuitable for use in 
large sample studies (Browning et al., 2011). According to Pischon et al. (2008), WC must 
BMI (kg/m2) Definition Associated health risks 
Underweight <18.5 Low (but increased the risk 
of other clinical problems) 
Normal-weight 18.5 to 24.9 Average 
Overweight 25 to 29.9 Increased 
Obese ≥30  
Class I 30 to 34.9 Moderately increased 
Class II 35 to 39.9 Severely increased 
Class III ≥40 Very severely increased 
  Table 1-2 Different cut off points and classifications of obesity into various groups. 
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be better defined to enable distinctions to be made between different stages of obesity that 
would help health professionals to predict the risks related to high WC with greater 
precision. The presence of high levels of adipose tissues in the abdominal cavity and 
surrounding the organs is indicated by a high WC value; compared to subcutaneous fat, 
this kind of visceral fat poses greater health risks. Numerous community and clinical 
organisations at both the local and the international level have adopted the sex-related 
intervention thresholds proposed by the WHO (Table 1-3). 
 
Classification Men Women 
Normal-weight <94 cm <80 cm 
Overweight 94 cm to 102 cm 80-88 cm 
Obese >102 cm >88 cm 
  Table 1-3 Waist circumference categories. 
 
WC can estimate abdominal fat and overall fat levels in an effective and straightforward 
way that is not connected to height. Owing to its efficiency in determining overall fat 
levels, WC has been used instead of BMI in clinical practice. On the downside, obtaining 
WC data is not as easy as obtaining BMI data because of several reasons, including the 
need to use a measuring tape, discomfort felt by individuals at having to take off their 
clothes, as well as the requirement to measure a particular area of the body. Stevens et al. 
(2010) conducted a prospective study involving up to 300,000 European participants and 
revealed that WC could anticipate the likelihood of death from obesity-related 
complications separately from BMI. Similarly, a review of cross-sectional and prospective 
studies by the WHO indicated a close correlation between WC and CVD as well as 
between WC and type 2 diabetes. Pischon et al. (2008) also reported that high fat levels in 
the abdominal cavity measured with WC instead of BMI were closely correlated with 
metabolic syndrome, diabetes, CVD, and all-cause mortality. 
 
1.3.3 Waist-to-hip ratio (WHR) 
Measured in centimetres, the WHR indicates how the waist circumference is related to the 
hip circumference. Based on risks and the likelihood of mortality, the WHO has 
established sex-particular thresholds for WHR as it did for WC (Table 1-4). 
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Classification Men Women 
Normal-weight <0.94 <0.80 
Overweight 0.94 to 0.99 0.80-0.84 
Obese ≥1 ≥0.85 
Table 1-4 Waist-to-hip-ratio categories. 
 
Although WHR can be used instead of WC to measure abdominal adiposity, the higher 
risks associated with high WHR values may stem from either abdominal fat or from a 
smaller body stature and frame, making interpretation of this index more challenging 
(Pischon et al., 2008). The hip circumference is indicative of both body fat and body 
stature and frame. Meanwhile, the prospective study carried out by Janssen et al. (2004) 
has revealed that, in the case of older individuals, mortality can be more effectively 
anticipated by WHR than by BMI, especially death as a result of myocardial infarction and 
CVD. On the other hand, there is evidence that individuals with a small hip circumference 
are more prone to diabetes and cardiovascular complications (Heim et al., 2010). 
 
An earlier review found that the cut-offs for threshold of higher risk WHR in South Asian 
ethnic groups was ≥0.80 and ≥0.90 for women and men respectively (Lear et al., 2010). 
Lower cut-off thresholds for non-European groups have also been proposed by numerous 
studies. However, the predictability of WHR is not as good as that of WC because of issues 
related to the collection of data through measurement. To ensure the validity and reliability 
of the data, two measurements must be taken and the person taking the measurements has 
to touch the individuals being measured on the waist and the hips (Heim et al., 2010), 
creating a potentially uncomfortable situation for the persons being measured.  
 
Valid association between WHR measurements and certain conditions such as CVD, type 
2 diabetes, high blood pressure, and specific types of cancers, particularly breast cancer 
(Heim et al., 2010). Factors such as age, sex and ethnicity do not influence the accuracy of 
WHR in indicating abdominal adiposity. Furthermore, BMI, WC and WHR may differ in 
terms of their interpretation as indicators of CVD and type 2 diabetes, but the differences 
are not marked and lack statistical significance. Janssen et al. (2004) reviewed data from 
across the UK but did not find evidence that BMI, WHR and WC estimates differed 
significantly. Nonetheless, out of the three indices, WHR is considered to estimate high 
cholesterol levels most accurately. There is substantial evidence in favour of high odd 
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ratios once other obesity indicators are taken into account, but even after BMI and WC 
adjustment, WHR is still associated with the highest degree of prediction. 
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1.4 Obesity-related morbidity and mortality 
Health is adversely affected by obesity in a variety of ways. People with obesity are more 
likely to suffer not only from CVD, high blood pressure and peripheral vascular disease, 
but also from changes in lung function, such as reduced lung compliance, anomalies of 
ventilation and perfusion, and respiratory muscle weakness and diminished performance. 
Depressed ventilator drive, obstructive sleep and bronchospasm are also likely 
consequences of obesity. Sternal wound infections and leg infections may also develop in 
individuals with obesity (Gronniger, 2006). In the US alone, around 300,000 people die 
from obesity-related complications every year. Sleep apnoea, respiratory problems, high 
blood pressure, joint degeneration (e.g. osteoarthritis) and cancer, especially in female 
individuals, are the most pervasive implications of obesity.  
 
1.4.1 Cardiovascular diseases  
Most individuals with hypertension are typically overweight and are six times more likely 
to experience hypertension-related complications than individuals of normal weight 
(Alwan, 2011). Furthermore, as emphasised by Poirier et al. (2006), in addition to being 
more prevalent among individuals who are overweight, high blood pressure can also 
develop in young individuals who gain weight. For instance, an increase in body weight of 
10 kg elevates the systolic and diastolic blood pressure by 3 mmHg and 2.3 mmHg, 
respectively, which in turn heightens the likelihood of chronic heart failure and stroke by 
12% and 24%, respectively. Brown et al. (2000) reported that the prevalence of 
hypertension in men increased progressively with the BMI increasing from 15% at a BMI 
of ≤25 kg/m2 to 42% at a BMI of ≥30 kg/m2. 
 
The blood volume, stroke capacity and cardiac output are all elevated in individuals who 
are overweight. In individuals whose blood pressure is normal, such a high output state is 
associated with diminished peripheral vascular resistance (Trullas et al., 2013), but in 
individuals who are obese this resistance is inadequate or elevated in the presence of 
hypertension (Lavie et al., 2009). There are two main causes underpinning the factors 
associated with hypertension and ensuing coronary heart disease:  
1. The effect of obesity on body hemodynamics  
       2. Processes such as defective endothelial function, resistance to insulin, anomalies in 
the sympathetic nervous system, and adipocyte-produced cytotoxic substances that 
create a direct correlation between obesity and elevated peripheral resistance.  
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Another perspective that is gathering support is that obesity plays a role in the activation of 
the sympathetic nervous system and alterations in renal morphology and function. 
Evidence also exists that hypertension in the people with obesity develops with the crucial 
involvement of renal dysfunction manifested as enhanced tubular sodium reabsorption and 
the resetting of pressure natriuresis. In addition, Krauss et al. (1998) indicated that obesity 
is correlated with dyslipidaemia, while increased LDL-C, low HDL-C and proliferation of 
triglycerides are all caused by excessive weight. 
 
In the case of female individuals, the correlation between obesity and hypertension is not 
very different, with BMI of 25 kg/m2 and 30 kg/m2 being respectively associated with 15% 
and 38% likelihood of coronary artery disease as a result of the fact that arteriosclerosis 
develops in the main arteries that supply the myocardium (Lavie et al., 2009). Aside from 
interfering with body hemodynamics, obesity also enhances the demand for oxygen to 
about 15 ml/kg per minute, causing the heart to work harder (Gluckman et al., 2009) and 
resulting in a rise in the blood volume. Shihab et al. (2012) indicated that the likelihood of 
incident hypertension was greater among male individuals in the US who are overweight 
or obese than among male individuals of normal weight. 
 
Earlier studies suggested that obesity is an independent risk factor for coronary heart 
disease (CHD) and atherosclerosis (Lavie et al., 2007; 2009). The relationship between 
BMI and the risk of CHD events is poorly understood, due to the effect of other potential 
confounding factors such as non-intentional weight loss, smoking and medication. In the 
West of Scotland Coronary Prevention Study (WOSCOPS) that comprised 6,082 male 
participants, Logue et al. (2011) found that obesity was associated with an increased risk of 
fatal CHD events after an adjustment was made for confounding factors. A collaborative 
analysis of large prospective studies (comprising 894,576 participants), undertaken by 
Whitlock et al. (2009), found a 30% increase in mortality for every 5 kg/m2 increase in 
BMI above 25 kg/m2. Mortality was higher in those with a BMI of 30-35 kg/m2 (median 
survival was reduced by 2-4 years) and a BMI of 40-45 kg/m2 (reduced by 8-10 years). It 
has been suggested that the excess mortality was due to vascular disease; whereas, the 
higher mortality of people with a BMI below 22.5 kg/m2 was due to smoking related 
diseases or malnutrition. Additionally, in the 14-year follow-up of the Framingham Heart 
Study participants (Kenchaiah et al., 2002), it was found that the risk of heart failure 
increased 5% and 7% in men and women respectively for every 1 kg/m2 increase in BMI. 
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1.4.2 Type 2 diabetes 
Type 2 diabetes has become markedly more prevalent in the last two decades. In Scotland, 
around 284,122 people were diagnosed with diabetes and this represents 5.3% of the 
population (NHS Scotland, 2015). Regardless of the fact that type 2 diabetes is more 
prevalent in patients with obesity, 13% of individuals with type 2 diabetes had a BMI of 
18.5-24.9 kg/m2, 31.5% had a BMI of 25-29.9 kg/m2, and 55.5% had a BMI ≥30 kg/m2 
(NHS Scotland, 2014). There is ample research that supports the fact that weight gain and 
obesity enhance the likelihood of type 2 diabetes, especially among individuals with higher 
levels of abdominal fat as opposed to fat in the peripheries of gluteal-femoral areas of the 
body (Kissebah and Krakower, 1994). 
 
According to Hu et al. (1999), female individuals are more likely to have type 2 diabetes if 
they are obese and do not engage in physical activity. Similarly, Carey et al. (1997) 
indicated that a BMI ≥23 kg/m2 heightens the risk of diabetes, while a BMI ≥35 kg/m2 is 
associated with almost 100 relative risks. Eckel et al. (2011) investigated the correlation 
between type 2 diabetes and obesity and discovered that the development of type 2 
diabetes has an adverse impact on the function of pro-inflammatory cytokines such as 
Tumour Necrosis Factor (TNF) and Interleukin-6 (IL-6), mitochondria, insulin resistance, 
fatty acid metabolism, and the endoplasmic reticulum. People with obesity have higher 
levels of free fatty acids, which determine a decrease in insulin production and an 
overproduction of hepatic glucose (Boden, 2008). In fact, the elevated prevalence of type 2 
diabetes is based on obesity and the distribution of visceral fat as a major risk factor. As 
explained by Mancini and Halpern (2008), a chronic inflammatory condition with 
resistance to insulin may develop as a result of the substances contained in visceral fat. 
 
Formiguera and Canton (2004) argued that obesity and type 2 diabetes are primarily linked 
through insulin resistance, which refers to the fact that insulin can no longer regulate the 
metabolism of carbohydrates and lipids effectively. In individuals with obesity and type 2 
diabetes, insulin resistance takes the form of reduced transport and metabolism of glucose 
in adipocytes and skeletal muscle as well as dysfunctional inhibition of hepatic glucose 
output (Formiguera and Canton, 2004). When the pancreas is no longer able to overcome 
insulin resistance by producing sufficient insulin, it leads to the development of type 2 
diabetes. 
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Furthermore, Ye (2013) reports that glucose homeostasis is affected in different ways by 
the various adipose tissue sub-types, as these do not have the same function. Among the 
different processes underpinning the correlation between obesity and type 2 diabetes are 
cytokine overproduction, deposition of ectopic adipose tissue, and inadequate functioning 
of the mitochondria. A moderate decrease in body weight is enough to avoid both type 2 
diabetes and obesity; this can be achieved in various ways, including lifestyle changes, 
behavioural intervention, obesity drugs, or bariatric surgery (SIGN 116, 2010). 
 
1.4.3 Cancer 
According to statistics reported by Vucenik et al. (2012), in the UK, one out of twenty 
types of cancers is associated with obesity or higher-than-normal weight. Research has 
revealed that individuals with overweight are more likely to develop certain types of 
cancer. As stated by the International Agency for Research on Cancer (IARC), the existing 
evidence is ample enough to support the correlation between obesity and cancer, 
especially, post-menopausal breast cancer, oesophageal adenocarcinoma, endometrial 
cancer, colorectal cancer and renal cell cancer (IARC, 2002). Fat deposition and exposure 
to growth factors are the reasons that increase the susceptibility of individuals with 
overweight to the influence of hormones. Furthermore, individuals who are obese are more 
likely to develop some types of cancers because the oestrogens in their blood are higher 
than usual. 
 
To determine how a BMI rise of 5 kg/m2 is correlated with the risk of twenty types of 
cancers with greater or lesser prevalence, Renehan et al. (2008) carried out a meta-analysis 
and found that the risk of endometrial cancer (RR 1.59, 95% CI: 1.5 to 1.68, p <0.001), 
oesophageal adenocarcinoma (RR 1.59, 95% CI: 1.31 to 1.74, p <0.001), kidney cancer 
(RR 1.34, 95% CI: 1.25 to 1.43, p <0.001) and gallbladder cancer (RR 1.59, 95% CI: 1.02 
to 2.47, p =0.04) was considerably higher, especially in female individuals. Furthermore, 
the increase in BMI was also significantly correlated with leukaemia, postmenopausal 
breast cancer, thyroid cancer, multiple myeloma, pancreatic cancer and colon cancer. On 
the other hand, male individuals were particularly at risk of oesophageal adenocarcinoma, 
colon cancer, thyroid cancer and renal cancer, as well multiple myeloma, rectal cancer, 
malignant melanoma and leukaemia. 
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1.4.4 Respiratory diseases 
Obesity may also trigger different respiratory problems. Elevated ventilation demand, 
tissue perfusion, breathing overload, reduced functional residual capacity, low performance 
of respiratory muscles, and peripheral lung segment blockage are common occurrences in 
people who are overweight. As explained by Zammit et al. (2010) such conditions usually 
result from the fact that the ventilation demand is not balanced with perfusion 
insufficiency, particularly in a prone position. Severely people with obesity often develop 
obstructed respiratory syndrome. 
 
Severely individuals who are obese display respiratory insufficiency and pulmonary 
hypertension. As the expanding pulmonary structures are subjected to increased pressure 
due to the greater weight, sleep disorders and breathing obstructions are highly prevalent 
among individuals with obesity. The condition known as sleep apnoea is characterised by 
recurring intervals of breathing obstruction and hypopnoea during sleep, a sensation of 
sleepiness during the day as well as irregular cardiopulmonary function (Zammit et al., 
2010). Furthermore, Murugan and Sharma (2008) highlighted the fact that additional 
respiratory diseases are also more likely to develop in people who are obese, such as 
bronchial asthma, pneumonia, pulmonary embolism, pulmonary hypertension, deep vein 
thrombosis and chronic obstructive pulmonary disease. 
 
1.4.5 Additional obesity-related morbidities 
The hormonal irregularities that accompany obesity are responsible for about 6% of 
primary infertility, interfering with normal reproductive function in the case of women and 
making men impotent (Esposito et al., 2004). Furthermore, the kidneys, liver, gall bladder, 
muscles and bones, and the endocrine system are all severely affected by the increased 
levels of lipids in the body (Reeuwijk et al., 2010). The likelihood of secondary disorder 
development increases in direct proportion with the levels of adipose tissue in the body. 
 
The kidneys are under massive pressure in individuals who are obese as they have to 
eliminate the toxins and sustain the demands made by an elevated BMI on the metabolism. 
As a result of hyperfiltration, the likelihood of kidney disease is high. Additional condition 
that is prevalent in individuals with obesity is osteoarthritis (OA), and additional 
musculoskeletal conditions such as back pain and gout (Grotle et al., 2008). Moreover, 
compared to individuals of normal weight, people with obesity are more likely to develop 
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cholelithiasis and cholecystitis, while their risk of developing Alzheimer’s disease is 42% 
greater (Beydoun et al., 2008). 
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1.5 Health implications of weight reduction 
The findings of the review of weight loss studies conducted by Poobalan et al. (2007) 
revealed that conditions associated with obesity, such as diabetes, high blood pressure, and 
high cholesterol and LDL levels, all improved as a result of a weight reduction of 5-10%. 
According to the Action for Health in Diabetes (Look AHEAD) study, substantial weight 
reduction also leads to ample clinical benefits (Wing et al., 2011). However, it remains 
unknown whether clinical outcomes such as myocardial infarction, stroke and sudden 
death are influenced in any way by weight reduction.  
 
1.5.1 Weight loss and mortality 
The link between obesity and increased risk of mortality is well documented. However, 
studies found that patients suffering from obesity and other diseases such as rheumatoid 
arthritis or heart failure were associated with decreased mortality “obesity paradox”. For 
example, in a meta-analysis of studies with a total of 28,209 participants with cardiac 
failure (Oreopoulos et al., 2008), patients with a BMI of 25-29.9 kg/m2 and BMI ≥30 
kg/m2 had 16% and 27%, lower all-cause mortality respectively than patients with a BMI 
of 18.5-24.9 kg/m2 during a period of 2.7 years. In a prospective cohort of 779 participants 
with rheumatoid arthritis, Escalante et al. (2005) found that, after adjusting for smoking, 
medication and duration of disease, the mortality rate was 66% lower in patients with a 
BMI >30 kg/m2 than those with a BMI of 20-24.9 kg/m2.  
 
The results of the study conducted by Gregg et al. (2003) indicated that the likelihood of 
death decreased when moderate deliberate weight reduction was achieved, but the 
likelihood of death increased as a result of inadvertent weight reduction in the case of 
overweight and obese adult Americans aged 35 years or older. Likewise, Wannamethee et 
al. (2000) reported that the mortality rate rose by 29-77% due to inadvertent weight 
reduction, owing to the natural history of a range of conditions, including depression, end-
stage heart disease, and cancer. Likewise, the mortality rate decreased by 25% among 
female and male individuals with diabetes-related weight reduction, while a weight 
reduction of 20-29lb (9-13 kg) led to the most significant mortality rate decrease of 33% 
(Williamson et al., 2000). Moreover, a prospective cohort study (Sjostrom et al., 2007) of 
2,010 participants who had bariatric surgery and 2,017 who were following conventional 
treatment programmes, showed that over 10.9 years of follow up, the overall mortality rate 
within the surgery group was reduced by 29% (101 deaths in the surgery group and 129 
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deaths in the control group). Another retrospective cohort study carried out by Adams et al. 
(2007), involving 9,949 patients who had undergone gastric bypass and a control group of 
participants suffering from severe obesity who applied for driver’s license, found that, over 
7 years, long-term mortality decreased by 40% among the surgery group and there were 
92% fewer deaths caused by diabetes and 60% fewer deaths caused by cancer. 
 
On the other hand, Trullas et al. (2013) reported that no BMI category was associated with 
a heightened mortality risk as a result of weight reduction equal to or greater than 5%. 
However, there are some chronic debilitating conditions, such as cardiac cachexia or 
chronic obstructive pulmonary disease (COPD), that lead to massive weight reduction, 
which increases the likelihood of death (Graessler et al., 2009). Furthermore, some studies 
have suggested that all-cause mortality benefits differ according to sex. Indeed, Poobalan 
et al. (2007) revealed that female individuals who deliberately lose weight enjoy all-cause 
mortality benefits in the long-term, but the long-term benefits for male individuals are yet 
to be fully elucidated.  
 
In conclusion, in the general population, the risk of mortality increases with a BMI >25 
kg/m2; however, a higher BMI in people with a disease such as CHD or rheumatoid 
arthritis is associated with a decrease in the mortality rate. A study by Martin-Ponce et al. 
(2010) that included 400 patients aged ≥60 years who were hospitalised at the internal 
medicine unit found that patients who suffered from obesity had a better long-term survival 
chance than those with lower BMI scores. The study also concluded that people with 
obesity were younger, suffered less from anorexia, had better nutrition and had more 
muscle mass. It has been suggested that the better odds of survival associated with obesity 
are due to factors other than any beneficial effects of excess weight, such as reverse 
causality due to disease-related weight loss. Additionally, it is suggested that in case of 
ageing and illness with obesity, a “healthy BMI may be >25 kg/m2, but not over 30 kg/m2. 
  
1.5.2 Diabetes 
Complicated comorbidities are more likely to occur in individuals with obesity and type 2 
diabetes (Nilsson, 2008). According to the findings of a number of studies, lifestyle 
modifications, including physical activity, medication, and surgery, are effective in helping 
diminish the incidence of type 2 diabetes in relation to obesity (Nilsson, 2008). However, it 
is still unclear how weight loss benefits patients with type 2 diabetes. Souto-Gallardo Mde 
et al. (2011) have reported that hypoglycaemic medication was needed less frequently 
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and/or diabetes showed remission as a result of weight reduction. Similarly, Aucott et al. 
(2004) revealed that the status of type 2 diabetes and impaired glucose tolerance (IGT) 
improved after moderate weight reduction.  
 
The Look AHEAD study reported a correlation between weight reduction and enhanced 
diabetes control. Carried out in the US, this study comprised 5,145 overweight and obese 
individuals with type 2 diabetes who were randomly divided into two groups; where 
members of one group receiving standard diabetes support and education and members of 
the other receiving intensive lifestyle intervention. The latter programme consisted of 
collective and one-on-one meetings geared towards reducing weight and hindering 
renewed weight gain via an approach involving lower energy intake and enhanced physical 
activity (Pi-Sunyer et al., 2007). At baseline, all participants had a BMI ≥25 kg/m2 or ≥27 
kg/m2 in the case of those taking insulin. Additionally, all participants were older than 40 
years of age. The main goal was to establish whether an approach combining diet, physical 
exercise and behavioural changes, including formulation of objectives and maintenance of 
weight reduction to 7% or more of the original body weight, could accomplish long-term 
weight loss that would lower cardiovascular morbidity and mortality in patients with type 2 
diabetes. Male and female participants with type 2 diabetes were subjected to an exercise 
test, since the ultimate goal was to diminish the risk of cardiovascular conditions, while 
weight loss was a primary objective.  
 
Participants were not included for randomisation in the intervention group if they did not 
satisfy the criteria for age-related maximal heart rate. Registered dieticians, behavioural 
psychologists, exercise specialists and lifestyle counsellors made up the intervention teams 
that managed the sessions. They met with the participants regularly during the first six 
months, with an individual session being scheduled during the fourth week of each month. 
The results revealed that the intervention group accomplished 8.6% weight loss (P <0.001) 
when the support group achieved only 0.7% weight loss. At twelve months, people with 
type 2 diabetes lost a significant amount of weight owing to the intensive intervention, 
resulting in better diabetes management and diminished risk of CVD and use of drugs (Pi-
Sunyer et al., 2007). 
 
Williamson et al. (2000) conducted a prospective study on 4,970 participants with type 2 
diabetes who were 13 years or older, who were monitored for deliberate and inadvertent 
weight reduction. Results showed that mortality due to cardiovascular disease and diabetes 
decreased by 28% among those who lost weight deliberately. In a different study, the 
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medical records of deceased individuals with type 2 diabetes were investigated by Lean et 
al. (1990), who observed that individuals lived 3-4 months longer for every kilogramme of 
weight lost. Similarly, Knowler et al. (2002) reported that the risk of type 2 diabetes was 
considerably lowered by modest weight reduction of 3-4 kg (5%).  
 
The Diabetes Prevention Programme (DPP) showed that it was possible to prevent the 
onset of type 2 diabetes with an intensive programme of lifestyle changes and diet. The 
DPP succeeded in reducing the incidence of type 2 diabetes by 58% in a population that 
was at high risk of developing this disease by lifestyle intervention and physical activity 
that aimed to achieve 7% weight loss (Knowler et al., 2002). It randomly assigned 3,234 
individuals without diabetes and with an elevated FPG to a group that received a placebo, 
metformin (850 mg twice a day) or was given a lifestyle intervention programme. At 3 
years, the cumulative incidence of diabetes in the placebo, metformin and lifestyle 
intervention groups was 28.9%, 21.7% and 14.4%, respectively. 
 
1.5.3 Lipid profile 
Blood cholesterol, low density lipoproteins (LDL) and triglycerides all occur at high levels 
in the serum of individuals who are obese (Jebb et al., 2011). Overweight individuals 
usually have reduced levels of high density lipoproteins (HDLs) and there is generally an 
increased level of triglyceride in those who are insulin resistant. The main recommendation 
for improvement of lipid profile in patients who are also obese is weight loss (Graessler et 
al., 2009). However, the issue regarding the impact of weight loss on HDL concentration 
has been extensively debated, with HDL blood levels being higher in the case of 
individuals who maintain a stable weight than those who lose weight. This is because all 
lipids levels fall during weight loss and increase once the weight stabilises. 
 
Poobalan et al. (2004) systematically reviewed 13 studies conducted in various countries 
and concluded that lipid levels, particularly LDL and total cholesterol levels, were 
favourably impacted in the long-term by weight reduction. In the long-term, cholesterol 
levels decreased by around 5% (0.23 mmol/l) with an average weight reduction of 10 kg. 
However, as highlighted by Pi-Sunyer (1996), a weight reduction of 10 kg in the short-
term could result in a greater decline in cholesterol levels of up to 10%. Furthermore, the 
findings obtained by Avenell et al. (2004) from systematically reviewing randomised 
controlled trials (RCTs) indicated that LDL, total cholesterol and triglyceride levels 
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decreased while HDL levels rose in the case of individuals with overweight or obesity who 
lost between 5 and 10 kg. 
 
1.5.4 Hypertension 
There is a positive correlation between weight changes and blood pressure. According to 
several studies, blood pressure decreases as a result of weight reduction and enhances 
blood peripheral resistance by reducing fatty plaques in arteries and capillaries that had 
obstructed the blood flow. It is suggested that a range of pathophysiological mechanisms 
may be involved but these have not been identified with certainty. Extracellular volume 
diminishes as a result of weight reduction and in turn reduces hypervolaemia and cardiac 
output, inhibits the sympathetic nervous system, reduces resistance to insulin and 
normalises the correlation between aldosterone and renin, which ultimately leads to the 
reduction in blood pressure (Mertens and Van Gaal, 2000). 
  
The results obtained by earlier intervention studies revealed that cardiovascular risk factors 
associated with obesity (e.g. high blood pressure and diabetes) were considerably reduced 
after intentional weight reduction of 5-10% (Sjostrom et al., 1999). Furthermore, Neter et 
al. (2003) reviewed a series of RCTs and found that, for each kilogramme of weight lost, 
the diastolic pressure dropped by 0.92 mmHg. The Hypertension Prevention Collaborative 
Research Group (1992) compared how the diastolic and systolic blood pressures were 
affected by weight loss among 308 individuals with hypertension and among 256 
individuals with normal blood pressure. The hypertensive group lost 23.9 kg (4.3%) 
following a year and a half of intervention, which caused the diastolic and systolic blood 
pressures to decrease to 22.3 mmHg and 22.9 mmHg, respectively. Meanwhile, a Look 
AHEAD study found that the systolic pressure (-5.33 vs. -2.97 mm Hg; p <0.001) and 
diastolic blood pressure (-2.92 vs. -2.48mmHg; p =0.01) of individuals subjected to an 
intensive intervention over four years improved more significantly than those in control 
group (Wing, 2010).   
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1.6 Therapeutic interventions for obesity  
1.6.1 Existing guidelines 
The initial step in the treatment of obesity is to identify individuals who are overweight or 
obese. In the UK and the US, weight management is typically undertaken in the context of 
primary care, since the numbers of patients who are overweight or obese has become so 
high (SIGN 8, 1996; Sciamanna et al., 2000). Although awareness about growing levels of 
obesity is high, measurements are not conducted on a regular basis. According to the 
findings of an audit conducted in the UK, the recognition of obesity within primary care 
was inadequate with weight or BMI measurements were included in the medical records of 
just two-thirds of the patients of forty general practices that indicated they were interested 
in weight management (Laws, 2004). In the UK, as part of the Quality and Outcomes 
Framework (QOF) set up in 2006, general practitioners (GPs) are rewarded for recording 
individuals with a BMI ≥30 kg/m2 who are aged ≥16 years. In 2010, in England, it was 
found that prevalence of obesity according to the standard set in the QOF (10.5%) was 
lower than the prevalence recorded in the health survey (26.1%); this result may reflect the 
fact that not all patients were measured or had yet visited their GP (NHS, 2012). In 
Scotland, the Scottish Intercollegiate Guideline Network (SIGN) guidelines were issued in 
2010 to support management of adult obesity within a clinical context. These guidelines 
include measures for preventing obesity via primary intervention targeted at people of 
normal weight or within the obesity range. 
 
Weight gain prevention, achievement of weight reduction of 5-10% or more, and 
improvement of health and risk factors are the goals outlined by SIGN 115 (2010) for 
weight management in the case of individuals with obesity. Furthermore, the guidelines 
emphasise that physical exercise, diet modifications, and behaviour management should be 
integrated in weight management. It is recommended that the BMI should not exceed 25 
kg/m2, diets should be dominated by foods with lower energy density, such as wholegrains, 
cereals, vegetables and salads, and alcohol consumption should be limited. SIGN 
guidelines recommend that healthcare professionals should encourage individuals to weigh 
themselves and consider the patient’s willingness to change before offering weight loss 
interventions. Additional recommendations include the use of medication in support of 
diet, physical exercise and behavioural modifications in individuals with a BMI ≥28 kg/m2 
with comorbidities or a BMI ≥30 kg/m2, after comprehensive consideration of risks and 
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benefits. Another option that should be taken into account in adult weight management is 
bariatric surgery (SIGN 115, 2010). 
 
The guidelines for obesity treatment that have been issued by the NICE (2014) specify that 
every NHS department should play a role in identifying and managing individuals who are 
overweight or obese. One of the greatest difficulties confronting healthcare practitioners in 
the UK is ensuring that patients stay physically active. To effectively deal with obesity, a 
multi-faceted strategy has been advocated by the NICE lifestyle guidelines (NICE lifestyle, 
2014). Ijzelenberg et al. (2012) advocated the prioritisation of commercial programmes for 
obesity management such as community-based programmes focusing on healthy eating and 
physical activity. Additionally, to motivate individuals to improve their lifestyle, cognitive 
behavioural therapy should also be included in weight management programmes. 
 
An approach integrating physical activity, diet and behavioural changes is considered the 
most effective in managing obesity and excessive weight. However, bariatric surgery or 
medication therapy is necessary in the case of some individuals. No treatment is 
commenced before an assessment of a patient is conducted to determine any potential 
risks. This so-called “risk-benefit assessment” helps to establish which treatment would be 
most effective (Neff and le Roux, 2013). The amount of excessive weight and patients’ 
preferences are taken into account when deciding on a specific treatment course. 
 
In conclusion, the NICE (2014) recommend that multicomponent interventions should be 
the treatment of choice for people with obesity. Patients should be given all the 
information they need regarding realistic targets for weight loss (5-10% of initial weight) 
and know that the main requirement to reach the target diet is that energy expenditure 
should be higher than the total energy intake. In addition, 45-60 minutes/day of physical 
activity may help to prevent obesity in people who cannot reduce their energy intake; and 
60-90 minutes/day of physical activity may be needed for people who are obese and have 
recently lost weight. Furthermore, the NICE (2014) guidelines recommend drug treatment 
for patients who have not yet reached their target weight loss through lifestyle 
interventions and the consideration of bariatric surgery for those with a BMI >50 kg/m2. 
 
1.6.2 Modifications in lifestyle and physical activity 
Weight gain is the result of sedentariness, lack of physical activity, and unhealthy eating 
patterns. Hence, improving these aspects is the focus of the majority of weight 
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management programmes (Esposti et al., 2006). Behavioural programmes seeking to 
improve lifestyle choices are referred to as lifestyle interventions. At the same time, weight 
management programmes put great emphasis on physical activity as a solution to redress 
the balance between energy intake and energy consumption. Changes in what individuals 
eat and drink, how much they eat and drink and how often are necessary to reduce the 
intake of calories and, thus, to achieve weight reduction. The energy intake should be 
reduced by 600 kcal/day or 3,500 kcal/week, in order to attain the recommended weight 
loss of 0.5 kg per week.  
 
Diets with low fat content, modest energy prescription, low or extremely low caloric 
content, protein-sparing modified fasts, and diets low in both carbohydrates and fat can all 
help to reduce the energy intake. A range of diets with at least one-year follow-up was 
compared in the context of a detailed health technology assessment (HTA). In the case of a 
600 kcal deficit diet or diet with low fat content, the average amount of weight lost over 
twelve comparisons was -4.6 kg (95% CI: -7.20 to -0.60 kg), while standard interventions 
led to an increase in weight of 0.60 kg (95% CI: -1.30 to +2.40 kg) (NICE, 2006; SIGN, 
2010). Similarly, at the one-year follow-up, a moderate weight reduction of 5-6% as a 
result of hypocaloric diets with 800-1800 kcal/day intake and less than 800 kcal/day was 
recorded by Tsai and Wadden (2006). In a different study, a moderate weight loss of 5 kg 
was recorded at the one-year follow-up as a result of diets low in carbohydrates (<30 
g/day) and low in fats (<30% of overall energy intake from fat per day) (Nordmann et al., 
2006). Additionally, the results obtained by Pi-Sunyer et al. (2007) in the Look AHEAD 
study indicated that lifestyle interventions of high intensity led to a 5% weight reduction in 
68% of the participants and a minimum of 10% weight reduction in 37% of the 
participants. 
 
The benefits of physical activity include maintenance of weight reduction in the long-term 
and maintenance of a lean body mass during dieting. The UK guidelines suggest that, in 
order to derive health benefits, adult individuals should engage in moderately intense 
physical activity for a minimum of 150 minutes weekly. However, this interval may need 
to be prolonged, since the recommendation of 150 minutes was formulated based on 
physical activity that participants in longitudinal observational studies themselves reported. 
According to the SIGN guidelines (SIGN 115, 2010), individuals with overweight or 
obesity issues should aim for 225-300 minutes of moderately intense physical activity per 
week, which could be completed in five sessions of 45-60 minutes weekly and would 
result in the burning of 1,800-2,500 kcal/week. Furthermore, physical activity should be 
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undertaken in conjunction with other strategies of weight management. Jakicic et al. 
(2008) reported that adult female individuals with obesity exhibited a dose-response 
relationship with regard to the level of physical activity they engaged in and the ability to 
maintain the weight they lost in the long-term. Hence, to summarise, behavioural therapy, 
physical activity, and dietary intake represent the three cornerstones through which 
lifestyle interventions can achieve beneficial changes. 
 
Other study reported that, after one year, greater weight reduction was achieved through an 
intervention consisting of 45 minutes of physical activity three times a week and a low fat 
diet aimed at reducing the caloric intake by 600 kcal/day than through a programme 
consisting of diet alone. The diet-only group achieved an average weight reduction of 4.10 
kg (range -4.00 kg to -5.10 kg), while the physical activity combined with dieting group 
lost on average of -5.60 kg (range -5.10 kg to -8.70 kg) (NICE, 2006). Furthermore, diet 
alone is not as efficient as an intervention comprising physical exercise, behavioural 
therapy and hypocaloric diet, as attested by a meta-analysis of five studies, which revealed 
that diet alone led to a weight reduction of just 0.48 kg (range 0.53 kg to -2.40 kg), while 
the combined intervention achieved a weight reduction of 4.60 kg (range -3.33 kg to -5.87 
kg) (NICE, 2006; SIGN 115, 2010). 
 
The treatment of adult with obesity benefits greatly from behavioural programmes (Shaw 
et al., 2005) which are designed to bring about changes in the way individuals act and 
think that are in line with changes in patterns of physical activity and diet. To lose weight 
and prevent regaining it, individuals must have a range of behavioural skills. Behavioural 
therapy aims to equip individuals with techniques and practices that will change their 
attitude to physical activity and eating. Some behavioural change techniques include 
patient monitoring, motivational enhancement, and cognitive behavioural therapy. It has 
been demonstrated that, in comparison with diet alone, diet combined with behavioural 
therapy achieved greater weight reduction after one year. 
 
Shaw et al. (2005) indicated that greater weight reduction was achieved through lifestyle 
interventions focusing on development of healthy eating behaviour coupled with physical 
exercise than through interventions focusing on just physical exercise or just diet. There 
are various factors that can determine the extent of treatment success. Thus, treatment 
success can be diminished by family traits, such as parents with obesity (Sabin, 2007) 
and/or siblings, attachment avoidance on the part of the mother, as well as maternal 
depression. Reinehr et al. (2010) argued that outcomes after five years could be anticipated 
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based on BMI decrease during interventions. The processes of weight management can be 
more comprehensively understood and obesity treatments can be improved once the factors 
that most favourably and unfavourably affect weight loss are better understood. 
 
1.6.3 Medication-based treatment 
The efficiency of medication-based treatments of obesity, either on their own or integrated 
with behavioural therapy, has been the focus of many studies. The main purpose of 
medication-based treatments is to regulate food consumption and body weight (Ornellas 
and Chavez, 2011), particularly in individuals who struggle with maintaining weight 
reduction through changes in eating habits and lifestyle. 
 
1.6.3.1 Orlistat  
Orlistat is used to treat obesity in the long term. It often modifies the digestion of fats by 
restraining the pancreatic lipases (Heck et al., 2000). Hence, fats are not hydrolysed 
completely and excretion of faecal fat is augmented. This medicine is usually available in 
120 mg capsules with the recommended dose being 120 mg to be taken three times daily 
(Berne, 2005). Orlistat’s effectiveness in facilitating weight loss has been verified in 
various other meta-analyses and randomised trials (Li et al., 2005; Torgerson et al., 2004).  
 
In numerous other trials related to patients with diabetes, orlistat resulted in a significantly 
higher of weight loss and diminished glycosylated haemoglobin (HbA1c) at 1 year when 
compared to the placebo groups (Kelley et al., 2002). Yancy et al. (2010) conducted 
another trial, in which 146 patients suffering from obesity (that is, having a BMI of 
39.3kg/m2) were examined. A low-fat diet (less than 30% of routine energy) in 
combination with orlistat resulted in a loss of weight (9% on an estimate) that was 
analogous with a low ketogenic carbohydrate diet (originally less than 20g 
carbohydrates/day). A 1-year trial was conducted at various centres by Miles et al. (2002) 
to evaluate the effects of orlistat. The trial aimed to check the effects of 120 mg 
orlistat/three times a day versus a placebo in patients who are overweight or obese with 
type 2 diabetes who were being treated with metformin. At the end of the 1-year treatment, 
weight loss was significantly greater in the group which was on orlistat than the placebo 
group. Glycaemic control improved immensely in the group which was treated with orlistat 
and the HbA1c serum was significantly reduced. Miles et al. (2002) concluded that the 
orlistat treatment was very helpful in reducing weight and improved the control of 
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glycaemia along with blood pressure and serum lipid levels in patients suffering from 
obesity and type 2 diabetes who were being treated with metformin.  
  
In another 57-week randomised double-blind placebo-controlled study, 120 mg of orlistat 
or a placebo was administered orally three times/day together with hypocaloric diet to 391 
men and women aged 18 years and over who were suffering from obesity (with a BMI of 
28-40 kg/m2) and type 2 diabetes and who were being treated with oral sulfonylureas (SUs) 
(Hollander et al., 1998). After 1 year of treatment, the mean weight change in the orlistat 
group and the placebo group was -6.2 ± 0.45% and -4.3 ± 0.49% (p <0.001), respectively. 
There are numerous clinical trials which indicate that early weight loss is greater and the 
rate of weight regain is lowered when a patient is treated with orlistat than when they are 
treated with a placebo and lifestyle changes.  
 
Another controlled trial was conducted to analyse the tolerance levels and effectiveness of 
orlistat over a 2-year period in participants without diabetes (Sjostrom et al., 1999). In the 
first year, the group which was on orlistat lost more weight than the group which was 
given the placebo treatment (10.2% [10.3 kg] vs. 6.1% [6.1 kg]). A total of 743 patients 
from 15 European centres whose BMI was between 28-47 kg/m2 were included in this 
trial. 688 patients were treated with 120 mg of orlistat 3 times/day or a placebo for 1 year. 
By the second year, patients who were on orlistat gained half the weight they had lost back 
again when compared to the patients on who switched to placebo (p <0.001). The group of 
patients who switched from the placebo to orlistat during the second year had an additional 
weight loss of 0.9 kg. Apart from the weight loss, it was observed that the orlistat group 
showed lesser concentrations of glucose and insulin, lower cholesterol levels, LDL/HDL 
ratio and LDL when compared to the placebo group.  
 
This study finally confirmed that orlistat, when taken in conjunction with an appropriate 
diet, promotes a significant loss of weight and lessens the chances of weight gain in 
patients who are obese over a period of 2 years. When orlistat is taken for more than 2 
years, the patient should be closely monitored for adverse events. Further study showed 
that orlistat, taken at a dose of 120 mg/three times daily in conjunction with a low caloric 
diet, can reduce weight by 30 % in patients with type 2 diabetes and hypertension (Berne, 
2005).  
 
In a 4-year double blind (XENDOS) study of 3,304 patients with overweight, Torgerson et 
al. (2004) concluded that the use of orlistat along with lifestyle changes exhibited better 
58 
results when compared to the changes achieved by adjustment to lifestyle alone. The study 
concluded that orlistat combined with lifestyle changes reduced the incidence of type 2 
diabetes. Prospective subjects who participated in the study were advised of the lifestyle 
changes they had to make and were given either a placebo three times a day or 120 mg of 
orlistat three times a day. The BMI of the subjects was less or equal to 30 kg/m2 and they 
had an impaired percentage of 21% or normal percentage of 79% glucose tolerance. The 
primary aim was to check the onset of type 2 diabetes and observe whether there were any 
changes in body weight. The intention of the analysis was to shed light on effective 
treatment choices. The percentage of the patients who completed the treatment were 52% 
in the group treated with orlistat and 34% in the group which received the placebo 
treatment (p <0.0001). The mean weight loss was significantly greater in the orlistat group 
when compared with the placebo group (-10.6 kg vs. -6.2 kg; p <0.001). At the end of 4 
years, the degree of incidence for diabetes in the patients who received the orlistat 
treatment was 6.2% and 9% in the patients who received the placebo treatment, which 
corresponded to an overall risk reduction of 37.3% (p =0.003). The mean weight change in 
the orlistat group and the placebo group was -5.8 kg and -3.0 kg, p <0.001, respectively. 
 
Worldwide, over the past ten years, it is estimated that 40 million individuals were treated 
with orlistat. Douglas et al. (2013) conducted a population-based study using data on acute 
liver injury incidences from the use of orlistat reported through the “UK Clinical Practice 
Research Data link”. They found that acute liver injury incidences from the use of orlistat 
augmented (roughly doubled) ninety days before and thirty days after the treatment began 
in comparison with background prevalence. The data suggested that this linkage is not 
causal. On the other hand, patients taking orlistat are warned to contact healthcare 
professionals if they see sign of anorexia, pale coloured stools, jaundice, and itching. In 
addition, a study reported a statistically significant decrease in the presence of all assessed 
fat-soluble vitamins after 4 years of treatment in the orlistat group when compared with the 
placebo group (Torgerson et al., 2004). 
 
1.6.3.2 Other drugs 
Liraglutide (Victoza®) is a glucagon-like peptide-1 (GLP-1) long-acting analogue. 
Liraglutide is administered once a day by subcutaneous injection and has shown benefits 
for glycaemic control at doses up to 1.8 mg/day and for weight loss at doses of up to 3.0 
mg once daily (Astrup et al., 2012). Its effect is on the gastrointestinal tract and the brain 
by as it suppresses appetite and energy intake in both normal-weight people and people 
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with obesity as well as in individuals with type 2 diabetes and it delays gastric emptying 
(Astrup et al., 2009). The fact that liraglutide causes dose-dependent weight loss, decreases 
the concentration of HbA1c, improves β-cell function and systolic blood pressure (Vilsboll 
et al., 2007) makes it a treatment option for both type 2 diabetes and obesity.  
 
The taking of liraglutide in diabetes trials is linked significantly with weight reductions 
(2.0 to 2.5 kg). The loss in weight is also observed in people without diabetes receiving 
liraglutide over a 20-week. Astrup et al. (2009) conducted an RCT among 564 participants 
with a BMI in the range 30-40 kg/m2. Of these, 95 were distributed at random to one of 
four liraglutide doses (1.2 mg, 1.8 mg, 2.4 mg, or 3 mg); 98 were allocated to the placebo 
group; and 95 were allocated to the orlistat 120 mg group. An intervention comprising 500 
kcal/day energy-deficit diet and physical exercise was applied to all participants. Results 
indicated that, by comparison to the placebo (all doses) and orlistat (vs. 2.4 and 3 mg 
liraglutide), a more significant weight reduction was achieved by liraglutide administered 
together with lifestyle intervention. The four liraglutide doses led to an average weight 
reduction of 4.8, 5.5, 6.3 and 7.2, respectively, while the placebo and orlistat induced 
weight reduction of 2.8 and 4.1 kg.  The percentage of individuals who lost more than 5% 
of their weight in the liraglutide 3.0 mg group was 76% (n =70) when compared with the 
individuals in the placebo group (30%, n =29) or the orlistat group (44%, n =42).  
 
Moreover, in an earlier RCT (SCALE study) conducted in 27 countries in North America, 
Europe, Asia, South America, Africa, and Australia from 1 June 2011 to 18 March 2013 
(Pi-Sunyer et al., 2015), 3,731 participants without diabetes received counselling on 
lifestyle modification; 2,487 participants received liraglutide 3 mg, and 1,244 participants 
received a placebo. At week 56, the mean weight change in the people in the liraglutide 
group was -8.4±7.3 kg and in people in the placebo group was -2.8±6.5. The estimated 
treatment difference was -5.6 kg (95% CI: -6.0 to -5.1 kg), p <0.001. 
 
Drugs such as phentermine and topiramate (Qsymia®) (not available in the UK, but 
available in the US) given in combination are an option for obese adult without coronary 
heart disease and who do not suffer from hypertension (Bays, 2010). Phentermine, a 
nonselective stimulator of synaptic noradrenaline, dopamine and serotonin release, has 
been widely used (mainly outside of Europe) as a short-term appetite suppressant since the 
1960s (Ryan and Bray, 2013). Topiramate is an anticonvulsant drug and approved for the 
prophylaxis of migraine headaches. It has shown substantial weight reduction in 
individuals with obesity but is not currently approved as a treatment for obesity (Garvey et 
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al., 2012). The US FDA in 2012 approved an extended-release topiramate and phentermine 
preparation (in one capsule) for adults having a BMI ≥27 kg/m2 along with at least one 
comorbidity related to obesity or a BMI ≥30 kg/m2 (e.g., dyslipidaemia, diabetes and 
hypertension) (Gadde et al., 2011). Such a combination was thought to increase the loss in 
weight in the initial year of use, as was demonstrated by the subsequent trials: 
 
In a CONQUER study (Gadde et al., 2011), the phentermine-topiramate combination and 
its controlled release (15/92 mg or 7.5/46 mg) was compared with the placebo in 2,487 
adults having a BMI of 27 to 45 kg/m2 and two or more comorbidities. After one year, the 
mean weight loss was -1.4 kg (95% CI -1.8 to -0.7 kg) in the placebo group, -8.1 kg (95% 
CI: -8.5 to -7.1 kg; p <0.0001) in the group given 7.5 mg of phentermine and 46 mg of 
topiramate and -10.2 kg (95% CI: -10.4 to -9.3; p <0.0001) in the group given 15 mg of 
phentermine and 92 mg of topiramate. Only 61% of the participants successfully 
completed the 1 year treatment, which raised questions regarding the outcomes of the trial. 
 
In the SEQUEL study (Garvey et al., 2012), which was a 52 week extension of the 
CONQUER study, around 676 (78%) of the participants participated in the trials. The 
results showed a significant mean weight loss than the placebo group (108 weeks of 
baseline data) with a loss of -2.1 kg, -9.6 kg, and -10.9 kg in the placebo, 7.5 mg 
phentermine / 46 mg topiramate, and 15 mg phentermine / 92 mg topiramate groups, 
respectively (p =0.0001). Hence, phentermine-topiramate treatment proved to be less 
effective in enhancing weight loss in the second year, but a number of participants were 
able to maintain the weight lost in one year.  
 
The combination of bupropion and naltrexone (Contrave®) was evaluated successfully in 
various clinical trials. Naltrexone is a pure opioid antagonist and bupropion is an 
antidepressant of a dopamine reuptake inhibitor. In a RCT including naltrexone and 
bupropion versus double placebo, the loss in weight was enhanced in individuals assigned 
to treatments given actively (with a mean weight change of -1.3% in the placebo group, -
6.1% in the naltrexone 32 mg/ bupropion group (p <0.0001) and -5.0% in the naltrexone 16 
mg / bupropion group (p <0.0001)) (Greenway et al, 2010).  
 
Lorcaserin (Belviq®) also known as Lorqess is an optional treatment with an efficacy that 
is comparable to orlistat. It was officially launched in the USA in June 2013 (Manning et 
al., 2014). It is a selective serotonin 2C receptor agonist that could be useful in reducing 
body weight. It causes less adverse effects when compared to orlistat but information on its 
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safety in the long-term is limited. In one a long running RCT 3,182 adults who are obese 
with a BMI of 30–45 kg/m2 or 27–45 kg/m2 and at least one weight related comorbidity 
were randomised to receive lorcaserin 10 mg twice daily or a placebo twice daily (Smith et 
al., 2010). These participants also took part in programmes on lifestyle adjustment related 
to exercise and nutritional counselling.  
 
The average weight loss was 5.8±0.2 kg in individuals taking lorcaserin and 2.2±0.1 kg in 
individuals taking the placebo during year 1 (p <0.001). In the second years, the placebo 
group patients continued to get the placebo, while the lorcaserin group patients were 
reassigned randomly to receive either the placebo or lorcaserin. In one year, the individuals 
receiving lorcaserin successfully lost 5% or more of their baseline body weight and the 
majority of the patients who had received lorcaserin during the 2 years maintained their 
loss in body weight (67.9 vs. 50.3%, p <0.001). After two years, the participants who had 
been reassigned to the placebo had gained the weight back.  
 
1.6.4 Surgical intervention  
Most individuals fail to reach their weight reduction goal only through lifestyle 
interventions, despite the fact that diet and physical activity are undoubtedly important in 
the treatment of obesity (Tuah et al., 2011). As reported by Douketis et al. (2005), 
individuals lost less than 5 kg after 2-4 years of dietary and lifestyle interventions, whereas 
the amount of weight lost after 1-2 years of medication-based treatment was 5-10 kg and 
the greatest weight reduction of 25-75 kg was achieved after 2-4 years as a result of 
surgery. Individuals with obesity can reduce their weight most effectively through bariatric 
surgery, including the Roux-en-Y gastric bypass (RYGB), adjustable gastric banding 
(AGB) and sleeve gastrectomy (SG) (Buchwald and Oien, 2009). In the case of the 
morbidly obese, biliopancreatic diversion is the optimal method of bariatric surgery (Smith 
et al., 2008); however, no one does this operation in the UK as it can be very dangerous.  
 
According to the SIGN guidelines (SIGN 115, 2010), bariatric surgery ought to be 
incorporated in a general clinical approach for weight management intended for adults. 
Following subject evaluation of risk-benefit, several conditions must be met by individuals 
to qualify for bariatric surgery, including: 
• BMI equal to or greater than 35 kg/m2. 
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• Development of at least one serious comorbidity (e.g. arthritis and type 2 diabetes) 
that could be significantly improved through weight loss. 
• Proof of completion of a weight management programme combining dieting, 
physical exercise, behavioural therapy, and medication-based treatment, but 
without success in alleviating comorbidities. 
 
O’Brien et al. (2006) conducted an RCT among 80 participants who had a BMI of 30-35 
kg/m2 and displayed morbidities associated with obesity. Results showed that, at 24 
months, greater weight reduction was achieved with the adjustable gastric banding than 
with an intensive intervention comprising diet, lifestyle changes and medication-based 
treatment (87.2% vs. 21.8%, p <0.001). In a different study, Dixon et al. (2008) reported 
that the greater weight reduction achieved through surgery contributed significantly to 
improvement of type 2 diabetes. At the 24-month follow-up of 60 individuals, the group 
assigned surgery had accomplished an average weight reduction of 20.7%, with 73% of 
individuals in this group achieving type 2 diabetes improvement. By contrast, the group 
assigned standard treatment achieved an average weight reduction of 1.7%, with 13% of 
the individuals in this group exhibiting type 2 diabetes improvement. Furthermore, 
Colquitt et al. (2005) also found that, at the 24-month follow-up, the likelihood of 
hypertriglyceridemia and low HDL cholesterol was more diminished as a result of bariatric 
surgery than as a result of the most effective non-surgical weight management programme. 
In their RCT conducted on 150 individuals, Schauer et al. (2012) confirmed that, at the 12-
month follow-up, the medical therapy group (-5.4±8.0 kg) had not achieved the level of 
weight reduction achieved by the gastric bypass (-29.4±9.0 kg) and the sleeve gastrectomy 
(-25.1±8.5 kg) groups. Moreover, the systematic review undertaken by Vest et al. (2012) 
indicated that bariatric surgery not only diminished risk factors associated with 
cardiovascular disease, but also improved left ventricular hypertrophy and diastolic 
function. 
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1.7 The impact of weight management services  
The NHS Commissioning Board issued recommendations on the clinical commissioning 
for specialised obesity surgery, which introduced different tiers of weight management 
services. Tier 1 usually covers universal services such as primary care; tier 2 includes 
lifestyle interventions; tier 3 covers specialist weight management programmes; and tier 4 
includes bariatric surgery (NHS Commissioning board, 2013). The NICE guidelines 
recommend multi-component lifestyle interventions, including diet, physical activity and 
behavioural change, as the treatments of choice for obesity (NICE, 2014).  
 
The NICE (2014) has recommended a number of programmes for obesity treatment that 
are offered by different health management agencies throughout the UK. To ensure value 
for money, programmes must produce long-term weight loss results rather than just 
temporary weight loss. However, the outcomes accomplished by different group-based 
projects available in the UK have not been long-lasting. A series of recommendations have 
been formulated by NICE (2014) for the local authorities responsible for liaising with 
clinical commissioning bodies, local healthcare providers, and health and wellbeing 
boards. Lifestyle change and health education are the focus of these recommendations and 
the active participation of health and medical professionals, including pharmacists, general 
practitioners (Jolly et al., 2011) as well as health visitors and community health officers, is 
advocated. Among the recommendations made are the implementation of a comprehensive 
strategy of obesity prevention and management. This would offer assurance of service 
safety, dissemination of information about local weight management programmes via the 
commissioners, introduce different strategies from health and social care practitioners to 
promote lifestyle intervention services, and disseminate information about available 
obesity and health management programmes. Such information would include the option 
of referral for individuals with overweight and obesity to the relevant health intervention 
programmes, and the promotion of practices and techniques to assist individuals to 
improve their motivation and adopt a more positive attitude towards healthy eating and a 
healthier lifestyle (Jebb et al., 2011).  
 
Numerous providers of weight management programmes exist in the UK and access to 
these programmes can be secured via the National Health Service (NHS) or commercial 
sources. Commercial weight management programmes require payment to provide 
assistance and help with weight loss. 
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A number of commercial weight management programmes are currently available in the 
UK, including Weight Watchers, Slimming World, and the Rosemary Conley programmes. 
These group-based programmes allow participants to join at any time. Each programme 
combines individual support with group discussion that is overseen by the programme 
leader. Generally, meetings last between 60 minutes to one and a half hours and are 
organised in community spaces. The whole structure of these programmes revolves around 
the reduction of energy intake by 600 kcals per day and to achieve a weekly weight 
reduction of 0.5-1 kg. In addition, these programmes include support to increase physical 
activity and behavioural modification. For every 3.2 kg lost and at the 5% and 10% of 
body weight loss target, the participants receive rewards. 
 
Most of the available evidence obtained to date has resulted from the evaluation of the tier 
2 weight management. However, the NHS Glasgow and Clyde Weight Management 
Service (GCWMS) is a tier 3 weight management service available in the UK that will be 
assessed in this study. The different studies that assessed various weight management 
programmes are listed in Table 1-5. Included are the studies conducted by Morrison et al. 
(2011) and Logue et al. (2014) that discussed the results of the GCWMS in 2011 and 2014, 
respectively. The search for these studies was conducted on 2 January 2017, and was 
limited to studies published between January 2007 and December 2016. Search terms such 
as weight management, weight loss, programme, tier 2, tier 3, obesity management, and 
intervention were applied to the Ovid database. A manual search was also conducted, and 
certain studies were included based on colleagues’ recommendations. 
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Study, Author and Year Study Population Methods and interventions Results 
1- Specialist health visitor-led weight 
management intervention in primary 
care: exploratory evaluation. 
(Jackson et al., 2007). (Tier 2). 
Individuals with a BMI ≥30 
kg/m2. 
Weight management clinic managed by specialist health 
visitors in the context of primary care. Collection of 
clinical outcome data and data about self-reported food 
intake was undertaken at weeks 1, 13, 27 and 52. 
Collection of quantitative and qualitative data regarding 
patients’ satisfaction with the clinic was undertaken at 
week 26. 
Clinic attendance included 89 individuals. In the long-term, there 
was a reduction in average body weight and BMI. About one in 
ten individuals had diabetes that was not diagnosed. There was a 
statistically significant reduction in the average self-reported 
intake of cakes, desserts and snacks and an increase in the intake 
of fruit and vegetables per week. The clinic was deemed highly 
satisfactory by the patients, and they considered that the 
contribution of the specialists health visitors as being especially 
valuable. 
2- Planning to lose weight: 
randomised controlled trial of an 
implementation intention prompt to 
enhance weight reduction among 
overweight and obese women. 
(Luszczynska et al., 2007). (Tier 2). 
Individuals in the age group 18-
76 years old, with a BMI greater 
than 25 kg/m2 were included. The 
average weight and average BMI 
were 89 kg and 33.3 kg/m2, 
respectively. 
The control and weight groups consisted of 29 and 27 
participants, respectively. The conditions involved 
watchers with implementation intention prompt (IIP) and 
the programme lasted for two months. 
Control: -2.1 kg 
(95% CI: 1.11-3.09), 
-2.4% 
 
IIP: -4.2 kg 
(95% CI: 3.19-5.07), 
-4.7% 
3- Evaluation of the Counterweight 
Programme for obesity management 
in primary care: a starting point for 
continuous improvement. 
(Counterweight Project Team, 
2008). (Tier 2). 
1906 individuals with BMI ≥30 
kg/m2 or BMI ≥28 kg/m2 and 
obesity-associated morbidities. 
Prospective appraisal of a novel ongoing improvement 
framework for weight management in the context of 
primary care. Weight change and proportion of 
individuals losing at least 5% of their body weight at one 
and two years represented the primary outcome measures. 
Average weight loss at one and two years was respectively -3.0 
kg (95% CI: -3.5 to -2.4 kg) among 642 individuals and -2.3 kg 
(95% CI: -3.2 to -1.4 kg) among 357 individuals. Weight loss of 
clinical significance was achieved and maintained with this 
intervention in the context of routine primary care. 
4- Process evaluation of an internet-
based resource for weight control: use 
and views of an obese sample. 
(MCconnon et al., 2009). (Tier 2). 
A number of 221 individuals 
from Leeds, UK, in the 18-65 
years age group and with a BMI 
≥30 kg/m2. They could access the 
Internet one or more times 
weekly and were English literate. 
Weight control website active for one year. Collection of 
data was undertaken at baseline, half a year and one year 
in the context of a community-based RCT and the data 
were used for questionnaire-based assessment. 
At half a year, 59 individuals (53%) indicated that they had used 
the website, while at one year, 32 of them (29%) stated website 
usage. Regarding promotion of favourable behaviour change for 
weight regulation, a marginally negative score was obtained. 
5- Evaluation of attendance and 
weight loss in an intensive weight 
management clinic compared to 
standard dietetic care. (Hickson et al., 
2009). (Tier 2). 
Individuals with obesity 
participating in an intense weight 
management clinic (IWMC) or a 
general dietetic outpatient clinic. 
Collection of data was undertaken from consecutive 
individuals suffering from obesity who participated in an 
IWMC or general dietetic outpatient clinic. 
There was no significant difference between clinics in terms of 
weight loss rate. The intensive clinic achieved an average weight 
loss of 1.8% as indicated by the final recorded weight, whereas 
the general clinic did not achieve any overall weight loss. 
6- Primary care referral to a 
commercial provider for weight loss 
treatment versus standard care: a 
randomised controlled trial (Lancet), 
772 individuals (668 female and 
104 male) 18 years of age or 
older with a BMI of 27-35 kg/m2. 
Average weight and average BMI 
Primary care practices situated in Germany, Australia and 
the UK. The commercial Weight Watchers programme 
and standard care involved 378 and 395 participants, 
respectively, and lasted for one year. 
Weight loss achieved in the commercial programme and standard 
care was -5.06 kg (-5.8%) and -2.25 kg (-2.6%), respectively (p 
<0.0001). 
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(Jebb et al., 2011). (Tier 2). were 86.7 kg and 31.4 kg/m2, 
respectively. 
7- Comparison of range of 
commercial or primary care led 
weight reduction programmes with 
minimal intervention control for 
weight loss in obesity: Lighten Up 
randomised controlled trial. (Jolly et 
al., 2011). (Tier 2).  
740 participants (495 female and 
245 male) were all 18 years of 
age or older. 
Caucasian Europeans, regardless 
of ethnicity, had a BMI ≥28 
kg/m2 with comorbidities or BMI 
≥30 kg/m2 without comorbidities. 
South Asians had BMI ≥23 kg/m2 
with comorbidities or BMI ≥25 
kg/m2 without comorbidities. 
Average weight and average BMI 
were 93.3kg and 33.6 kg/m2, 
respectively. 
Interventions took place at 17 primary care practices in 
South Birmingham, England. The programmes Weight 
Watchers (WW), Slimming World (SW), Rosemary 
Conley (RC), Size Down (SD), and Choice and 
Comparator (C) all had 100 participants each. The general 
practice (GP) and pharmacy (P) groups each included 70 
participants. 
 
The interventions lasted for three months. 
 
WW: -4.4 kg (95% CI: 3.6 to 5.3), -4.7% 
SW: -3.6 kg (95% CI: 2.7 to 4.4), -3.8% 
RC: a -4.2 kg (95% CI: 3.2 to 5.2), -4.5% 
SD: -2.4 kg (95% CI: 1.7 to 3.1), -2.5% 
Choice: -3.3 kg (95% CI: 2.5 to 4.1), -3.6% 
C: -2 kg (95% CI: 1.2 to 2.8), -2.1% 
GP: -1.4 kg (95% CI: 0.4 to 2.3), -1.5% 
P: -2.1 kg (95% CI: 1.0 to 3.2), -2.3% 
8- Weight Watchers on prescription: 
An observational study of weight 
change among adults referred to 
Weight Watchers by the NHS. (Ahem 
et al., 2011). (Tier 2). 
29,560 individuals enrolling in 
the Weight Watchers programme 
during 2 April – 6 October 2009 
via the Weight Watchers NHS 
Referral Scheme. 
Observational study for the purpose of measuring weight 
loss upon completion of twelve sessions. Medians and 
inter-quartile ranges (IQR) were used to represent the 
data. 
The median weight change among the participants was -2.8 kg 
[IQR -5.9 - -0.7 kg]. A weight reduction ≥5% was achieved by 
33% of all course, while a minimum of 5% weight loss was 
accomplished by 57% of participants who completed the 
programme. 
9- Evaluation of the first phase of a 
specialist weight management 
programme in the UK National 
Health Service: prospective cohort 
study. (Morrison et al., 2011). (Tier 
3, NHS). 
Individuals with BMI ≥35 kg/m2 
or BMI ≥30 kg/m2 with 
comorbidities who had received 
referral to the GCWMS during 
the period 2004-2006. 
 
The specialist weight management programme GCWMS 
To estimate probability of weight loss ≥5 kg in all 
participants and those who completed the programme as 
well as the probability of completion (95% confidence 
intervals), multiple logistic regression analysis was 
applied in a prospective cohort study. 
Weight loss ≥5 kg was achieved by 35.5% of the 809 participants 
who completed the programme. Men 40 years of age or older, 
with a BMI ≥50 kg/m2 and suffering from depression were more 
likely to lose ≥5 kg. Factors detrimental to weight loss were 
diabetes mellitus and low socioeconomic status. Participants 40 
years of age or older, with a BMI ≥50 kg/m2 were also more 
likely to complete the programme. Participants of low 
socioeconomic status were less likely to continue with the 
programme until the end, hence their probability of losing ≥5kg 
was limited. 
10- Attendance and weight outcomes 
in 4754 adults referred over 6 months 
to a primary care/commercial weight 
management partnership scheme. 
(Stubbs et al., 2012). (Tier 2). 
575 male and 4,179 female 
participants enrolled in a 
Slimming World programme via 
referral scheme during the period 
May 2004-November 2009. 
The Slimming World programme consisted of 24 weekly 
sessions. 
 
Male participants lost more weight than female participants (p < 
0.001). A weight reduction of 5% or more was achieved by 
74.5% of the total number of participants and by 79.3% of 
participants who attended at least 20 sessions. A 10% weight 
reduction was achieved by 37.3% of the total number of 
participants. 
11- Weight loss and dropout during a 
commercial weight-loss program 
including a very-low-calorie diet 
(VLCD), a low-calorie diet (LCD), or 
9,037 participants joined the Itrim 
weight loss programme during 
the period 1 January 2006 – 31 
May 2009. 
Observational cohort study that established a correlation 
between commercial weight loss data and the National 
Health Care Registers. Participants were allocated to three 
groups: VLCD =500 kcal formula, LCD =1200-1500 kcal 
The VLCD, LCD and restricted normal diet groups achieved a 
weight loss of 11.4 kg, 6.8 kg, and 5.1 kg, respectively, at twelve 
months. Participants were more likely to withdraw from the 
programme if they were younger and did not lose much weight 
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restricted normal food: observational 
cohort study. (Hemmingsson et al., 
2012). (Tier 2). 
formula and restricted normal diet =1500-1800 kcal/day. initially (p =0.001). 
12- Outcomes of a specialist weight 
management programme in the UK 
National Health Service: prospective 
study of 1838 patients. (Logue et al., 
2014). (Tier 3, NHS). 
Individuals with BMI ≥35 kg/m2 
or BMI ≥30 kg/m2 with 
comorbidities who were referred 
to the GCWMS during 2008-
2009 
 
Structural educational lifestyle programme combining 
cognitive behavioural therapy, 600 kcal reduction per day, 
physical activity instructions, hypocaloric diet and 
medication-based treatment. 
The prospective observational study employed LOCF and 
BOCF to report average weight loss of 5 kg and 5% 
weight reduction for all participants and those who 
completed phase 1, phase 1+2 and phase 1+2+3. 
The proportions of participants who lost ≥5 kg by the end of 
phase 1, phase 2, and phase 3, respectively, were 26%, 30%, and 
28%. Male participants, especially those who were 29 years of 
age or younger, lost a greater amount of weight. 
13- A community pharmacy weight 
management programme: an 
evaluation of effectiveness. 
(Morrison et al., 2013). (Tier 2). 
Participants were selected from 
among individuals living in Fife 
region, Scotland, with a BMI ≥30 
kg/m2 or a BMI ≥28 kg/m2 with 
comorbidity, who did not have 
access to the Counterweight 
programme via GP practices. 
 
Community pharmacies that had received training and 
relevant materials from Counterweight consultants 
provided the Counterweight programme. During each 
session, pharmacy personnel weighed each participant, 
and the documented weight data enabled estimation of 
weight loss and attendance at 3, 6, and 12 months. 
A weight reduction ≥5% was accomplished by 32 of the 314 
participants (41.6%, 4.1 kg average weight reduction) who 
attended the programme for a minimum of one year. Application 
of the Last Observation Carried Forward indicated that, within a 
year of joining the programme, the target weight reduction was 
accomplished by 15.9% of participants 
14- Evaluation of a multidisciplinary 
Tier 3 weight management service for 
adults with morbid obesity, or obesity 
and comorbidities, based in primary 
care. Fakenham. (Jennings et al., 
2014). (Tier 3, NHS). 
 
230 individuals 18 years of age or 
older with BMI ≥40 kg/m2 or 
BMI ≥30 kg/m2 comorbidity. 
The purpose of the cohort study was to assess the FWMS. 
The goal was to achieve 5% weight loss at one year for all 
participants and 5% weight loss at half a year for 50% of 
participants. 
Of the 170 participants whose weight was measured at one year, 
weight reduction of ≥5% was achieved at three months by 25.2% 
of them, at six months by 44.1%, at nine months by 59.1%, and 
at one year by 60%. Programme completion was achieved by 117 
participants, and of these, weight reduction >5% was achieve at 
three months by 34.2%, at six months by 53.8%, at nine months 
by 65.8%, and at one year by 72.6%. 
15- Evaluation of the 'Live Life 
Better Service', a community-based 
weight management service, for 
morbidly obese patients. (Wallace et 
al., 2016). (Tier 2). 
Individuals living in Derbyshire, 
UK, who were morbidly obese, 
with BMI >40 kg/m2 or BMI ≥35 
kg/m2 with comorbidities. 
Mean weight loss was calculated based on a one-group 
pre-post design. Measurements were conducted at 
baseline, 12 weeks, 24 weeks, 12 months, 18 months and 
24 months, and the paired sample t-test gave the 
significance (p ≤0.05). 
Participants who were committed to the programme achieved a 
weight reduction of statistical significance at 3 months and 24 
months of 4.9 kg and 18.2 kg, respectively. 
16- An evaluation of a multi-
component adult weight management 
on referral intervention in a 
community setting. (Birnie et al., 
2016). (Tier 2). 
559 individuals 18 years of age or 
older, living in South 
Gloucestershire, UK, with a BMI 
≥30 kg/m2 or BMI ≥28 kg/m2 
with comorbidities. 
A community-based multidimensional weight 
management programme for adults lasting for three 
months and combining diet Weight Watchers (WW), 
physical activity (Exercise on Prescription, EOP) and 
behavioural change (motivational interviewing). 
 
Average weight reduction was 3.7 kg, the greater amount of 
weight (5.9 kg on average) being lost by participants who 
completed the programme. These participants achieved 5% 
weight reduction in a greater proportion (58%) than those who 
did not complete the programme (19%) and those who followed 
only the WW or EOP component (19%). 
Table 1-5 Studies evaluating different weight management programmes.
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1.7.1 Tier 2 weight management programme 
Developed on the theoretical framework of Evidence-Based Quality Assessment, the 
Counterweight programme is a weight management programme that is intended for people 
with obesity and delivered within primary care settings by trained primary care and 
pharmacy support personnel. There are four stages to this programme, namely, practice 
audit, evaluation of needs, practice support and training, and practice patient intervention 
and assessment led by nurses (Laws, 2004). The programme is managed by weight 
management consultants and dieticians, who provide expert support for obesity 
management, relevant materials, as well as training for nursing staff from 65 general 
practices in the UK. Patient education based on published materials is provided by practice 
nurses over the course of nine sessions spanning one year following the preliminary 
screening. The first-line interventions consist of six one-to-one sessions of up to half an 
hour long focusing on the formulation of a customised eating plan or six group sessions 
lasting 60 minutes each, which are organised over a period of 3 months and focus on the 
setting of goals. Follow-up is undertaken at 6, 9, 12, and 24 months, with the overall goal 
being reduction of food intake by more than 500 kcal a day. 
 
The programme targets individuals with a BMI ≥30 kg/m2 or with a BMI ≥28 kg/m2 and a 
comorbidity. The established weight loss goal over nine sessions spanning one year is 
more than 5% of body weight. A proportion of 31% of participants achieve this weight loss 
goal, having started from an average BMI of 37 kg/m2. Hence, by comparison to 
participants who do not complete the programme, those that do have a greater likelihood of 
attaining a clinically significant weight reduction of 5% or more. Programme completion 
requires attendance to at least four sessions over three months, at least five sessions over 
half a year or at least six sessions over a year. 
 
A comparison of the weight reduction results achieved after one year by the Weight 
Watchers programme and standard GP care was undertaken across the UK, Australia and 
Germany. The participants were all 18 years of age and older and had a BMI of 27-35 
kg/m2 and one or more risk factors for comorbidities (Jebb et al., 2011). At baseline, the 
average BMI was 31 kg/m2 and a weight reduction equal to or greater than 5% was 
attained by a proportion of 60% of the participants who completed the programme 
(McCombie et al., 2012).  
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Jolly et al. (2011) reported on the Lighten Up study, which included participants recruited 
via welcome letters distributed by GPs. These participants were randomly allocated to one 
of three commercial programmes, namely, Weight Watchers, Slimming World or the 
Rosemary Conley programme, or were alternatively allocated to a weight management 
programme delivered by the NHS. At baseline, the average BMI in this study was 33.8 
kg/m2 and the primary results were delivered upon completion of the first three months, 
while the achieved weight reduction was reported at the end of 12 months. Ethnicity and 
occurrence of comorbidities were the criteria applied to recruit participants. Participants 
without comorbidity were selected if their BMI was ≥30 kg/m2, while participants of South 
Asian ethnicity were recruited even if their BMI was lower. The findings implied that, out 
of the other commercial programmes and primary care interventions, the Weight Watchers 
programme was the only programme to lead to a weight reduction of clinical significance. 
More specifically, the primary care programme determined weight reduction in 15.7% of 
participants, while the Weight Watchers programme achieved weight reduction in 31% of 
participants. 
 
The importance of session attendance to successful weight loss was highlighted by the fact 
that the Weight Watchers programme had higher attendance rate when compared to the 
primary care programme. The studies differed in terms of how they reported the 
programme results, how they gathered data and how they addressed the issue of absent 
data. In the case of the Weight Watchers study, the average weight loss achieved by 
participants with overweight and obesity recruited via primary care services was reported 
at one year, while the Last Observation Carried Forward (LOCF) was employed to deal 
with absent data. On the other hand, in the case of the Lighten Up study, weight reduction 
was reported from baseline to programme completion and the final weight achieved was 
reported on the basis of participants’ self-reporting. 
 
Age, sex, deprivation and baseline weight are among the factors that can affect attendance 
or weight reduction in the context of group-based weight management programmes, 
therefore affecting the overall success of the programmes. However, Kim et al. (2007) did 
not find weight reduction to be affected by age (p =0.7), sex (p =0.3) or initial weight (p 
=0.7). By contrast, a study that assessed the Counterweight programme observed that a 
greater amount of weight was lost by individuals in the 35-44 year age group, which was 
of statistical significance (Counterweight Project Team, 2008). The study further reported 
that the average amount of weight loss among women (-2.8 kg; 95% CI: -3.3 to -2.2 kg) 
was lower than the average amount lost by men (-3.4 kg; 95% CI: -4.5 to -2.3 kg). 
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Although observed difference was implied by the 95% CIs overlap, no statistical 
significance was obtained. In a different study, Lloyd and Khan (2011) examined the 
determinants of effective weight reduction achieved by individuals with a BMI equal to or 
greater than 28 kg/m2 who participated in the Healthy Choices Programme organised in 
Dorset, UK, during the period 1 October 2008 to 30 September 2009. Weight reduction 
greater than 5% was achieved by participants of 45 years of age or older and weight 
reduction was more successful among participants with a BMI of 30-34.9 kg/m2 (class I) 
that the other classes of overweight or obese individuals.   
 
The weight loss achieved by participants in the Counterweight programme provided by 
community pharmacies was examined by Morrison et al. (2011), who found that, at one 
year, by using the Baseline Observation Carried Forward (BOCF) the average weight 
reduction of 314 participants was 1.01 kg and about 10.2% of participants had lost 5% of 
body weight. By contrast, the findings of a Lighten Up study regarding the weight loss 
among participants in a weight management programme delivered by pharmacies indicated 
that, at one year, the average weight loss by using the BOCF was 1.19 kg and 14.3% of 
participants had lost 5% of their body weight. 
 
1.7.2 Tier 3 weight management programme 
In regards to tier 3 weight management services, individuals aged 18 years or older, with a 
BMI ≥40 kg/m2 or with a BMI ≥30 kg/m2 with comorbidity received referral from GPs or 
practice nurses for participation in a multidisciplinary tier 3 Fakenham weight management 
service (FWMS) delivered in primary care settings. The purpose of this programme was to 
achieve a weight reduction of 5% in all participants at one year and to achieve this 
reduction at half a year in the case of half of the participants. The Tier 3 interventions 
included are clinical evaluation, medication-based treatment, low-energy liquid diets 
(LELDs), psychological therapy and bariatric surgery (Jennings et al., 2014). The 
programme was twelve months long and the 17 patients recruited for the programme had 
been referred through the individual funding request (IFR) procedure, with the same 
intervention being applied over a period of half a year. The twelve-month programme 
encompassed 10-15 sessions, while the six-month programme comprised 9-15 sessions. 
Participants completing the full programme had an average BMI of 44.1 kg/m2, while the 
IFR participants had an average BMI of 49.9 kg/m2. At half a year, a weight loss of 5% 
was achieved by 44.1% of the full programme participants and by 53.8% of the 
completers, while at twelve months, 5% weight reduction was achieved by 60% of the full 
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programme participants and by 72.6% of the completers. Based on these results, the study 
confirmed that, by contrast to other services in primary care settings, a Tier 3 weight 
management programme was the most adequate for individuals who are obese with 
complex comorbidity. 
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1.8 The impact of anti-diabetic medication on weight change 
The main features of the metabolic disorder of type 2 diabetes mellitus are reduced 
sensitivity to insulin and gradually rising glucose levels due to the disruption of beta cell 
function. According to the WHO, diabetics usually display levels of fasting plasma glucose 
(FPG) equal to or greater than 7 mmol/l and levels of venous plasma ≥11.1 mmol/l at 120 
minutes following a glucose load comprising 75 g anhydrous glucose dissolved in water. 
 
The suggested cut-off point for diabetes diagnosis is 48 mmol/l HbA1c. Regulation of 
glucose as much as possible and prevention of macro- and micro-vascular complications 
are the major objectives of type 2 diabetes treatment (UKPDS, 1998). Blood glucose can 
be regulated with various types of drugs, some of which can cause weight reduction or 
weight gain (Hollander, 2007). The manner in which these drugs act is explained below. 
Biguanides: This class of drugs decreases glucose production and glycogenolysis by 
reducing the resistance of peripheral and hepatic tissues to insulin (Figure 1-3). 
 
SUs: This class of drugs binds to a particular SU receptor to stimulate pancreatic β cells to 
produce more insulin (Figure 1-3). As a result, the negative energy balance from 
glycosuria is reversed by glycaemic control, or else the levels of glucose in the blood are 
lowered, generating a feeling of hunger. 
 
Thiazolidinediones (TZDs): This class of drugs reduces the resistance of hepatic and 
peripheral tissue to insulin as a way of mediating its function (Figure 1-3). The rise in 
plasma volume determined by TZDs may lead to weight gain. 
 
Dipeptidyl peptidase-4 (DPP-4) inhibitors: This class of drugs suppresses the DPP-4 
enzyme and defers the breakdown of glucagon-like peptide-1 (GLP-1), thus prolonging the 
action of glucose-based insulin production. Inhibition of the discharge of pancreatic 
glucagon and decrease of hepatic glucose synthesis are also achieved by this class (Figure 
1-3).  
 
GLP-1: This class of drugs promotes insulin production, insulin gene expression and the 
maturation of pancreatic β cells, whilst also counteracting the incretin effect that causes 
insulin to be produced in larger quantities after glucose is orally administered (Bosenberg 
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and Van Zyl, 2008). Gastric emptying suppression or reduction of calorific intake through 
the central nervous system may occur, resulting in weight reduction. 
 
α-Glucosidase Inhibitors: This class of drugs suppresses several gut enzymes, thereby 
deferring polysaccharide disintegration, and lowers the levels of postprandial glucose, 
which leads to a drop in postprandial concentrations of insulin (Bosenberg and Van Zyl, 
2008). Digestion of carbohydrates is suppressed and gastric emptying is postponed through 
GLP-1, which may result in weight reduction. 
 
 
Figure 1-3 Mechanism of action of biguanides, SUs, DPP-4 inhibitors 
and TZDs (plus=stimulation, minus=inhibition) (DeFronzo, 1999). 
“Reproduced from the American College of Physicians with permission”. 
License number: 4073791152037. 
 
Sodium/glucose co-transporter 2 inhibitors (SGLT2): A novel class of oral anti-diabetic 
medication that have been available since 2013; these drugs enhance elimination of urinary 
glucose without dependence on insulin production or activity, thereby lowering 
hyperglycaemia (Kim and Chung, 2014) (Figure 1-4). NHS Scotland has approved 
dapagliflozin for use in some type 2 diabetics and the US Food and Drug Administration 
(FDA) has approved the use of canagliflozin. By intensifying elimination of renal glucose, 
these drugs promote calorie consumption and hence may result in weight reduction (Van 
Gaal and Scheen, 2015). 
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Figure 1-4 Mechanism of action of SGLT2 (Kim and Chung, 
2014). “Reproduced from Springer with permission”. License 
number: 4060400726094. 
 
Individuals who are overweight or obese and have type 2 diabetes should be first and 
foremost prescribed anti-diabetic medication that either contributes to weight reduction or 
does not affect weight at all. The American Diabetes Association (ADA) and the European 
Society for the Study of Diabetes (EASD) have developed an algorithm for 
hyperglycaemia management in type 2 diabetics that gives due consideration to the impact 
of drugs on weight. According to the SIGN 116 (2010) and ADA/EASD (Inzucchi et al., 
2015) recommendations, if metformin proves inefficient in regulating glycaemia or is 
contraindicated for individuals with overweight and obesity, then GLP-1 and DPP-4 
inhibitors should be used (Bonora, 2007). By contrast, Hollander (2007) argued that 
glycaemic control rather than weight change should be the main priority of the algorithm 
for type 2 diabetes management. Weight is beneficially influenced by metformin, which is 
thus suggested as the first choice of medication to be prescribed for individuals with type 2 
diabetes. 
 
Metformin should be used together with insulin, SU or a TZD as a second stage in the 
management of type 2 diabetes, since every one of these drugs causes an increase in 
weight. On the other hand, weight is reduced or left unchanged by DPP-4 inhibitors and 
GLP-1 analogues (Phung et al., 2010). There is ample evidence in support of the fact that 
certain anti-diabetic medication can either increase or decrease weight. Phung et al. (2010) 
reviewed a series of RCTs and found that the use of SU together with metformin led to a 
1.99 kg (95% CI: 0.86 to 3.12 kg) weight increase in two trials, while the use of TZD with 
metformin led to weight increase of 2.30 kg (95% CI: 1.70 to 2.90 kg) in one trial. By 
contrast, four trials using DPP-4 inhibitors reported a weight loss of -0.09 kg (95% CI: -
0.47 to 0.30 kg), while two trials employing GLP-1 analogues obtained a weight reduction 
of -1.76 kg (95% CI: -2.90 to -0.62 kg). Furthermore, Kim and Chung (2014) reported 
considerable weight loss of 2.5 kg and 3.5 kg due to administration of canagliflozin in 100 
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and 300 mg concentration, respectively, during week 52 of treatment, which contrasted 
with the placebo. There was a big change on weight loss and cardiovascular outcomes 
when used empagliflozin in patients with type 2 diabetes. An earlier RCT (EMPA-REG 
OUTCOME trial) of 7,020 participants with type 2 diabetes and a BMI ≤45 kg/m2 were 
randomly assigned to receive 10 mg or 25 mg of empagliflozin or a placebo once a day. 
All the participants had experienced CVD. After 3 years, there was a significant lower rate 
of death from cardiovascular causes (3.7%) in the empagliflozin group when compared 
with the placebo group (5.9%) and lower rate of hospitalisation for heart failure (2.7% vs. 
4.1%, respectively) (Zinman et al., 2015). 
 
Domecq et al. (2015) systematically reviewed 257 RCTs and conducted a meta-analysis to 
explore the correlation between commonplace medication and weight change. They found 
that pioglitazone and gliclazide increased weight by 2.6 kg and 1.8 kg, respectively. On the 
other hand, metformin, acarbose, liraglutide and exenatide reduced weight by 1.1 kg, 0.4 
kg, 1.7 kg, and 1.2 kg, respectively. In the SCALE diabetes RCT (Davies et al., 2015) that 
was conducted in 9 countries, from June 2011 to January 2013, to assess the efficacy of 
liraglutide for weight loss among people with type 2 diabetes, 211 participants received 1.8 
mg liraglutide (diabetes dose) and 212 patients received a placebo. All the patients were 
put on a 500 kcal/d deficit diet and ≥150 min/week exercise regime. At week 56, the mean 
weight loss in the liraglutide group and the placebo group was -5.0 kg and -2.2 kg, 
respectively (the estimated weight difference between the two groups was -2.8 kg). 
 
Marre et al. (2009) carried out a double-blind RCT among 1,041 participants from 21 
European and Asian countries, with average age and average weight of 56 years old and 82 
kg, respectively. They were allocated to different groups that were given 2-4 mg/day 
glimepiride alongside 0.6, 1.2, or 1.8 mg of liraglutide, or else that were given placebo or 
rosiglitazone over a period of 26 weeks. Upon trial completion, liraglutide in 1.8 mg dose 
and placebo resulted in an average weight reduction of 0.2 kg and 0.1 kg, respectively (p 
<0.05). There was statistical significance (p <0.0001) to the difference between liraglutide 
(-0.2 kg) and rosiglitazone (+2.1 kg). 
 
To sum up, on the basis of the results of the RCTs outlined above it can be concluded that 
some anti-diabetic drugs, such as drugs falling within the SUs and TZDs groups, might 
cause weight gain. Other group of drugs, such as metformin or GLP-1 and SGLT2 group 
drugs, might cause weight loss or not affect weight at all. 
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1.9 Summary of the introduction 
Obesity is characterised by excessive body fat accumulation, mainly caused by increased 
calories intake and reduced energy expenditure. Genetic and lifestyle factors are the most 
important factors that play a role in the development of obesity. BMI is the most 
commonly used measure of obesity; it is easily measured and understood by the patient 
population. Obesity prevalence is rapidly increasing worldwide, in developed and 
developing countries. Worldwide, around 1.4 billion adults are overweight and more than 
500 million are obese. 2.8 million individuals are dying annually from complications 
related to being overweight or obese. In Scotland, about 61.9% of the adult population are 
overweight or obese, and 27% are obese. Obesity is associated with increased morbidity 
and mortality; however, moderate weight losses (5–10%) are associated with 
improvements in obesity-related cardiovascular and metabolic abnormalities. There are 
three interventions for obesity treatment, namely, lifestyle changes and physical activity, 
pharmacotherapy and surgery. The SIGN guidelines recommend that weight management 
programmes should include physical activity, dietary change and behavioural components 
and the use of pharmacotherapy if BMI ≥28 kg/m2 with comorbidities or BMI ≥30 kg/m2. 
The increasing the prevalence of obesity is associated with increase in the incidence of 
type 2 diabetes. Orlistat is the only drug that has been approved in the UK for use in 
obesity treatment, and its effectiveness on both weight loss and glycaemic control has been 
recently proven through a number of trials. Previous studies have suggested that a modest 
weight loss is associated with improvements in the status of type 2 diabetes. There are 
different classes of anti-diabetic medications that may improve glycaemic control; weight 
loss, weight gain and weight maintenance were vary between the different groups.  
 
2  
3  
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4 1.10 Aims and objectives 
The main evidence regarding the effect of orlistat has been compiled in the context of its 
application to patients without diabetes, although there have been several small to medium 
sized studies on the effect of orlistat in patients with type 2 diabetes. In this context, the 
first aim of my thesis is to review the evidence of the effect of orlistat on diabetic 
outcomes. 
 
There is limited published evidence on the effectiveness of interventions in weight 
management programmes; the second aim of my thesis is to use large samples from the 
GCWMS to evaluate the effectiveness of the weight management programmes available in 
the UK. 
 
There is a clear guideline (SIGN 115, 2010) for using anti-diabetic medications in patients 
suffering from obesity; the third aim of my thesis is to determine the anti-diabetic 
prescribing pattern and to investigate the relationship between anti-diabetic medications 
and weight change within the context of a weight management intervention. 
 
The thesis comprises five studies that address the following specific objectives: 
 
1. To undertake a systematic review and meta-analysis of published studies to review the 
evidence on the effects of orlistat on weight loss, HbA1c and FPG using the Cochrane 
reviews methodology. 
2. To investigate the proportion of patients losing 5 kg of weight starting from entry into 
the GCWMS programme until the end of lifestyle phase treatment for individuals of 
different ages, genders and socioeconomic groups. 
3. To study the proportion of patients losing 5 kg of weight starting from entry into the 
GCWMS programme until the end of phase 2 with three different interventions (orlistat, 
LDL and FWL). 
4. To investigate the proportion of patients referred to the GCWMS on weight-neutral, 
mixed and weight-gaining anti-diabetic medications. 
5. To investigate the effect of baseline anti-diabetic medications on weight change for 
patients within a weight management programme.  
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Chapter 2: Effect of orlistat on glycaemic 
control in overweight and obese patients 
with type 2 diabetes mellitus: A 
systematic review and meta-analysis of 
randomised controlled trials 
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2.1 Chapter summary 
Orlistat is an effective adjunctive treatment to support lifestyle modifications to treat 
obesity. While the majority of current evidence concerns the effect of orlistat in obese 
patients without diabetes, some studies suggest patients who are obese and have diabetes 
mellitus lose more weight and experience greater improvements in their diabetic outcomes 
when treated with orlistat in conjunction with a lifestyle intervention than when treated by 
lifestyle interventions alone. The aim of this study was to review evidence to reveal the 
effects of orlistat on glycaemic control in patients who are overweight or obese with type 2 
diabetes.  
 
It comprises a systematic review of randomised controlled trials of orlistat in people with 
type 2 diabetes reporting diabetic outcomes, in studies published between January 1990 
and September 2013. Articles published in English in MEDLINE and EMBASE were 
searched. Inclusion criteria included all randomised controlled trials of orlistat carried out 
on adult participants with a body mass index of 25 kg/m2 or above, diagnosed with type 2 
diabetes, and reporting weight change and at least one diabetic outcome.  
 
In total, 765 articles were identified, of which 12 fulfilled the inclusion criteria. The overall 
mean weight reduction (3, 6 and 12 months) in the orlistat group was -4.25 kg (95% CI: -
4.5 to -3.9 kg). The mean weight difference between the treatment and control groups was 
-2.10 kg (95% CI: -2.3 to -1.8 kg, p <0.001), the mean glycosylated haemoglobin (HbA1c) 
difference was -6.12 mmol/mol (95% CI: -10.3 to -1.9 mmol/mol, p <0.004), and the mean 
fasting plasma glucose (FPG) difference was -1.16 mmol/l (95% CI: -1.4 to -0.8 mmol/l, p 
<0.001).  
 
Treatment with orlistat combined with a lifestyle intervention resulted in significantly 
greater weight loss and better glycaemic control in patients who are overweight or obese 
with type 2 diabetes, than lifestyle intervention alone. 
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2.2 Introduction 
Estimates suggest that by 2015, approximately 2.3 billion adults will be overweight, and at 
least 700 million will be obese (WHO, 2014b). Obesity is causally associated with multiple 
metabolic abnormalities including type 2 diabetes mellitus (Birks et al., 2012). The World 
Health Organization reports that more than 347 million people worldwide suffer from 
diabetes, and of these most are overweight or obese. It is thought that in 2005, 
approximately 3.4 million people died from diabetes, and this number is predicted to 
double by 2030 (WHO, 2014a). Some researchers have also suggested that up to two out of 
every three cases of type 2 diabetes result from obesity (Davidson et al., 1999). 
Specifically, type 2 diabetes has most commonly been associated with obesity and 
advancing age; it is characterised by insulin resistance, relative insulin deficiency and 
gestational diabetes (American Diabetes Association, 2010). Thus, to improve blood 
glucose control, the preferred standard recommendation for care is weight loss (American 
Diabetes Association, 2010; SIGN 116, 2010). 
 
Orlistat (tetrahydrolipstatin) is a pancreatic and gastric lipase inhibitor, whose primary 
effect is to reduce the absorption of fat and therefore calories. Long term use has been 
linked to reductions in blood pressure (Siebenhofer et al., 2013). It is one of the few 
pharmacologic treatment options available to assist patients with type 2 diabetes in 
reducing their body weight to improve glycaemic control (Yanovski and Yanovski, 2002). 
Orlistat works by partially inhibiting the hydrolysis of triglycerides, thereby reducing the 
absorption of monoglycerides and free fatty acids. Orlistat is minimally absorbed into the 
circulation because of its lipophilic nature. After ingestion of 360 mg of orlistat, only <2% 
is expelled in urine and approximately 97% in stool. The half-life of orlistat is 14-19 hrs, 
thus most of the drug is excreted unchanged (Zhi et al., 1996).  
 
As discussed in Chapter 1 (page 56-58), the beneficial effects of orlistat on both weight 
loss and blood glucose have recently been proven through a number of trials. As stated 
above, there is evidence that orlistat in addition to lifestyle change achieves greater weight 
loss than lifestyle change alone (Jindal et al., 2012). Weight loss might also reduce the risk 
of developing diabetes (Stevens et al., 2015). While several RCTs have been carried out to 
describe changes in glycaemic control among patients who are obese treated with orlistat, 
the majority have only sampled a small number of individuals, and therefore the findings 
lack sufficient statistical power.  
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To the best of our knowledge, no previous attempts have been made to systematically 
review and synthesise the results of these trials.  
 
Importantly, no serious adverse effects have been reported during orlistat treatment, and 
there have been no indications that it affects gastric or pancreatic secretion, or gastric 
emptying time. A short-term study claimed that orlistat results in several mild adverse 
effects on the gastrointestinal system (Kaya et al., 2004). These adverse effects include 
diarrhoea, faecal incontinence, flatulence and oily spotting. They are typically mild, with 
over 50% of cases lasting <1week in duration and the majority confined to the first year of 
treatment (80%) (Aronne, 1998). However, it is thought that orlistat might increase the 
chance of gallstones forming, due to the reduction in meal related contraction of 
gallbladder (Hopman et al., 1984).  
 
The Canadian Diabetes Association clinical practice guidelines highlight that the addition 
of orlistat for 1 year in patients who are overweight or obese (BMI =28-40 kg/m2) with 
type 2 diabetes, being treated with other anti-hyperglycaemic agents or insulin, results in a 
decrease in body weight and improved HbA1c (Cheng and Fantus, 2005). In addition, a 
European evidence-based guideline recommends that for patients who are obese with or 
without impaired glucose tolerance, orlistat in addition to lifestyle changes can be used as a 
second line strategy to prevent type 2 diabetes (Paulweber et al., 2010). Moreover, SIGN 
guidelines on the management of diabetes considered pharmacotherapy as an adjunct to 
lifestyle interventions, such as encouraging weight loss for patients with obesity and type 2 
diabetes to improve their metabolic control (SIGN 116, 2010).   
 
The aim of this research, therefore, was to systematically review the evidence from RCTs 
on the effects of orlistat in weight loss and type 2 diabetes, such as HbA1c and FPG, for 
people who are overweight or obese, and to combine the results using meta-analysis. 
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2.3 Materials and methods: 
2.3.1 Systematic review 
A systematic review of RCTs published between January 1990 and September 2013 was 
performed. The relevant search terms were applied to EMBASE and MEDLINE databases 
as follows: 
 
• Obes* OR overweight OR BMI OR body mass index OR hyperphagia OR            
adipose tissue OR fat 
• Diabet* OR diabetes mellitus OR NIDDM OR non-insulin dependent 
diabetes OR DM        
• Orlistat OR xenical OR alli 
The search was performed on 30 September 2013, and was limited to studies on human 
subjects and articles written in English.  
 
Inclusion criteria 
The inclusion criteria were as follows:  
• Participants with BMI greater than or equal to 25 kg/m2  
• Diagnosed with type 2 diabetes  
• Using orlistat at the time of the study 
Studies with patients with BMIs of 25 or greater were included, on the assumption that 
their weight was considered a clinical problem requiring treatment with orlistat. In 
addition, the inclusion criteria encompassed studies with these outcomes:  
• BMI or weight (kg) 
• HbA1c or FPG 
Participant criteria included: 
• Adults ≥18 years  
• Both sexes  
All the completed RCTs included assessed the effects of orlistat plus lifestyle change 
versus a lifestyle-control group. Those reporting at least one diabetic outcome (HbA1c or 
FPG) were considered eligible trials. In addition, a comparison between the two groups 
was performed as follows:  
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a) Lifestyle intervention + orlistat VS Lifestyle intervention 
b) Lifestyle intervention + orlistat VS Lifestyle intervention + placebo. 
 
The extracted journal articles were all scanned using the Cochrane reviews methodology in 
three stages by two independent authors (having attended a systematic review and meta-
analysis of health research course at London School of Hygiene and Tropical Medicine 
from 2nd to 6th September 2013). Any disagreements were resolved by discussion. The 
articles were initially identified by scanning the title and abstract; in cases where they still 
appeared to be relevant, then the complete article was then examined. All final decisions 
were derived according to a standardised approach, applying study selection criteria 
outlined above. The risk of bias in the trials was reduced by assessing the trial quality, 
including the quality of the sequence generation and random allocation concealment, the 
blinding of outcome assessors, evidence of incomplete outcome data and any selective 
reporting of outcomes (Higgins et al., 2008).   
 
The Data were extracted from each study and reported according to Preferred Reporting 
Items for Systematic Review and Meta-Analysis (PRISMA) guidelines (Moher et al., 
2010). A matrix table of study characteristics was produced, and from this relevant 
information was extracted by two independent authors. The information included author, 
year of publication, publication country, age and sex of participants, follow-up duration, 
sample size, type of intervention, baseline for outcomes, outcomes results, and the 
differences between the baseline and results for each group of participants. The authors of 
the studies were contacted in some instances where necessary to provide additional 
information not included in the published papers. 
 
2.3.2 Meta-analysis 
A random effects meta-analysis was undertaken to resolve of the differences in study 
designs and locations. The effect size of the mean weight, HbA1c and FPG differences 
between orlistat and the control groups was analysed. I-squared statistics were calculated 
to determine the degree of heterogeneity, and the association between weight change and 
HbA1c change examined using a simple linear regression. All the statistical analyses were 
performed using Stata version 12.1 (StataCorp, College Station, Texas). 
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2.4 Results 
The search identified 765 potentially eligible citations, of which 453 were excluded 
because they were duplicates (Figure 2-1). After reviewing the titles and the abstracts of 
the 312 articles, 35 were still considered relevant and the full articles were obtained. Of the 
35 articles, 14 fulfilled the inclusion criteria. Two studies (Hollander et al., 1998; Derosa et 
al., 2012) did not provide necessary information required for the meta-analysis within the 
publications. Contact was attempted with the corresponding authors by both email and 
phone to retrieve this additional information, but no response was received. One of these 
studies (Hollander et al., 1998) had previously been provided for a meta-analysis for the 
National Institute for Health Research (NIHR) (Avenell et al., 2004); however, the authors 
of the meta-analysis no longer held the additional data [personal communication]. The 
final 12 trials published between 2002 and 2010 were selected (Table 2-1). All the studies 
were RCTs; one study was only involved female participants (Kuo et al., 2006), but the 
remainder included both sexes.  
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        Figure 2-1 Search strategy for RCTs on glycaemic outcomes among patients with 
overweight and obesity treated with orlistat. 
 
N of records 
screened N=312 
 
 N of records excluded 
N= 144 (review) 
N=111 (by title) 
    N=22 (by abstract) 
N of records after duplicates and 
limit to 1990-current 
N=312 
N of records identified through 
database (Medline, EMBASE) 
N=765 
 
N of full-text articles 
assessed for 
eligibility 
N= 35 
N of studies 
included  
N=12 
N of full-text articles excluded, with 
reasons 
N = 9 Due to not matching    
inclusion criteria 
N = 9 removed due to lack of HbA1c 
and FPG 
N = 3 review articles 
N = 2 author did not respond to 
queries (lack of outcome data) 
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Author/ Year Country Age range Sex Duration N 
Mean BMI (SD) at baseline kg/m2 Dropout rate (N) 
      Orlistat                   Control Orlistat      Control 
P. Kopelman/2009 UK 18-65 M/F 3 months 250 35.0 (±4.1) 34.0 (±4.1) 4 7 
C. Kuo/2006 Taiwan - F 3 months 60 27.2 (±1.1) 26.9 (±0.9) No No 
C. Berne/2005 Sweden 30-75 M/F 12 months 220 32.6 (±3.1) 32.9 (±3.0) 15 17 
T.P. Didangelos/2004 Greece 30-72 M/F 6 months       126                      - - No No 
B. Guy-Grand/2004  France 18-65 M/F 6 months 193 33.8 (±0.3) 33.5 (±0.4) No No 
Kelley/2004 US - M/F 6 months 52 34.0 (±5.0) 35.9 (±5.0) 9 4 
M. Hanefeld/2002 Germany 18-70 M/F 12 months 383 34.5 (±5.6) 33.7 (±5.2) 6 8 
J.M. Miles/2002 US 40-65 M/F 12 months 504 35.6 (±4.7) 35.2 (±3.1) 90 115 
A. Halpern/2003 Brazil 18-70 M/F 6 months 338 34.6 (±0.8) 34.5 (±0.9) 25 33 
D.E. Kelley/2002 US 40-65 M/F 12 months 550 35.8 (±4.9) 35.6 (±4.1) 137 148 
G. Cocco/2005 Switzerland ≥35 M/F 6 months 90 36.5 (±1.9) 36.0 (±1.8) No No 
M.F. Pathan/2004 Bangladesh 40-65 M/F 6 months 36 31.6 (±3.5) 29.8 (±3.2) No No 
Table 2-1 Baseline characteristics and dropout rate of included studies (F: Female; M: Male; N: number; SD: Standard deviation).  
87 
The number of participants ranged from 36 to 550, providing a total 2,802 participants. 
Three (25%) of the studies had been conducted in United States (Kelley et al., 2004; Miles 
et al., 2002; Kelley et al., 2002), one (8.3%) in the United Kingdom (Kopelman et al., 
2009), one (8.3%) in Taiwan (Kuo et al., 2006), one (8.3%) in Sweden (Berne and Orlistat 
Swedish Type 2 diabetes study, 2005), one (8.3%) in Greece (Didangelos et al., 2004), one 
(8.3%) in France (Guy-Grand et al., 2004), one (8.3%) in Germany (Hanefeld and Sachse, 
2002), one (8.3%) in Brazil (Halpern et al., 2003), one (8.3%) in Switzerland (Cocco et al., 
2005), and one (8.3%) in Bangladesh (Pathan et al., 2004) (Table 2-1). The youngest 
participants were 18 and the oldest 75 years, with multiple age ranges tested in most 
studies. The trials varied in duration between 3 and 12 months. Ten studies (83.3%) 
included participants taking hypoglycaemic agents, but two (16.6%) did not (Kelley et al., 
2004; Hanefeld and Sachse, 2002). Details of the interventions and outcomes are apparent 
in Table 2-2. 
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Author/ 
Year 
Intervention/ dose  Baseline Results (primary end point) Difference (primary end point) 
 
a) Orlistat b) Control pa 
Wt. 
(Kg) 
HbA1c 
(%) & 
mmol/mol 
FPG 
mmol/l 
N Wt. (Kg) 
HbA1c 
(%) & 
mmol/mol 
FPG 
mmol/l 
Wt. 
(Kg) 
HbA1 (%) 
& 
mmol/mol 
FPG 
mmol/l 
1) P. Kopelman/ 2009 Orlistat 360mg+hd+rf 
(N=124) 
hd +rf + placebo (N=126) NO 
 
a) 101 
b) 98 
7.2/55 
7.2/55 
 a) 120 
b) 119 
97.22 
95.14 
6.67/49 
6.83/51 
 -3.78 
-2.86 
-0.53/-6 
-0.37/-4 
 
2) C. Kuo/2006 Orlistat 360mg+hd 
(N=30) 
hd + placebo (N=30) 
 
NO 
 
a) 76.8 
b) 78.3 
9.8/84 
9.6/81 
11.2 
12.1 
a) 30 
b) 30 
74.3 
77.9 
8.1/65 
9.4/79 
7.8 
11.2 
-2.5 
-0.4 
-1.7/-19 
-0.2/-2 
-3.40 
-0.9 
3) C. Berne/2005 Orlistat360mg+hd+rf+ 
pa (N=111) 
hd +rf +pa+ placebo 
(N=109) YES 
a) 95.3 
b) 95.7 
7.6/60 
7.6/60 
11.2 
10.9 
a) 96 
b) 92 
90.54 
93.98 
6.5/48 
7.38/56 
9.3 
10.64 
-4.76 
-1.72 
-1.1/-12 
-0.22/-4 
-1.9 
-0.26 
4) T.P. Didangelos/2004 Orlistat 360mg+hd+pa 
(N=94) 
 
hd+pa (N=32) 
 
 
YES a) 93.4 b) 87.3 
 
8.0/64 
7.9/63 
 
10.0 
9.7 
 
a) 94 
b) 32 
87.8 
83.4 
 
6.4/46 
7.1/54 
 
7.5 
9.6 
 
-5.6 
-3.9 
-1.6 /-18 
-0.8/-9 
-2.5 
-0.1 
5) B. Guy-Grand/2004  Orlistat 360mg+hd+rf 
(N=97) 
hd +rf + placebo (N=96) 
 
NO 
 
a) 94.3 
b) 91.3 
7.6/60 
7.7/61 
9.9 
10.6 
a) 97 
b) 96 
90.4 
90.0 
7.1/54 
7.6/60 
8.51 
10.1 
-3.9 
-1.3 
-0.54/-6 
0.18/-1 
-1.39 
-0.50 
6) Kelley/2004 Orlistat 360mg+hd+rf+pa 
(N=26) 
 
hd +rf+pa + placebo(N=26) YES 
 
a) 99.0 
b)102.0 
8.13/65 
7.82/62 
10.87 
8.77 
a) 17 
b) 22 
87.0 
92.0 
6.48/46 
6.85/51 
6.82 
6.99 
-10.1 
-9.4 
-1.65/-19 
-0.97/-11 
-4.05 
-1.78 
7) M. Hanefeld/2002 Orlistat 360mg+hd+rf 
(N=195) 
hd +rf + placebo (N=188) 
 
 NO 
 
a) 99.4 
b) 98.4 
8.6/70 
8.6/70 
10.95 
10.95 
a) 189 
b) 180 
94.1 
95.0 
7.7/61 
8.1/65 
9.35 
10.25 
-5.3 
-3.4 
-1.1/-9 
- 1.0/-5 
-1.6 
-0.7 
8) J.M. Miles/2002 Orlistat 360mg+hd+rf +pa 
(N=250) 
hd +rf+pa + placebo 
(N=254) 
YES 
 
a)102.1 
b)101.1 
8.87/73 
8.79/72 
11.6 
11.1 
a) 160 
b) 139 
97.4 
99.3 
8.12/65 
8.38/67 
9.6 
10.4 
-4.7 
-1.8 
-0.75/-8 
-0.41/-5 
-2.0 
- 0.7 
9) A. Halpern/2003 Orlistat 360mg+hd+rf +pa 
(N=164) 
hd+rf+pa +placebo (N=174)  
YES 
a) 89.7 
b) 89.5 
8.37/67 
8.49/68 
11.05 
11.50 
a) 139 
b) 141 
84.8 
86.4 
7.76/61 
8.27/66 
10.05 
11.49 
-4.24 
-2.58 
-0.61/-6 
-0.22/-2 
-1.00 
-0.01 
10) D.E. Kelley/2002 Orlistat 360mg+hd+rf +pa 
(N=274) 
hd +rf+pa+placebo (N=276)  
YES 
a) 102.0 
b)101.8 
9.01/75 
8.99/74 
10.91 
11.16 
a) 137 
b) 128 
98.11 
100.53 
8.39/67 
8.72/72 
9.28 
10.08 
-3.89 
-1.27 
-0.62/-8 
-0.27/-2 
-1.63 
-1.08 
11) G. Cocco/2005 Orlistat 360mg+hd+rf +pa 
(N=45) 
hd +rf+pa+placebo (N=45)  
YES 
a) 106.99 
b) 105.98 
7.28/55 
6.92/52 
10.93 
10.33 
a) 45 
b) 45 
101.58 
103.50 
6.78/50 
6.88/51 
9.19 
9.71 
-5.55 
-2.65 
-0.5 /-5 
-0.04/-1 
-1.74 
-0.62 
12) M.F. Pathan/2004 Orlistat 360mg+hd+rf +pa 
(N=21) 
 
hd +rf+pa (N=15) YES 
 
a) 76.9 
b) 73.4 
8.9/74 
8.0/64 
 
9.8 
10.0 
 
a) 21 
b) 15 
73.8 
72.3 
 
6.9/52 
6.9/52 
 
7.7 
7.7 
 
-3.1 
-1.1 
-2.00/-22 
-1.1/-12 
-2.1 
-2.3 
Table 2-2 Studies results for weight loss using orlistat and type 2 diabetes outcomes (hd: hypocaloric diet; rf: reduced fat; pa: physical activity; FPG: Fasting 
Plasma Glucose; Wt.: Weight; N: Number). 
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Ten of the twelve trials included a placebo control and two did not (Didangelos et al., 
2004; Pathan et al., 2004). All of the studies included a hypocaloric diet and some 
continued physical activity; although no specific information regarding levels or types of  
physical activity was provided in four of the studies (Kuo et al., 2006; Hanefeld and 
Sachse, 2002; Kopelman et al., 2009; Guy-Grand et al., 2004). All, with the exception of 
two, studies included a reduced fat diet (Kuo et al., 2006; Didangelos et al., 2004). 
Diabetes duration was not reported in the majority of the trials, with the exception of one 
trial, which was restricted to those with known duration of type 2 diabetes of ≤5 years 
(Kelley et al., 2004). The mean BMI values at baseline for the trials included for the 
orlistat group and the control group, ranged from 27.2 to 36.5 and 26.9 to 36.0 kg/m2, 
respectively (Table 2-1). 
 
All the trials reported results in terms of weight (kg), HbA1c and FPG, with the exception 
of one study, in which only weight and HbA1c were provided (Kopelman et al., 2009) 
(Table 2-2). Some of the included studies reported outcomes for different durations of 
time, in addition to the primary end point; these were then compared in the meta-analysis. 
All of the included trials reported gastrointestinal side effects from orlistat, including 
abdominal pain, defecation urgency, diarrhoea, faecal incontinence and oily stool, except 
for one trial (which did not choose to report side effects) (Pathan et al., 2004). 
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2.4.1 Weight change 
The trials included in this review reported weight losses for primary end points of 3, 6 and 
12 months (Table 2-2). Kelley’s (2004) study reported the largest weight loss for both the 
orlistat and placebo control groups, while Kuo (2006) and Pathan (2004) reported the 
smallest. There were also patterns determined by the duration of the trials. Studies of three 
months of duration provided the smallest weight change compared with those of six and 
twelve months duration. Figure 2-2 displays rapid weight loss within three months duration 
in both the treatment and control groups. However, the mean weight loss was higher for 
the treatment group (i.e. the mean weight change for the eight studies at three months 
duration in orlistat and control groups was -3.67 and -2.32 kg, respectively (Figure 2-2 
and Table 2-3). The included studies reported continued weight loss within the time in the 
orlistat group (i.e. the mean weight change of ten studies at six months and four studies at 
twelve months in the orlistat group was -4.52 and -4.63 kg, respectively). A greater overall 
(3, 6 and 12 months) mean weight reduction was reported when administering the orlistat 
treatment compared to a lifestyle intervention with or without placebo (-4.25 kg, 95% CI: -
4.5 to -3.9 vs -2.27 kg, 95% CI: -2.6 to -1.8 kg, p <0.001). 
 
Figure 2-3 and Table 2-4 depict an overall effect size in weight loss between the 
treatment groups and control groups of -2.10 kg (95% CI: -2.3 to -1.8, p <0.001), which 
indicates the difference in weight change between the treatment groups and the control 
groups was significantly greater with orlistat. The results were grouped into those reporting 
3, 6 and 12 monthly primary end points, respectively. As expected, longer duration trials 
were associated with greater weight losses. The overall I-squared (test of heterogeneity) 
was 76.6%, p =0.001, which indicates substantial heterogeneity between the studies. There 
was no significant heterogeneity between the studies reporting weight change after three 
months (I-squared =31%, p =0.17). 
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Figure 2-2 Mean weight change in all patients receiving orlistat or placebo by 
duration. 
 
Duration 
(Months) 
N. of 
studies 
 Orlistat Control 
N 
Pooled estimate Heterogeneity  
N 
Pooled estimate 
 
Heterogeneity 
ES 
(95% CI) P 
I2 
(%) P 
ES 
(95% CI) P 
I2 
(%) 
 
 
P 
 
3 8 1165 -3.67 
(-4.30 to -3.04) 
 
0.001 
 
88.8 0.001 1174 -2.32 (-3.37 to -1.26) 0.001 95.7 0.001 
6 10 1271 -4.52 
(-4.81 to -4.23) 0.001 92.5 0.001 1207 
-2.42 
(-2.96 to -1.88) 0.001 95.6 0.001 
12 4 824 -4.63 
(-5.24 to -4.01) 0.001 71.6 0.014 819 
-2.02 
(-2.86 to -1.18) 0.001 85.1 0.001 
Table 2-3 Pooled estimate of mean weight change (kg) by duration in orlistat and control 
group (ES: effect size; Cl: confidence interval; N: Number). 
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NOTE: Weights are from random effects analysis
.
.
.
Overall  (I-squared = 76.6%, p = 0.000)
Kelley (2002)
12 months
Berne (2005)
Didangelos (2004)
Miles (2002)
Halpern (2003)
Halpern (2003)
Miles (2002)
Miles (2002)
Berne (2005)
Cocco (2005)
6 months
Hanefeld (2002)
Hanefeld (2002)
Kopelman (2009)
Author
Subtotal  (I-squared = 84.2%, p = 0.000)
Berne (2005)
Guy-Grand (2004)
Pathan (2004)
Kelley (2002)
Kelley (2004)
Subtotal  (I-squared = 0.0%, p = 0.428)
Kelley (2004)
3 months
Hanefeld (2002)
Subtotal  (I-squared = 31.4%, p = 0.177)
Kelley (2002)
Kuo (2006)
US
Sweden
Greece
US
Brazil
Brazil
US
US
Sweden
Switzerland
Germany
Germany
UK
Country
Sweden
France
Bangladesh
US
US
US
Germany
US
Taiwan
274  -3.3 (0.31)
111  -4.76 (0.43)
94  -5.6 (0.48)
250  -4.2 (0.2)
164  -4.24 (0.01)
164  -3.58 (0.39)
250  -4.7 (0.3)
250  -3.6 (0.3)
111  -3.71 (0.25)
45  -5.55 (0.29)
195 -5.3 (0.37)
195  -5.0 (0.6)
124  -3.78 (0.72)
N mean SE
111  -5.3 (0.6)
97  -3.9 (0.04)
21  -3.1 (0.82)
274  -3.89 (0.27)
26  -10.1 (1.4)
26  -5.6 (0.63)
195  -4.1 (0.497)
274  -4.1 (1.0)
30  -2.5 (0.1)
276  -1.5 (0.31)
109  -1.72 (0.37)
32  -3.9 (0.80)
254  -1.9 (0.2)
174  -2.58 (0.12)
174  -2 (0.46)
254  -1.8 (0.3)
254  -1.9 (0.3)
109  -1.72 (0.6)
45  -2.65 (0.27)
188 -3.4 (0.39)
188  -3.6 (0.7)
126  -2.86 (0.54)
N mean SE
109  -2.5 (0.7)
96  -1.3 (0.03)
15  -1.1 (0.10)
276  -1.27 (0.28)
26  -9.4 (1.3)
26  -5.5 (0.604)
188  -3.1 (0.492)
276  -1.3(0.9)
30  -0.4 (0.05)
-2.10 (-2.39, -1.81)
-1.80 (-2.66, -0.94)
-3.04 (-4.15, -1.93)
-1.70 (-3.55, 0.15)
-2.30 (-2.85, -1.75)
-1.66 (-1.90, -1.42)
-1.58 (-2.76, -0.40)
-2.90 (-3.73, -2.07)
-1.70 (-2.53, -0.87)
-1.99 (-3.26, -0.72)
-2.90 (-3.69, -2.11)
-1.90 (-2.95, -0.85)
-1.40 (-3.20, 0.40)
-0.92 (-2.68, 0.84)
ES (95% CI)
-2.23 (-2.73, -1.74)
-2.80 (-4.60, -1.00)
-2.60 (-2.70, -2.50)
-2.00 (-3.64, -0.36)
-2.62 (-3.38, -1.86)
-0.70 (-4.44, 3.04)
-2.64 (-3.09, -2.19)
-0.10 (-1.81, 1.61)
-1.00 (-2.37, 0.37)
-1.73 (-2.11, -1.34)
-2.80 (-5.43, -0.17)
-2.10 (-2.32, -1.88)
100.00
5.46
4.12
1.98
7.63
9.84
3.83
5.63
5.63
3.46
5.89
4.39
2.07
2.14
Weight
43.94
2.07
10.40
2.41
6.08
0.56
20.22
2.25
3.13
35.84
1.09
9.93
%Treatment Control
  
0-5 -2.1 5
Favours treatment Favours control
 
Figure 2-3 Forest plots for the weight difference (kg) between orlistat and control groups 
by duration (ES: Effect Size; I-squared: test of heterogeneity). 
 
 
 
Duration 
(Months) N. of studies 
Difference 
Pooled estimate Heterogeneity 
ES 
(95% CI) P-value 
I2 
(%) P-value 
3 8 -1.73 
(-2.12 to -1.34) 
0.001 
 
31.1   0.17 
6 10 -2.23 
(-2.73 to -1.74) 
0.001 84.2  0.001 
12 4 -2.64 
(-3.09 to -2.19) 
0.001 0.0  0.42 
Total difference          -2.10 
  (-2.39 to -1.81) 
0.001 76.6  0.001 
Table 2-4 Pooled estimate of mean weight difference (kg) 
between the orlistat and control groups (ES: effect size; Cl: 
confidence interval; N: Number). 
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2.4.2 Glycaemic values 
The reduction in both HbA1c and FPG in the orlistat treatment groups was greater than in 
the control groups (Table 2-2). 
 
2.4.2.1 HbA1c 
Pathan (2004) reported the largest HbA1c change and Cocco (2005) the smallest. Overall 
mean HbA1c levels decreased more in the treatment groups than in the control groups (-
11.05 mmol/mol, 95% CI: -15.0 to -7.0 vs -4.08 mmol/mol, 95% CI: -4.8 to -3.2, p 
<0.001), and the overall effect size difference was -6.12 mmol/mol (95% CI: -10.3 to -1.9, 
p <0.004). This indicates a difference in HbA1c between the treatment groups and the 
control groups; it was significantly greater with orlistat (Figure 2-5 and Table 2-6). There 
was no significant difference in HbA1c changes between the treatment and control groups 
at 3 months (-6.46 mmol/mol [95% CI -14.06 to 1.13], p <0.095), and concerning this there 
was considerable heterogeneity between studies (I2 =99.3%, p =0.001). Among studies 
reporting 6-monthly outcomes, the additional change in HbA1c in the treatment groups 
was -5.04 mmol/mol (95% CI: -5.86 to -4.21 mmol/mol). Heterogeneity remained 
considerable (I2 =82.8%, p <0.001). At 12 months, the additional HbA1c change in the 
orlistat treatment groups was –5.29 mmol/mol (95% CI: -7.31 to -3.27 mmol/mol), again 
with considerable heterogeneity (I2 =100%, p <0.001). The greatest effect from orlistat on 
HbA1c level occurred after 3 months duration in 5 studies -11.36 mmol/mol (95% CI: -
17.53 to -5.19 mmol/mol) (Figure 2-4 and Table 2-5). 
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Figure 2-4 Mean HbA1c change in all patients receiving orlistat or placebo by duration. 
 
 
Duration 
(Months) 
N. of 
studies 
Orlistat Control 
 
 
 
N 
Pooled estimate Heterogeneity 
 
 
N 
 
Pooled estimate 
 
Heterogeneity 
ES 
(95%CI) P I
2
 (%) P ES (95%CI) P 
I2 
(%) P 
3 5 725 -11.36 (-17.53 to -5.19) 0.001 99.4 0.001 720 
-4.33 
(-6.02 to -2.63) 0.001 90.8 0.001 
6 9 1021 -10.86 (-13.02 to -8.69) 0.001 99.3 0.001 953 
-4.57 
(-6.16 to -2.97) 0.001 98.7 0.001 
12 4 
 
824 -9.06 (-10.29 to -7.82) 0.001 88.4 0.001 
 
819 -3.98 ( -5.07 to -2.89) 0.001 84.9 0.001 
Table 2-5 Pooled estimate of mean HbA1c (mmol/mol) change by duration in orlistat and 
control groups (ES: Effect size; Cl: confidence interval; N: Number). 
95 
NOTE: Weights are from random effects analysis
.
.
.
Overall  (I-squared = 100.0%, p = 0.000)
Kuo (2006)
Berne (2005)
Kelley (2002)
Kopelman (2009)
Berne (2005)
Subtotal  (I-squared = 82.8%, p = 0.000)
Subtotal  (I-squared = 92.0%, p = 0.000)
Hanefeld (2002)
Kelley (2002)
12 months
Cocco (2005)
Pathan (2004)
6 months
Hanefeld (2002)
Kelley (2002)
Berne (2005)
Author
Hanefeld (2002)
Subtotal  (I-squared = 99.3%, p = 0.000)
Didangelos (2004)
Guy-Grand (2004)
Miles (2002)
Halpern (2003)
Kelley (2004)
3 months
Taiwan
Sweden
US
UK
Sweden
Germany
US
Switzerland
Bangladesh
Germany
US
Sweden
Country
Germany
Greece
France
US
Brazil
US
30  -19 (0.01)
111  -12 (2.18)
274  -9.8 (0.44)
124  -6 (0.90)
111  -12 (0.91)
195  -9.8 (1.37)
274  -8 (0.87)
45  -5 (0.51)
21  -22 (2.48)
195  -9 (0.37)
274  -8.8 (1.0)
111  -13.1 (1.6)
N mean SE
195  -9.8 (1.6)
94  -18 (0.35)
97  -6 (0.03
250  -8 (0.05)
164  -6 (0.13)
26  -19 (4.26)
30  -2 (0.01)
109  -7.5 (1.63)
276  -3.71 (0.44)
126  -4 (0.90)
109  -2.4 (0.84)
188  -7.5 (0.76)
276  -2 (0.87)
45  -1 (0.39)
15  -12 (1.75)
188  -5 (0.36)
276  -2.5(0.54)
109  -5.4 (3.27)
N mean SE
188  -7.5(2.7)
32  -9 (1.29)
96  -1 (0.03)
254  -5 (0.05)
174  -2 (0.12)
26  -11 (3.38)
-6.12 (-10.30, -1.94)
-17.00 (-17.03, -16.97)
-4.40 (-9.73, 0.93)
-6.19 (-7.41, -4.97)
-2.00 (-4.51, 0.51)
-9.60 (-12.04, -7.16)
-5.04 (-5.86, -4.21)
-5.29 (-7.31, -3.27)
-2.30 (-5.36, 0.76)
-6.00 (-8.41, -3.59)
-4.00 (-5.27, -2.73)
-10.00 (-15.97, -4.03)
-4.00 (-5.03, -2.97)
-6.21 (-8.42, -4.00)
-7.70 (-14.83, -0.57)
ES (95% CI)
-2.21 (-8.34, 3.92)
-6.46 (-14.06, 1.13)
-9.00 (-11.64, -6.36)
-5.00 (-5.10, -4.90)
-3.00 (-3.14, -2.86)
-4.00 (-4.35, -3.65)
-8.00 (-18.66, 2.66)
100.00
5.84
5.33
5.81
5.72
5.72
48.54
23.10
5.66
5.73
5.81
5.22
5.82
5.74
4.99
Weight
5.19
28.35
5.70
5.84
5.84
5.83
4.23
%Treatment Control
  
0-20 -10 -6.12 10 20
Favours treatment Favours control
Figure 2-5 Forest plots for the HbA1c difference (mmol/mol) between the orlistat and 
control groups by duration (ES: Effect Size; I-squared: test of heterogeneity). 
 
 
Duration 
 (Months) N. of studies 
Difference 
Pooled estimate Heterogeneity 
ES 
(95% CI) P-value I
2
 (%) P-value 
         3              5 -6.46 
(-14.06 to 1.13) 
0.09 
 
99.3 0.001 
6 9 -5.04 
(-5.86 to -4.21) 
0.001 82.8 0.001 
12 4 -5.29 
(-7.31 to -3.27) 
0.001 92.0 0.001 
Total difference 
-6.12 
(-10.30 to -1.94) 
0.004 100 0.001 
Table 2-6 Pooled estimate of mean HbA1c difference (mmol/mol) 
between the orlistat and control groups (ES: Effect size; Cl: 
confidence interval; N: Number). 
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2.4.2.2 FPG 
Kelley’s (2004) study reported the largest FPG change, while Halpern (2003) found the 
smallest FPG change (Table 2-2). The mean overall FPG levels fell more significantly in 
the treatment groups than in the placebo groups (-2.05 mmol/l, 95% CI: -2.3 to -1.7 vs -
0.80 mmol/l, 95% CI: -1.0 to -0.5, p <0.001), and the overall effect size difference was -
1.16 mmol/l (95% CI: -1.4 to -0.8, p <0.001). The FPG difference between the orlistat and 
control groups (-1.36 mmol/l, 95% CI: -2.59 to -0.13) over a three months duration was 
larger than that at the six and twelve month intervals (Figure 2-7 and Table 2-8). 
However, there was considerable heterogeneity between the studies (I2 =98.9%, p <0.001). 
Over the six and twelve month periods, the differences in FPG were -1.12 mmol/l (95% 
CI: -1.34 to -0.90) and -1.06 mmol/l (95% CI: -1.44 to -0.68), respectively. At 12 months, 
heterogeneity was low (I2 =15.5%, p =0.31). The highest changes in FPG occurred within 
three months of the commencement of the trial in four studies, -2.42 mmol/l (CI: -3.43 to -
1.4 mmol/l) in the treatment groups and -1.04 mmol/l (-1.26 to-0.82 mmol/l) in the control 
groups (Figure 2-6 and Table 2-7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
97 
 
 Figure 2-6 Mean FPG change in all patients receiving orlistat or placebo by 
duration 
 
 
 
 
 
Duration 
(Months) 
N. of 
studies 
Orlistat Control 
 
 
N 
Pooled estimate Heterogeneity 
 
 
N 
 
Pooled estimate 
 
Heterogeneity 
ES 
(95%CI) P 
I2 
(%) P 
ES 
(95%CI) P 
I2 
(%) P 
3 4 604 -2.42 (-3.43 to -1.41) 0.001 98.9 0.001 595 
-1.04 
(-1.26 to -0.82) 0.001 83.2 0.001 
6 10 1271 -1.91 (-2.19 to -1.64) 0.001 97.9 0.001 1207 
-0.67 
(-0.95 to -0.39) 0.001 97.4 0.001 
12 4 
 
824 
-1.77 
(-2.00 to -1.55) 0.001 0.0 0.45 
 
824 
-0.73 
(-0.99 to -0.48) 0.001 0.0 0.48 
Table 2-7 Pooled estimate of mean FPG (mmol/l) change by duration in the orlistat and 
control group (ES: effect size; Cl: confidence interval; N: Number). 
98 
NOTE: Weights are from random effects analysis
.
.
.
Overall  (I-squared = 97.4%, p = 0.000)
Kelley (2002)
Hanefeld (2002)
Kelley (2002)
Kuo (2006)
Kelley (2002)
Hanefeld (2002)
6 months
Kelley (2004)
3 months
Cocco (2005)
Berne (2005)
Subtotal  (I-squared = 15.5%, p = 0.314)
Berne (2005)
Halpern (2003)
Berne (2005)
Pathan (2004)
Miles (2002)
Subtotal  (I-squared = 88.7%, p = 0.000)
Didangelos (2004)
12 months
Miles (2002)
Subtotal  (I-squared = 98.9%, p = 0.000)
Hanefeld (2002)
Guy-Grand (2004)
Author
US
Germany
US
Taiwan
US
Germany
US
Switzerland
Sweden
Sweden
Brazil
Sweden
Bangladesh
US
Greece
US
Germany
France
Country
274  -1.91 (0.07)
195  -1.6 (0.18)
274  -1.71 (1.0)
30  -3.4 (0.06)
274  -1.63 (0.3)
195  -1.55 (0.6)
26  -4.05 (0.49)
45  -1.74 (0.06)
111  -2.6 (0.6)
111  -1.9 (0.32)
164  -1 (0.02)
111  -2.4 (0.5)
21  -2.1 (0.25)
250  -2.3 (0.2)
94  -2.5 (0.11)
250  -2 (0.2)
195  -1.95 (0.2)
97  -1.39 (0.02)
N mean SE
276  -1.16 (0.06)
188  -0.7 (0.23)
276  -1.16(0.9)
30  -0.9 (0.02)
276  -1.08 (0.3)
188  -0.95 (0.7)
26  -1.78 (0.44)
45  -0.62 (0.12)
109  -0.85 (0.7)
109  -0.26 (0.45)
174  -0.01 (0.02)
109  -1.0 (0.5)
15  -2.3 (0.75)
254  -1.0 (0.2)
32  -0.1 (0.16)
254  -0.7 (0.2)
188  -1.2 (0.286)
96  -0.5 (0.02)
N mean SE
-1.16 (-1.47, -0.85)
-0.75 (-0.93, -0.57)
-0.90 (-1.47, -0.33)
0.55 (-0.27, 1.37)
-2.50 (-2.62, -2.38)
-0.55 (-1.38, 0.28)
-0.60 (-1.58, 0.38)
-2.27 (-3.56, -0.98)
-1.12 (-1.39, -0.85)
-1.75 (-3.10, -0.40)
-1.06 (-1.44, -0.68)
-1.64 (-2.73, -0.55)
-0.99 (-1.05, -0.93)
-1.40 (-2.77, -0.03)
0.20 (-1.36, 1.76)
-1.30 (-2.28, -0.32)
-1.12 (-1.34, -0.90)
-2.40 (-2.80, -2.00)
-1.30 (-1.85, -0.75)
-1.36 (-2.59, -0.13)
-0.75 (-1.42, -0.08)
-0.89 (-0.95, -0.83)
ES (95% CI)
100.00
7.75
6.27
5.13
%
7.84
5.09
4.47
3.38
7.48
3.20
21.76
4.05
7.92
3.14
2.68
4.47
53.67
7.03
6.36
24.57
5.84
7.92
Weight
Treatment Control
  
0-4 -2 -1.16 2 4
Favours treatment Favours control
 
Figure 2-7 Forest plots for the FPG difference (mmol/l) between the orlistat and control 
groups by duration (ES: Effect Size; I-squared: test of heterogeneity). 
 
Duration 
(Months) N. of studies 
Difference 
Pooled estimate Heterogeneity 
ES 
(95% CI) P-value I
2
 (%) P-value 
3 4 -1.36 
(-2.59 to -0.13) 
0.030 
 
98.9 0.001 
6 10 -1.12 
(-1.34 to -0.90) 
0.001 88.7 0.001 
12 4 -1.06 
(-1.44 to -0.68) 
0.001 15.5 0.314 
Total difference 
-1.16 
(-1.47 to -0.85) 
0.001 97.4 0.001 
Table 2-8 Pooled estimates for the mean FPG difference (mmol/l) 
between the orlistat and the control groups (ES: effect size; Cl: 
confidence interval; N: Number). 
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2.4.3 Relationship between weight and HbA1c  
In order to investigate the relationship between weight differences and HbA1c differences, 
Figure 2-8 shows a regression line for the weight difference and the HbA1c difference. 
The majority of the study points are clustered toward the lower left corner of the plot for 
the control groups and the upper middle for the treatment group. There are four outlier 
studies, which lie away from the main data cluster, denoting where HbA1c reduction is far 
greater than that expected for the weight loss reported (Kuo et al., 2006; Kelley et al., 
2004; Didangelos et al., 2004; Pathan et al., 2004). The adjusted R2 is 19.3%, indicating 
19.3% of the variability in the HbA1c difference can be explained by its dependence on 
weight difference. The estimated coefficient for the treatment and control groups is -1.25, 
which tells us the average HbA1c decreases by 1.25 mmol/mol for every 1 kg drop in 
weight (Table 2-9). 
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   Figure 2-8 Simple linear regression between HbA1c difference and weight 
difference at the primary end point (The circle sizes represent the sample sizes). 
 
 
HbA1c 
difference 
Coefficient 
mmol/mol 
Standard 
error 
P-value Confidence 
interval  
R-squared Adjusted 
R-squared 
Weight 
difference 
1.25 0.49 0.018 0.23 to 2.26 0.229 0.193 
Table 2-9 Weight difference and HbA1c difference regression model for the 
treatment and control groups. 
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2.4.4 Effects of physical activity and placebo 
The effects of physical activity and placebo were also considered, and are as shown in 
Table 2-10. There was no significant difference apparent in the weight differences 
between those studies that included physical activity and those that did not, at any of the 
time points. The effect of the placebo on weight change could only be evaluated at 6 
months, and at this point no significant effect was found. Physical activity apparently had 
no effect on HbA1c at any of the time points. The addition of a placebo was associated 
with a significant difference in HbA1c at 6 months, only. FPG effects were not influenced 
by either physical activity or the use of a placebo at any time point. 
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 3 months 6 months 12 months 
Total 
P-value (PA) 
Weight (PA) 
Kg 
N. of study 
Results 
(difference 
between 
treatment and 
control) 
P-value N. of study 
Results (difference 
between treatment 
and control) 
p-value N. of 
study 
Results 
(difference 
between 
Treatment and 
control) 
 
p-value 
 
 
 
 
 
0.686 
Yes 5 -1.4 0.501 8 -2.1 0.618 3 -2.8 0.267 
No 3 -1.3 2 -2.0 1 -1.9 
Placebo         
 
Yes 8 -1.4 
 
8 -2.1 0.588 4 -2.6 
 
No 0 0 2 -1.8 0 0 
HbA1c (PA) 
mmol/mol 
        
  
Yes 2 -5.2 0.796 7 -6.9 0.432 3 -6.2 0.643 
0.837 
No 3 -7.1 2 -3.6 1 -4.0 
Placebo         
 
Yes 5 -6.3 
 
7 -5.3 0.012 4 -5.6 
 
No 0 0 2 -9.5 0 0 
FPG (PA) 
mmol/l 
        
  
Yes 2 -1.07 0.567 8 -1.1 0.603 3 -1.1 0.683 
0.899 
No 2 -1.62 2 -0.7 1 -0.9 
Placebo         
 
Yes 4 -1.3 
 
8 -1.0 0.513 4 -1.0 
 
No 0 0 2 -1.1 0 0 
                    Table 2-10 Effects of physical activity and placebo on weight loss, HbA1c and FPG (PA: Physical activity; N: Number).
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2.5 Assessment of bias 
The risk of bias was assessed using guidelines provided by the Cochrane Collaboration 
(Higgins & Green, 2008), and as set out in Table 2-11. Generally, bias was found to be 
low in all the included studies, as shown in Table 2-12. However, allocation concealment 
and blinding of participants and personnel were not reported in Didangelos’ (2004) study; 
sequence generation was unclear, nor was it apparent which were the primary and 
secondary outcomes intended in Cocco’s (2005) study; and the blinding of participants and 
personnel was not reported by Pathan (2004). All the studies reported the blinding of 
outcome assessment, and none reported missing data. 
 
Type of bias Description Relevant domains in the 
Risk of Bias tool 
Selection bias Systematic differences between the 
baseline characteristics of the groups 
• Sequence generation 
• Allocation 
concealment 
 
Performance bias 
 
Systematic differences between the 
groups in the care that is provided, or 
in exposure to factors other than the 
interventions of interest 
 
• Blinding of 
participants and 
personnel 
• Other sources of bias 
 
 
Detection bias 
 
Systematic differences between 
groups in how outcomes are 
determined 
 
 
• Blinding of outcome 
assessment. 
• Other sources of bias 
 
 
Attrition bias 
 
Systematic differences between  
groups in withdrawals from a study 
 
 
• Incomplete outcome 
data 
 
 
Reporting bias 
 
Systematic differences between 
reported and unreported findings 
 
 
• Selective outcome 
reporting 
Table 2-11 Classification scheme used to assess bias (Cochrane Handbook). 
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RCT Sequence 
generation 
Allocation 
concealment 
 
Blinding of 
participants 
and 
personnel 
 
Blinding of 
outcome 
assessment 
 
Incomplete 
outcome 
data 
 
Selective 
outcome 
reporting 
No (%) 
of 
criteria 
in 
each 
study 
(n=6) 
P. Kopelman/2009 Y Y Y Y Y Y 6 (100) 
C. Kuo/2006 Y Y Y Y Y Y 6 (100) 
C. Berne/2005 Y Y Y Y Y Y 6 (100) 
T.P. Didangelos 
/2004 
Y N N Y Y Y 4 (66.6) 
B. Guy Grand/2004  Y Y Y Y Y Y 6 (100) 
Kelley/2004 Y Y Y Y Y Y 6 (100) 
M. Hanefeld/2002 Y Y Y Y Y Y 6 (100) 
J.M. Miles/2002 Y Y Y Y Y Y 6 (100) 
A. Halpern/2003 Y Y Y Y Y Y 6 (100) 
D.E. Kelley/2002 Y Y Y Y Y Y 6 (100) 
G. Cocco/2005 UNCLEAR Y Y Y Y N 4 (66.6) 
M.F. Pathan/2004 Y Y N Y Y Y 5 (83.3) 
No. (%) of studies 
containing criterion 
(n=12) 
11 (91.6) 11 (91.6) 10 (83.3) 12 (100) 12 (100) 11 (91.6)  
Table 2-12 Study design criteria aimed at reducing bias: Abbreviations: Y, the criterion 
was present (low risk of bias); N, the criterion was not present (high risk of bias); 
UNCLEAR (uncertain risk of bias). 
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2.6 Summary of the main findings 
• Greater reduction in weight, HbA1c and FPG in the orlistat treatment groups 
compared with the control groups. 
• The reductions in HbA1c and FPG in the treatment group occurred quickly in the 
first 3 months. 
• With orlistat treatment, longer duration studies were associated with greater weight 
loss when compared with shorter duration trials. 
• There was no significant effect of adding physical activity to the overall outcomes. 
• There was a significant effect of the absence of a placebo on HbA1c differences 
between orlistat and control group at 6 months duration. 
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2.7 Discussion 
The initial systematic review and meta-analysis of the RCTs was conducted to describe the 
effects of orlistat on glycaemic control among patients with overweight and obesity. It was 
found that the addition of orlistat to lifestyle changes increased weight loss, and was 
associated with greater reductions in both HbA1c and FPG levels that were clinically 
significant. The addition of physical activity to the regimen did not significantly affect 
overall weight loss or glycaemic control. There was also little evidence that the use of a 
placebo influenced the observed results. 
 
A previous systematic review by Avenell et al. (2004) reported a weight reduction in the 
first year across eight RCTs including patients both with and without diabetes. Only one of 
these studies met the criteria for the review (Hollander et al., 1998); however, the 
published data were not sufficient for inclusion as further information would have been 
required but was not available from either the author of the study or the authors of the 
systematic review. The mean weight difference between the orlistat plus diet group and the 
placebo plus diet groups after 12 months was -3.01 kg (95% CI: -3.48 to -2.54 kg, p 
<0.00001). Of eight RCTs, six RCTs reported a FPG outcome and three reported a 
difference in HbA1c (both in patients with and without diabetes). The mean HbA1c change 
difference was -1.85 mmol/mol (95% CI: -2.62 to -1.09 mmol/mol, p <0.00001), and the 
mean FPG difference was -0.24 mmol/l (95% CI: -0.34 to -0.14 mmol/l, p <0.00001). Both 
the HbA1c and FPG reductions in Avenell’s study were smaller than the research results, 
and this is probably because the non-diabetic patients included in Avenell’s analysis had 
lesser capacity for glycaemic improvements, despite greater weight losses.   
 
All the results in the studies included in this systematic review and meta-analysis showed a 
reduction in weight and glycaemic values in the orlistat and control groups, although the 
mean reduction within the time frame in the orlistat group was greater than in the control 
groups. The reduction of weight, HbA1c and FPG was clinically and statistically 
significant after using orlistat. The reductions in HbA1c and FPG in the orlistat group 
occurred in the first 3 months. They were followed by modest rises thereafter, despite 
continued weight losses of up to 12 months. It might be that, as adherence to lifestyles 
reduces over time, glycaemic control deteriorates. Miles et al. (2002) found that, when 
patients were treated with orlistat 120 mg, an improvement in glycaemic control occurred 
quickly with the onset of caloric restriction, prior to any weight loss. Additionally, Rowe et 
al. (2005) showed that, 6 months of orlistat treatment in patients with obesity and diabetes 
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(receiving insulin) was associated with significant reduction in the mean dose of insulin 
without any correlation with weight loss being observed. 
 
Outlier studies were identified as those where the results were at a distance from the main 
data cluster, for unclear reasons, although in some cases these might be a consequence of 
the small sample size used in the studies, or because they recruited different patient 
populations with diabetes durations of ≤5 years (Kelley et al., 2004). Two studies (Kuo et 
al., 2006; Pathan et al., 2004) were of Asian populations, and there were several potential 
reasons reported, resulting in a greater effect size when using orlistat. Asian populations 
develop type 2 diabetes at lower BMIs (22 kg/m2 versus 30 kg/m2 in white Europeans), 
because of the capacity reductions for storing fat in the primary superficial subcutaneous 
adipose tissue compartment (Sattar and Gill, 2014), which might mean that less absolute 
weight loss was required to improve insulin sensitivity. In addition, differences in the 
dietary needs of the Asian population might help with orlistat’s action to reduce blood 
glucose levels.  
 
In this review, the effects of physical activity and the placebo on weight loss, HbA1c and 
FPG were unclear, due to insufficient numbers of studies reporting effects without physical 
activity, especially over 6 to 12 months durations. Similarly, a low number of studies 
reported outcomes in the absence of placebo; although, at 6 months duration there was a 
significant effect from the absence of placebo on HbA1c difference (i.e. the mean HbA1c 
difference in the presence and absence of placebo in 6 months duration was -5.3 and -9.5, p 
=0.012, respectively). The reason for this might be that patients in the control group 
effectively remembered to take their anti-diabetic medications with the placebo, or were 
not disheartened when blinded to their intervention. Consequently, more studies need to be 
undertaken to confirm the effects of physical activity and placebo on weight loss and 
glycaemic values. 
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2.8 Research Strengths and limitations 
This systematic review and meta-analysis was conducted on the basis of the Cochrane 
reviews methodology, and was reported based on PRISMA guidelines. Two major 
databases were used to identify relevant trials. The pooled estimates were derived from 
twelve trials comprising 2,802 participants in total. Previous studies of orlistat included 
obese patients with and without diabetes; this research is the first systematic review to 
focus solely on patients with diabetes excluding others, and the effect of orlistat on 
glycaemic control. The strengths of this review were the inclusion of RCTs, the assessment 
of two types of intervention and the generation of meta-analysis.   
 
The limitations of the review are the insufficient sample sizes in some studies and the 
potential to overestimate the long-term effects of treatment based on inferences from short 
term interventions (<6 months). In addition, treatment strategies were mixed between 
dietary management and a variety of oral hypoglycaemic agents. There was considerable 
heterogeneity between the studies identified. This remained after the results were stratified 
by length of trial and was found in the meta-analysis of weight, HbA1c and FPG. There are 
a number of ways in which the patients, the interventions and the evaluation of the 
intervention’s effects might vary between studies. There were differences in the ages of the 
patients and in the mean baseline weights. Dietary habits, physical environments that might 
promote or inhibit physical activity and seasonal variations in weight, might also influence 
the effectiveness of weight loss interventions.  
 
The presence of other comorbidities, such as heart failure, which might affect capacity for 
physical activity and use of medications that might promote weight gain, may also vary 
between the patients in different studies. Details of advice given about physical activity, 
and regarding whether the advice was followed were lacking. Orlistat 60 mg has been 
available as an over-the-counter medication in the US since 2007, and in the EU since 
2009, but as this review only included studies using a prescription-only dose of 120mg, we 
cannot say whether the use of a 60mg dose by patients with obesity and diabetes improves 
glycaemic control, and further research is needed to describe these patients. 
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2.9 Research Implications  
As observed above, the findings of all the included studies show that treatment with orlistat 
combined with lifestyle interventions provides benefits for individuals who are overweight 
or obese with type 2 diabetes. It therefore follows that orlistat should be considered an 
effective adjunctive treatment to lifestyle intervention and anti-diabetic medications to 
improve glycaemic control among patients who are overweight or obese with type 2 
diabetes. However, further research is needed to confirm the effect of orlistat in real life; 
this is investigated in Chapter 4. Future research into the effects of orlistat on glycaemic 
control in overweight and obese patients with type 2 diabetes would be improved by the 
provision of additional detail concerning physical activity interventions, and objective 
monitoring of physical activity (e.g. by using an accelerometer). In addition, giving full 
details of the behaviour change techniques used would allow the coding of interventions 
within a systematic review, which would further help to build cumulative knowledge of 
which interventions are effective (Michie et al., 2013; Presseau et al., 2015). Recordings of 
comorbidities and medications and longer follow-up periods beyond 12 months are 
suggested. Further research is needed to measure the adherence to orlistat, as it is generally 
believed that people do not adhere to orlistat treatment. 
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Chapter 3: Evaluation of the effectiveness of 
phase 1 (lifestyle) of the Glasgow and Clyde 
Weight Management Service programme 
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3.1 Chapter summary 
There is a paucity of evidence regarding the effectiveness of weight management services. 
The aim of the data collected for this chapter was to evaluate the effectiveness of the 
lifestyle intervention component of the NHS Glasgow and Clyde Weight Management 
Service (GCWMS), particularly to achieve ≥5 kg weight loss, exploring the effects of age, 
sex, initial weight, BMI, and co-morbidities such as diabetes and hypertension. In this 
prospective cohort study, all the individuals who started GCWMS between 2008 and 2014 
were included. Last observation carried forward (LOCF), and programme completers were 
reported using mean weight changes with 95% confidence intervals, and 5 kg and 5% 
weight losses at the end of the lifestyle programme were observed.  
 
Of 23,650 patients referred to GCWMS, 13,255 (56.0%) attended assessment, 8,173 
(61.5%) individuals attended their first session and 7,329 (55.3%) individuals attended at 
least two sessions of the lifestyle programme. At the first visit, 72.9% were female, 40.5% 
were from the most deprived quintile, 21.4% had diabetes, 16.2% had hypertension, mean 
weights and BMI were 115.2 kg and 42.2 kg/m2 respectively. In total, 30.5% of those who 
opted in and attended ≥2 sessions (7,329) lost ≥5 kg by the end of the lifestyle programme, 
and among 4,042 completers, 46% (n =1,854) lost ≥5 kg. Weight loss (≥5 kg) occurred at a 
higher rate among men, aged ≥40 years, BMI ≥50 kg/m2. Those with diabetes mellitus, 
young men, young women, and socio-economically deprived groups achieved lesser 
weight loss.  
 
The weight management programme was effective for achieving 5 kg weight loss, but only 
in less than 50% of those patients who completed a lifestyle programme. Those who did 
not complete the programme (44.8% dropped out) experienced a lack of weight loss. A 
higher proportion of the patients completing the programme lost ≥5 kg. Therefore, it is 
necessary to evolve the GCWMS in order to facilitate an improved impact. 
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3.2 Introduction 
The prevalence of obesity is becoming more extensive in the UK, where it is becoming a 
major cause of serious diseases, including cancers and coronary artery disease (Kopelman, 
2007). Treatment guidelines developed in the UK recommend multicomponent weight 
management programmes which include calorie deficient diets, regular physical activity 
(225-300 minutes/week) and behavioural components such as motivational interviewing 
for the management of patients with overweight or obesity (SIGN 115, 2010). The NHS 
Greater Glasgow and Clyde area of Scotland has a population of 1.2 million individuals. 
GCWMS is among the biggest services in the UK. The service is provided by a team 
comprising dietitians, psychologists, physiotherapists and administrative staff. GCWMS is 
accessible to patients aged 18 years and over with complex obesity (defined as BMI of ≥30 
kg/m2 with obesity-related comorbidities, or BMIs of ≥35 kg/m2), who have been referred 
by a GP or hospital doctor.  
 
The goal of the service is to support patients to achieve weight losses of at least 5 kg. This 
is based on good evidence that a 5 kg weight loss is a clinically significant target known to 
improve obesity associated health conditions (Robertson et al., 2014). GCWMS is only 
successful if participants are motivated to change their lifestyles, and all of the eligible 
patients are referred by their health professionals and they receive a leaflet about the 
service. Once a referral has been sent by the GP, patients have to phone the GCWMS 
booking centre within two weeks to arrange an assessment appointment. The assessment 
includes questions about the patient’s weight and diet history, their levels of activity, 
physical health and moods and motivations. Furthermore, patients might undergo further 
assessment from a physiotherapist or a clinical psychologist to direct them toward the best 
treatment. GCWMS offers small group and individual programmes to individuals suffering 
from anxiety, mild learning difficulties, sensory impairment and literacy issues.  
 
GCWMS is offered in three phases: the treatment in phase 1 (lifestyle intervention) 
includes a combination of diet (600 kcal deficit diet), exercise and behavioural 
interventions over nine sessions (90 min) delivered once every two weeks over a 16-week 
period (9 fortnightly sessions). Behavioural interventions include patient monitoring, 
motivational enhancement, and cognitive behavioural therapy such as goal setting, problem 
solving, and slowing the rate of eating. These sessions involve dietician talks, encouraging 
healthy eating based on the Eatwell Plate (Food Standards Agency, 2007) and behavioural 
change, in addition to weekly exercise sessions and psychological talks (full details of the 
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sessions can be seen in Figure 3-1). After completing phase 1, patients can choose to enter 
phase 2, which consists of four sessions (one hour) delivered at monthly intervals, and 
including a variety of treatment options including further lifestyle advice (FWL), a 
prescribed low-calorie diet (LCD) or pharmacotherapy (orlistat). Phase 2 treatments are 
determined by patient choice; generally, if patients successfully lose ≥5 kg, they can move 
on to FWL by attending three monthly sessions over 3 months, and if they have lost less 
than 5 kg, they will be selected for a LCD, or pharmacotherapy. Patients can then enter a 
weight maintenance programme (phase 3) directly following the end of the lifestyle phase, 
or at the end of phase 2, dependent on the patient’s choice.  
 
Phase 3 consists of 12 sessions (one hour) delivered at monthly intervals. The patient can 
choose to repeat phase 2 once again and then enter a maintenance programme if they fail to 
achieve their target weight loss (5 kg). In addition, patients can opt for bariatric surgery if 
they fail to lose 5 kg and have a BMI >40 kg/m2, or BMI >35 kg/m2 with comorbidities 
(Figure 3-2). 
 
There is a lack of evidence evaluating multidisciplinary tier 3 weight management 
programmes available in the UK. Therefore, the aim of this research was to evaluate the 
effectiveness of the lifestyle intervention offered by the GCWMS programme to achieve 5 
kg or more weight loss, exploring the effects of age, sex, initial weight and BMI, as well as 
co-morbidities such as diabetes and hypertension. The main research question posed was: 
what proportion of patients lose 5 kg of weight during the lifestyle phase of the GCWMS? 
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GCWMS programme: the lifestyle phase  
Session 1: General talk 
- Programme overview; 
- Causes of obesity; 
- Benefits of 5-10 kg weight loss; 
- Eat Well Plate; 
- Becoming more active; 
- Lifestyle diaries. 
Session 2: Taking control 
- PDP; 
- Barriers and benefits to becoming more 
active. 
 
Session 3: Planning for success 
- Menu planning, shopping, and guide to   
food labelling; 
-  Binge eating. 
 
Session 4: Changing habits 
- Cooking and eating out/takeaways; 
- Dealing with social pressure to eat; 
- What you can do to incorporate physical 
activity. 
 
Session 5: Go do it 
- Solve unhelpful thinking - thoughts,  
feelings, and behaviour; 
- Diet quiz. 
 
Session 6: Riding the craving wave 
- Cravings vs. hunger; 
- Practical dietary tips; 
- Physical activity quiz. 
 
 
Session 7: Keep it real 
- Diet myths/fad diets, and the balance  
of good health; 
- Staying motivated to be active; 
- Body image. 
 
 
Session 8: The journey so far 
- Relapse prevention; 
- Support; 
- High risk situations; 
- What activity changes have been made? 
 
Session 9: Programme review and phase 
2 offering  
 
 
Figure 3-1 Patients’ journey at the lifestyle phase. 
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                                               Lifestyle programme                16 weeks (fortnightly)                    
 
                                                                                      Further weight loss  
                                      
 
 
               Bariatric surgery                                       Maintenance programme 
                                                                                                   12 monthly sessions 
Figure 3-2 Diagram of the phases of the Glasgow and Clyde Weight Management Service. 
 
 
 
 
 
 
 
 
 
GP Referral Opt in Assessment 
Opt in 
Weight loss <5 kg Weight loss >5 kg 
Phase 1 
          Phase 2 (12 weeks, monthly) 
Weight loss >5 kg Weight loss <5 kg 
Patient with BMI >35 with co-morbidities or BMI >40 kg/m2 
Phase 3 
Low calorie diet 
OR 
Pharmacotherapy 
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3.3 Materials and methods 
3.3.1 Data source  
The data were collected by the dietitians at the time when the participants attended their 
sessions at the GCWMS. The subjects’ weight and height were measured by the dietitians 
on calibrated scales, and then noted. These data were then recorded and transferred to a 
database by the dietitians. This prospective cohort study used data obtained for all referrals 
made to the GCWMS from 2008 to 2014. The data were collected on a live database and 
stored on a Microsoft Structured Query Language (SQL) server. The data analyst at 
GCWMS extracted the data by running a SQL query for each table including all of the 
requested fields. The output from each of the SQL queries was transferred to a comma-
delimited text file and then transferred to the data development manager. After this, the 
text files were imported into an access database.  
 
3.3.2 Inclusion and exclusion criteria   
Of the 23,650 patients identified, 13,255 opted into the service for assessment (by phoning 
the service after referral and making an appointment). Of these, 8,226 patients opted into 
the lifestyle programme, and the final number of patients attending the first session was 
8,173 patients. Of these 8,173 patients, 7,329 individuals attended at least two sessions in 
the lifestyle phase and were included in the analysis (Figure 3-3). Therefore, because the 
weight would not change if the individuals attended only one session, only those patients 
attending at least two sessions with weights recorded were included in the baseline 
characteristics and weight change outcomes (n  =7,329).  
   
Since human error is always possible, the data were checked and cleaned by the author. 
Records with ages below zero, a height of 1m or less, and a weight of less than 30 kg were 
excluded, as they were unlikely to produce valid data. Individuals aged less than 18 years 
and with a BMI below 30 kg/m2 were excluded, because the programme is for adults with 
BMI ≥35 kg/m2 or 30 to 34.9 kg/m2 with co-morbidities, and therefore the data are 
unlikely to be valid. Therefore, 53 patients were excluded because of their age (below 18 
years) and BMI (less than 30 kg/m2). If the same patient was referred more than once, 
information from the earliest referral only was included (Morrison et al., 2011; Dixon et 
al., 2012), and the same referral was used in phase 2.  
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                                                                  53 patients with invalid data 
                                                                     
 
 
 
 
 
 
Figure 3-3 Flowchart showing all the referrals to the GCWMS between 2008 and 2014. 
 
 
 
 
 
All referrals N=29,593 
Unique patients N=23,650 
 
Repeat referrals 
N=5,943 
Patients attended the 
assessment N=13,255 
Patients opted to the 
lifestyle phase   N=8,226 
Final patients who attended 
≥1 session N=8,173 
Attended ≥2 session 
N=7,329 
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3.3.3 Definition of programme completion 
It has been established that attendance is directly related to weight loss; therefore, 
programme completion was defined prior to analysis as completion of the programme with 
attendance at 80% of the sessions; i.e. seven or more sessions attended during the lifestyle 
phase. Those who completed six or fewer sessions were labelled non-completers. 
 
3.3.4 Variables definitions 
Co-morbidity information regarding the presence or absence of diabetes mellitus and 
hypertension were obtained using data from the GP referral form. The patients were 
classified as having diabetes and hypertension if either was noted on their GP referral form 
or mentioned by the patients at assessment. However, as social, educational and economic 
information were not available for the patients, we estimated socioeconomic status using 
the Scottish Index of Multiple Deprivation (SIMD). Scotland is divided into 6,505 
datazones by postcode of residence; each contains around 350 households and has a mean 
population of 800 people. The SIMD for each datazone is constructed using information 
pertaining to seven domains: income and benefits, employment, health, education 
(including skills and training), housing, crime, and access to services. The SIMD is used to 
derive quintiles of socioeconomic status for the Scottish population; ranges from 1 (most 
deprived) to 5 (least deprived).  
 
Finally, age was categorised into six groups: 18-29, 30-39, 40-49, 50-59, 60-69 and ≥70 
years. BMI was categorised into four groups: (30-34.9 kg/m2), (35-39.9 kg/m2), (40-49.9 
kg/m2) and (≥50 kg/m2). Weight was categorised into five groups: (˂75 kg), (75-99 kg), 
(100-124 kg), (125-149 kg) and (≥150 kg).  
 
3.3.5 Statistical analysis and weight loss outcomes 
Missing data relating to weight are very common where a patient has left a programme 
early or not attended an appointment. Where data are missing, the method of LOCF was 
used. In other words, when the weight measurement is missing, it is replaced by the 
participant’s last observed value. The characteristics of patients at referral, assessment and 
the first session were reported. However, patient’s weights at the first session were also 
used as a baseline for this research. Mean weight change and 95% CI, 5 kg and 5% weight 
loss were reported. Differences in the means between the two groups and more than two 
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groups were tested using a t-test and ANOVA test, respectively. A stratified analysis was 
used to estimate the effects of potential confounding factors on weight change. These 
factors were sex, age, deprivation, initial weight/BMI, and presence of diabetes/or 
hypertension. All the statistical analyses were performed using Stata version 12.1 
(StataCorp, College Station, Texas). 
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3.4 Results 
3.4.1 Referral number by GP practice code 
In order to investigate whether there was any variation in GPs referral rates for patients to 
the weight management programme, the number and percentage of referrals by GPs to the 
GCWMS were identified. Over a six-year duration, from 2008 to 2014, around 386 GP 
practices made 29,593 referrals. Table 3-1 shows that 107 GP practices had fewer than 10 
referrals in total within a six-year period. This equates to 27.7% of GPs making <10 
referrals. On the other hand, 69 practices made between 100-250 referrals, and just five GP 
practices made more than 250 referrals. The bar chart represents the variation between the 
numbers of referrals by different GP practices. The majority of these practices had 100 
referrals or fewer, and some had very low referred numbers to GCWMS (Figure 3-4). 
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Referral number 
categories 
Number of   
practices 
% 
<10 107 27.7 
10- <50 87 22.5 
50- <100 118 30.5 
100- 250 69 17.8 
>250 5 1.3 
Table 3-1 Number of referred patients to the GCWMS from   
2008-2014 by GP practices code. 
 
 
 
Figure 3-4 Number of referred patients to the GCWMS from 2008-2014 
by GP practice code. 
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3.4.2 Referral and baseline characteristics 
3.4.2.1 Referral 
Of the 23,650 patients referred between 2008 and 2014 (Table 3-2 shows baseline 
characteristics), the highest proportion of patients referred were aged between 40-59 years 
(47.8%). The majority of these referred patients were woman (71.1%), the mean age was 
46.2 years and the men were older than women (mean ages 49.0 and 45.1 years, 
respectively). The majority of the patients were in the most deprived quintile of SIMD 
(47.4%) with only 9.8% in the least deprived quintile. The mean initial weight at referral 
was 111.2 kg, range 25-286 kg. BMI was also high; the mean BMI at referral was 40.6 
kg/m2, and the range 15.1-112.5 kg/m2. Patients with a BMI lower than 30 kg/m2 were then 
excluded due to invalid data. Most of the patients had a BMI between 35 and <50 kg/m2 
(76.4%). 18.4% and 13.4% of the patients had diabetes and hypertension, respectively.  
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  N=23,650          N=13,255 (56%)      N=7,329 (31%) 
Variables At referral At assessment At first visit Ref/ 1visit 
Age 
18-29 
30–39 
40–49 
50–59 
60–69 
≥70 
Missing 
N % N % N % % 
3,624 
3,950 
5,816 
5,482 
3,455 
1,204 
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15.3 
16.7 
24.6 
23.2 
14.6 
5.1 
0.5 
1,635      
2,066      
3,296      
3,241      
2,152        
721 
144 
 
12.3      
15.6      
24.9     
24.5      
16.2       
5.4 
1.1 
671      
1,050 
1,821 
1,946 
1,374 
437 
30 
 
9.2 
14.3 
24.8 
26.6 
18.7 
6.0 
0.4 
18.5 
26.5 
31.0 
35.5 
39.5 
36.0 
Gender 
Male 
Female 
Missing 
 
6,778 
16,823 
49 
 
 
28.7 
71.1 
0.2 
 
3,693 
9,543 
19 
 
 
27.9 
72.0 
0.1 
 
1,979 
5,345 
5 
 
 
27.0 
72.9 
0.1 
 
29.0 
31.5 
 
SIMD 
Most deprived 
2 
3 
4 
Least deprived 
Not known 
 
11,206 
4,427 
3,101 
2,456 
2,321 
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47.4 
18.7 
13.1 
10.4 
9.8 
0.5 
 
5,738      
2,480      
1,884      
1,497      
1,495 
161 
 
 
43.3 
18.7 
14.2 
11.3 
11.3 
1.2 
 
2,966 
1,410 
1,099 
 891 
924 
39       
 
40.5 
19.2 
15.0 
12.2 
12.6 
0.5 
 
26.5 
32.0 
35.5 
36.0 
40.0 
BMI 
30–34.9 
35–39.9 
40–49.9 
≥50 
Missing 
 
3,393 
8,934 
9,124 
2,032 
167 
 
14.3 
37.8 
38.6 
8.6 
0.7 
 
1,464 
4,620 
5,576 
1,501 
94 
 
11.0 
34.9 
42.1 
11.3 
0.7 
 
840       
2,346 
3,197 
946       
 
11.5 
32.0 
43.6 
12.9 
 
24.5 
26.0 
35.0 
46.5 
Weight kg 
˂75 
75–99 
100–124 
125–149 
≥150 
Missing 
 
327 
7,268 
10,373 
4,335 
1,345 
2 
 
 
1.4 
30.7 
43.9 
18.3 
5.7 
0.0 
 
119 
3,700 
5,850 
2,669 
917 
 
 
0.9 
27.9 
44.1 
20.1 
6.9 
 
44 
1,930 
3,252 
1,558 
545        
 
0.6 
26.3 
44.4 
21.3 
7.4 
 
13.5 
26.5 
31.5 
36.0 
40.5 
Diabetes 
 No 
  Yes 
        Missing 
 
19,287 
4,363 
 
81.6 
18.4 
 
10,563 
2,598 
94 
 
79.7 
19.6 
0.7 
 
5,757 
1,572 
 
78.6 
21.4 
 
30.0 
36.0 
Hypertension 
 No 
  Yes 
        Missing 
 
20,492 
3,158 
 
86.6 
13.4 
 
10,211 
2,950 
     94 
 
77.0 
22.3 
0.7 
 
6,139 
1,190 
 
83.8 
16.2 
 
30.0 
37.6 
Table 3-2 Characteristicsof patients at referral, assessment and at first visit. 
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3.4.2.2 Attendance 
In total, 7,329 participants attended at least 2 sessions and their characteristics can be seen 
in Table 3-2. The average weight of those patients who attended at least one session was 
115.2 kg (range 52.6 to 271.9 kg), (129.2 kg in men and 109.9 kg in women). The mean 
BMI in the first session of the lifestyle phase was 42.2 kg/m2 (range 30.04 to 85 kg/m2), 
(42.0 in men and 42.3 in women). The majority of the patients had a BMI between 35 and 
˂50 kg/m2 (75.6%), and nearly (70.7%) of patients weighed between 75 to 124 kg. 72.9% 
of the patients present at the first session were females, and in the most deprived quintile 
(40.5%) of the SIMD with only (12.6%) in the least deprived quintile. 21.4% and 16.2% of 
the patients at the first session respectively suffered from diabetes and hypertension. 
 
3.4.2.3 Opt in rate 
Table 3-2 shows just 31% of the total referred patients attended at least 2 sessions. There 
was a low opt in rate for young people compared with old people, as only 18.5% of the 
referred patients aged from 18-29 years attended ≥2 sessions, whereas 39.5% of referred 
patients aged (60-69 years) attended at least 2 sessions. In total, 31.5% and 29.0% of the 
referred females and males respectively attended the first session. There was a slightly 
higher opt in rate from referral to first session found for those from the highest quintile of 
SIMD versus the lowest (40.0% vs. 26.5%). Furthermore, the opt in rate was higher among 
heavier people than lighter ones; for example, 46.5% of the referred patients with a BMI 
≥50kg/m2 turned up compared to 24.5% of those with BMI =34.9 kg/m2. Therefore,  
more than 100 kg, or with a BMI of more than 40 kg/m2, had a higher opt in rate. Just 
36.0% and 30% of the referred patients with and without diabetes respectively attended the 
first session. Moreover, 37.6% of the referred patients with high blood pressure turned up; 
whereas, 30.0% of referred patients with normal blood pressure attended ≥2 sessions. 
Likewise, those with diabetes or hypertension had a higher opt-in rate than the patients 
without diabetes and those with normal blood pressure. 
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3.4.2.4 BMI classification for individuals attending at least one session 
Nearly two thirds (56.2%) of the 8,173 GCWMS patients referred between 2008-2014 and 
who attended at least one session had a baseline BMI ≥40 kg/m2; the distribution of BMI 
data is positively skewed (Figure 3-5), and according to WHO groups (2014b), this 
percentage of patients are classified as class III obese (Table 3-3).  
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Figure 3-5 Histogram of baseline BMIs among 8,173 patients attending the 
GCWMS, 2008-2014. 
 
Obesity classes       Frequency  
 
Percentage 
30-34 Class I 
 
939 
 
11.4 
 35-39 Class II 
 
2,633 
 
32.2 
 >=40 Class III 
 
4,601 56.2 
Total 
 
8,173 100 
Table 3-3 Baseline Body Mass Index of the 8,173 GCWMS patients, 2008-
2014. 
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3.4.3 Weight loss outcomes 
3.4.3.1 Completers and non-completers 
In total, 4,042 patients (55.1%) completed the lifestyle programme, attending 80% of the 
total sessions. A higher proportion of men completed the lifestyle programme than women, 
almost 60% and 53% respectively. In addition, the proportion of patients from the most 
affluent areas was higher than from the most deprived areas in cases of programme 
completion (62% vs. 51.8%). Age ≥30 years, BMI ≥50 kg/m2 and weight ≥150 kg were 
associated with a greater proportion of programme completion. In addition, a higher 
proportion of patients with diabetes and hypertension completed the programme (57.8% 
and 57.0%, respectively) compared to patients who are obese without diabetes or 
hypertension (Table 3-4).  
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 Total (completers & non-completers) (attended at least 2 sessions) Completers (subgroup of total) (attended at least 7 sessions) 
  
N 
Mean weight 
change and 95% 
CI 
P-
value 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
N (%) of 
total 
Mean weight change 
and 95% CI 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
All  7,329 -3.58 (-3.6 to -3.4)  2,232 (30.5%) 
1,874 
(25.5%) 4042 (55.1) -5.09 (-5.2 to -4.9) 1,854 (46%) 1,591 (39.5) 
Gender Male 1,979 -4.51 (-4.7 to -4.2) 
0.001 
762 (38.5) 575 (29) 1186 (59.9) -6.14 (-6.4 to -5.8) 643 (54) 499 (42) 
 
Female 5,345 -3.23 (-3.3 to -3.1) 1468 (27.5) 1297 (24) 2853 (53.3) -4.65 (-4.8 to -4.4) 1209 (42) 1090 (38) 
 
Missing 5     3    
SIMD 1 (most deprived) 2,966 -3.32 (-3.4 to -3.1) 
0.001 
847 (28.5) 703 (24) 1537 (51.8) -4.91 (-5.1 to -4.6) 690 (45) 589 (38) 
 
2 1,410 -3.60 (-3.8 to -3.3) 448 (32) 381 (27) 786 (55.7) -5.17 (-5.4 to -4.8) 379 (48) 324 (41) 
 
3 1,099 -3.67 (-3.9 to -3.4) 336 (30.5) 283 (26) 614 (55.8) -5.06 (-5.4 to -4.6) 274 (44.5) 234 (38) 
 
4 891 -3.80 (-4.0 to -3.5) 279 (31) 235 (28.5) 513 (57.5) -5.30 (-5.7 to -4.8) 235 (46) 204 (40) 
 
5 (least deprived) 924 -4.06 (-4.3 to -3.7) 312 (34) 262 (28.5) 573 (62) -5.30 (-5.6 to -4.9) 268 (47) 232 (40.5) 
 
Missing 39     19    
Age ≤29 671 -2.27 (-2.6 to -1.9) 
 
0.001 
140 (21) 103 (15) 288 (42.9) -3.84 (-4.4 to -3.2) 104 (36) 81 (28) 
 
30-39 1,050 -3.41 (-3.6 to -3.1) 309 (29.5) 240 (23) 536 (50.9) -5.15 (-5.5 to -4.7) 254 (47) 201 (37.5) 
 
40-49 1,821 -3.62 (-3.8 to –3.4) 563 (31) 453 (25) 974 (53.1) -5.47 (-5.7 to -5.1) 474 (48.5) 395 (40.5) 
 
50-59 1,946 -3.82 (-4.0 to -3.6) 627 (32) 523 (27) 1108 (56.9) -5.22 (-5.5 to -4.9) 518 (47) 436 (39) 
 
60-69 1,374 -3.94 (-4.1 to -3.7) 458 (33) 418 (30.5) 849 (61.7) -5.10 (-5.3 to -4.8) 390 (46) 361 (42.5) 
 
≥70 437 -3.59 (-4.0 to -3.1) 127 (29) 129 (29.5) 272 (62.2) -4.50 (-4.9 to -4.1) 108 (40) 110 (40.5) 
 
Missing 30     15    
Male ≤29 109 -3.75 (-4.7 to -2.7) 
0.56 
39 (36) 23(21) 52 (47.7) -5.70 (-7.3 to -4.0) 26 (50) 18 (34.5) 
 
30-39 211 -4.24 (-5.0 to -3.4) 78 (37) 49 (23) 113 (53.5) -6.25 (-7.3 to -5.1) 65 (57.5) 41 (36) 
 
40-49 449 -4.64 (-5.1 to -4.1) 168 (37.5) 123 (27.5) 247 (55) -6.88 (-7.6 to -6.1) 144 (58) 107 (43) 
 
50-59 599 -4.55 (-4.9 to -4.1) 232 (39) 178 (30) 358 (59.7) -6.23 (-6.8 to -5.6) 192 (53.5) 150 (42) 
 
60-69 481 -4.69 (-5.1 to -4.2) 194 (40) 155 (32) 327 (67.9) -5.79 (-6.3 to -5.2) 173 (53) 142 (43.5) 
 
≥70 117 -4.30 (-5.0 to -3.6) 46 (39) 43 (37) 81 (69.2) -5.07 (-5.9 to -4.2) 39 (48) 37 (45.5) 
 
Missing 12     8    
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  Total (completers & non-completers) (attended at least 2 sessions) Completers (subgroup of total) (attended at least 7 sessions) 
 
 N Mean weight change 
and 95% CI P-value 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
N (%) of 
total 
Mean weight change 
and 95% CI 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
Female ≤29 562 -1.98 (-2.2 to -1.6) 
0.001 
101 (18) 80 (14) 236 (41.9) -3.43 (-4.0 to -2.8) 78 (33) 63 (26.5) 
 30-39 839 -3.22 (-3.5 to -2.9) 231 (27.5) 191 (23) 423 (50.4) -4.85 (-5.3 to -4.4) 189 (44.5) 160 (38) 
 40-49 1,372 -3.29 (-3.5 to -3.0) 394 (29) 329 (24) 725 (54.8) -4.98 (-5.3 to -4.6) 329 (45.5) 287 (39.5) 
 50-59 1,347 -3.48 (-3.6 to -3.2) 394 (29) 344 (25.5) 749 (55.6) -4.72 (-5.0 to -4.4) 325 (43.5) 285 (38) 
 60-69 893 -3.54 (-3.7 to -3.3) 
 
264 (29.5) 263 (29.5) 522 (58.4) -4.66 (-4.9 to -4.3) 217 (41.5) 219 (42) 
 ≥70 320 -3.33 (-3.7 to -2.9) 81 (25) 86 (27) 191 (59.6) -4.26 (-4.6 to -3.8) 69 (36) 73 (38) 
BMI 30–34.9 840 -2.93 (-3.2 to -2.6) 
0.001 
193 (23) 220 (26) 468 (55.7) -4.09 (-4.4 to -3.7) 163 (35) 187 (40) 
 
35–39.9 2,346 -3.34 (-3.5 to -3.1) 668 (28.5) 643 (27.5) 1258 (53.6) -4.86 (-5.0 to -4.6) 561 (44.5) 542 (43) 
 
40–49.9 3,197 -3.66 (-3.8 to -3.5) 994 (31) 775 (24) 1754 (54.8) -5.17 (-5.3 to -4.9) 818 (46.5) 657 (37.5) 
 
≥50 946 -4.44 (-4.7 to -4.1) 377 (40) 236 (25) 562 (59.4) -6.18 (-6.6 to -5.7) 312 (55.5) 205 (36.5) 
Weight ˂75 44 -2.19 (-3.4 to -0.8) 
 
0.001 
5 (11.5) 12 (27) 21 (47.7) -3.27 (-4.0 to -2.5) 4 (19) 9 (43) 
 
75–99 1,930 -2.86 (-3.0 to -2.6) 440 (23) 503 (26) 1033 (53.5) -4.08 (-4.3 to -3.8) 370 (36) 417 (40.5) 
 
100–124 3,252 -3.48 (-3.6 to -3.3) 969 (30) 831(25.5) 1765 (54.2) -4.88 (-5.0 to -4.6) 791 (45) 697 (39.5) 
 
125–149 1,558 -4.12 (-4.3 to -3.9) 575 (37) 377 (24) 899 (57.7) -5.88 (-6.2 to -5.5) 489 (54.5) 340 (38) 
 
≥150 545 -5.23 (-5.6 to -4.8) 243 (44.5) 151 (27.5) 324 (59.4) -7.32 (-8.0 to -6.5) 200 (61.5) 128 (39.5) 
Diabetes No 5,757 -3.67 (-3.7 to -3.5) 0.001 1801 (31) 1496 (26) 3133 (54.4) -5.26 (-5.4 to -5.0) 1487 (47.5) 1270 (40.5) 
 
Yes 1,572 -3.24 (-3.4 to -3.0) 431 (27.5) 378 (24) 909 (57.8) -4.4 (-4.7 to -4.2) 367 (40.5) 321 (35.5) 
Hypertension No 6,139 -3.53 (-3.6 to -3.4) 0.03 1844 (30) 1560 (25.5) 3364 (55) -5.01 (-5.2 to -4.9) 1547 (46) 1331 (39.5) 
 Yes 1,190 -3.83 (-4.0 to -3.5) 388 (32.5) 314 (26.5) 678 (57) -5.08 (-5.4 to -4.7) 307 (45) 260 (38.5) 
     Table 3-4 Subgroup analyses for the lifestyle phase of the GCWMS, using the LOCF method. First referrals from 2008 to 
2014 inclusive (n =7,329). P-values were determined by using a t-test and ANOVA test (p-value <0.05 considered 
statistically significant) (CI: Confidence Interval; N: Number). 
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After completing the lifestyle intervention programme, the results showed completers 
(those attending at least 7 sessions) had greater weighted losses than non-completers (those 
attending fewer than 7 sessions). The mean weight change and 95% CI in completers and 
non-completers was -5.09 kg (95% CI: -5.2 to -4.9 kg) and -1.72 kg (95% CI: -1.8 to -1.6 
kg), respectively. In addition, the mean weight change in completers and all patients (total) 
was -5.09 kg and -3.58 kg respectively. By the end of the lifestyle phase, almost 55% of 
patients who attended at least two sessions, also attended at least seven sessions; and of 
these ‘completers’, 46% lost 5 kg or more. 30.5% of all patients (7,329) lost at least 5 kg at 
the end of the lifestyle phase (Table 3-5). Appendix 1 represents the mean weight change 
by the number of sessions attended, in order to establish whether a smaller number of 
sessions attended by the patients could lead to a clinically significant weight loss. Those 
who attended more sessions achieved a greater weight loss than the participants who 
attended fewer sessions. 
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 N % Mean weight change 
and 95% CI (kg) Lost ≥5 kg Lost ≥5% 
Phase 1 (total)      
Completers  
(≥7 sessions) 
4,042 55.1 -5.09 (-5.2 to -4.9) 1,854 (46%) 1,591 (39.5%) 
Non-completers (˂7 
sessions) 3,287 44.8 -1.72 (-1.8 to -1.6) 378 (11.5%) 283 (8.5%) 
Total (All) 
(≥2 sessions) 
7,329  -3.58 (-3.6 to -3.4) 2,232 (30.5%)      1,874 (25.5%) 
Overall % success 23,650 -              - 9.4% 8% 
Table 3-5 Weight loss at the end of the lifestyle phase from the first session in the same 
phase and the overall % success for referred patients (CI: Confidence Interval).
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3.4.3.2 Sex, age and SIMD 
Generally, men were more successful at achieving the 5 kg target weight loss (mean losses 
in men and women were 4.51 and 3.23 kg, respectively). Patients in the least deprived 
quintile lost more weight in both groups (completers and others) than the patients in the 
most deprived quintile did; however, deprivation did not appear to affect the proportion 
losing their target weight. The success rates for weight loss for men in all age groups, 
ranging from 30 to 70 years, were around 40% (37 to 40%) compared to around 30% (27.5 
to 29.5%) in women. Young men and young women had less success; 36% men vs. 18% of 
women aged under 30 years achieved 5 kg weight loss.  
 
3.4.3.3 Initial BMI, diabetes and hypertension 
Those patients who were heaviest (BMI ≥50 kg/m2 and weight ≥150 kg) achieved the 
greatest proportion of individuals losing 5 kg or more (40% and 44.5%). Patients with 
diabetes were less likely to achieve the ≥5 kg target weight loss (27.5% for those with 
diabetes and 31% for those without); the total mean weight change, and 95% CI in people 
with diabetes and people without diabetes were -3.24 kg (95% CI: -3.4 to -3.0 kg) and -
3.67 kg (95% CI: -3.7 to -3.5 kg) respectively. On the other hand, participants with 
hypertension were generally more successful at losing the 5 kg target weight than patients 
without hypertension (the mean weight change of 95% CI in patients with and without 
hypertension was -3.83 kg (95% CI: -4.0 to -3.5 kg) and -3.53 kg (95% CI: -3.6 to -3.4 kg), 
respectively.  
 
3.4.3.4 Target weight loss (5 kg and 5%) 
5 kg and 5% weight loss were looked at as these targets are mentioned in the guidelines 
(SIGN 115, 2010). Therefore, in terms of meeting the 5 kg and 5% weight loss target, male 
patients performed better than female patients with a 38.5% losing ≥5 kg and 29% ≥5% 
when compared to 27.5% losing ≥5 kg and 24% ≥5%. However, young men and young 
women (≤29 years) had the lowest proportion of individuals losing their target 5 kg or 
more. The heaviest participants (≥50 kg/m2) comprised the greatest proportion (40%) of 
individuals losing 5 kg or more, compared with the lighter individuals (≤35 kg/m2). 
Individuals without diabetes and those with hypertension were more successful at losing 
≥5%. In total, 55.1% of those participants who started GCWMS completed the lifestyle 
phase programme, and of those, 39.5% had lost 5% or more of their initial weight. Overall, 
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among all the patients who attended at least 2 sessions, 25.5% lost ≥5% of their initial 
body weight (Table 3-5). 
 
3.4.3.5 Overall percentage success 
Of the 23,650 participants who were referred to the GCWMS between 2008-2014, 9.4% of 
patients lost at least 5 kg and 8% lost ≥5% of their starting weight (Table 3-5). 
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3.5 Summary of the main findings 
• There was a low number of referrals from each health practice across the six-year 
duration studied; 27.7% of the total GPs had <10 referrals. 
• Many people referred to the GCWMS never attended, with only 31% of referred 
patients attending their first session. 
• The majority of those referred were women, from the most deprived areas, with 
BMIs between 35 and 50 kg/m2, did not have diabetes and had blood pressure 
within the normal range. 
• Half of the patients attending at least one session were classified as class III obese. 
• A higher proportion of men, those from the least deprived areas, those who were 
older and those with a higher initial body weight completed the lifestyle programme. 
• Patients aged 60-69 years, men, those from the least deprived areas, those with 
higher BMIs, those with high blood pressure, and individuals without diabetes were 
more likely to lose 5 kg. 
• This lifestyle (phase 1) programme was effective at achieving 5 kg weight loss, but 
only for fewer than 50% of the patients who completed the lifestyle phase. A greater 
proportion of those completing the programme (attended ≥7 sessions) lost their 
target (≥5 kg) compared with non-completers. 
• In terms of the % success for all patients referred to GCWMS, 9.4% and 8% lost 5 
kg and 5%, respectively. 
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3.6 Discussion 
This research evaluated the first phase (lifestyle) of GCWMS (n =7,329). The service’s 
established goal is for attendees to achieve at least a 5 kg weight loss, because there is 
evidence that moderate weight loss of 5–10 kg is associated with significant clinical 
benefits in individuals with obesity (Avenell et al., 2004). This research evaluated the 
effectiveness of the lifestyle phase of this large weight management programme by 
reporting the proportion of patients who lost at least 5 kg of weight during the lifestyle 
phase. Overall, the study found that 9.4% of all the patients referred lost at least 5 kg and 
30.5% of the participants who attended at least 2 sessions lost ≥5 kg. Among those patients 
who completed the lifestyle phase, over 46% achieved their target weight loss. 
 
3.6.1 GP practice referral 
There was a variation between the numbers of referrals from each GP practice. Low 
referral rates from the majority of GPs practices will not have occurred due to a lack of 
with obesity needing a weight management programme. The Scottish Health Survey 
(2011) reported that 24% of adults in Glasgow are obese; therefore, the possible reasons 
might have been patients preferring not to enrol in a weight management programme, or 
GPs’ lack of concern or interest in the programme. In addition, GPs might have preferred 
to avoid disputes with patients because of the unsuccessful overall percentage weight loss 
among referred patients, as fewer than 10% lost ≥5% of their initial weight. It is important 
to consider that the practice size and location may influence the number of referrals. 
 
A previous qualitative study explored GPs’ views about managing patients with obesity 
(21 GPs from 15 different practices in London); it concluded that GPs believe obesity 
management to be the patient’s responsibility, and so are unwilling to offer medical 
solutions (Epstein and Ogden, 2005). A further qualitative study (conducted in Portugal 
and interviewed 16 GPs) reported that GPs are frequently negative when discussing their 
role in treating patients with obesity (Teixeira et al., 2015). The majority of GPs believe 
that they will struggle to make any improvements simply by advising their patients to 
adopt long term lifestyle changes. GPs also commented on some barriers, such as lack of 
patient motivation, insufficient time allocated to counselling, lack of training, and 
communication problems with patients when talking about their weight. Additional 
previous studies have reported that 83% of GPs would raise weight as a problem with 
patients who are obese, but only 15% discussed weight management with them (Laws, 
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2004). Overall, the existing research found that GPs think the main cause of obesity is 
eating too much, an issue that is within patients’ control. The recommendations about what 
could be done to help motivate GPs’ and other primary care staff on this issue are 
discussed in Chapter 7. 
 
3.6.2 Referred patients’ characteristics 
In order to examine how representative the referred population to those who were eligible 
in NHS Greater Glasgow and Clyde, data from the Scottish Health Survey (2008-2011) 
were examined by another researcher (Daniel Slack, abstract in UKCO, 2015). A total of 
40% of the eligible population were men, of whom only 28.6% were referred to the 
GCWMS; and there was an over-representation of younger adults (aged 18-29) and those 
with a higher BMI. A total of 15.3% of the referred participants were aged 18-29 compared 
with 5.9% of the eligible population; 8.6% of those with a BMI >50 kg/m2 were referred, 
compared to 0.7% of the eligible population. However, it was found that the spread of 
deprivation was similar in both the eligible population and the participants referred to the 
GCWMS, which might indicate that they have greater need and fewer resources.  
 
Despite prevalence of obesity in both sexes being similar, just 28.7% (n =6,778) of all 
patients (n =23,650) referred to the GCWMS from 2008 to 2014 were men. Similarly, only 
18.5% of the referrals to a North Somerset scheme, 10.5% to Weight Watchers and 10.7% 
to Slimming World audits were for men (Dixon et al., 2012); leading to the conclusion that 
fewer men are referred to UK weight management centres. This research shows that the 
majority of the referred individuals were women (71.1%), indicating a reluctance among 
men to enrol in a lifestyle programme, or a reluctance among clinicians to refer men; this is 
consistent with the previous research (89.3% of the referred patients were women in 
Stubbs et al., 2011 and 81.5% in Dixon et al., 2012). Additionally, this finding concurs 
with another study that reported 73.7% of participants referred to Special Lifestyle 
Management (SLiM) were women.  
 
A previous study evaluated the rate of weight loss for 34,271 participants referred for a 12-
week course of Slimming World sessions (Stubbs et al., 2011). Of the referred patients, 
89% were women, and it has been suggested this might be because this programme failed 
to recognise gender concerns.   
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Other suggested reasons might be the fact that more men are in full-time employment 
(38%) compared with female (25%) (The Scottish Government, 2012) and therefore cannot 
commit to attending regular daytime appointments, or because the associations for men 
with increasing body size differ from those for women (i.e. men who are overweight and 
obese are generally less interested in their weight than their female counterparts (Gray et 
al., 2009; Stibb, 2004). Moreover, in case of illness, men are less likely to consult a 
physician and also generally less likely to participate in health services offered (Mansfield 
et al., 2003). A previous systematic review of the evidences for the management of obesity 
in men was funded by the Health Technology Assessment programme in the UK, and 
recommended providing a weight management programme in social places, such as 
workplaces and sports clubs, to attract men to enrol in weight management programmes 
(Robertson et al., 2014). In addition, according to the predictions of the Foresight report 
more men than women are overweight or obese; thus, further alterations to practices are 
needed to increase referral rates for men and to establish why men do not engage with 
weight management programmes (Government Office for Science, 2007). 
 
This research and previous findings in the two studies that evaluated the GCWMS show 
that most of the referred individuals were from the most deprived areas (47.4%), compared 
to those from the most affluent areas; (62% in Morrison et al. and 43.3% in Logue et al. 
studies). The reason might be because of the difficulties overcoming long term unhealthy 
food habits (Turrell et al., 2002) and their lower level of education (Drewnowski and 
Specter, 2004).  
 
3.6.3 Opt-in and dropout rate 
GCWMS offers longer term support, of up to two years, to individuals who choose to 
continue losing weight. However, some patients choose to leave the programme after the 
first or second month, possibly due to factors such as weight regain, failure to lose weight, 
or confidence brought about by their weight loss success, as they believe they can follow 
the same treatment plan at home independently without the assistance of the service. This 
explains the reasons for the missing data and using the LOCF method. A previous study (n 
=124), which recruited patients with BMI >30 kg/m2 from outpatients’ clinic in Croatia or 
via GP referral to a weight management study for 12 months, was performed to identify 
factors that predict dropout rates. This study found the overall drop rate was 32.3% and 
resulted from reasons ranging from lack of motivation (15.3%), to psychological problems 
or health-related issues (8.0%). Moreover, it was not possible to contact the patients (6.4%) 
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due to unhappiness with the programme (2.4%); in addition to their lower education level 
(Hadziabdic et al., 2015).  
 
Young patients dropped out of the programme at a higher rate than older people (81.5% of 
young patients aged 18-29 years dropped out) and this result is consistent with previous 
findings of the multidisciplinary tier 3 of the Fakenham weight management service 
(FWMS) (Jennings et al., 2014). It was found that the mean age of participants who were 
assessed but not recruited was lower than those who attended (45.2 vs. 52.7 years, p 
=0.001). A possible explanation of this might be the priority given to family members and 
children or work commitments. Another possible explanation is insufficient weight loss 
reducing their motivation to attend sessions.  
 
Moreover, patients from the most deprived areas were more likely to drop out, as only 
26.5% of the total number of patients referred turned up. This could be due to a lack of 
transportation or the need to prioritise work. A higher proportion of patients with BMI ≥50 
kg/m2 had turned up, possibly due to their concern that their body weight was damaging 
their overall health. In contrast, a RCT (2 year’s duration in the US) compared weight loss 
achieved through self-help weight loss and with a designed commercial programme (12 
weeks), and suggested that most of the patients who dropped out had higher starting BMIs 
(Heshka et al., 2003). This discrepancy could be due to the difference in the BMI at 
baseline between the two studies for recruited patients; individuals with BMI ≥30 kg/m2 
were included in this research, whereas, Heshka et al.’s study included patients with BMI 
27-40 kg/m2. The RCT thus stopped at BMI =40 kg/m2, while the current study includes 
patients with much higher BMIs, some with BMI of >50 kg/m2. 
 
A further interesting finding was that referred patients with hypertension and diabetes had 
a higher likelihood of turning up (37.6% and 36% respectively), compared with people 
without hypertension and without diabetes (30% and 30% respectively). It seems possible 
that this result is due to high blood pressure being an age-related problem and therefore as 
more older individuals turned up than younger ones; this creates the illusion of a highly 
significant effect. Another possible explanation, however, might be that a diagnosis of 
hypertension and diabetes heightened patients’ anxieties regarding their general health.  
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3.6.4 Completion rate 
Some studies have used the higher threshold of 80% to define programme completion; this 
was consistent with the current research (Stubbs et al., 2011; Dixon et al., 2012). 
Elsewhere, previous studies have applied a lower threshold and defined completed cases as 
participants who attended four or more appointments in 3 months, five or more sessions in 
6 months, or six or more sessions in 12 months (McCombie et al., 2012); defining 
completers as those who attended at least half the sessions (Morrison et al., 2011; Logue et 
al., 2014). Studies using the current threshold for completion (80%) may lead to a more 
accurate reflection of the true effectiveness of weight management programmes when 
compared with studies that define completion as attendance of 50% of the sessions. 
However, lower thresholds (around the 50% attendance rate) are a more realistic reflection 
of the median number of sessions attended by patients and therefore these studies using 
these lower thresholds include more patients when compared to studies using higher 
thresholds (80%) that then tend to focus on individuals that achieve higher weight losses. 
80% is equivalent to the threshold of drug adherence used in the majority of medication 
trials as they wish to measure the effect of exposure to the full course of treatment; by 
using 80% attendance then it is ensuring exposure to the full course of behavioural 
treatment. The research results show a significant difference in completion rates between 
the sexes; men who completed the programme achieved their target weight loss. Stubbs et 
al. (2011) and Brown et al. (2015) reported completion rates of 57.4% in Slimming World 
and 55.2% in SLiM respectively among women (compared with 53.3% in the current 
research).    
 
55.1% of the participants who attended at least 2 sessions completed the treatment 
programme. This research shows a low completion rate in younger participants and those 
in the most deprived quintile, which is consistent with the finding of a previous 
randomised trial (Heshka et al., 2003). In terms of comparing completion rate with other 
services, 56% of SLiM patients completed a 6 month course of treatment (Brown et al., 
2015); and from the Lighten Up RCT at 3 months duration, 66%, 63% and 64% of 
participants completed the Weight Watchers, Sliming World or Rosemary Conley 
programmes (Jolly et al., 2011). Another study reported that out of 34,271 participants 
referred to Sliming World between 2004 and 2009, those who attended 12 sessions over a 
three-month period; totalled 58.1%, where programme completion was measured by 
attendance at minimum of 10 sessions out of 12 (Stubbs et al., 2011). In conclusion, the 
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completion rate at GCWMS was low but consistent with other services; hence, this is a 
problem of all services and an area that needs further improvement. 
 
3.6.5 Weight loss outcomes and comparison with other weight management 
programmes 
To the best of our knowledge, this research is one of very few examples of an evaluation of 
the effectiveness of a lifestyle intervention made by a specialist weight management 
programme targeting subjects who are obese with BMI ≥30 kg/m2. The research findings 
show that the NHS GCWMS achieved a 5 kg weight loss in 30.5% of participants 
following the lifestyle intervention. This equates with 25.5% of participants losing 5% of 
their initial body weight when a LOCF analysis is used, as the mean weight was greater 
than 100 kg at baseline. In total, 46% of participants who completed the programme 
achieved at least 5 kg weight loss and 39.5% of the individuals lost 5% of their weight.  
 
In comparison with an earlier study by Morrison et al. (2011), which evaluated the lifestyle 
phase of all patients referred to the GCWMS between 2004 and 2006, 13.6% of patients 
who opted into the programme lost at least 5 kg compared with 30.5% in the current 
research. 35.5% of the patients completing the programme lost at least 5 kg, compared 
with 46% in this study. Additionally, a previous BMJ paper by Logue et al. (2014), which 
evaluated the GCWMS (2008-2009) over 12 months, reported that 26% of patients who 
opted in and 36% of those completing the programme had lost ≥5 kg at the end of the 
lifestyle phase. These results are better than the results obtained in the earlier two studies; 
this might be attributable to the fact that as the patient figures spanned 6 years (2008-2014) 
the service may have improved over time. Another reason why the results are better might 
be that a higher threshold for completion than that used in previous studies was used in this 
study. As attendance is linked with successful weight loss, higher thresholds will 
selectively detect participants with higher weight losses. This will not affect all the patients 
included in the study; however, this research included participants who attended at least 2 
sessions, whereas the other two papers included all the patients who attended ≥1 session. 
  
In comparing the current results of the GCWMS with the other tier 3 weight management 
programme, the following table summarises the results of the three different weight 
management services (GCWMS, FWMS, and SLiM): 
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Results GCWMS FWMS SLiM 
Mean age (years) 46.2 52.7 48.2 
Sex (% of females) 71.1 70 73.7 
Initial weight (kg) 115.2 124.4 135 
Initial BM (kg/m2) 42.2 44.1 49.1 
Mean weight change 
(kg) 
 
-3.58 after 4 months 
 
-3.6 after 3 months -4.1 after 6 months 
 
≥5% weight loss (%) 
 
25.5 after 4 months 
39.5 (completers) 
 
25.2 after 3 months 
34.2 (completers) 
 
24.9 after 6 months 
32.3 (completers) 
 
Dropout rate (%) 
 
44.8 after 3 months 
 
14.3 after 6 months 
 
44 after 6 months 
Completion definitions Attended ≥7 
sessions over 4 
months 
 
Attended all the 
sessions (10-15 
sessions) over 1 
year 
 
Attended all 
sessions (6 
sessions) over 6 
months 
Table 3-6 Summary of the results from three different weight management programmes 
(tier 3). 
 
In comparison with the SLiM programme in Birmingham, a total of 828 participants with 
BMI ≥35 kg/m2 with comorbidity or ≥40 kg/m2 without comorbidity were enrolled 
between 2009 and 2013, within SLiM over 48 months duration (Brown et al., 2015). SLiM 
included monthly sessions over 6 months of lifestyle interventions and behavioural 
modification; and those who attended all 6 sessions were defined as completers. The mean 
weight change in the current study for all the participants (LOCF) was -3.58 kg (95% CI: -
3.6 to -3.4 kg) over 4 months duration, compared with -4.1 kg (95% CI: -3.6 to -4.6 kg) for 
all the SLiM participants at 6 months duration. 25.5% by the end of the lifestyle phase of 
the current study, and 24.9% at the end of SLiM, achieved at least 5% weight loss, and this 
might be due to the higher mean weight (135 kg) and BMI (49.1 kg/m2) at baseline for the 
SLiM patients. In cases of completion, the mean weight change was -3.7 and -5.5 kg (95% 
CI: -4.9 to -6.2 kg) at 3 and 6 months duration on the SLiM programme, compared to -5.09 
kg (95% CI: -5.2 to -4.9 kg) for the GCWMS patients. Moreover, 44.4% and 32.3% of 
SLiM patients lost ≥5 kg and ≥5% of initial weight respectively, compared with 46% and 
39.5% of GCWMS participants completing the programme. The completion rate for SLiM 
(56%) was very similar to that for the GCWMS; patients had a higher BMI at baseline 
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(49.1 kg/m2), and hence a lower percentage weight loss. In conclusion, SLiM achieved a 
lesser result than the GCWMS; this might be due to the fact that SLiM comprises a lower 
intensity lifestyle treatment and patients with a higher BMI than GCWMS.  
 
Additionally, in comparison with other multidisciplinary FWMS in primary care (more 
details about the service are given in Chapter 1, page 70), the mean weight change at 3 
months duration for 218 participants was -3.6 kg and 25.2% of the participants lost at least 
5% of initial weight. There are some similarities in the outcomes between this programme 
and the results of the current research; in addition, the patients had almost the same 
characteristics as the GCWMS participants. The FWMS included participants with BMI 
≥30 kg/m2 with co-morbidity or ≥40 kg/m2; however, it provided monthly sessions and 
one-year outcomes were reported. Those included in the FWMS were heavier than the 
participants in the GCWMS (the mean weight at baseline was 124.4 kg vs. 115.2 kg). 
Some limitations can be noticed as the percentage of 5 kg weight loss was not reported, in 
addition, the FWMS was evaluated from the initial set up in August 2011 to August 2012, 
and this relatively shorter period may not reflect its ultimate effectiveness (Jennings et al., 
2014).  
 
Comparisons with other weight management service (tier 2 services) outcomes are 
reasonable, with caution, as tier 2 is also a lifestyle weight management programme. 
However, there were differences between the methods used and the duration of the studies, 
in addition to the higher BMIs of the GCWMS participants. The GCWMS participants had 
a mean BMI of 42.2 kg/m2, which is higher than the Counterweight programme (BMI 37.1 
kg/m2) or the Lighten Up trials (33.9 kg/m2 in Weight Watchers, 33.8 kg/m2 in Slimming 
World, 33.4 kg/m2 in Rosemary Conley and 33.1 kg/m2 in GP subgroup). For instance, the 
Lighten Up RCT reported that the proportions of patients achieving 5% loss in body 
weight at one year follow-up in Weight Watchers, Slimming World, and Rosemary Conley 
were 31%, 21% and 26%, respectively (Jolly et al., 2011). Additionally, there were 
differences in the data collection procedures between the current research and the Lighten 
Up study, as they used patient self-reporting for final weight; and the data were from RCTs 
where the mean BMIs were below 38 kg/m2.  
 
A previous study that evaluated a multicomponent lifestyle modification of the Live Life 
Better Service in the UK, from the period April 2010 to 30 April 2013, reported that 26% 
of 242 participants had lost at least 5% of their initial weight after 12 weeks duration 
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(mean weight change was -4.9 kg). However, it recruited participants with BMI ≥35 kg/m2 
with a comorbidity or BMI >40 kg/m2, which differ from the inclusion criteria for the 
current research. Unfortunately, this study did not report the proportion of patients who 
lost 5 kg and the outcomes for the completers to allow a comparison with the current data 
(Wallace et al., 2016).  
 
Another recent study evaluated a tier 2 multi-component weight management programme 
on referral (WMOR) that was offered through NHS South Gloucestershire in the UK from 
October 2008 to November 2010 (Birnie et al., 2016). This programme included a 12 week 
course of sessions consisting of dietary advice, physical activity, and information on 
behavioural change. Participants were able to access group meetings of Weight Watchers 
as well as receiving vouchers for a 12 week course of supervised group sessions. The mean 
weight change for all participants (n =559) in the study was -3.7 kg (95% CI: -3.4 to 4.1 
kg). This figure is higher than the current result, as 32% of all participants and 58% of 
patients who completed the WMOR programme lost ≥5% of their initial weight. The 
participants in the WMOR programme were lighter (BMI ≥28 kg/m2 and co-morbidities) 
than the GCWMS participants, and the definition of course completion was higher than in 
the current research, which may explain the difference in the percentage weight loss.  
 
Another study (n =29,326 from 2007 to 2009) evaluated the weight change among 
participants referred to Weight Watchers by the NHS in the UK. 33% of all patients, and 
54% of those completed the programme and attended 12 sessions at Weight Watchers over 
3 months lost ≥5% initial weight (Ahern et al., 2011). This might be due to the lower 
average BMI of the Weight Watchers’ patients at baseline, as the average BMI in the study 
was 35.1 kg/m2 and 42.2 kg/m2 in GCWMS. Therefore, the most successful programme is 
Weight Watchers, possibly a result of the higher attendance levels it commands (Dixon et 
al., 2012). Only 36% of participants attended Slimming World completed the programme 
of treatment compared with 44.8% for Rosemary Conley and 56% for Weight Watchers. In 
contrast with GCWMS, the Weight Watchers programme not only provides group support 
and dietary counselling, but also offers a variety of food products that can be purchased 
from supermarkets. Additionally, it provides support through technological media such as 
smart phones and computers.  
 
Compared with the initial experience of the application of a Counterweight programme 
(1,256 participants) (more information about the programme is provided in Chapter 1, page 
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68), the current research shows the mean weight loss after 16 weeks’ duration was -3.58 
kg; the mean weight change in the Counterweight programmes for patients at three months 
(n =599) was -3.4 kg (Laws, 2004). This equates to 25.5% and 25.3% of patients losing 
≥5% of their initial weight in the GCWMS and Counterweight programmes respectively. 
Of the 47.6% of those completing the Counterweight programme by attending 4 out of 6 
sessions, 28% had lost ≥5% of weight. However, 55.1% completed the lifestyle 
programme in GCWMS, and of these, 39.5% lost 5% or more of their initial weight. 
Therefore, when complete cases are considered, GCWMS is more successful than 
Counterweight programme in achieving 5% weight loss. The possible reasons may be due 
to the differences in completion rate, programme and methodological approach, and may 
be because the GCWMS patients were more motivated than Counterweight programme 
patients. It is relatively easy for Counterweight patients to attend appointments in a 
practice provided by practice nurses, whereas the GCWMS patients generally had to travel 
further to attend sessions, perhaps indicating higher motivation. 
 
3.6.6 Weight loss outcomes for subgroups 
3.6.6.1 Men and women 
This research shows men lost more weight than women in terms of both absolute kg and 
5% of body weight at baseline, which is consistent with others findings (Dixon et al., 2012; 
Morrison et al., 2011). A previous study (n =34,271) audited the rate and extent of weight 
loss for participants referred to the Sliming World in the UK between 2004 and 2009 for 
12 weekly sessions. It found that the average weight change and percentage weight change 
for men and women were -5.8 kg (-4.9%) and -3.8 kg (-3.9%), respectively (Stubbs et al., 
2011). This potentially may be related to men having on average a higher weight at 
baseline. In the HTA report, a previous systematic review of RCTs assessing UK 
interventions, examined the management of obesity in men only, or men and women in the 
same trial. It suggested that whilst it is apparently more difficult for men to join a weight 
loss programme in the first place, when they do opt in and embark on one, they are more 
conscientious in their approach (Robertson et al., 2014). Further work is needed to ensure 
the programme is more successful in women to improve overall retention. 
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3.6.6.2 BMI 
A previous study (evaluating the lifestyle phase of GCWMS between 2004 and 2006) 
showed that individuals with BMI ≥50 kg/m2 were more likely to complete a programme 
than those with BMIs between 35 and 39 kg/m2, although they were no more likely to lose 
weight when they did (Morrison et al., 2011). While, the current research found the same 
results concerning completion status, it also revealed that those with BMI ≥50 kg/m2 were 
more likely to lose 5 kg or more. In total, 23% of patients with a BMI=30-34.9 kg/m2 and 
40% of those with BMI ≥50 kg/m2 lost at least 5 kg. It is likely the greater success among 
patients with higher BMIs was at least partially because nearly 60% completed ≥80% 
sessions.  
 
The Counterweight Project Team (2008) evaluated the counterweight programme of 1,906 
patients with BMIs ≥30 kg/m2, or ≥28 kg/m2, and with obesity-related comorbidities, from 
65 UK general practices. They found that after 12 months duration of lifestyle change, the 
mean weight changes for participants with BMI <30 kg/m2 and BMI >40 kg/m2 were -1.87 
kg (95% CI: -3.8 to -0.05 kg) and -4.6 kg (95% CI: -5.9 to -3.2 kg), respectively. This is in 
agreement with the current findings that show participants with a higher BMI lost more 
weight than those with a lower BMI. Moreover, the current result is consistent with a 
recent study reporting the weight outcomes in 1.3 million adults over 3 months attending 
the Slimming World programme in the UK (Stubbs et al., 2015). It was suggested that the 
absolute weight loss improved when increasing the BMI category (p <0.001), as the mean 
weight change was -3.1 kg, -3.9 kg, -4.5 kg and -5.4 kg for those with BMIs <30 kg/m2, 
30-34.9 kg/m2, 35-39.9 kg/m2 and ≥40 kg/m2, respectively. This might be due to greater 
health concerns, and making radical changes to obvious bad eating habits. 
 
3.6.6.3 Age 
Young individuals (≤29 years) were less likely to complete the programme and lose weight 
than older participants. In total, 42.9% of those aged ≤29 years completed the programme 
and their mean weight change was -3.84 kg (95% CI: -4.4 to -3.2 kg), compared with 
62.2% of those aged ≥70 years. Generally, participants aged ≥30 year from both sexes lost 
more weight than the group aged ≤29 years. This is broadly consistent with the results of 
the Counterweight programme study, which evaluated 642 participants attending the 
programme for 12 months (Counterweight Project Team, 2008). The mean weight change 
for those aged <25 year was -1.69 kg (95% CI: -4.8 to -1.4 kg), and -2.71 kg (95% CI: -3.5 
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to -1.9 kg) for those aged ≥65 years. In addition, an earlier evaluation paper published in 
the BMJ Open, which reported the outcomes over a 12 month period and evaluated the 
GCWMS phases, suggested that young men had the greatest success and young women the 
least success (Logue et al., 2014).  
 
However, this research found that both young men and young women had the lowest levels 
of success in losing weight, although the difference was not statistically significant for the 
male group. The differences might be a result of the different types of intervention offered 
for the patients in phase 2 (FWL, pharmacotherapy or LCD), as the BMJ paper evaluated 
the three phases. In contrast, this research evaluated phase 1, and patients were only 
offered a lifestyle intervention. Moreover, this result concurs with an earlier study 
evaluating the lifestyle phase of the GCWMS over 2 years; this found 679 participants 
aged <40 years (31.1%) completed the treatment programme, compared with 42.9% in the 
age bracket ≥60 years. Respectively, 33.1% and 35.3% of patients aged <40 years and ≥60 
years lost at least 5 kg in weight (Morrison et al., 2011). As stated earlier, the possible 
reasons for this might be patients’ reduced enthusiasm because they are not yet suffering 
from any health issues, and the greater priority given to family or work commitments. 
 
3.6.6.4 SIMD 
As stated above, the majority of patients referred were in the most deprived quintile. 
However, they were less likely to turn up, with only 26.5% doing so compared with 40% 
from the least deprived quintile.  In addition, those in the least deprived quintile lost more 
weight than those in the most deprived quintile (-4.06 kg (95% CI: 4.3 to -3.7 kg) and -
3.32 kg (95% CI: -3.4 to -3.1 kg)), respectively. In terms of programme completion, a 
higher proportion of patients from the least deprived quintile completed the programme, 
but there was no significant difference in weight loss in relation to socio-economic status. 
A total of 62% of patients in the least deprived quintile and 51.8% in the most deprived 
quintile completed the programme, and the mean weight change was -5.30 kg (95% CI: -
5.6 to -4.9 kg) and -4.91 kg (95% CI: -5.1 to -4.6 kg). An evaluation of GCWMS by 
Morrison et al. (2011) that covered the years 2004 to 2006 found that 49.3% and 34.4% of 
the people in the least deprived quintile and the most deprived quintile completed the 
programme. Unfortunately, there were no data from other weight management 
programmes to compare the effect of SIMD with current results. A possible reason for the 
poor attendance and completion of the programme could, as stated earlier, be due to a lack 
of transportation or the need to prioritise work. The recommendation highlights approaches 
 147 
to improve retention within the service for patients opted in from more deprived areas, 
such as providing education in the area itself, and providing transportation for individuals 
to attend appointments.  
 
3.6.6.5 Diabetes 
The current research shows the absence of diabetes was associated with increased mean 
weight loss; the mean weight change was -3.24 kg (95% CI: -3.4 to -3.0 kg) and -3.67 kg 
(95% CI: -3.7 to -3.5 kg) in patients with and without diabetes, respectively. This 
difference was statistically significant, p-value =0.001. This finding concurs with another 
study that evaluated the Counterweight programme over 65 GP practices delivering 
interventions to 1906 participants with a BMI ≥30 kg/m2. It shows that the mean weight 
change in patients with 12 monthly data in a Counterweight programme was -3.30 kg (95% 
CI: -3.9 to -2.7 kg) in patients without diabetes and -1.63 kg (95% CI: -2.4 to -0.7 kg) in 
patients with diabetes (Counterweight Project Team, 2008). This may be due to the 
differences in dietary adherence or because some anti-diabetic drugs may cause weight 
gain. This is based on a good range of evidence showing that some anti-diabetic drugs, 
such as metformin, GLP-1 and SGLT2, might cause weight loss or no change in weight, 
whilst others, such as SUs and TZDs, may cause weight gain (Bonora, 2007; Krentz, 2008; 
Solini, 2015). Additionally, Wing et al. (1987) found that people who were overweight and 
suffered from type 2 diabetes (12 subjects: 6 men and 6 women) lost less weight than their 
spouse without type 2 diabetes. After a behavioural 20-weeks weight-control programme, 
the weight change in participants with and without type 2 diabetes was -7.5 kg and -13.4 
kg, p <0.01, respectively.  
 
In comparison with the SLiM programme, the mean weight change for patients with 
diabetes who completed the lifestyle intervention at GCWMS (n =909) was -4.4 kg (95% 
CI: -4.7 to -4.2 kg), compared with -5.7 kg for the SLiM patients with diabetes after six 
months (n =142). In addition, a recent pilot study (n =34) evaluated the clinical outcomes 
of a 12 week lifestyle intervention programme that was delivered in a primary care setting 
in the UK and recruited participants with type 2 diabetes or pre-diabetes. It was found that 
the mean weight change was -3.1 kg (±2.3) after three months (Huntriss & White, 2016). 
 
The Via Christi Weight Management programme (VCWM) is another weight loss 
programme, established in 1994 in the US as a partner of the Health Management 
Resources (HMR) that offers medically supervised weight loss. The programme comprises 
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two phases: phase 1 (LCD with behavioural modification) and phase 2 (maintenance). In 
comparison with the VCWM, a previous study sought to determine the effect of a LCD and 
behavioural change programme (12 weeks) in weight change for patients who are obese 
(BMI ≥30 kg/m2) with and without diabetes. From 2009 to 2010, 310 charts were reviewed 
for patients with and without diabetes enrolled in the VCWM in the US. Data were 
collected before and after participants underwent a programme of meal replacement and 
weekly physical activity over a 12 week period; the mean ages for patients with and 
without diabetes were 54 and 50 years respectively. It found that patients with diabetes lost 
an average of 11.7% of their initial body weight, compared with 12.5% in those without 
diabetes (Stanford et al., 2012). It could therefore be concluded from the above studies that 
people with diabetes were less successful at losing weight, possibly because of their use of 
anti-diabetic drugs, which is explored further in Chapter 6. 
 
3.6.6.6 Hypertension 
In this research, participants with hypertension were more successful at losing the 5 kg 
target weight, and the reason for this was not clear, as some anti-hypertensive medications 
can cause weight gain, such as beta-blockers and some may cause weight loss, such as the 
diuretic group. The current results show that patients with hypertension lost a greater 
weight than those without hypertension. This result appears to be consistent with another 
study that aimed to evaluate rates and predictors of weight loss among 2,906 participants 
with obesity in the US who received regular primary care from 2008 to 2011, and who 
achieved hypertension control over a year. It found that participants who were prescribed 
antihypertensive medication (OR: 1.37, 95% CI: 1.07 to 1.76) were more likely to achieve 
clinically significant weight loss, compared with participants without antihypertensive 
drugs (Ho et al., 2016). This might be a result of the increased concern of participants with 
hypertension about their health, leading to improved dietary adherence. In addition, as this 
study shows, older people were more likely to lose their target weight, in which case the 
results might be attributable to age interaction, as the mean age for patients with and 
without hypertension was 55.2 years and 43.8 years respectively. However, to date few 
studies have conducted detailed investigation into weight loss comparisons between 
patients with and without hypertension. 
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3.7 Target weight loss and clinical benefits 
Currently, the GCWM target is to achieve a 5 kg weight loss. However, given the higher 
BMI of individuals in this specialist weight management service, 5 kg is equal to 4.2% of 
mean body weight (mean initial weight was 115.2 kg). Based on the SIGN guidelines, 
“weight loss targets should be based on the participants’ comorbidities and risks, rather 
than their weight alone. As those with BMI 25-35 kg/m2 are less likely to have obesity-
related comorbidities, a 5-10% (5-10 kg) weight loss is needed to reduce the risk of 
metabolic disorders and cardiovascular disease. As obesity-related comorbidities are more 
likely to be present in patients with BMI >35 kg/m2, a weight loss in excess of 15-20% will 
be required for comorbidity improvement” (SIGN 115, 2010).  
 
A previous RCT that included subjects with BMI ≥27 kg/m2 and aged 60 years or older, 
reported that a 5% weight loss was associated with reduced knee pain and improved 
physical function in patients with obesity and knee osteoarthritis (Bales and Buhr, 2008). 
On the other hand, another RCT included 192 patients with obesity and osteoarthritis, who 
were treated with a very-low-energy diet (VLED) (415 kcal/d) or a low-energy diet (LED) 
(810kcal/d) for eight weeks, followed by a 1,200 kcal/d diet for eight weeks (Riecke et al., 
2010). It was found that patients lost 12% of their initial body weight in both groups, with 
60% of patients in both groups experiencing reduced symptoms and improved mobility. In 
addition, patients enrolled on the Cambridge Weight Plan formula diet (800 kcal/d) were 
able to achieve a 10 to 12 kg weight loss over eight weeks. This amount of weight loss 
could prevent type 2 diabetes and improve metabolic control for patients on insulin 
treatment (Leeds, 2016).  
 
Another RCT was carried out on 60 participants with a BMI >27 kg/m2 and had plaque 
psoriasis were recruited from the outpatients clinic in Denmark (Jensen et al., 2013). After 
16 weeks of LED (800 to 1000 kcal/d) or routine dietary guidance (control group), the 
mean weight change in the LED and control groups was -15.8 kg and -0.4 kg, respectively. 
The mean change in the Psoriasis Area and Severity Index (PASI) in the LED group was -
2.3 and -0.3 in the control group. The mean difference was -2.0 (95% CI: -4.1 to 0.1; p 
=0.06), which is not statistically significant. Moreover, Vilar-Gomez et al. (2015) found 
that a modest weight loss (7%-10%) was associated with significant improvements in liver 
histology in patients with obesity and non-alcoholic steatohepatitis (NASH). However, 
≥10% weight loss was a prompt resolution of steatohepatitis and improving fibrosis. 
Furthermore, Johansson et al. (2011) found that with the LED programme, participants 
 150 
who lost ≥15 kg showed greater improvement in the apnoea-hypopnoea index after 1 year 
than those who lost 10-14.9 kg (-30 vs. -15, p =0.004), or those who lost less than 10 kg (-
30 vs. -15, p =0.008). 
 
Therefore, due to the higher initial BMI and range of comorbidities in the GCWMS, and 
the clinical benefits of losing ≥10 kg of initial weight, the weight loss target of the 
GCWMS might need to be reviewed and a higher target set. 
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3.8 Research strengths and limitations 
The main strength of this study is that real-life data were obtained from the NHS, 
providing the largest weight management service dataset available for a programme 
targeting participants with severe and complex obesity. In addition, the large sample size, 
and data such as weight and height were measured by trained dieticians and not self-
reported. The mean weight change among all patients referred to the GCWMS was 
reported, and not only those who completed the programme. Therefore, it was possible to 
ascertain the benefits from attending the programme of treatment for certain. The threshold 
that defined programme completion was high when compared with previous studies that 
used lower thresholds. On the other hand, the higher threshold of 80% to mark programme 
completion means that the weight lost by the group of participants who completed the 
programme was likely to be greater. In addition, the research reported the outcomes for 
completers and non-completers, yielding exact quantification of the achievements of the 
GCWMS.  
 
It is both a strength and limitation of this research that the included sample was not 
randomly allocated. However, multiple imputations are not applicable for use in this 
research as the missing data are not random, which might produce misleading results. 
Moreover, BOCF was not used, because it was assumed that it could assign unrealistic 
weight regain to subjects whose weight loss near to the end of the programme is known. 
Consequently, this study benefits from the use of LOCF to minimise the number of 
individuals who dropped out from the analysis and to allow the analysis to examine weight 
loss over time. However, it would underestimate weight loss in the short term and 
overestimates it in the long term (Jorgensen et al., 2014); in addition, it ignores the 
trajectory of weight loss. Jorgensen et al. (2014) randomly allocated 561 individuals to 
groups receiving an anti-obesity drug or a placebo for 60 weeks and measured the rate of 
weight loss in each group using different analysis methods. At the end of treatment, 
participants lost 6.8 kg (SE 0.66), 6.4 kg (SE 0.90) and 1.5 kg (SE 0.28) through LOCF, 
multiple imputation, and BOCF respectively. The researchers concluded that LOCF is a 
conservative analysis and had a lower SE than the multiple imputation method. 
 
Whilst using real-life data have massive benefits, its use in this study also caused some 
problems, resulting in poorly specified information or missing data. Additionally, there 
was a lack of weight measurement when some referred patients missed some of the 
treatment sessions; another good source of weights was not readily available. For example, 
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as GP records are not available for research at this point, if the participant drops out it is 
not possible to determine what subsequently happened to them. There was no control 
group, as the results depended on participants joining the programme, which differed from 
the approach adopted in RCTs. Generally, RCTs provide data that illustrate the efficacy, 
quality and safety of an intervention as endpoints, rather than real world data describing its 
effectiveness. This study could therefore provide more realistic answers in normal 
conditions, in contrast to the highly standardised context of RCTs. The comorbidity data, 
such as diabetes and hypertension are also potentially unreliable, as while these were 
highlighted in the referral forms from GPs, no access is permitted to the patients’ medical 
records to confirm this. In addition, the data are limited by the lack of additional 
information regarding factors such as the change in clinical risk factors (e.g. glycaemic 
control, blood pressure and lipids) or changes in medication doses. A further limitation is 
that as long-term weight loss outcomes are not available (no GP data are available), the 
opportunity to evaluate the maintenance phase would be useful to illustrate the effect of 
GCWMS over a longer time frame.   
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3.9 Research implications 
The lifestyle phase of the GCWMS programme showed modest results, achieving ≥5kg 
weight loss in 30.5% of individuals who attended at least 2 sessions. This chapter suggests 
the lifestyle treatment phase is clinically effective for patients who completed the treatment 
programme, among whom 46% were successful in losing at least 5 kg. In addition, it 
showed that greater absolute weight loss is achievable by those with higher starting BMIs, 
which might indicate that the GCWMS goal of ≥5 kg weight loss might not be sufficient to 
mitigate risk adequately in patients with BMIs ≥40 kg/m2. Behavioural change is very 
important if patients are to complete the programme and ultimately guarantee effective 
weight management. Therefore, it is necessary to evolve the GCWMS in order to facilitate 
an improved impact. Some recommendations are needed for GCWMS to improve their 
service; such as, attracting more men to join the programme, encouraging patients from 
areas of higher socioeconomic deprivation to opt in, and motivating patients to complete 
the programme to achieve better results. The lifestyle treatment phase, which includes 
dietary management, exercise and behavioural interventions, should be considered one of 
the main treatment plans at GCWMS. Therefore, in the next chapter (Chapter 4), the 
effectiveness of phase 2 treatment will be evaluated by exploring the effect of different 
interventions in phase 2 (orlistat, LDL and FWL). Further implications and 
recommendation for the development of the GCWMS will be discussed in Chapter 7. 
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6 4.1 Chapter summary 
In addition to the insufficient evidence concerning the effectiveness of weight management 
services, there is a dearth of studies evaluating the effectiveness of different interventions 
for treating individuals with obesity. The objective of this research was to evaluate the 
effectiveness of these interventions (orlistat, low-calorie diet (LCD) and further lifestyle 
advice (FWL)) in phase 2 of GCWMS, setting a target of achieving ≥5 kg weight loss, 
exploring the effects of age, sex, initial weight, BMI and co-morbidities such as diabetes 
and hypertension.  Subjects with BMI ≥30 kg/m2, and who had attended at least 2 sessions 
in the lifestyle phase and 2 sessions in phase 2 were included. LOCF and programme 
completers were reported in terms of mean weight changes with 95% confidence intervals, 
5 kg and 5% weight losses at the end of phase 2 based on a starting point of the first clinic 
visit in the lifestyle phase.  
 
Of the 4,709 individuals who chose to participate in phase 2, 3,262 patients attended 2 
sessions or more. Of these 536, 1,043 and 1,683 patients selected orlistat, LCD and FWL, 
respectively. The majority of the patients were female, from the most deprived quintile, 
had a BMI between 35 kg/m2 and 50 kg/m2, and had neither diabetes nor hypertension. The 
mean weight change for the participants who opted into the service and attended at least 2 
sessions in each phase (the lifestyle phase and phase 2) was -6.56 kg (95% CI: -6.7 to -6.3 
kg); and 54.9% of those lost their target weight. The mean weight change at the end of 
phase 2, starting with the first clinic visit in the lifestyle phase was -3.31 kg (95% CI: -3.7 
to -2.9 kg), -2.39 kg (95% CI: -2.6 to -2.1 kg) and -10.17 kg (95% CI: -10.4 to -9.8 kg) for 
patients who used orlistat, LCD and FWL, respectively. In terms of target weight loss, 31% 
of all patients on orlistat, 22% on LCD and 83% on FWL lost at least 5 kg. 39.5%, 25.5% 
and 86.5% of those who were on orlistat, LCD and FWL, respectively and completed the 
programme lost ≥5 kg from their initial body weight. A greater proportion of patients who 
completed the programme lost their target weight (≥5 kg), when compared with all patients 
who opted in or non-completers.    
 
Outcomes from the phase 1 lifestyle stage influenced the selection of the phase 2 
intervention. Those who were successful in the lifestyle phase, and who expressed a 
preference for further lifestyle intervention, had the highest weight loss by end of phase 2. 
Orlistat and LCD were selected by those failing to lose significant weight with lifestyle 
change alone, but they did not result in large numbers achieving ≥5 kg weight loss. 
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Targeting effective interventions at specific populations and increasing the intensity of 
phase 2 interventions might improve the programme’s overall effectiveness. 
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4.2 Introduction 
GCWMS followed the guidelines to treat individuals with obesity known to be eligible for 
treatment, as stated in Chapter 3 (SIGN 15, 2010; NICE, 2014). Phase 2 treatment is 
offered to patients who have completed four months of the lifestyle programme. The three 
choices offered in phase 2 are LCD or orlistat, if a 5 kg weight loss has not been achieved, 
or FWL (a continuation of the phase 1 programme) if patients have successfully lost ≥5 kg 
in the lifestyle phase. A 1,200 or a 1,500 calorie plan may be prescribed for patients who 
offered LCD based on their personalised dietary prescription (PDP), and if they struggle to 
reach their target weight loss through a low-fat diet or opted for it rather than prescribed 
diet, then they were treated with orlistat 120 mg, three times a day.  
 
Orlistat (120 mg) is a non-systemically acting lipase inhibitor, which can be taken three 
times daily to help patients lose extra weight. Patients with obesity at GCWMS can use 
orlistat for 3 months in phase 2; and their protocols recommended continuing treatments 
for longer than 3 months if patients have lost at least 5% of their initial body weight when 
starting the drug treatment. Patients can continue using orlistat throughout the maintenance 
phase (phase 3) and for up to 12 months if they continue losing weight. If patients gain 
more than 3 kg during the programme, then the drug should be discontinued. When 
patients are discharged from the service, but are continuing to use orlistat, then monitoring 
them becomes the responsibility of their GP. Those with type 2 diabetes might need longer 
treatment with orlistat, as their weight loss would be expected to be slower (NHS Great 
Glasgow and Clyde, 2016). 
 
A previous systematic review and meta-analysis of 44 RCTs by Douketis et al. (2005) 
investigated lifestyle, pharmacologic and surgical treatment of weight loss (researched 
from 1966 to 2003). The main objective was to investigate the absolute weight loss and the 
proportion of participants who lost ≥5% of initial body weight and the effects of weight 
loss on cardiovascular risk factors. It showed that the mean weight change after 1 year for 
9,953 subjects in 19 studies receiving orlistat in addition to lifestyle change was 6.1±2.0 
kg. The mean weight change after 2 years was 7.2±1.6 kg, based on LOCF. The same 
study concluded that lifestyle treatment provides less than 5 kg weight loss after 2-4 years, 
and that pharmacotherapy provides 5-10 kg weight loss after 1-2 years.  
 
In Chapter 3, a cohort study of 7,329 patients was conducted to evaluate the effectiveness 
of lifestyle treatment; it found 30.5% of all patients who attended ≥2 sessions had lost ≥5 
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kg. While in this study, the effectiveness of phase 2 treatment was evaluated by studying 
the variation in effectiveness when adding another intervention to lifestyle change. The 
principal aim of GCWMS is to achieve a reduction of 5 kg or more in patient’s weight; 
there was a lack of evidence concerning the effect of different interventions on weight 
management services. Therefore, the main objective of this study was to investigate the 
proportion of patients who lost ≥5 kg starting from the first clinic visit in the lifestyle phase 
until the end of phase 2 for each group of patients using LCD, orlistat or FWL. One of the 
aims of this research was to learn which interventions resulted in greater weight loss. 
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4.3 Materials and methods 
4.3.1 Data source  
This study used the same data from the GCWMS as that used in the previous study 
(Chapter 3, page 116) for evaluating the lifestyle phase. Of 7,329 individuals who attended 
≥2 sessions in the lifestyle phase, 4,709 patients chose phase 2 by selecting different 
interventions.  
 
4.3.2 Inclusion and exclusion criteria 
The eligible subjects were adults (aged ≥18 years) with a BMI of ≥30 kg/m2. Of 4,709 
individuals, 3,262 patients attended ≥2 sessions in phase 2. For this study, those 
participants who attended fewer than 2 sessions were excluded and the patients who 
attended ≥2 sessions in the lifestyle phase and ≥2 sessions in phase 2 were included.  
 
4.3.3 Definition of programme completion 
In phase 2, the patients attended 4 monthly sessions over a period of 3 months, and 
programme completion was defined as attending ≥3 sessions, equal to 80% of the phase 2 
sessions. Therefore, weight loss outcomes were reported for those patients who attended 
seven sessions or more in the lifestyle phase and at least three sessions in phase 2. 
 
4.3.4 Variables definitions 
Age was categorised into six groups: 18-29, 30-39, 40-49, 50-59, 60-69 and ≥70 years. 
BMI was categorised into four groups: (30-34.9 kg/m2), (35-39.9 kg/m2), (40-49.9 kg/m2) 
and (≥50 kg/m2). Weight was categorised into five groups: (˂75 kg), (75-99 kg), (100-124 
kg), (125-149) and (≥150 kg). The data included information about the presence or absence 
of diabetes and hypertension in addition to SIMD. The presence of hypertension and 
diabetes was highlighted on the referral form by the referring clinician. 
 
4.3.5 Statistical analysis 
All statistical analyses were completed using Stata version 12.1 (Stata Corporation, 
College Station, Texas, USA). Statistical significance was defined as p <0.05. Mean 
weight change and 95% CI were reported for the three different interventions used in the 
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phase 2 treatment. Differences in the means between two groups and across more than two 
groups were tested using the t-test and ANOVA test, respectively. In addition, 5 kg and 5% 
weight loss were reported and the effect of age, sex, deprivation quintiles, initial BMI, 
diabetes and hypertension were explored. For missing data, the last observation carried 
forward method was applied. 
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4.4 Results  
4.4.1 Baseline characteristics 
Figure 4-1 shows that out of the 4,709 participants, 803 patients were offered orlistat, 
1,686 patients were offered LCD and 2,220 were offered FWL. 1,447 patients were 
excluded because they attended fewer than 2 sessions in phase 2. Therefore, 3,262 patients 
were eligible for inclusion. Of these, 536 (16.4%), 1,043 (32.0%) and 1,683 (51.6%) 
selected orlistat, LCD and FWL, respectively. LCD and orlistat were recommended for 
those patients who had not lost ≥5 kg in the lifestyle phase.
 
                                        
 
  
                                                                        
 
 
 
 
 
 
   
 
 
  
              Figure 4-1 Flowchart showing the number of patients who offered phase 2 treatment and 
their interventions at the GCWMS. 
Phase 1 (attended ≥2 
sessions) 
(N=7,329) 
 
Did not offer phase 2 
(N=2,620) 
Offered phase 2 (N=4,709) 
(Attended) 
Orlistat 
N=803 LCD N=1,686 
FWL 
N=2,220 
Attended 1 session in phase 
2 (N= 1,447) 
 
Attended ≥2 sessions in 
phase 2 (N=3,262) 
 
Orlistat 
N=536 
LCD 
N=1,043 
 
FWL 
N=1,683 
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Most of the patients in the first session of phase 2 treatment who selected one of the three 
different types of interventions were female, from the most deprived quintile. A higher 
proportion of patients with a BMI between 35 kg/m2 and 49.9 kg/m2 and around one 
fourth and one third of the patients had hypertension and diabetes, respectively (Table 4-
1). However, the proportion of female patients who selected orlistat (81.5%) was higher 
than those who selected LCD (76.7%) or FWL (66.0%). Likewise, the proportion of 
young participants selecting orlistat in phase 2 was higher than those who selected LCD 
or FWL. That is, 10.4%, 7.1% and 4.8% of patients (aged 18-29 years) in phase 2 
selected orlistat, LCD and FWL, respectively. The proportion of patients from the most 
deprived quintile who selected orlistat (41.8%) was higher than those who selected LCD 
(37.0%) or FWL (36.2%). In addition, the percentage of people without diabetes who 
selected orlistat was greater than that of the two groups who selected LCD or FWL. 
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N=536 
 (16.4%) 
N=1,043  
(31.9%) 
N=1,683 
(51.5%) 
Variables 7,329 Lifestyle phase 
Orlistat 
(≥2 sessions) 
LCD 
(≥2 sessions) 
FWL 
(≥2 sessions) 
          Age 
 
    N % N % N % N % 
18-29 
30–39 
40–49 
50–59 
60–69 
≥70 
Missing 
671 
1,050 
1,821 
1,946 
1,374 
437 
30 
 
9.2 
14.3 
24.8 
26.6 
18.7 
6.0 
0.4 
56 
107 
152 
135 
69 
15 
2 
10.4 
20.0 
28.3 
25.2 
12.9 
2.8 
0.4 
74 
115 
209 
286 
259 
93 
7 
7.1 
11.0 
20.0 
27.4 
24.8 
8.9 
0.7 
80 
217 
403 
487 
381 
112 
3 
4.8 
12.9 
23.9 
28.9 
22.6 
6.7 
0.2 
Gender  
1,979 
5,345 
5 
 
 
27.0 
72.9 
0.1 
 
98 
437 
1 
 
18.3 
81.5 
0.2 
 
243 
800 
 
23.3 
76.7 
 
570 
1,111 
2 
 
33.9 
66.0 
0.1 
       Males 
 Females 
Missing 
SIMD  
2,966 
1,410 
1,099 
891 
924 
39 
 
40.5 
19.2 
15.0 
12.2 
12.6 
0.5 
 
224 
118 
78 
57 
52 
7 
 
 
41.8 
22.0 
14.6 
10.6 
9.7 
1.3                                    
 
384 
191 
180 
123 
161 
4 
 
 
37.0 
18.3 
17.2 
11.7 
15.4 
0.4                                   
 
610 
351  
250  
224 
238 
10
 
36.2 
20.9 
14.9 
13.3 
14.1 
0.6
Most deprived 
 2 
 3 
 4 
Least deprived 
Not known 
BMI  
840 
2,346 
3,197 
946 
 
11.5 
32.0 
43.6 
12.9 
 
46 
171 
254 
65 
 
8.6 
31.9  
47.8 
12.1                   
 
164 
318 
439 
122 
 
15.7 
30.5   
42.1 
11.7                 
 
187 
499 
736  
261      
 
11.1 
29.5 
43.7 
15.5 
30–34.9 
35–39.9 
40–49.9 
≥50 
 Weight kg  
44 
1,930 
3,252 
1,558 
545 
 
0.6 
26.3 
44.4 
21.3 
7.4 
 
3 
154 
241 
106 
32 
 
0.5 
28.7 
45.0 
19.8 
6.0                                
 
14 
331 
458 
177 
63 
 
1.3 
31.7 
43.9 
17.0 
6.0                             
 
4 
373   
739 
411   
156
 
0.2 
22.2 
43.9 
24.4 
9.3 
˂75 
75–99 
100–124 
125–149 
≥150 
 Diabetes*  
5,757 
1,572 
 
78.6 
21,4 
 
442 
94 
 
82.5 
17.5 
 
755 
288 
 
72.4 
27.6 
 
1,309 
374 
 
77.8 
22.2 
 No 
  Yes 
 Hypertension*  
6,139 
1,190 
 
83.8 
16.2 
 
451 
85 
 
84.2 
15.8 
 
860 
183 
 
 
82.5 
17.5 
 
1,394 
289 
 
82.8 
17.2 
 No 
  Yes 
 
              Table 4-1 Characteristics of patients in phase 2 (LCD: low calorie diet; FWL: 
further weight loss). (*): Diabetes/Hypertension highlighted on referral form. 
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4.4.2 Phase 2 selection 
Table 4-2 shows the results for the lifestyle weight loss phase, and the patient’s selection 
in phase 2. The mean weight changes at the end of the lifestyle phase for participants who 
were offered orlistat, LCD or FWL were -1.40 kg (95% CI: -1.6 to -1.1 kg), -1.89 kg (95% 
CI: -2.0 to -1.7 kg) and -8.27 kg (95% CI: -8.4 to -8.0 kg), respectively. Those who did not 
select any intervention in phase 2 lost -1.6 kg (95% CI: -1.7 to -1.5 kg) in the lifestyle 
phase. 
 
 
Intervention N Mean weight change and 95% 
CI 
Orlistat (≥2 sessions) 536 -1.40 (-1.6 to -1.1) 
LCD (≥2 sessions) 1,043 -1.89 (-2.0 to -1.7) 
FWL (≥2 sessions) 1,683 -8.27 (-8.4 to -8.0) 
Never chose phase 2 2,620 -1.6 (-1.7 to -1.5) 
Table 4-2 Lifestyle phase outcomes (mean weight change) among different group choices 
in phase 2 (CI: Confidence interval; N: Number). 
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4.4.3 Effect of orlistat 
4.4.3.1 Weight loss outcomes for all participants and completers for those 
who selected orlistat in phase 2 
Table 4-3 shows that 45.7% (n =245) of those patients (n =536) who started the GCWMS 
were considered to have completed the lifestyle phase and phase 2 (orlistat); of those, 
39.5% had lost ≥5 kg and their mean weight change was -4.33 kg (95% CI: -4.9 to -3.6 
kg). On the other hand, 31% of all patients (completers and non-completers) had lost 5 kg 
or more and their mean weight change at the end of phase 2 was -3.31 kg (95% CI: -3.7 to 
-2.9 kg).  
 
 
Phase 1 + Phase 2      
(orlistat) N % 
Mean weight change 
and 95% CI (kg) Lost ≥5 kg Lost≥5% 
Completers 
(≥7 p1 and ≥3 p2 
sessions) 
245 45.7 -4.33 (-4.9 to -3.6) 97 (39.5%) 81 (33%) 
 
Non-completers 
(˂7 p1 and ˂3 p2 
sessions) 
291 45.2 -2.45 (-2.9 to -1.9) 69 (24%) 58 (20%) 
 
Total 
(≥2 sessions) 
536  -3.31 (-3.7 to -2.9) 166 (31%) 139 (26%) 
Table 4-3 Cumulative weight loss at the end of phase 2 (orlistat) from first clinic visit in 
lifestyle phase (CI: Confidence interval; p1: phase 1; p2: phase 2; N: Number). 
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4.4.3.2 Mean weight change and target weight loss (5 kg) for subgroup of 
participants who selected orlistat in phase 2 
Table 4-4 shows that out of 536 individuals who were offered orlistat and attended ≥2 
sessions, 81.5% were female and 41.8% were from the most deprived quintile. The mean 
age was 46.5 years and the mean weight and BMI were 113.6 kg and 42.5 kg/m2, 
respectively. In total, 82.5% and 84.2% of patients had no diabetes or hypertension, 
respectively. There was no difference in the proportion of males (30.5%) to females (31%) 
achieving their target weight loss at the end of phase 2. There was no clear trend between 
initial BMI or weight and successful weight loss. Men and women aged ≥70 years had 
more success with weight loss; however, the sample size of these two groups (n =2 and n 
=13 respectively) was small. In addition, presence or absence of diabetes or high blood 
pressure and deprivation did not seem to affect the proportion of patients achieving their 
target weight loss.  
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 Total (completers & non-completers) Completers  
  N Mean weight change 
and 95% CI 
P-
value 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
N (%) of 
total 
Mean weight 
change and 95% 
CI 
Lost ≥5 
kg 
N (%) 
Lost ≥5% 
N (%) 
All  536 -3.31 (-3.7 to -2.9)  165 (31%) 139 (26%) 245 (45.5) -4.33 (-4.9 to -3.6) 97 (39.5%) 81 (33%) 
Gender Male 98 -3.33 (-4.3 to -2.3) 
0.93 
30 (30.5) 19 (19.5) 48 (49) -4.46 (-5.7 to -3.1) 18 (37.5) 12 (25) 
 
Female 437 -3.29 (-3.7 to 2.8) 135 (31) 120 (27.5) 196 (45) -4.28 (-5.0 to -3.5) 78 (40) 69 (35) 
 
Missing 1     1    
SIMD 1 (most deprived
224 
 
-3.13 (-3.8 to -2.4) 
0.46 
61 (27) 48 (21.5) 111 (49.5) -4.45 (-5.6 to -3.2) 41 (37) 31 (28) 
 2 118 
 
-3.66 (-4.3 to -2.9) 40 (34) 33 (28) 47 (40) -4.47 (-5.4 to -3.5) 20 (42.5) 16 (34) 
 3 78 
 
-3.94 (-4.9 to -2.9) 33 (42.5) 27 (34.5) 34 (43.5) -4.73 (-6.1 to -3.3) 16 (47) 15 (44) 
 4 57 
 
-2.66 (-3.4 to -1.8) 14 (24.5) 13 (23) 29 (51) -3.17 (-4.5 to -1.8) 10 (34.5) 9 (31) 
 
5 (least 
deprived
52 
 
-3.01 (-4.3 to -1.6) 17 (32.5) 16 (31) 22 (42) -4.21 (-5.9 to -2.4) 9 (41) 8 (36.5) 
 Missing 7     2    
Age ≤29 56 
 
-2.99 (-4.4 to -1.5) 
0.32 
17 (30.5) 14 (25) 24 (43) -4.97 (-7.1 to -2.7) 10 (41.5) 9 (37.5) 
 30-39 107 
 
-2.54 (-3.4 to -1.6) 27 (25) 21 (19.5) 47 (44) -3.15 (-4.6 to -1.7) 13 (27.5) 10 (21) 
 40-49 152 
 
-3.42 (-4.0 to -2.7) 48 (31.5) 38 (25) 70 (46) -4.44 (-5.4 to -3.4) 31 (44.5) 23 (33) 
 50-59 135 
 
-3.83 (-4.7 to -2.8) 46 (34 39 (29) 65 (48) -4.79 (-6.4 to -3.1) 26 (40) 22 (34) 
 60-69 69 
 
-3.14 (-3.9 to -2.3) 60 (29) 17 (42.5) 30 (43.5) -4.35 (-5.4 to -3.2) 13 (43.5) 11 (36.5) 
 ≥70 15 
 
-4.46 (-6.0 to -2.8) 6 (40) 8 (53.5) 8 (53.5) -4.12 (-5.5 to -2.7) 3 (37.5) 5 (62.5) 
 Missing 2     1    
Male ≤29 9 -4.74 (-9.7 to 0.2) 
0.79 
5 (55.5) 3 (33.5) 5 (55.5) -4.56 (-6.9 to -2.1) 2 (40) 1 (20) 
 30-39 18 -3.60 (-6.0 to -1.1) 7 (39) 3 (16.5) 11 (61) -3.82 (-7.5 to -0.1) 4 (36.5) 2 (18) 
 40-49 22 -3.36 (-5.3 to -1.4) 5 (22.5) 3 (13.5) 7 (32) -5.69 (-10.8 to -0.5) 3 (43) 2 (28.5) 
 50-59 27 -2.69 (-4.4 to -0.9) 6 (22) 5 (18.5) 11 (40.5) -4.72 (-6.2 to -3.1) 4 (36.5) 3 (27) 
 60-69 20 -2.94 (-4.7 to -1.1) 6 (30) 3 (15) 13 (65) -4.03 (-6.1 to -1.9) 5 (38.5) 3 (23) 
 ≥70 2 -6.75 (-10.6 to -2.8)  1 (50) 2 (100) 1 (50) -4.80 0 1 (100) 
168 
 
 Total (completers & non-completers) Completers 
 
 N Mean weight change 
and 95% CI 
P-
value 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
N (%) of 
total 
Mean weight 
change and 95% 
CI 
Lost ≥5 
kg 
N (%) 
Lost ≥5% 
N (%) 
Female ≤29 47 -2.65 (-4.1 to -1.1) 
0.13 
12 (25.5) 11 (23.5) 19 (40.5) -5.08 (-7.8 to -2.3) 8 (42) 8 (42) 
 30-39 89 -2.32 (-3.2 to -1.3) 20 (22.5) 18 (20) 36 (40.5) -2.95 (-4.5 to -1.3) 9 (25) 8 (22) 
 40-49 129 -3.41 (-4.0 to -2.7) 42 (32.5) 35 (27) 62 (48) -4.27 (-5.2 to -3.3) 27 (43.5) 21 (34) 
 50-59 108 -4.11 (-5.2 to -3.0) 40 (37) 34 (31.5) 54 (50) -4.81 (-6.7 to -2.8) 22 (40.5) 19 (35) 
 60-69 49 -3.23 (-4.1 to -2.2) 14 (28.5) 14 (28.5) 17 (34.5) -4.60 (-5.8 to -3.3) 8 (47) 8 (47) 
 ≥70 13 -4.11 (-5.8 to -2.4) 5 (38.5) 6 (46) 7 (54) -4.02 (-5.6 to -2.4) 3 (43) 4 (57) 
 Missing 2         
BMI 30–34.9 
 
46 
 
-3.52 (-4.4 to -2.5)  14 (30.5) 18 (39) 15 (32.5) -4.17 (-5.3 to -2.9) 5 (33.5) 9 (60) 
 
 
35–39.9 
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-3.16 (-3.7 to -2.5)  56 (32.5) 48 (28) 81 (47.5) -4.54 (-5.2 to -3.8) 39 (48) 33 (40.5) 
 
40–49.9 
 
254 
 
-3.53 (-4.1 to -2.8) 0.55 79 (31) 63 (25) 116 (45.5) -4.54 (-5.6 to -3.3) 43 (37) 34 (29.5) 
 
 
≥50 
 
65 -2.66 (-3.8 to -1.5)  17 (26) 10 (15.5) 33 (50.5) -3.1 (-4.5 to -1.6) 10 (30) 5 (15) 
Weight ˂75 
 
3 
         
-3.26 (-6.9 to 0.4)  1 (33.5) 1 (33.5) 2 (66.5) -4.54 (-9.1 to 0.07) 1 (50) 1 (50) 
 
75–99 
 
154 
 
-3.40 (-3.9 to -2.8)  54 (35) 61 (39.5) 70 (45.5) -4.43 (-5.2 to -3.6) 34 (48.5) 40 (57) 
 
100–124 
 
241 -3.06 (-3.6 to -2.5) 0.38 68 (28) 50 (20.5) 106 (44) -3.77 (-4.4 to -3.0) 35 (33) 24 (22.5) 
 
125–149 
 
106 
 
-4.00 (-5.2 to -2.7)  35 (33) 23 (21.5) 52 (49) -5.29 (-7.5 to -3.0) 21 (40.5) 13 (25) 
 
≥150 
 
32 -2.41 (-4.4 to -0.3)  8 (25) 4 (12.5) 15 (47) -4.38 (-7.3 to -1.3) 6 (40) 3 (20) 
Diabetes No 442 -3.39 (-3.8 to -2.9)  140 (31.5) 117 (26.5) 200 (45) -4.38 (-5.1 to -3.6) 81 (40.5) 68 (34) 
 Yes 94 -2.93 (-3.8 to -2.0) 0.40 26 (27.5) 22 (23.5) 45 (48) -4.10 (-5.2 to -2.9) 16 (35.5) 13 (29) 
Hypertension No 451 -3.35 (-3.8 to -2.9)  137 (30.5) 116 (25.5) 203 (45) -4.28 (-5.0 to -3.5) 75 (37) 64 (31.5) 
 Yes 85 -3.07 (-3.9 to -2.2)    0.62 28 (33) 22 (26) 41 (48) -4.52 (-5.5to -3.4) 21 (51) 16 (39) 
                  Table 4-4 Subgroup analyses of weight loss from the lifestyle phase until the end of phase 2 (patients who chose   
orlistat). P-values were determined using t-test and an ANOVA test (p-value <0.05 considered statistically significant) 
(CI: Confidence interval; N: Number). 
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4.4.3.3 Weight loss outcomes at the end of lifestyle phase and at the end of 
phase 2 for the group of patients who selected orlistat 
Table 4-5 shows that of the 536 patients still enrolled at the end of phase 2 (orlistat) who 
had already attended the lifestyle phase, 73.2% lost less than 5 kg in the lifestyle phase and 
18.6% gained less than 2.5 kg. Whereas, at the end of phase 2 (phase 1 + orlistat phase), 
50.3% had lost less than 5 kg and 10.6% had gained less than 2.5 kg. In terms of target 
weight loss, 2.5% of the patients lost ≥5 kg at the end of the lifestyle phase, compared with 
30.9% at the end of orlistat phase. 
 
 
Weight change 
Lifestyle phase 
(N=536) 
N (%) 
Phase 1+2 (N=536) 
N (%) 
Weight gain 
>7.5 4 (0.7) 8 (1.4) 
5 – < 7.5 4 (0.7) 6 (1.1) 
2.5 – < 5.0 21 (3.9) 29 (5.4) 
0 – < 2.5 100 (18.6) 57 (10.6) 
Weight loss 
0 – > (-2.5) 229 (42.7) 119 (22.2) 
-2.5 – > (-5.0) 164 (30.5) 151 (28.1) 
-5.0 – < (-7.5) 10 (1.8) 101 (18.8) 
> -7.5 4 (0.7) 65 (12.1) 
Table 4-5 Weight gain and weight loss in the lifestyle phase, the lifestyle 
phase + phase 2 for the patients who selected orlistat. 
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4.4.4 Effect of LCD 
4.4.4.1 Weight loss outcomes for all participants and completers who 
selected LCD in phase 2 
Of the 1,043 patients who selected LCD, 51.5% completed the programme; 37% of the 
patients were from most deprived quintile; 76.7% were female; the mean age was 52.4 
years; and the mean weights and BMIs was 111.5 kg and 41.7 kg/m2, respectively. In 
addition, 27.6% and 17.5% of the patients had diabetes and hypertension respectively. 
 
At the end of phase 2, of the patients who used LCD, 22% and 18% had lost ≥5 kg and 
≥5%, respectively; and the mean weight change was -2.39 kg (95% CI: -2.6 to -2.1 kg). In 
terms of completing the programme, treatment by attending seven or more sessions in the 
lifestyle phase and three or more sessions in phase 2, mean weight change was -2.84 kg 
(95% CI: -3.1 to -2.5 kg); and around 25.5% and 20.5% of completers had lost ≥5 kg and 
≥5%, respectively (Table 4-6). 
 
 
Phase 1 + Phase 2          
(LCD) N % 
Mean weight change 
and 95% CI (kg) Lost ≥5 kg Lost ≥5% 
Completers 
(≥7 p1 and ≥3 p2 
sessions) 
538 51.5 -2.84 (-3.1 to -2.5) 137 (25.5%) 111 (20.5%) 
 
Non-completers 
(˂7 p1 and ˂3 p2 
sessions) 
505 48.4 -1.91 (-2.3 to -1.4) 91 (18%) 76 (15%) 
 
Total 
(≥2 sessions) 
1,043  -2.39 (-2.6 to -2.1) 228 (22%) 188 (18%) 
Table 4-6 Cumulative weight loss at end of phase 2 (LCD) from the first clinic visit in the 
lifestyle phase (CI: Confidence interval; p1: phase 1; p2: phase 2; N: Number). 
 
 
 
 
 
 
 
 171 
4.4.4.2 Outcomes for subgroups who selected LCD in phase 2 
Table 4-7 shows that young men (aged ≤29 years) were more successful at achieving their 
target weight loss (33%), whereas a small proportion (16%) of young women (aged ≤29 
years) lost ≥5 kg. Deprivation did not affect the proportion losing their target weight. In 
general, older participants lost significantly more weight than younger ones (p =0.001); 
and the lighter patients at baseline lost significantly more weight than the heaviest patients 
(p =0.02). There was no statistically significant difference between people with diabetes 
and those without diabetes in terms of their weight loss, the mean weight change was -2.26 
kg (95% CI: -2.6 to -1.8 kg) and -2.40 kg (95% CI: -2.7 to -2.0 kg); p-value =0.53. In 
addition, there was no difference between those with and without hypertension in terms of 
weight loss (p =0.22). 
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Total (completers & non-completers) Completers  
  N Mean weight change 
and 95% CI 
P-
value 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
N (%) of 
total 
Mean weight 
change and 95% 
CI 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
All  1,043 -2.39 (-2.6 to -2.1)  228 (22) 188 (18) 538 (51.5) -2.84 (-3.1 to -2.5) 137 (25.5) 111 (20.5) 
Gender Male 243 -2.41 (-2.8 to -1.9) 
0.93 
59 (24) 29 (12) 129 (53) -2.78 (-3.3 to -2.2) 35 (27) 18 (14) 
 
Female 800 -2.38 (-2.7 to -2.0) 169 (21) 159 (20) 409 (51) -2.86 (-3.2 to -2.4) 102 (25) 93 (23) 
 
Missing          
SIMD 1 (most deprived) 
384 
        
-2.48 (-3.0 to -1.8) 
0.86 
98 (25.5) 69 (18) 197 (51) -2.85 (-3.4 to -2.2) 55 (28) 39 (20) 
 2 191 
 
-2.07 (-2.5 to -1.5) 34 (18) 30 (15.5) 96 (50) -2.35 (-3.0 to -1.6) 19 (20) 15 (15.5) 
 3 180 
 
-2.45 (-3.0 to -1.8) 36 (20) 31 (17) 88 (49) -3.24 (-4.2 to -2.2) 26 (29.5) 23 (26) 
 4 123 
 
-2.59 (-3.2 to -1.9) 31 (25) 28 (22.5) 65 (53) -2.87 (-3.7 to -2.0) 19 (29) 16 (24.5) 
 5 (least 
deprived) 
161 
 
-2.31 (-3.0 to -1.5) 29 (18) 30 (18.5) 89 (55) -2.91 (-3.5 to -2.2) 18 (20) 19 (21) 
 Missing 4     3    
Age ≤29 74 
 
-0.34 (-2.5 to 1.8) 
0.001 
13 (17.5) 10 (13.5) 32 (43) -2.13 (-4.6 to 0.3) 8 (25) 7 (22) 
 30-39 115 
 
-2.68 (-3.6 to -1.6) 26 (22.5) 19 (16.5) 59 (51) -2.779 (-3.7 to -1.8) 15 (25.5) 10 (17) 
 40-49 209 
 
-2.08 (-2.5 to -1.6) 42 (20) 30 (14.5) 101 (48) -2.67 (-3.3 to -1.9) 26 (25.5) 20 (20) 
 50-59 286 
 
-2.23 (-2.7 to -1.7) 59 (20.5) 50 (17.5) 142 (49.5) -2.09 (-2.7 to -1.4) 28 (19.5) 22 (15.5) 
 60-69 259 
 
-3.02 (-3.5 to -2.4) 65 (25) 56 (21.5) 147 (56.5) -3.60 (-4.1 to -3.0) 42 (28.5) 34 (23) 
 ≥70 93 
 
-3.08 (-3.6 to -2.5) 23 (24.5) 22 (23.5) 54 (58) -3.5 (-4.2 to -2.7) 18 (33) 18 (33) 
 Missing 7     3    
Male ≤29 6 -3.41 (-6.7 to -0.04) 
0.18 
2 (33) 1 (16.5) 4 (66.5) -4.10 (-7.8 to -0.3) 1 (25) 1 (25) 
 30-39 19 -2.96 (-3.9 to -1.9) 4 (21) 0 9 (47) -3.21 (-4.6 to -1.7) 2 (22) 0 
 40-49 45 -1.24 (-2.1 to -0.2) 8 (17.5) 2 (4.5) 17 (38) -1.68 (-3.2 to -0.1) 3 (17.5) 1 (6) 
 50-59 69 -2.48 (-3.4 to -1.5) 18 (26) 9 (13) 35 (50.5) -3.04 (-4.0 to -2.0) 11 (31.5) 4 (11.5) 
 60-69 82 -2.81 (-3.4 to -2.1) 22 (27) 13 (16) 48 (58.5) -2.82 (-3.7 to -1.9) 13 (27) 8 (16.5) 
 ≥70 17 -2.44 (-4.0 to -0.8)  5 (29.5) 4 (23.5) 14 (82.5) -2.62 (-4.6 to -0.6) 5 (35.5) 4 (28.5) 
 Missing 5     2    
 173 
 
 
Total (completers & non-completers) Completers 
 
 N Mean weight change 
and 95% CI 
P-
value 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
N (%) of 
total 
Mean weight 
change and 95% 
CI 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
Female ≤29 68 -0.07 (-2.4 to 2.3) 
0.001 
11 (16) 9 (13) 28 (41) -1.85 (-4.6 to 0.9) 7 (25) 6 (21.5) 
 30-39 96 -2.62 (-3.8 to -1.4) 22 (23) 19 (20) 50 (52) -2.70 (-3.8 to -1.5) 13 (26) 10 (20) 
 40-49 164 -2.32 (-2.8 to -1.7) 34 (20.5) 28 (17) 84 (51) -2.87 (-3.6 to -2.1) 23 (27.5) 19 (22.5) 
 50-59 217 -2.15 (-2.7 to -1.5) 41 (19) 41 (19) 107 (49) -1.79 (-2.6 to -0.9) 17 (16) 18 (17) 
 60-69 177 -3.11 (-3.8 to -2.4) 43 (24) 43 (24) 99 (56) -3.98 (-4.7 to -3.2) 29 (29) 26 (26) 
 ≥70 76 -3.22 (-3.7 to -2.6) 18 (23.5) 18 (23.5) 40 (52.5) -3.80 (-4.4 to -3.1) 13 (32.5) 14 (35) 
 Missing 2     1    
BMI 30–34.9 
 
164 
 
-2.95 (-3.3 to -2.5) 
0.04 
37 (22.5) 48 (29) 93 (56.5) -3.57 (-4.1 to -3.0) 27 (29) 32 (34.5) 
 
 
35–39.9 
 
318 
 
-2.40 (-2.8 to -1.9) 70 (22) 68 (21.5) 168 (53) -2.81 (-3.3 to -2.2) 48 (28.5) 45 (26.5) 
 
40–49.9 
 
439 -2.39 (-2.7 to -1.9) 93 (21) 58 (13) 220 (50) -2.84 (-3.3 to -2.3) 49 (22) 28 (12.5) 
 
 
≥50 
 
122 -1.35 (-2.9 to 0.2) 29 (23.5) 14 (11.5) 57 (46.5) -1.74 (-3.3 to -0.1) 14 (24.5) 7 (12) 
Weight ˂75 
 
14 
        
-3.03 (-4.3 to -1.7) 
0.02 
3 (21.5) 5 (35.5) 8 (57) -4.21 (-5.1 to -3.2) 3 (37.5) 4 (50) 
 
75–99 
 
331  
 
-2.77 (-3.1 to -2.4) 71 (21.5) 91 (27.5) 184 (55.5) -3.05 (-3.5 to -2.5) 47 (25.5) 56 (30.5) 
 
100–124 
 
458 
 
-2.41 (-2.8 to -1.9) 93 (20) 66 (14.5) 239 (52) -2.83 (-3.3 to -2.3) 57 (24) 38 (16) 
 
125–149 
 
177 
 
-2.18 (-3.1 to -1.1) 47 (26.5) 21 (12) 79 (44.5) -3.15 (-4.1 to -2.1) 26 (33) 12 (15) 
 
≥150 
 
63 -0.67 (-2.2 to 0.8) 15 (25) 5 (8) 28 (44.5) -0.28 (-2.7 to 2.2) 5 (18) 2 (7) 
Diabetes No 755 -2.40 (-2.7 to -2.0) 
   0.53 
174 (23) 145 (19) 390 (51.5) -2.90 (-3.3 to -2.4) 101 (26) 85 (21.5) 
 
Yes 288 
 
-2.26 (-2.6 to -1.8) 55 (19) 43 (15) 148 (51.5) -2.67 (-3.1 to -2.1) 37 (25) 27 (18) 
Hypertension No 860 -2.31 (-2.6 to -1.9) 
0.22 
190 (22) 157 (18) 431 (50) -2.84 (-3.2 to -2.4) 115 (26.5) 96 (22) 
 Yes 183 
 
-2.77 (-3.3 to -2.2) 39 (21) 31 (17) 107 (58.5) -2.84 (-3.4 to -2.2) 23 (21.5) 16 (15) 
        Table 4-7 Subgroup analyses of weight loss from the lifestyle phase up to the end of phase 2 (patients who chose LCD). 
P-values were determined with a t-test and ANOVA test (p-value <0.05 considered statistically significant) (CI: 
Confidence interval; N: Number). 
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4.4.5 Effect of FWL 
4.4.5.1 Weight loss outcomes for all participants and completers who 
selected FWL in phase 2 
Patients who were offered FWL in phase 2 did well to lose weight in the lifestyle phase. At 
the end of phase 2, out of 1,683 subjects who offered FWL, 62.5% completed the 
programme and continued to do what had been successful for them in the lifestyle phase. 
The majority of the patients were females from the most deprived quintile. However, a 
higher proportion of men and those from the least deprived quintile completed the 
programme. A higher proportion of men and women aged ≥40 years completed the FWL 
programme than those aged ≤29 years or 30-39 years. The mean age of patients who 
selected the FWL was 51.8 years, and men were generally older than the women (mean 
ages 53.8 and 50.7 years, respectively). Their mean BMIs and weights were 42.8 kg/m2 
and 118.7 kg, respectively. In addition, 22.2% of individuals had diabetes and 17.2% had 
hypertension.  
 
Among the 1,683 patients offered FWL, 1,394 (83%) lost at least 5 kg and 1,297 (77%) 
lost ≥5%; and the mean weight change was -10.17 kg (95% CI: -10.4 to -9.8 kg). 
Furthermore, of the 1,054 individuals who completed the programme, 86.5% lost 5 kg or 
more and 82% lost ≥5% at the end of phase 2 (Table 4-8). 
 
 
Phase 1 + Phase 2          
(FWL) N % 
Mean weight change 
and 95% CI (kg) Lost ≥5 kg Lost ≥5% 
Completers 
(≥7 p1 and ≥3 p2 
sessions) 
1,054 62.6 -11.13 (-11.5 to -10.7) 913 (86.5%) 864 (82%) 
 
Non-completers 
(˂7 p1 and ˂3 p2 
sessions) 
629 37.3 -8.56 (-9.0 to -8.1) 479 (76%) 431 (68.5%) 
 
Total 
(≥2 sessions) 
1,683  -10.17 (-10.4 to -9.8) 1,394 (83%) 1,297 (77%) 
Table 4-8 Cumulative weight loss at the end of phase 2 (FWL) from first clinic visit in the 
lifestyle phase (CI: Confidence interval). 
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4.4.5.2 Outcomes for subgroups who selected FWL in phase 2 
Table 4-9 shows men lost more weight than women (p =0.001); the heaviest subjects (≥40 
kg/m2) were lost significantly more weight than the other groups, and were among the 
greatest proportion losing ≥5 kg. Individuals without diabetes lost more weight than people 
with diabetes, and so the mean weight change was -10.54 kg (95% CI: -10.8 to -10.1 kg; p 
=0.001). However, there was no difference between those with and without hypertension in 
terms of weight loss (p =0.90). 
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Total (completers & non-completers) Completers 
  N Mean weight change 
and 95% CI 
P-
value 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
N (%) of 
total 
Mean weight change 
and 95% CI 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
All  1,683 -10.17 (-10.4 to -9.8)  1394 (83) 1297 (77) 1054 (62.6) -11.13 (-11.5 to -10.7) 913 (86.5) 864 (82) 
Gender Male 570 -10.97 (-11.5 to -10.3) 
0.001 
468 (82) 414 (72.5) 368 (64.5) -11.97 (-12.7 to -11.2) 319 (86.5) 291 (79) 
 
Female 1111 -9.76 (-10.1 to -9.4) 926 (83) 883 (79.5) 684 (61.5) -10.68 (-11.1 to -10.2) 594 (87) 573 (83.5) 
 
Missing 2     2    
SIMD 1 (most deprived) 610 -10.24 (-10.7 to -9.7) 
0.74 
510 (83) 468 (76.5) 388 (63.5) -11.33 (-12.0 to -10.6) 339 (87) 320 (82.5) 
 2 351 -9.77 (-10.4 to -9.1) 286 (81.5) 262 (74.5) 211 (60) -10.53 (-11.3 to -9.6) 180 (85) 165 (78) 
 3 250 -10.36 (-11.1 to -9.6) 209 (83.5) 195 (78) 154 (61.5) -11.37 (-12.3 to -10.3) 137 (89)   130 (84.5) 
 4 224 -10.42 (-11.2 to -9.5) 190 (85) 180 (80.5) 140 (62.5) -11.58 (-12.7 to -10.4) 126 (90) 120 (85.5) 
 5 (least 
deprived) 238 -10.23 (11.1 to -9.3) 194 (81) 187 (78) 155 (65) -10.89 (-11.9 to -9.8) 129 (83) 127 (82) 
 
Missing 10     6    
Age ≤29 80 
 
-9.20 (-10.5 to -7.8) 
0.009 
63 (78.5) 58 (72.5) 47 (58.5) -10.06 (-12.0 to -8.0) 39 (83) 37 (78.5) 
 30-39 217 
 
-10.4 (-11.3 to -9.5) 175 (80) 155 (71) 123 (56.5) -11.52 (-12.7 to -10.3) 105 (85) 96 (78) 
 40-49 403 
 
-10.90 (-11.6 to 10.1) 336 (83) 310 (76.5) 262 (65) -12.02 (-12.9 to -11.1) 224 (85.5) 210 (80) 
 50-59 487 
 
-10.06 (-10.6 to -9.4) 398 (81.5) 374 (76.5) 300 (61.5) -11.24 (-12.0 to -10.4) 258 (86) 245 (81.5) 
 60-69 381 
 
-10.14 (-10.7 to -9.5) 331 (87) 310 (81.5) 244 (64) -10.75 (-11.4 to -10.0) 222 (91) 212 (87) 
 ≥70 112 
 
-8.44 (-9.2 to -7.5) 90 (80) 89 (79.5) 77 (68.5) -9.07 (-10.1 to -8.0) 66 (85.5) 65 (84.5)  
 Missing 3     1    
Male ≤29 19 -11.16 (-14.4 to -7.8) 
0.14 
15 (79) 14 (73.5) 11 (58) -12.52 (-17.4 to -7.6) 9 (82) 9 (82) 
 30-39 57 -9.75 (-11.8 to -7.6) 41 (72) 27 (47.5) 28 (49) -11.15 (-14.2 to -8.0) 21 (75) 15 (53.5) 
 40-49 109 -12.26 (-13.8 to -10.6) 90 (82.5) 79 (72.5) 69 (63) -13.35 (-15.3 to -11.3) 58 (84) 54 (78) 
 50-59 188 -10.92 (-12.0 to -9.8) 153 (81) 139 (73.5) 117 (62) -12.42 (-13.8 to -11.0) 102 (87) 93 (79.5) 
 60-69 157 -11.12 (-12.2 to -10.0) 136 (86.5) 124 (79) 114 (72.5) -11.55 (-12.7 to -10.3) 105 (92) 97 (85) 
 ≥70 39 -8.69 (-10.4 to -6.9)  32 (82) 30 (77) 29 (74.5) -9.08 (-11.1 to -7.0) 24 (82.5) 23 (79) 
 Missing 1         
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 Total (completers & non-completers) Completers 
 
 N Mean weight change 
and 95% CI 
P-
value 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
N (%) of 
total 
Mean weight change 
and 95% CI 
Lost ≥5 kg 
N (%) 
Lost ≥5% 
N (%) 
Female ≤29 61 -8.59 (-10.0 to -7.1) 
0.009 
48 (78.5) 44 (72) 36 (59) -9.30 (-11.4 to -7.2) 30 (83) 28 (78) 
 30-39 160 -10.67 (-11.6 to -9.6) 134 (83) 128 (79.5) 95 (59.5) -11.63 (-12.9 to -10.3)        84 (88.5) 81 (85) 
 40-49 293 -10.40 (-11.1 to -9.6) 245 (83) 230 (78) 192 (65.5) -11.54 (-12.5 to -10.5) 165 (86) 155 (80.5) 
 50-59 298 -9.47 (-10.0 to -8.8) 244 (82) 234 (78.5) 182 (61) -10.42 (-11.2 to -9.5) 155 (85) 151 (83) 
 60-69 224 -9.46 (-10.0 to -8.8) 195 (87) 186 (83) 130 (58) -10.06 (-10.8 to -9.2) 117 (90) 115 (88.5) 
 ≥70 73 -8.30 (-9.2 to -7.3) 58 (79.5) 59 (81) 48 (65.5) -9.06 (-10.1 to -7.9) 42 (87.5) 42 (87.5) 
 Missing 2     1    
BMI 30–34.9 
 
187 
 
-8.16 (-8.8 to -7.4) 
0.001 
141 (75.5) 141 (75.5) 114 (61) -9.17 (-10.0 to -8.3) 94 (82.5) 95 (83) 
 
 
35–39.9 
 
499 
 
-9.31 (-9.8 to -8.8) 413 (82.5) 410 (82) 311 (62) -10.23 (-10.8 to -9.5) 272 (87.5) 270 (87) 
 
40–49.9 
 
736 
 
-10.57 (-11.0 to -10.0) 620 (84) 560 (76) 474 (64.5) -11.61 (-12.2 to -10.9) 413 (87) 383 (81) 
 
 
≥50 
 
261 -12.16 (-13.1 to -11.2) 222 (85) 188 (72) 155 (59.5) -12.99 (-14.2 to -11.7) 136 (87.5) 118 (76) 
Weight ˂75 
 
4 -5.65 (-7.7 to -3.5) 
0.001 
3 (75) 3 (75) 2 (50) -6.75 (-6.8 to -6.6) 2 (100) 2 (100) 
 
75–99 
 
373 -8.31 (-8.7 to -7.8) 296 (79) 309 (82.5) 216 (58) -8.80 (-9.3 to -8.2) 179 (83) 188 (87) 
 
100–124 
 
739 
 
-9.78 (-10.2 to -9.3) 615 (83) 581 (78.5) 473 (64) -10.91 (-11.4 to -10.3) 417 (88) 399 (84.5) 
 
125–149 
 
411 -11.20 (-11.9 to -10.4) 342 (83) 291 (70.5) 264 (64) -12.50 (-13.4 to -11.5) 227 (86) 202 (76.5) 
 
≥150 
 
156 -13.94 (-15.3 to -12.5) 140 (89.5) 115 (73.5) 99 (63.5) -13.80 (-15.4 to -12.1) 90 (91) 75 (75.5) 
Diabetes No 1,309 -10.54 (-10.8 to -10.1) 
0.001 
1102 (84) 1022 (78) 819 (62.5) -11.51 (-11.9 to -11.0) 713 (87) 673 (82) 
 
Yes 374 
 
-8.92 (-9.5 to -8.3) 294 (78.5) 277 (74) 235 (63) -9.85 (-10.5 to -9.1) 202 (86) 193 (82) 
Hypertension No 1,394 -10.17 (-10.5 to -9.8) 
0.90 
1,157 (83) 1,080 (77.5) 879 (63) -11.17 (-11.6 to -10.7) 760 (86.5) 722 (82) 
 Yes    289 
 
-10.22 (-10.9 to -9.5) 239 (82.5) 219 (75.5) 175 (60.5) -11.0 (-11.9 to -10.1) 155 (88.5) 144 (82) 
        Table 4-9 Subgroup analyses of weight loss from the lifestyle phase up to the end of phase 2 (patients who choose FWL). P-values 
were determined using a t-test and ANOVA test (p-value <0.05 considered statistically significant) (CI: Confidence interval; N: 
Number).
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4.4.6 Cumulative effects of different phases - entry to phase 2 of the 
programme depended on the lifestyle phase weight loss 
To explore the difference between the effects of the lifestyle phase and the different 
interventions in phase 2, those who selected orlistat, LCD and FWL were divided into 3 
groups (tertiles) based on mean weight change (Figure 4-2). Overall, the majority of the 
patients in the FWL group lost more weight in the lifestyle phase and continued to lose 
weight in phase 2. Those who selected FWL and LCD lost most of their weight in the 
lifestyle phase compared with phase 2. Conversely, orlistat intervention showed a notably 
positive effect for the group of patients who gained weight in the lifestyle phase, or who 
lost a small amount of weight in the lifestyle phase. Unfortunately, the group of 
participants who completed the first 2 phases and selected the LCD did not achieve their 
weight loss targets. It is important to consider the intensity and duration of phase 2 
treatment. 
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Figure 4-2 The cumulative mean weight change for patients who used different types 
of interventions and completed the programme categorised by tertile weight change. 
(A) orlistat (n =245), (B) FWL (n =1,054) and (C) LCD (n =538) (wt: weight; p1: 
phase 1; p2: phase 2). 
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4.4.7 Overall outcomes at the end of phase 2 
Of 3,262 patients enrolled within the GCWMS who attended phase 2 through the lifestyle 
phase, 54.9% lost at least 5 kg and 49.7% lost ≥5% of their initial weight at the beginning 
of the lifestyle phase. The mean weight change was -6.56 kg (95% CI: -6.7 to -6.3 kg). The 
maximum weight loss was achieved by patients who selected FWL as 83% of them lost at 
least 5 kg of weight compared with 31% and 22% of those who selected orlistat and LCD, 
respectively (Table 4-10). 
 
 
 
Intervention N % Mean weight change 
and 95% CI (kg) Lost ≥5 kg Lost ≥5% 
Orlistat (≥2 sessions) 536 16.4 -3.31 (-3.7 to -2.9) 166 (31%) 139 (26%) 
LCD (≥2 sessions) 1,043 32.0 -2.39 (-2.6 to -2.1) 228 (22%) 188 (18%) 
FWL (≥2 sessions) 1,683 51.6 -10.17 (-10.4 to -9.8) 1,394 (83%) 1,297 (77%) 
Overall at the end of 
phase 2 3,262  -6.56 (-6.7 to -6.3) 1,793 (54.9%) 1,623 (49.7%) 
Table 4-10 Total lifestyle phase + phase 2 outcomes and weight change among groups of 
patients who selected different interventions (CI: Confidence interval; N: Number). 
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4.5 Summary of the main findings 
• 44.5% of those patients who attended the lifestyle phase went on to attend phase 2. 
• Those patients who did well (lost ≥5 kg) in the lifestyle phase were offered FWL in 
phase 2. 
• The majority of the patients participating in the three different interventions lost 
most of the weight in the lifestyle phase. However, in terms of completion, those 
who were on orlistat reached their weight loss target in phase 2, although just 2.5% 
had lost ≥5 kg in the lifestyle phase. 
• There was no difference in weight loss outcomes according to sex, SIMD, age, 
initial BMI, and presence or absence of diabetes and hypertension in the weight 
loss of the orlistat group. 
• There was a variation between initial BMI and mean weight change for those on 
LCD and FWL (i.e. the mean weight loss was higher in the lighter participants on 
LCD and higher in heaviest people on FWL). 
• Patients who did well in the lifestyle phase continued to lose weight in phase 2. 
• Those on LCD experienced a smaller amount of weight loss than the patients on 
FLW or orlistat interventions.  
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4.6 Discussion 
This study set out to assess the impact of different interventions on weight loss, such as 
FWL, LCD and orlistat, by reporting weight change outcomes at the end of the second 
phase of a NHS weight management programme (phase 2). The research demonstrated that 
NHS GCWMS achieved a 5 kg weight loss in 54.9% of the participants who attended at 
least 2 sessions in phase 2 when the LOCF analysis was used. This equated to 49.7% of 
patients losing 5% of their body weight. 83% of those selecting FWL lost at least 5 kg at 
the end of phase 2, compared with 31% and 22% of participants selecting orlistat and 
LCD, respectively. Therefore, 77% of patients selecting FWL, 26% selecting orlistat, and 
18% of patients selecting LCD lost 5% of their body weight. 
 
4.6.1 Opt in and baseline characteristics 
The results reported in this chapter outline the effectiveness of the different interventions 
offered for patients in the phase 2 treatment of the larger weight management programme. 
The mean BMIs for those participants offered orlistat and LCD was lighter than the 
participants who offered the FWL intervention, indicating that they might have been 
heavier when starting the lifestyle phase. SIGN guidelines stated that the most effective 
first line for the prevention and management of obesity is dietary and lifestyle intervention 
(SIGN 115, 2010). In total, 45.5% of participants completing the lifestyle phase dropped 
out and did not complete the weight management programme. The reason for this is 
unknown, although it might be that the patients had achieved the desired weight loss and 
felt that they no longer needed the service, or possibly it indicated a lack of success and 
weights regain (Logue et al., 2014). Other factors might include health-related problems, 
lack of motivation and disappointment.  
 
Of the participants included in phase 2, 51.5% selected FWL, based on success losing 
weight during the lifestyle phase. In general, a higher proportion of patients from the most 
deprived quintile, females and those with a BMI between 40 and 49.9 kg/m2 continued to 
opt in to phase 2; however, men, those in least deprived area, older individuals and patients 
with higher BMIs had low dropout rates. The suggested reasons for the higher dropout rate 
in younger patients are, as mentioned in the previous chapter, the priority given to work 
and to caring for children, and the lack of transportation for those in the most deprived 
areas, which might lead them to leave the programme. Those with higher BMIs had lower 
dropout rates, which might be due to concern about their health. 44% of patients included 
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in phase 2 had a BMI ≥40 kg/m2, and currently the goal of GCWMS is to achieve 5 kg 
weight loss. Hence, the GCWMS goal of >5 kg weight loss might not be sufficient to 
ensure functional improvement in patients with BMI >40 kg/m2 as it falls short of the 
target of 10-15% weight loss set by SIGN guidelines. 
 
4.6.2 Weight loss outcomes and comparisons with other weight 
management programmes 
To the best of our knowledge, this is the first study to evaluate the effectiveness of each 
intervention in a real-life weight management programme; whereas, previous studies 
evaluated a single intervention or programme phases, regardless of the types of 
interventions.  
 
A tier 3 service of the Fakenham programme (FWMS) reported that 44.1% of all 
participants and 53.8% of completers lost ≥5% of initial weight after six months (Jennings 
et al., 2014) (full details in page 70). FWMS offers a lifestyle change for participants to 
help them achieve their target weight loss over one year. The patients were considered for 
treatment with orlistat, LELDs or bariatric surgery if they met the clinical criteria. During 
the period of study, just 36 participants were prescribed orlistat due to a national shortage 
of the drug; 9 patients were prescribed LELDs. As this study did not report the results for 
each intervention, it is not possible to compare the results of phase 2 of the GCWMS with 
FWMS. There are no other tier 3 service providers that have published the outcomes of 
each intervention. 
 
4.6.2.1 Orlistat 
Orlistat (360 mg/day) users in phase 2 had completed the lifestyle intervention in phase 1. 
Mean weight loss improved (-1.9 kg) for all 536 participants using orlistat, compared with 
the same group of participants (-1.4 kg) in the lifestyle phase. In the HTA journal, a 
previous systematic review of eight RCTs by Avenell et al. (2004) stated that the addition 
of orlistat to the diet was accompanied by weight loss at 12 months; the mean difference in 
weight between orlistat plus diet versus placebo plus diet was -3.01 kg (95% CI: -3.48 to -
2.54 kg). This suggests that using orlistat after the issuance of dietary advice can improve 
long-term weight loss.  
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While several RCTs have studied the effect of orlistat on weight loss, the majority of them 
reported the effects on patients who spent at least a year using the drug. A RCT was 
undertaken to assess the efficacy of orlistat to promote weight loss in patients with a BMI 
28-47 kg/m2 over 2-years duration (Sjostrom et al., 1998). In total, 743 participants from 
15 European centres entered four-week single blind, hypocaloric diet, and then were 
assigned to orlistat 360 mg or placebo. At the end of the first year, the mean weight change 
for the orlistat and placebo groups was -10.3 kg and -6.1 kg, respectively. Moreover, the 
mean weight loss at the end of the first 3 months for the orlistat and placebo group was -
7.2 kg and -5.2 kg, respectively.  
 
Another one-year RCT compared the effect of orlistat 360 mg versus placebo on 
cardiovascular disease in 339 participants with BMIs between 30 and 50 kg/m2 from 8 
centres in Australia and New Zealand. The mean weight loss at a one-year duration for 
those who used orlistat in conjunction with a lifestyle change was -4.7 kg (Swinburn et al., 
2005). Additionally, based on the HTA programme, a previous RCT by Micic et al. (1999) 
reviewed the clinical effectiveness of orlistat in the treatment of obesity over 6 months 
duration. This tested 119 patients with BMI ≥30 kg/m2 recruited for a two-week diet and 
then randomised to receive orlistat 360 mg or a placebo. The mean weight change in the 
orlistat group was -10.7 kg compared with -7.3 kg in the placebo group (O'Meara et al., 
2001). A prospective randomised study was carried out to evaluate the efficacy and safety 
of orlistat 360 mg in 80 patients with obesity (BMI ≥30 kg/m2) at an outpatient department 
in India over a 24 week duration. The mean weight change reported was -1.59 kg, -4.65 kg 
and -5.25 kg at 8 weeks, 16 weeks and 24 weeks, respectively (Jain et al., 2011).  
 
A cohort trial, based on real life data, assessed the effect of orlistat on body weight over 3 
years, when delivered in a primary care setting in a UK population. Mean BMI in that 
study was 37.2 kg/m2, and the weight change in the first 4 months for all 99,420 
participants was -0.94 kg/month (95% CI: -0.93 to -0.95 kg/month), meaning the patients 
lost 2.82 kg after 3 months duration (Douglas et al., 2015).  
 
The SIGN guidelines and United States guidelines recommend orlistat for patients with 
BMI ≥30 kg/m2 or 28 kg/m2 plus comorbidity, who have not achieved their target weight 
loss through lifestyle intervention. However, based on the above results, the evidence for 
the effectiveness of orlistat on obesity depends on the results of RCTs, and it is not known 
how the efficacy measures in the trials relate to effectiveness in the general population. In 
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conclusion, orlistat was approved for obesity treatment based on its positive benefits as 
established in RCTs; however, in real life, orlistat is associated with a lesser effect on 
weight loss than in RCTs (Douglas et al., 2015). The current study showed a lower level of 
weight loss (-3.31 kg within 3 months) than that achieved in RCTs (-7.2 kg at the end of 3 
months). 
 
For the subgroup of participants with type 2 diabetes, the current results of the effect of 
orlistat in real life on weight loss (-2.93 kg (95% CI: -3.8 to -2.0 kg) at 3 months) was less 
than the weight loss observed in the systematic review and meta-analysis of the RCT (-
3.67 kg (95% CI: -4.30 to -3.04 kg) at 3 months) (page 90). In the LOOK AHEAD study, 
of the 722 individuals who lost less than 5% (at 6 months) of their initial weight after an 
ILI, 291 patients took orlistat for 6 months and lost an additional 1.8% of their weight 
(Wadden et al., 2009); a result comparable to GCWMS. This may be because the patients 
in the GCWMS and the LOOK AHEAD study had first gone through the lifestyle 
intervention phase and then used orlistat; while the participants in the RCTs underwent 
lifestyle interventions and took orlistat at the same time. Therefore, the latter may have 
been on a low-fat diet following the lifestyle intervention and certain fats may need to be 
present in the diet for orlistat to have effect. 
 
Due to the unpleasant side effects of orlistat, such as oily stools, patients may stop taking 
this medication. A longitudinal study undertaken by Hollywood and Ogden (2011) 
recruited 566 individuals who was prescribed orlistat by their GP and were registered on 
the Xenical support system. These patients completed a baseline questionnaire within the 
first three months of starting the treatment and filled up a follow-up questionnaire after six 
months. Patients who stopped taking the medication by six months, those who continued 
taking the medication and those who reported flexible adherence based on their diet were 
grouped as non-adherers, adherers and lifestyle adherers, respectively. The researchers 
found that within six months, 47.5%, 30.4% and 22.1% could be classified as non-
adherers, adherers and lifestyle adherers, respectively. Therefore, it is recommended that 
clinicians should not focus only on advising patients about the consequences of eating a 
high fat diet, but should also promote healthy dietary changes and inform patients about 
the effectiveness of this kind of medication on weight management. Also, it is important 
that health care professionals, GPs, patients, and policy makers understand the possible 
effects of orlistat use as part of the protocol in routine weight management services.  
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4.6.2.2 LCD 
To date, a number of trials appear to have suggested that LCD (800-1800 kcal/day) is 
associated with modest weight loss (5-6%) at 12 months duration. A previous systematic 
review and meta-analysis of 80 RCTs after ≥1-year follow-up by (Franz et al., 2007) 
reported weight loss at 6, 12, 24, 36, and 48 months for different interventions. The 
intervention for 51 studies was diet alone, and the mean weight losses at 6, 12, 24, and 48 
months was -4.9, -4.6, -4.4, and -3.0 kg, respectively. Moreover, a previous RCT, 
performed in three hospitals in the Netherlands and two hospitals in Poland reported a 
weight change at 12, 24 and 36 months of female patients with obesity and breast cancer. 
The mean weight difference between the treatment group and the control group at 12 
months was -6.2 kg (95% CI: -9.0 to -3.4 kg); however, the sample size for the study was 
small, reflecting the wide confidence interval (De Waard et al., 1993). Additionally, a 
recent RCT was conducted in the Netherlands on 57 participants with BMI =28-35 kg/m2 
with no comorbidities randomised to a LCD (1,250 kcal/day) for 12 weeks. It found the 
mean weight change was -8.2 kg (Vink et al., 2016); whereas, the mean weight change in 
the current study for a group of participants (n =1,043) selecting LCD (600 kcal deficit 
diet) was -2.39 kg. However, the aforementioned trial suffered from a small sample size in 
contrast with the current research and different methodological used.  
 
In the lifestyle phase, LCD was selected by the patients; however, in phase 2, a prescribed 
LCD was offered to the patients, giving a daily meal plan. The participants in the current 
study were recruited for lifestyle interventions for 4 months prior to the selected LCD, and 
they had lost -1.89 kg (95% CI: -2.0 to -1.7 kg). This might reflect the fact that this group 
of participants were less motivated to lose weight. Furthermore, some of the participants 
suffered from diabetes, which may have caused more modest weight loss, as it is known 
that people with type 2 diabetes lose less weight than those without diabetes (Stanford et 
al., 2012). Based on the above and the intensity of the programme (monthly follow up), 
those who selected LCD as part of a routine weight management programme were less 
likely to lose weight compared to those in RCTs. Although, in GCWMS, this was 
effectively rescue therapy; i.e. giving prescribed LCD to those who had failed to lose 
weight.  
 
A RCT undertaken by Jakicic et al. (2012) was conducted with 363 individuals who were 
overweight or obese with a BMI in the range of 25-40 kg/m2. Of these individuals, 198 
were allocated randomly to a stepped-care weight loss intervention (STEP), while 165 
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were allocated randomly to a standard behavioural weight loss intervention (SBWI). 
Although the intervention combining physical exercise, a hypocaloric diet and counselling 
on a week or month basis for a year and a half was applied to participants in both groups, 
the programme was fixed in the case of the SBWI group, while the programme could be 
adjusted according to weight reduction goals in the case of the STEP group. The results 
revealed that, upon completion of the year-and-a-half programme, the SBWI group 
achieved a higher average weight reduction than the STEP group, with an average weight 
difference of -1.3 kg (95% CI: -2.8 to 0.2 kg). The weight percentage decreased by -8.1% 
(95% CI: -9.4% to -6.9%, p ˂0.001) and -6.9% (95% CI: -8.0% to -5.8%, p ˂0.001) in the 
SBWI group and the STEP group, respectively. However, the real interest is in the rate of 
success of the intensification of the programme; despite 5 steps to intesify the programme 
including phone counselling and liquid meal replacements, only 5% of the participants 
moved back to the target weight loss trajectory during the study. Therefore, it could be 
concluded that rescue interventions may not work.  
 
With regard to the difference between men and women in terms of weight loss, a previous 
study by Wamsteker et al. (2005) recruited 66 participants with obesity (48 women and 18 
men) to be treated in an outpatient clinic in the Netherlands from September 2000 to June 
2001 for 8 weeks. They were treated by LCD (800-1000 kcal/day) with meal replacement 
and the mean weight change was 10.2%. Moreover, there was no significant difference 
between men and women in terms of percentage weight loss, which concurs with the 
current research finding (-2.41 kg (95% CI: -2.8 to -1.9 kg) in men and -2.38 kg (95% CI: -
2.7 to -2.0 kg) in women). 
 
4.6.2.3 FWL 
The current study shows that participants who did well in the lifestyle phase were offered 
FWL and continued to lose weight in phase 2, but their weight loss in this phase was not 
considerable (-1.9 kg) compared with (-8.27 kg) in the lifestyle phase. The possible reasons 
might be the higher number of sessions in the lifestyle phase (fortnightly) compared with 
phase 2 (monthly). However, this group of participants were still more motivated to lose 
weight than those who selected orlistat or LCD, as 83% had lost at least 5 kg weight by the 
end of the lifestyle phase. After that, weight loss plateauing might be expected at the end of 
phase 2, and patients may experience some difficulties in losing weight. An example from 
the systematic review and meta-analysis of long term RCTs, found weight loss starts to 
plateau across all interventions after 6 months. For example, when adding exercise to LCD, 
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this resulted in a mean weight loss of -7.9 kg at 6 months, then plateaus at -6.7 kg at 12 
months (Franz et al., 2007). Unfortunately, the data did not explain the reasons why those 
who were selected for the FWL lost more weight in the lifestyle phase when compared 
with those in the LCD and orlistat group in phase 2. Behaviour and psychological effects 
may be suggested as possible reasons for this. In addition, it could be that the members in 
the group selected for the FWL were heavier (mean BMI was 42.8 kg/m2), more motivated 
and more likely to be male (33.9%) than the members of the groups who were offered 
orlistat or LCD. 
 
4.6.3 Completion and weight loss outcomes for subgroups           
Among those participants offered FWL and who completed the lifestyle phase and phase 2 
of the programme, 86.5% lost their target weight (≥5 kg); demonstrating they had met their 
target and achieved further meaningful weight loss (95% CI: -11.5 to -10.7 kg). Overall, 
the patients who completed the programme by attending ≥7 sessions in the lifestyle phase 
and ≥2 sessions in phase 2 lost more weight than the non-completers; however, a minority 
of people who used orlistat or LCD also lost their target weight. This might be due to the 
higher threshold for completion applied, and the assumption that attendance is directly 
correlated with weight loss. 45.2%, 48.4% and 37.3% of the patients offered orlistat, LCD, 
and FWL respectively, did not complete the requisite number of sessions. This might be 
because they did not reach their weight loss target, or due to the limited choices of 
appointment times and the service design. 
 
The findings showed that the patients without diabetes lost more weight than patients with 
diabetes when selecting FWL in phase 2; this is likely to be due to differences in dietary 
adherence, as suggested in the previous chapter, or might be because most of the patients 
were using anti-diabetic drugs, a common side-effect of which is weight gain. In addition, 
patients with diabetes might suffer from other complications, such as neuropathy, foot 
ulcers or heart disease. Therefore, increasing physical activity, which is an important 
aspect of the treatment of patients with obesity, is usually unsuccessful. However, there 
was no difference between the weight losses of people with and without diabetes offered 
orlistat or LCD, possibly because those with diabetes were successful at remembering to 
take the orlistat tablet with their anti-diabetic medication. This research and that in the 
previous chapter explored the effects of gender, SIMD, age and initial BMI on weight 
change. A previous study by Stubbs et al. (2011) reviewed the rate and extent of weight 
loss in a primary care/commercial weight management partnership system of 34,271 
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participants referred to Slimming World; it was found that regardless of sex, age and initial 
weight, if a patient is able to complete a programme of treatment and is encouraged to 
achieve reasonable weight loss in the first week, they will be likely to succeed in achieving 
their target weight loss. 
 
4.6.4 Early weight loss prediction 
It was found that many more patients achieved their target weight loss in the lifestyle phase 
than in phase 2, for each of the different interventions. This may be because the lifestyle 
phase was more effective than phase 2. Another possible explanation could be that weight 
loss begins quickly then starts to slow naturally (Stubbs et al., 2011). In total, 83% of the 
patients selecting FWL had lost their target (≥5 kg) at the end of the phase 2 treatment. In 
this group of patients, most weight was lost initially in the lifestyle phase, which indicated 
that early weight loss was a strong predictor of successful and long-term weight loss. This 
might be because early weight loss was a sign that the participants were more motivated. 
Additionally, the Look AHEAD trial included 2,327 participants with type 2 diabetes in 
the intensive lifestyle intervention (ILI); as individuals who had not achieved ≥2% weight 
loss within one month were 5.6 (95% CI: 4.5, 7.0) times more likelihood of not achieving 
10% or more weight loss within one year (Unick et al., 2014).  
 
Further analysis was performed for 2,290 Look AHEAD participants, to test the 
relationship between the first two months of weight loss and weight 8 years later. It was 
found that those who achieved ≥2% weight loss in the first month or ≥6% at second month 
were more likely to achieve a clinically significant weight loss by year 8 (Unick et al., 
2015). Another study by Jebb et al. (2011) reported that during commercial programmes, 
most weight is lost over 2 months and loss levels off over the following 12 months. The 
current findings show that initial body weight positively influences the rate of weight loss, 
which is in agreement with a previous systematic review by Finkler et al. (2012). This 
review examined the factors that might impact the rate of weight loss, and included 35 
studies published between January 1995 and December 2009. The same review also found 
that age was a significant factor in predicting the rate of weight loss with diet, which is 
consistent with the current research, in which older participants lost more weight compared 
to younger individuals. This might be because compliance improved in older adults more 
than in younger adults, or because of the patients’ higher level of concern about their 
health. 
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4.6.5 Attrition rate 
A previous Lancet study by Jebb et al. (2011) found that the attrition rates in commercial 
weight loss programmes or in routine clinical practice appear to be highest in the UK 
(64%), compared with Australia (41%) and Germany (25%). This is probably because of 
difficulties ensuring flexible appointments for participants or possibly due to a lack of 
success (Holzapfel et al., 2014). This study and the previous literature suggested a 
correlation between attendance and weight loss. Unfortunately, it is not possible to explore 
the attrition rate comparative to the amount of weight lost, as there was no information 
about the weight status of those who did not attend. Similarly, both attrition and weight 
loss are time-dependent, so it is not easy to establish whether the association between a 
short duration of attendance and poorer weight loss is causal. Overall, 45.2%, 48.4% and 
37.3% of the participants on orlistat, LCD and FWL respectively, dropped out and did not 
complete their sessions. Hence, there was a higher attrition rate in the LCD and orlistat 
groups compared with those on FWL; the reasons for this may be due to the challenge of 
adhering to a very LCD, or not meeting weight loss targets and/or dissatisfaction with the 
side effects of orlistat.  
 
It is not possible to compare the attrition rate at the end of phase 2 of the GCWMS with 
other tier 2 services as the results of each intervention were not reported by other services. 
However, the attrition rate at the end of the lifestyle phase of the GCWMS can be 
compared with other tier 2 programmes: in the Counterweight programme, attrition was 
52.4% at 3 months, 70% at 6 months and 77.5% at 12 months (Laws, 2004); in a study of 
Weight Watchers’ attendees, 44% of participants dropped out after 3 months and did not 
complete the programme (Ahern et al., 2011); the attrition rate over three months in the 
Rosemary Conley and Slimming World was 55.2% and 64%, respectively. Another study 
by Hickson et al. (2009) reported a high dropout rate for patients who attended an intensive 
weight management clinic (IWMC) or standard dietetic care in the UK and had a BMI ≥32 
kg/m2. Over six months, participants attended lifestyle intervention sessions, 45% attended 
the IWMC and 55% the standard care. However, of these, only 53% and 19% respectively 
completed the programme. Unfortunately, the reasons for the high drop-out rate in that 
study were not investigated; however, it has been suggested that it is important to identify 
motivated patients.  
 
With respect to the tier 3 programmes, the total dropout rate at the end of the lifestyle 
phase of the GCWMS (4 months) was 44.8%, compared with 14.3% in the FWMS (within 
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6 months) (Jennings et al., 2014). This striking difference might be due to the different 
choices of appointment times in primary care, or may have been influenced by the fact that 
the individuals attending the FWMS programme were motivated by the fact that attendance 
could help them qualify for a bariatric surgery referral. Attrition rate is not comparable in 
different weight management programmes due to the differences in the treatment 
programme setting. Encouraging support from a healthcare provider is aimed at motivating 
participants to complete the programme treatment, in order to reduce dropout rates, but 
underlying factors such as location and timing of appointment should be considered. 
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4.7 Research strengths and limitations 
As stated in the previous chapter, this research benefited from access to a diverse-socio-
economic population and a large sample size, in the form of the GCWMS data set. This 
assisted in evaluation of the effectiveness of the lifestyle phase and phase 2, and furthered 
understanding of diverse individuals’ challenges to control their weight. The data used in 
this research were extracted from a large NHS weight management service providing a 
real-life follow-up cohort study. A key strength of the present study was that the 
effectiveness of each intervention in phase 2 was evaluated separately, to determine the 
effectiveness of the interventions relative to lifestyle change to achieve target of weight 
loss. A specific strength of the study was that the outcomes of all patients referred to 
GCWMS were reported, rather than only the outcomes of those who completed the 
programme. It was observed that attendance is associated with weight loss; therefore, a 
higher threshold was used to define programme completion. There was no selection bias, 
as the data pertaining to all participants referred to the GCWMS were included in the 
study. In addition, the findings were high quality, as the measurements were objective and 
not self-reported. 
 
This analysis of real-life clinical data is by no means considered definitive in this area, and 
the limitations affecting the available data make it impossible to conduct a full exploration 
of all explanatory variables. A number of additional analyses exploring sex, age, initial 
BMI and socioeconomic status have already been added. Further complicating the study 
method and previous research through the addition of multivariate models lacking key 
variables would not alter the clinical message or provide further meaningful insights into 
this complex area. The major limitations in this study are lack of data because some 
patients missed their treatment sessions, and because some patients did not complete the 
programme of treatment.  
 
It was estimated that around 45%, 48% and 37% of the individuals offered orlistat, LCD 
and FWL, respectively did not complete the treatment programme. There was no 
information given about those who were never referred to the GCWMS, and it was 
unfortunate that the data did not include information about why the patients did not 
complete the programme of treatment. The study only detected cumulative weight loss 
over a 3 months’ duration, plus 4 months of treatment in the lifestyle phase, but did not 
report weight loss in phase 3 over 12 months, which is termed weight maintenance. NICE 
(2014) recommends that in terms of weight management interventions outcomes after 
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twelve months of results are crucial. Therefore, further research should be undertaken to 
investigate the effectiveness of the maintenance programme (phase 3). 
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4.8 Research implications 
This study confirmed that the patients who completed the programme were more likely to 
lose ≥5 kg. Outcomes from the phase 1 lifestyle stage influence the selection of the phase 2 
intervention. Those who do well in the lifestyle phase are offered FWL and have the 
highest weight loss by the end of phase 2. Orlistat and LCD are offered for those who 
failed to lose significant weight with lifestyle alone but do not result in large numbers 
achieving >5 kg weight loss. Conversely, 83% of the patients who selected FWL lost ≥5 
kg. Therefore, the findings of this study suggest a number of important implications to 
improve future weight management programmes, such as, targeting effective interventions 
at specific populations and increasing the intensity of phase 2 interventions to improve 
overall effectiveness. The real-life data showed minimal effect of orlistat and LCD on 
weight loss, and more research might be needed to confirm their effect. Encouraging 
women, young people and those from the most deprived areas to complete the programme 
might improve its overall effectiveness. Further work should be conducted to determine the 
effective interventions for patients referred to weight management programmes, in order to 
stratify patients into different treatment modalities, based on results and evidence. 
 
Chapters 3 and 4 evaluated the effectiveness of GCWMS in achieving target weight loss, 
and a portion of the results showed that patients with diabetes lost less weight than 
participants without. The SIGN guidelines highlight the drugs treatment plan for 
individuals with obesity and diabetes. Therefore, in the subsequent chapters (5 and 6), the 
prescribing pattern for anti-diabetic drugs will be investigated, and the observed effects of 
these medications on weight change reported. 
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Chapter 5: Prescribing patterns for weight-
neutral, mixed and weight-gaining anti-
diabetic medications at Glasgow and Clyde 
Weight Management Service 
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5.1 Chapter summary 
A number of different anti-diabetic drug groups are used to treat patients with type 2 
diabetes. They use different mechanisms to control blood glucose levels and have 
differential effect on body weight. Previous researchers have studied the prescribing 
pattern of anti-diabetic medications for patients with diabetes. Some of this has suggested 
an association between obesity and anti-diabetic medication; accordingly, the SIGN 
guidelines launched in 2010 highlighted treatment guidance for patients with both diabetes 
and obesity. The aim of this study was to observe the prescribing pattern for anti-diabetic 
drugs in subjects with type 2 diabetes and obesity. It was hypothesized that patients with 
obesity and diabetes were less likely to be prescribed weight-gaining drugs. The second 
objective of the research was to determine whether the introduction of the SIGN guidelines 
influenced prescribing practice, in terms of the patterns of weight-neutral, mixed and 
weight-gaining anti-diabetic drugs prescribed. 
 
A cross-sectional study was carried out including adult individuals of both sexes with type 
2 diabetes referred to the GCWMS. Their anti-diabetic drugs were classified into three 
categories based on their effect on body weight, using the Diabetes Update Guide to Meds 
& Kit, 2015 and the British National Formulary, 2016 (BNF). These categories included 
weight-neutral, mixed and weight-gaining anti-diabetic medications. The number and 
percentage of drug groups prescribed, and the proportion of patients on weight-neutral, 
mixed and weight-gaining anti-diabetic drugs were reported. Furthermore, a repeat cross-
sectional design was used to infer differences in the patterns of the prescribing of anti-
diabetic drugs following the introduction of the SIGN guidelines. 
 
A total of 3,063 individuals were included in this study (55.3% females and 44.5% males). 
The mean BMIs for females and males were 41.1 kg/m2 and 40.2 kg/m2, respectively, and 
overall the mean BMI at baseline for all age groups was lower among patients on weight-
gaining anti-diabetic drugs. Metformin was the most commonly prescribed drug for 
patients with obesity and type 2 diabetes, and sulfonylureas (SUs) and thiazolidinediones 
(TZDs) were the least prescribed drugs. A total of 47.8% of the subjects were prescribed 
weight-neutral anti-diabetic drugs and 39.4% were on the mixed drug regimen. A total of 
12.7% of the subjects were on drugs known to cause weight gain, and a further respective 
11.6% and 13.8% (p =0.13) were on weight-gaining drugs prior to and one year after the 
SIGN guidelines were issued. 
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In conclusion, there was no change in the anti-diabetic prescriptions issued by GPs to 
patients with obesity and type 2 diabetes after the SIGN guidelines were released.  
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5.2 Introduction 
In the UK, the majority of patients with type 2 diabetes are overweight or obese, estimated 
at 80-90% (Diabetes UK, 2009). The risk of type 2 diabetes in people with obesity (defined 
as BMI >35 kg/m2) is between 50-80 times higher than that in those with a BMI <23 kg/m2 
(Chan et al., 1994). Obesity is the major risk factor for the development of type 2 diabetes. 
However, many other factors, such as age, gender and SIMD, may influence the risk of 
type 2 diabetes. In terms of sex, a study by Sattar (2013) suggested that men’s have higher 
visceral fat levels result in higher liver fat and insulin resistance compared with women of 
similar BMI. This is consistent with an earlier study by Logue et al. (2011) that found that 
men developed diabetes in a lower BMI range compared with women across the age 
spectrum. The incidence of type 2 diabetes increases with age, the highest prevalence 
(10.4% of women and 15.7% of men) being found between 65 and 74 years of age in 
England (Craig & Mindell, 2008). Furthermore, people with type 2 diabetes are less 
overweight with increasing age, and older patients may not be treated as aggressively. 
These factors might affect the prescribing of anti-diabetic drugs - patients with higher 
BMIs may be prescribed weight-neutral drugs or patients over 70 years of age may be 
prescribed weight-gaining drugs. Prescription practice may also be influenced by patients’ 
sex. Women are more likely to develop osteoporosis than men with age; the SIGN 
guidelines (SIGN 116, 2010) recommend that the risk of bone fractures form part of the 
consideration when treating patients with pioglitazone. 
 
According to evidence, the majority of the oral anti-diabetic medications available are 
associated with weight gain, which makes the management of type 2 diabetes in 
individuals with overweight and obesity more challenging (Solini, 2015). According to the 
SIGN guidelines and the American Association of Clinical Endocrinologists (AACE), 
patients with obesity and type 2 diabetes should be provided with an individualised 
intervention, to include a lifestyle intervention, and pharmacotherapy or surgery to 
promote weight loss, in order to improve glycaemic control.  
 
Treatment for patients with obesity and type 2 diabetes is advised to proceed according to 
the obesity management algorithm. It is important to follow the algorithm and the 
guidelines when treating this group of patients, and as general practitioners will be the 
main prescribers, it is important that they have a clear understanding of why patients with 
diabetes and obesity require specific treatment plans, unless patients have uncontrolled 
glycaemic levels (NHS Scotland, 2014).  
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Due to the availability of numerous classes and the inclusion of multiple drugs in each 
class, it is essential for physicians to prescribe the most helpful oral hypoglycaemic drug 
for each patient, depending on their particular situation. Various anti-diabetic drugs can be 
used to control blood glucose while ensuring weight to remains neutral, such as 
Biguanides, Glucagon-like peptide-1 agonist (GLP-1 agonists), Dipeptidylpeptidase-4 
inhibitors (DPP-IV inhibitors) and Sodium-glucose co-transporter-2 inhibitors (SGLT2 
inhibitors). However, some are known to cause weight gain, such as SUs and TZDs 
(Inzucchi et al., 2015). Accordingly, drugs that assist weight to remain neutral or promote 
weight loss should be the first-line treatment in patients with obesity and type 2 diabetes 
(Bonora, 2007). However, the decision about which drug treatment to start for patients 
with diabetes and obesity depends not only on their weight, but also on the drug’s efficacy, 
associated side effects, cost and the patient acceptance of the treatment (Hollander, 2007). 
 
Often, clinical guidelines can take as long as 3 years to be completely implemented (NICE, 
2007). While, new guidelines and recommendation regarding drugs treatments are 
expected to be rapidly transferred into clinical practice, in reality, there is often 
considerable variation in the compliance of clinicians. Titler (2008) suggested that 
implementing the change in the guidelines might take several weeks to months, based on 
the nature of the practice change. A previous study by Cuspidi et al., (2002) investigated 
whether GPs in Italy manage patients with hypertension according to the recommendation 
of the WHO (1999) guidelines. Six hypertension outpatient centres participated and 228 
patients were included in the study. It was found that only 10% of the physicians were 
complied with the guidelines; the researcher suggested that the impact of guidelines on 
patients’ treatment in clinical practice seemed peripheral. Therefore, it might be possible to 
test a hypothesis that there would be a reduction in proportion of patients being prescribed 
weight-gaining anti-diabetic medication after the publication of SIGN guidelines in 2010. 
However, it might be argued that the introduction of the guidelines need not necessarily 
have a measurable effect in the situation that prescribing was already being performed 
completely in accordance with good clinical practice. 
 
Little evidence exists regarding the patterns of the prescription of anti-diabetic medications 
to patients with diabetes and obesity referred to weight management services. The aim of 
this research is to describe the proportion of patients with diabetes referred to the GCWMS 
from 2008 to 2014 on weight-neutral, mixed and weight-gaining anti-diabetic medications, 
and to compare the results based on three phases:  
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Phase 1: Before the SIGN guidelines were released in March 2010 (from January 2008 to 
the end of February 2010). 
Phase 2: A one-year-long transitional phase (from March 2010 to February 2011). 
Phase 3: After the release of the guidelines (from March 2011 to May 2014). 
 
In addition, the study also aims to evaluate the impact of age, sex and SIMD on anti-
diabetic drugs prescribing. Hence, it could conceivably be hypothesised that a reduction 
would be witnessed in the proportion of patients being prescribed weight-gaining anti-
diabetic medication after the publication of the SIGN guidelines in 2010.  
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5.3 Materials and methods 
5.3.1 Study procedure  
Once the patients were referred, all medications were imported into the GCWMS database 
from the Scottish Care Information (SCI) gateway referral. Search terms were used to 
ascertain the anti-diabetic drugs used for classification and coding according to the BNF, 
2016 categories. The anti-diabetic medications were recorded in the GCWMS database 
using their generic names or their trade names.  
 
These drugs were classified into seven groups: Biguanides, DPP-IV inhibitors, GLP-1 
agonists, SGLT2 inhibitors, TZDs, SUs and insulin. Drugs in all of these anti-diabetic drug 
groups were available in the UK in 2015, and their different trade names in addition to any 
combined medications available in the UK were identified using the Diabetes Update 
Guide to Meds & Kit (Diabetes UK, 2015), and BNF 2016 (Table 5-1). Based on the 
SIGN guidelines and a range of RCTs (Pi-Sunyer, 2008; Astrup et al., 2009; Phung et al., 
2010; Astrup et al., 2012) (page 72-75), the drugs were then categorised according to their 
effect on body weight as weight-neutral, mixed and weight-gaining drugs. With respect to 
the strength of evidence used in the formulation of these guidelines, high-quality evidence, 
such as meta-analyses and systematic reviews of RCTs, or RCTs with a very low or low 
risk of bias, was used to make recommendations for patients with obesity.  
 
After this, each category was classified into different groups, according to whether the 
expected weight change outcome might increase or decrease when patients used a 
combination of drug groups from the same category. 
 
1. Weight neutral: 
          1a. Metformin only 
          1b. Metformin +DPP-IV +/OR GLP-1 +/OR SGLT2 
 
2. Mixed: 
          2a. (SUs) AND (Metformin +/OR DPP-IV +/OR GLP-1 +/OR SGLT2) 
         2b. (TZDs + SUs) OR (TZDs) AND (Metformin +/OR DPP-IV +/OR GLP-1 +/OR          
SGLT2) 
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3. Weight gaining: 
           3a. SUs only 
           3b. SUs + TZDs 
           3c. any combination including insulin 
 
5.3.2 Data source, inclusion and exclusion criteria 
Participants of both sexes, aged ≥18 years, referred to the GCWMS between 2008 and 
2014 using anti-diabetic medication were included. Any patient on insulin only or on any 
combination not described above was excluded. Initial numbers in each subgroup, mean 
BMI, BMI categories, sex, SIMD and age were identified, and the subgroups combined 
according to their effect on body weight (i.e. 1a +1b and 2a +2b). A comparison was then 
performed between the number and the types of anti-diabetic drugs given to patients 
referred before the SIGN guidelines, during the first year, and one year after the guidelines 
were released. 
 
5.3.3 Statistical methods 
The results were reported as number, mean ± SD and percentages. The differences in 
patient characteristics, such as mean age and BMI, were tested using an independent t- test 
for the following two groups:  
- Patients with type 2 diabetes and obesity referred to the GCWMS on weight-neutral were 
compared with those referred on mixed drugs. 
- Patients with type 2 diabetes and obesity referred to the GCWMS on weight-neutral were 
compared with those referred using weight-gaining medication. 
A Chi-square test was used to measure the categorical variables; in addition, the 
differences between the proportions of patients referred (before and one year after the 
SIGN guidelines were published) on weight-gaining drugs were tested using the chi-square 
test. A limited number of studies suggested there was an association between the 
prescribing of anti-diabetic drugs and the baseline of age, sex, BMI and SIMD (Kamrai & 
Sac deva, 2010; Leal et al., 2013); therefore, a stratified analysis was used to control the 
effect of these known determinants (confounding factors) among the variables. P-value 
was considered as significant if <0.05 and all the statistical analyses were carried out using 
State version 12.1 (StataCorp, College Station, Texas). 
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SU TZD SGLT2 Inhibitors GLP-1 Agonists DPP-IV 
Inhibitors 
Biguanides Insulin Combined Medications 
Glibenclamide 
(Daonil®) 
(Euglucon®) 
Pioglitazone 
(Actos®) 
Canagliflozin 
(Invokana®) 
Liraglutide 
(Victoza®) 
Sitagliptin 
(Januvia®) 
Metformin 
(Glucophage®) 
Insulin Aspart 
(Novorapid®) 
Pioglitazone + Metformin 
(Competact®) 
Gliclazide 
(Diamicron®) 
(Diamicron Mr®) 
Rosiglitazone 
(Avandia®) 
 
Dapagliflozin 
(Forxiga®) 
Exenatide 
(Bydureon®) 
(Byetta®) 
Vildagliptin 
(Galvus®) 
Metformin M/R 
(Glucophage Sr®) 
Insulin Lispro 
(Humalog®) 
Vildagliptin + Metformin 
(Eucreas®) 
Glipizide 
(Minodiab®) 
(Glibenese®) 
 Empagliflozin 
(Jardiance®) 
Lixisenatide 
(Lyxumia®) 
Saxagliptin 
(Onglyza®) 
 Actrapid® 
Humulin S® 
Sitagliptin + Metformin 
(Janumet®) 
Tolbutamide 
(Tolbutamide®) 
 
   Alogliptin 
(Vipidia®) 
 Insulin Glargine 
(Lantus®) 
Saxagliptin + Metformin 
(Komboglyze®) 
    Linagliptin 
(TRAJENTA®) 
 Novomix® 30 Alogliptin + Metformin 
(Vipdomet®) 
Glimepiride 
(Amaryl®) 
     Humulin M3® Linagliptin + Metformin 
(Jentadueto®) 
      Humalog® 
Mix25, 
Humalog® Mix50 
Rosiglitazone + Metformin 
(Avandamet®) 
      Humulin® R  
      Levemir®  
Table 5-1 Medications available in the UK in 2015 (according to The Diabetes Update Guide to Meds & Kit, 2015 and BNF, 2016).
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13 5.4 Results 
5.4.1 Baseline characteristics 
In total, 3,193 of the subjects referred to the GCWMS from 2008 to 2014 were taking anti-
diabetic drugs: 72 individuals were excluded because they were on insulin treatment only, 
and 58 patients were excluded because they were on different combinations of anti-diabetic 
drugs to those described above. Of the remainder, 3,063 individuals met the inclusion 
criteria for this study. Out of the 3,063 participants, 1,693 (55.3%) were females and 1,364 
(44.5%) were males.  
 
The participants were further categorised based on their age: 112 (3.6%) individuals 
belonged to the age group 18-29 years; 280 (9.1%) patients were aged 30-39 years; 676 
(22.0%) patients were aged group 40-49 years; 986 (32.1%) were aged 50-59 years; 757 
(24.7%) were aged 60-69 years; and 252 (8.2%) were aged ≥70 years. Mean weights for 
males and females were 122.4 and 105.5 kg, respectively (p =0.001); however, this is 
because on average the men were also taller. There was a small but significant difference 
showing that the referred men were less obese than the women. The mean BMIs for males 
and females was 40.2 and 41.1 kg/m2, respectively (p =0.0004). It is estimated that 20.4% 
of the individuals had a BMI in the range 30-34.9, 31.2% were in the range 35-39.9, 38.6% 
were in the range 40-49.9, and 9.7% were in the range ≥50 kg/m2; furthermore, 46.8% of 
the patients with diabetes were from the most deprived quintile and 11.3% from the least 
deprived quintile. 
 
The weight-neutral drug category of Metformin (group 1a) was the most commonly 
individually prescribed drug (43.7%), followed by mixed drugs category of SUs with one 
or more weight-neutral anti-diabetic drug (group 2a) (25.5%). Whereas, the least 
prescribed drug group included weight gaining drugs category of SUs plus TZDs (group 
3b) (1.70%) (Table 5-2). 
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5.4.2 The association between BMI and anti-diabetic drugs prescribing 
It can be seen from Table 5-2 that there was an association between a patient’s BMI and 
their drugs prescription. People with higher BMIs were less likely to be prescribed weight-
gaining drugs. However, patients with higher BMIs were more likely to be prescribed 
metformin (1a) (p =0.015). Meanwhile, a higher proportion of participants with lower 
BMIs were prescribed weight gaining drugs (group 3a and 3b) compared with those with 
BMI ≥40 kg/m2. The strongest association found was between BMI and the prescription of 
drugs. However, it remains necessary to investigate the possibility that age and sex might 
be confounding factors. 
 
 
 
Anti-
diabetic 
drugs 
category 
 
30-34.9 
 
35–39.9 
 
40–49.9 
 
≥50 
 
Total P-value 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 
 
1-Weight- 
neutral 
1a 
1b 
Total 
244 
21 
265 
39.1 
3.4 
42.5 
412 
36 
448 
43.0 
3.8 
46.8 
535 
55 
590 
45.2 
4.6 
49.8 
148 
14 
162 
49.3 
4.7 
54.0 
1339 
126 
43.7 
4.1 
0.015 
0.51 
2- Mixed  
182 
76 
258 
 
29.1 
12.2 
41.3 
 
251 
118 
369 
 
26.2 
12.3 
38.5 
 
283 
182 
465 
 
24.0 
15.4 
39.4 
 
62 
53 
115 
 
20.6 
17.7 
38.3 
 
778 
429 
 
25.4 
14.0 
 
0.019 
0.028 
2a 
2b 
Total 
3-Weight- 
gaining 
 
 
35 
19 
47 
101 
 
 
 
5.6 
3.0 
7.5 
16.1 
 
 
61 
18 
60 
139 
 
 
6.4 
1.9 
6.3 
14.6 
 
 
 
41 
9 
78 
128 
 
 
 
3.5 
0.7 
6.6 
10.8 
 
 
 
8 
4 
11 
23 
 
 
2.7 
1.3 
3.7 
7.7 
 
 
145 
50 
196 
 
 
4.7 
1.7 
6.4 
 
 
0.003 
0.003 
0.15 
 
3a 
3b 
3c 
Total 
Number of 
patients 
 
624 (20.4%) 
 
 
956 (31.2%) 
 
1,183 (38.6%) 
 
300 (9.7%) 
 
3,063 
 
Table 5-2 Number and percentage of anti-diabetic group based on the patients’ BMI. N: 
Number. P-values were determined using the Chi-square test for trend (p-value <0.05 
considered statistically significant). (1a. Metformin only; 1b. Metformin+DPP-IV+/OR 
GLP-1 +/OR SGLT2; 2a. (SUs) AND (Metformin +/OR DPP-IV +/OR GLP-1 +/OR 
SGLT2); 2b. (TZDs + SUs) OR (TZDs) AND (Metformin +/OR DPP-IV +/OR GLP-1 
+/OR SGLT2); 3a. SUs only; 3b. SUs + TZDs; 3c. Any combination including insulin). 
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5.4.3 The association between age and anti-diabetic drugs prescribing 
Table 5-3 shows an association between age and drug prescriptions; older people (≥40 
years) were more likely to be prescribed mixed-drugs (2a, 2b) (p =0.001) or weight-
gaining drugs (SUs (3a) and SUs plus TZDs (3b)) (p =0.001 and 0.046, respectively). 
However, younger participants (18-29 years) were more likely to be prescribed metformin 
(1a) (p =0.001), than older people (≥60 years). This association might be due to the effect 
of BMI, which will be explored later. For example, as older patients generally have lower 
BMIs than younger ones, it is possible that the effect might be a result of differences in 
BMI. 
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Anti-
diabetic 
category 
 
18-29 
 
30–39 
 
40–49 
 
50–59 
 
60–69 
 
≥70 
 
Total 
 
 
  
 
P-value 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 1-Weight- 
neutral 
1a 
1b 
Total 
95 
1 
96 
84.8 
1 
85.8 
174 
15 
189 
62 
5.4 
67.4 
310 
38 
348 
45.9 
5.6 
51.5 
411 
42 
453 
41.7 
4.2 
45.9 
256 
25 
281 
33.8 
3.3 
37.1 
93 
5 
98 
36.9 
2 
38.9 
1339 
126 
43.7 
4.1 
0.001 
0.033 
2- Mixed  
7 
3 
10 
 
6.2 
2.5 
8.7 
 
52 
15 
67 
 
18.5 
5.4 
23.9 
 
162 
93 
255 
 
24 
13.8 
37.8 
 
270 
150 
420 
 
27.4 
15.2 
42.6 
 
225 
128 
353 
 
29.7 
17.0 
46.7 
 
62 
40 
102 
 
24.6 
15.9 
40.5 
 
778 
429 
 
25.4 
14.0 
 
0.001 
0.001 
2a 
2b 
Total 
3-Weight- 
gaining 
 
 
1 
0 
5 
6 
 
 
1 
0 
4.5 
5.5 
 
 
4 
1 
19 
24 
 
 
1.5 
0.3 
6.8 
8.6 
 
 
25 
8 
40 
73 
 
 
3.7 
1.2 
5.9 
10.8 
 
 
42 
17 
54 
113 
 
 
4.2 
1.7 
5.5 
11.4 
 
 
46 
15 
62 
123 
 
 
6.0 
2.0 
8.2 
16.2 
 
 
27 
9 
16 
52 
 
 
10.7 
3.6 
6.3 
20.6 
 
 
145 
50 
196 
 
 
4.8 
1.7 
6.4 
 
 
0.001 
0.046 
0.26 
 
3a 
3b 
3c 
Total 
Number of 
patients 112 (3.6%) 280 (9.1%) 676 (22.0%) 986 (32.2%) 757 (24.7%) 252 (8.2%) 3,063 
 
                 Table 5-3 Number and percentage distribution of anti-diabetic drugs category based on age group of patients. N:    
Number. P-values were determined using the Chi-square test for trend (p-value <0.05 considered statistically 
significant). (1a. Metformin   only; 1b. Metformin+DPP-IV+/OR GLP-1 +/OR SGLT2; 2a. (SUs) AND (Metformin 
+/OR DPP-IV +/OR GLP-1 +/OR SGLT2); 2b. (TZDs + SUs) OR (TZDs) AND (Metformin +/OR DPP-IV +/OR GLP-
1 +/OR SGLT2); 3a. SUs only; 3b. SUs + TZDs; 3c. any combination including insulin). 
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5.4.4 The association between sex and anti-diabetic drugs prescribing 
Table 5-4 shows that there was an association between sex and anti-diabetic drugs 
prescriptions; generally, men were more likely to be prescribed weight-gaining drugs 
(14.3%) than women (11.5%) (p =0.02). Moreover, men were more likely to be prescribed 
mixed-drugs (group 2a and 2b) than women. On the other hand, metformin (group 1a) 
alone was prescribed more frequently to females than males. The data showed it was 
prescribed to 49.7% of females and 36.0% of the males (p =0.001). The factor responsible 
for this difference might not necessarily be the sex of the patients. It may depend on the 
weight of the patients, which will be explored later. 
 
 
 
Anti-diabetic drug(s) 
category 
 
Males 
 
Females 
 
Total 
 
 
 
 P-value 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N 
 
% 
 
N 
 
% 
 
N 
 
% 
1-Weight-neutral 
1a 
1b 
Total 
492 
76 
568 
36.0 
5.5 
41.6 
842 
50 
892 
49.7 
3.0 
52.7 
1334 
126 
43.7 
4.1 
0.001 
0.001 
2- Mixed  
384 
217 
601 
 
28.1 
16.0 
44.1 
 
394 
212 
606 
 
23.3 
12.5 
35.8 
 
778 
429 
 
25.5 
14.0 
 
0.002 
0.007 
 
2a 
2b 
Total 
3-Weight-gaining  
 
87 
22 
86 
195 
 
 
 
6.4 
1.6 
6.3 
14.3 
 
 
57 
28 
110 
195 
 
 
3.4 
1.6 
6.5 
11.5 
 
 
144 
50 
196 
 
 
 
4.7 
1.6 
6.4 
 
 
 
0.001 
0.92 
0.82 
0.02 
3a 
3b 
3c 
Total 
 
Number of patients 
 
1,364 (44.5%) 
 
 
1,693 (55.3%) 
 
 
3,057 
(6 missing) 
 
Table 5-4 Number and percentage of anti-diabetic groups based on the patients’ 
sexes. N: Number. P-values were determined using the Chi-square test for trend 
(p-value <0.05 considered statistically significant). (1a. Metformin only; 1b. 
Metformin+DPP-IV+/OR GLP-1 +/OR SGLT2; 2a. (SUs) AND (Metformin 
+/OR DPP-IV +/OR GLP-1 +/OR SGLT2); 2b. (TZDs + SUs) OR (TZDs) AND 
(Metformin +/OR DPP-IV +/OR GLP-1 +/OR SGLT2); 3a. SUs only; 3b. SUs + 
TZDs; 3c. Any combination including insulin). 
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5.4.5 The association between SIMD and anti-diabetic drugs prescribing 
The socioeconomic status of the patients did not correlate with the prescribing patterns for 
anti-diabetic drugs; the p-value for each group of drugs was >0.05 as seen in (Table 5-5).
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Anti-
diabetic 
drugs 
category 
 
Most deprived 
 
2 
 
3 
 
4 
 
Least 
deprived 
 
Total 
 
 
 
 
 
P-value  
 
N 
 
 
% 
 
 
N 
 
 
% 
 
 
N 
 
 
% 
 
 
N 
 
 
% 
 
 
N 
 
 
% 
 
 
N 
 
 
% 1-Weight- 
neutral 
1a 
1b 
Total 
628 
62 
690 
43.7 
4.3 
48 
255 
24 
279 
45.4 
4.3 
49.7 
176 
17 
193 
44.1 
4.3 
48.4 
120 
10 
130 
39.3 
3.3 
42.6 
154 
13 
167 
44.3 
3.7 
48.0 
1333 
126 
43.7 
4.1 
0.54 
0.92 
2- Mixed  
367 
201 
568 
 
25.5 
14.0 
39.5 
 
144 
72 
216 
 
25.6 
12.8 
38.4 
 
99 
56 
155 
 
24.8 
14.0 
38.8 
 
81 
45 
126 
 
26.5 
14.7 
41.2 
 
82 
55 
137 
 
23.6 
15.8 
39.4 
 
 
773 
429 
 
25.4 
14.0 
 
0.91 
0.78 
2a 
2b 
Total 
3-Weight- 
gaining 
 
 
62 
20 
96 
178 
 
 
4.3 
1.4 
6.7 
12.4 
 
 
21 
9 
37 
67 
 
 
3.7 
1.6 
6.6 
11.9 
 
 
20 
7 
24 
51 
 
 
5.0 
1.8 
6.0 
12.8 
 
 
22 
6 
21 
49 
 
 
7.2 
2.0 
6.91 
16.1 
 
 
 
19 
8 
17 
44 
 
 
5.5 
2.3 
4.9 
12.6 
 
 
 
 
144 
50 
195 
 
 
4.8 
1.7 
6.4 
 
 
0.16 
0.78 
0.77 
3a 
3b 
3c 
Total 
Number 
of 
patients 
 
1,436 (46.8%) 
 
562 (18.3%) 
 
399 (13.0%) 
 
305 (10.0%) 
 
348 (11.3%) 
 
3,050 
(11 missing) 
 
                  Table 5-5 Number and percentage of anti-diabetic group based on the patients’ socioeconomic status.  
              P-values were determined using the Chi-square test for trend (p-value <0.05 considered statistically 
significant).   (1a. Metformin only; 1b. Metformin+DPP-IV+/OR GLP-1 +/OR SGLT2; 2a. (SUs)  AND 
(Metformin +/OR DPP-IV +/OR GLP-1 +/OR SGLT2); 2b. (TZDs + SUs) OR (TZDs) AND (Metformin 
+/OR DPP-IV +/OR GLP-1 +/OR SGLT2); 3a. SUs only; 3b. SUs + TZDs; 3c. Any combination 
including insulin).
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As the main association was between BMI and drug prescribing, the other factors are 
viewed as confounders of this association. In order to further investigate the relationship 
between sex and the prescription of anti-diabetic drugs, the results were subdivided into 
more specific BMI ranges (Table 5-6). 
 
 
 
Drugs BMI categories (kg/m2) 
 30-34.9 35-39.9 40-49.9 ≥50 
 
Sex 
F 
N (%) 
M 
N (%) 
F 
N (%) 
M 
N (%) 
F 
N (%) 
M 
N (%) 
F 
N (%) 
M 
N (%) 
Weight-neutral 
158 
(47.6) 
105 
(36.2) 
274 
(51.6) 
172 
(40.7) 
371 
(54.6) 
218 
(43.5) 
115 
(57.5) 
47 
(47.0) 
Mixed 
120 
(36.1) 
138 
(47.6) 
181 
(34.1) 
188 
(44.4) 
235 
(34.5) 
230 
(45.9) 
70 
(35.0) 
45 
(45.0) 
Weight-gaining 
54 
(16.3) 
47 
(16.2) 
76 
(14.3) 
63 
(14.9) 
74 
(10.9) 
53 
(10.6) 
15 
(7.5) 
8 
(8.0) 
Total 
332 
(100) 
290 
(100) 
531 
(100) 
423 
(100) 
680 
(100) 
501 
(100) 
200 
(100) 
100 
(100) 
P-value for weight-
gaining drugs 
0.98 0.80 0.86 0.88 
Table 5-6 Stratification of the relationship between sex and the prescribing of anti-diabetic 
drugs by BMI (N: Number; F: Female; M: Male). 
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Table 5-4 shows that women were more likely to be prescribed weight-neutral drugs and 
men more likely to be prescribed weight-gaining drugs (group 3a). Following 
stratification by BMI category, Table 5-6 illustrated that there was no difference in the 
proportion of men and women on weight-gaining drugs when take into account BMI (P-
values for the different BMI categories were 0.98, 0.80, 0.86 and 0.88). For example, for 
patients with a BMI between 30 and 34.9 kg/m2, the percentages of women and men on 
weight-gaining drugs were 16.3% and 16.2% respectively. Therefore, this association 
was not because of the patients’ sex itself, but might have been because men in the 
weight-gaining group (group 3a) were lighter than women; the mean BMIs of men and 
women were 38.5 kg/m2 and 39.2 kg/m2 respectively. 
 
With regard to the association between age and drug prescribing, Table 5-3 shows that 
older people were more likely to be prescribed weight-gaining anti-diabetic drugs, while 
younger people were more likely to be prescribed weight-neutral anti-diabetic drugs. 
However, this relationship may be explained by the patient’s BMI, as older patients were 
more likely to be lighter. In order to further investigate the relationship between age and 
the prescription of anti-diabetic drugs, the results were subdivided into finer BMI ranges 
(Table 5-7). 
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                 Drugs BMI categories (kg/m2) 
 30-34.9 35-39.9 40-49.9 ≥50 
 Age categories (year) 
 
18-
29 
 
N 
 
% 
 
30-
39 
 
N 
 
% 
 
40-
49 
 
N 
 
% 
 
50-
59 
 
N 
 
% 
 
60-
69 
 
N 
 
% 
 
≥70 
 
 
N 
 
   % 
 
18-
29 
 
N 
 
% 
 
 
30-
39 
 
N 
 
% 
 
 
40-
49 
 
N 
 
% 
 
 
50-
59 
 
N 
 
% 
 
 
60-
69 
 
N 
 
% 
 
 
≥70 
 
 
N 
 
   % 
 
 
18-
29 
 
N 
 
% 
 
 
 
30-
39 
 
N 
 
% 
 
 
40-
49 
 
N 
 
% 
 
 
 
50-
59 
 
N 
 
% 
 
 
 
60-
69 
 
N 
 
% 
 
 
 
≥70 
 
 
N 
 
   % 
 
 
 
18-
29 
 
N 
 
% 
 
 
 
30-
39 
 
N 
 
% 
 
 
 
40-
49 
 
N 
 
% 
 
 
 
 
50-
59 
 
N 
 
% 
 
60-
69 
 
N 
 
% 
 
≥70 
 
 
N 
 
   % 
 
Weight-neutral 
9 
 
75 
30 
 
73.1 
46 
 
45.5 
80 
 
42.1 
69 
 
35 
31 
 
37 
25 
 
   
89.3 
54 
 
71.1 
107 
 
52.9 
128 
 
42.4 
97 
 
38.8 
37 
 
37.8 
52 
 
86.7 
80 
 
63 
141 
 
51.3 
197 
 
50.3 
96 
 
35.7 
24 
 
40 
10 
 
83.3 
25 
 
69.4 
54 
 
55.1 
48 
 
47 
19 
 
6.4 
6 
 
54.5 
Mixed 
1 
 
8.3 
7 
 
17.1 
41 
 
40.5
6 
81 
 
42.6 
92 
 
46.7 
36 
 
43.4 
1 
 
3.5 
15 
 
19.7 
71 
 
35.1 
140 
 
46.4 
108 
 
43.2 
34 
 
34.7 
6 
 
10 
37 
 
29.1 
106 
 
38.5 
154 
 
39.3 
135 
 
50.2 
27 
 
45 
2 
 
16.7 
8 
 
22.2 
37 
 
37.7 
45 
 
44.1 
18 
 
34.9 
5 
 
45.4 
Weight-gaining 
2 
 
16.7 
4 
 
9.7 
14 
 
13.8 
29 
 
15.2 
36 
 
18.3 
16 
 
19.3 
2 
 
7.1 
7 
 
9.2 
14 
 
11.9 
34 
 
11.3 
45 
 
18 
27 
 
27.5 
2 
 
3.3 
10 
 
7.9 
28 
 
10.1 
41 
 
10.5 
38 
 
14.1 
9 
 
15 
0 
 
   0 
3 
 
8.3 
7 
 
7.1 
9 
 
8.8 
4 
 
9.7 
0 
 
0 
Total 
12 
 
100 
41 
 
100 
101 
 
100 
190 
 
100 
197 
 
100 
83 
 
100 
28 
 
100 
76 
 
100 
202 
 
100 
302 
 
100 
250 
 
100 
98 
 
100 
60 
 
100 
127 
 
100 
275 
 
100 
392 
 
100 
269 
 
100 
60 
 
100 
12 
 
100 
36 
 
100 
98 
 
100 
102 
 
100 
41 
 
100 
11 
 
100 
P-value  
0.002 
 
0.001 
 
0.001 
 
0.26 
Table 5-7 Stratification of the relationship between age and the prescribing of anti-diabetic drugs by BMI (N: Number; %: percentage).
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As the weight-gaining drugs were more likely to be prescribed to those with a lower BMI 
(Table 5-2), following the subdivision of patients according to age, it was found that the 
association between BMI and drug prescribing was confounded by the patient’s age. 
Table 5-7 shows that quite a similar proportion of patients aged between 30 and 39 years 
(9.7%, 9.2%, 7.9% and 8.3%) were using weight-gaining drugs in the four different BMI 
categories (30-34.9, 35-39.9, 40-49.9 and ≥50 kg/m2 respectively). Among those patients 
with a BMI of at least 50 kg/m2, the proportion using weight-gaining drugs was generally 
age-independent. 
 
Alternatively, Table 5-3 showed that a higher proportion of older people used weight-
gaining anti-diabetic drugs compared with younger patients. Furthermore, Table 5-7 
shows that among the patients with a BMI of between 30 and 34.9 kg/m2, a higher 
proportion (18.3%) of patients aged between 60 and 69 years used weight-gaining drugs 
compared to the proportion (9.7%) of patients aged 30-39 years. This may indicate that 
people lose more weight at older ages, which may result in them being prescribed more 
weight-gaining anti-diabetic drugs. Therefore, it can be concluded that the initial BMI 
may partially confound the relationship between patient age and drug prescribing. 
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5.4.6 Characteristics and proportion of patients in different anti-diabetic  
categories 
Table 5-8 shows patients prescribed weight-neutral drugs had mean BMIs 2 kg/m2 higher 
than those prescribed weight-gaining drugs, and this difference was statistically 
significant (p =0.001). In addition, individuals who were prescribed weight-neutral drugs 
were younger than those on mixed or weight-gaining drugs (mean ages were 50.7, 55.6 
and 56.6 years, respectively; and this difference was statistically significant (p =0.001). 
Meanwhile, there was no difference in the initial BMIs between those on weight-neutral 
drugs and patients on mixed drugs (p =0.08). 
 
 
 
Drug 
categories subgroup 
Total 
(n) 
Mean BMI 
± SD p-value 
Mean 
weight  
± SD 
Mean age 
± SD p-value 
1.Weight- 
neutral 
1a (n =1,339)  
1,465 
 
41.2  
(±7.0) 
1&2 
p-value= 
0.08 
 
113.0  
(±22.8) 
 
50.7  
(±12.9) 
1&2 
p-value= 
0.001 
 1b (n =126)   
 
  
 
2. Mixed 2a (n =778)  
1,207 
 
40.7  
(±7.0) 
1&3 
p-value= 
0.001 
 
113.8  
(±22.7) 
 
55.6  
(±10.2) 
1&3 
p-value= 
0.001 
 2b (n =492)       
3. Weight 
gaining 
3a (n =145)       
 
3b (n =50) 
 
3c (n =196) 
391 39.2  
(±6.2) 
 108.5  
(±21.6) 
 
56.6 
(±11.5) 
 
Table 5-8 Characteristics of included patients depending on type of anti-diabetic 
categories. P-values were determined using a t-test (p-value <0.05 considered statistically 
significant) (SD: standard deviation; n: number). 
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5.4.7 Proportion of patients in different anti-diabetic categories after the 
SIGN guidelines were released 
Overall, respectively, 47.8%, 39.4% and 12.7% of the included patients were on weight- 
neutral, mixed and weight-gaining anti-diabetic medication. The proportion of patients 
taking weight-neutral drugs before March 2010 was 48.2%, compared with 46.8% during 
the first year and 48.5% a year after the guidelines established. Likewise, a higher 
proportion of patients were prescribed weight-gaining anti-diabetic drugs (13.8%) a year 
after the publication of the current SIGN guidelines, compared with before the guidelines 
were released (11.6%), although this difference was not statistically significant (p =0.13) 
(Table 5-9) and (Figure 5-1).  
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Category 
N of all 
patients 
(total) 
(n =3,063) 
 
 
 
 
% 
Before the 
guidelines 
(n =1,037) 
(from January 
2008 to February 
2010) 
% 
 
Transitional 
phase (for a 
year) 
(n =1,038) 
(from March 
2010 to 
February 
2011) 
% 
 
After 
publication of 
guidelines 
(n =988) 
(from March 
2011 to May 
2014) 
 
 
 
 
% 
1.Weight-
neutral 
 
1,465 
 
47.8 
 
500 
 
48.2 
 
486 
 
46.8 
 
479 
 
48.5 
 
        
2. Mixed  
1,207 
 
39.4 
 
416 
 
40.1 
 
418 
 
40.3 
 
373 
 
37.7 
         
3. Weight- 
gaining 
 
391 
 
12.7 
 
121 
 
11.6 
 
134 
 
 
12.9 
 
136 
 
13.8 
p-value = 0.13 
(The difference in the proportion of patients on weight-gaining drugs before and after the SIGN guidelines were 
published was examined). 
Table 5-9 Proportion of patients referred in different anti-diabetic drugs categories 
based on three phases of the SIGN guidelines. P-values were determined using the 
Chi-square test (p-value <0.05 considered statistically significant). 
 
 
 
   Figure 5-1 Proportion of patients by GP prescribing pattern of anti-diabetic 
drugs before, during one year, and one year after the release of the SIGN 
guidelines.  
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5.4.8 Prescribing trends over the time 
In order to explore whether there were any year-on-year trends towards gradually 
improving compliance with guidelines, the prescribing trend for the three categories of 
anti-diabetic medications were reported. Figure 5-2 shows no clear trend over time for 
patients prescribed weight-neutral drugs. The increase in the prescribing percentage of 
weight-neutral drugs seen in the final year (2014) might be a result of changes in the 
groups of drugs approved for the treatment of type 2 diabetes since 2013. However, the 
only convincing trend over time was a small increase in the volume of weight-gaining 
drugs prescribed, although it is not clear if any change occurred after the release of the 
SIGN guidelines in 2010. As a result, there is no indication of a change in practice. 
 
 
Figure 5-2 Yearly prescribing trend for different anti-diabetic drugs categories from 
2008 to 2014 for patients who referred to the GCWMS. 
 
Therefore, a number of other factors (for example, the lower BMIs of the subjects 
towards the end of the study) may be responsible for the modest increases in the 
prescription of weight-gaining drugs. Paradoxically, it was found that people had higher 
BMIs in later years compared with the earlier years. For instance, the mean BMI of the 
patients in 2008 was 38.7 kg/m2, compared to 39.2 kg/m2 in 2014.  
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5.5 Summary of the main findings 
• The majority of the patients with diabetes were female, aged 40-<70, with BMIs 
30-<50, and from the most deprived quintile. 
• Metformin was the highest prescribed anti-diabetic drug, and the group of SUs 
plus TZDs was least prescribed to participants of both sexes. In addition, 
metformin was prescribed more to women than men; and a higher proportion of 
men were prescribed SUs groups compared with women. 
• The rate of metformin prescription rose as age decreased and BMI increased. 
However, the frequency with SU and SUs + TZDs were prescribed was 
predominantly higher in older patients. 
• There was no association between SIMD and anti-diabetic drugs prescribing. 
• Patients on weight-neutral anti-diabetic drugs were heavier and younger than 
those on weight-gaining anti-diabetic drugs. 
• Overall, 47.8% of patients referred to the GCWMS and included in this research 
were on neutral anti-diabetic drugs, and 12.7% were on weight-gaining anti-
diabetic drugs. 
• There was no significant difference in the prescribing habits noted after the 
guidelines were established (p =0.13). 
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5.6 Discussion 
The principal objective of this research was to determine whether the prescription of anti-
diabetic drugs to patients with type 2 diabetes was consistent with the patients’ BMIs. 
The secondary aim was to investigate whether the introduction in March 2010 of the 
SIGN guidelines was associated with a change in practices of prescribing anti-diabetic 
drugs. Additionally, based on the GCWMS data for patients with obesity and type 2 
diabetes, the pattern of prescribing anti-diabetic drugs was investigated; as were the 
effects of age, sex and SIMD. According to the Scottish Diabetes Survey in 2015; at that 
time, around 5.3% of adults in Scotland had been diagnosed with diabetes and prevalence 
was higher among men than women (6.0% and 4.5%, respectively) (NHS Scotland, 
2015). To our knowledge, this is the first study investigating the proportion of patients 
with obesity in different anti-diabetic drug categories; whereas previous evaluations of 
prescribing patterns for anti-diabetic medication in patients with diabetes were carried out 
at tertiary hospital level irrespective of BMI. 
 
5.6.1 Baseline characteristics 
In Scotland, 55.7% of patients diagnosed with type 2 diabetes are male (NHS Scotland, 
2014). However, in this research, just 44.6% of the patients with diabetes included in this 
study were male, as more females had chosen to enrol in the programme. The majority of 
patients with obesity and diabetes were in the age group 50-59 years, followed by the age 
group 60-69 years, concurring with previous studies (Shareef et al., 2015; Vengurlekar et 
al., 2008). The increasing prevalence of diabetes in these age groups may be consequence 
of their change in life style, stress, and lack of exercise (Vengurlekar et al., 2008). 
However, the sample might have been biased, as 26.5% of the total patients (n =7,329) 
who enrolled in the weight management programme were in the 50-59 year age group, 
which may explain the higher prevalence of diabetes in this group of patients.  
 
5.6.2 Prescribing pattern 
As all patients on insulin only were excluded, those that remained were the type 2 
diabetes patients. Metformin (group 1a) was the most commonly prescribed drug, which 
is consistent findings in other research (Shareef et al., 2015; Dhanaraj et al., 2013, Filion 
et al., 2009; Kamrai & Sachdeva, 2010). The reason for this could be that patients with 
obesity who have received metformin reportedly gain less weight and present with lower 
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hypoglycaemic effect than patients on other hypoglycaemic drugs, such as SUs group or 
TZDs group (Leal et al., 2013). A previous study (2-years follow-up) of 3,807 
participants, suggested that irrespective of BMI, metformin was the most commonly 
prescribed drug for patients with diabetes (Hartmann et al., 2015). However, this research 
found that a low proportion of patients were in either the SUs (4.8%) or SUs + TZDs 
(1.7%) group, possibly because these groups are more prone to causing excessive weight 
gain meaning they are not ideal for use in patients with obesity. These findings were 
consistent with a previous study that reported SUs and TZDs were not prescribed for 
subjects with a BMI between 35-40 kg/m2 (Kamrai & Sachdeva, 2010). 
 
When reviewing the literature, minimal data were found on the association between 
patient’s age, sex and initial BMIs and anti-diabetic drugs prescribing. Previous studies 
have also reported that some drugs have an adverse effect on elderly people, such as SUs 
that may cause hypoglycaemia, and other studies recommend metformin for people with 
high BMIs. Therefore, these factors might or might not justify prescribing. 
 
5.6.3 Impact of BMI 
Metformin was prescribed for individuals with a higher BMI, and weight-gaining drug 
groups (group 3a and 3b) were prescribed more for patients with a lower BMI. This 
might be because metformin does not cause weight gain, while SUs and TZDs drug types 
are avoided in patients with obesity, as they cause excess weight gain (Leal et al., 2013; 
Kamrai & Sachdeva, 2010). This indicates that there was an association between initial 
BMI and the prescribing of anti-diabetic drugs, although it is possible that these results 
were confounded by age. The proportion of patients with a relatively low BMI (between 
30 and 34.9 kg/m2) that were prescribed weight-gaining drugs was higher in older 
patients (that is, those aged at least 70 years) than those aged between 18 and 29 years. 
Therefore, the results may show an inverse relationship between BMI and age when 
prescribing anti-diabetic drugs.  
 
There was an association between sex and developing diabetes; this may be explained by 
a previous study that investigated the relationship between sex and BMI at diabetes 
diagnosis in Scotland. The large (n =95,059) study concluded that men were diagnosed 
with type 2 diabetes at lower BMIs than women (Logue et al., 2011). The potential 
mechanisms for this include men having more visceral and hepatic fat than women and 
being less insulin-sensitive (Geer and Shen, 2009). However, the current results 
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concluded that sex did not influence the relationship between BMI and anti-diabetic 
drugs prescribing. The DiaRegis cohort study (n =3,807) reported an increased likelihood 
of treatment with metformin and GLP-1 drugs among subjects with a BMI of ≥30 kg/m2, 
and a lower probability of treatment with SUs or insulin (Hartmann et al., 2015). 
 
5.6.4 Impact of age  
The current research shows an association between age and anti-diabetic drugs 
prescribing. For example, there was a statistically significant difference in metformin 
prescribing in different age groups, particularly between young and the old participants 
(chi-square test represent p-value =0.001). This shows that metformin was prescribed 
more frequently for young patients as monotherapy, while older patients required a 
combination of anti-diabetic drugs to achieve better glycaemic results. On the other hand, 
a previous study of 492 patients from Indian hospital, found metformin was prescribed 
more for older people and the authors suggested this might be due to the increase risk of 
hypoglycaemia in elderly people who are also being treated with SUs; consequently, 
metformin is a good option for controlling hypoglycaemia (Kamrai & Sachdeva, 2010). 
These differences might also explain the effect of other confounding factors, such as 
initial BMI. This research suggested that the relationship between patients’ ages and the 
prescribing of anti-diabetic drugs was confounded by the initial BMIs for those with BMI 
≥50 kg/m2. Young patients have higher BMIs, which would explain the higher 
prescribing of weight-neutral anti-diabetic drugs in this group. An equivalent relationship 
was seen in older patients, whose lower BMIs might explain the increase in the 
prescription of weight-gaining anti-diabetic drugs. Earlier findings confirmed that there 
was a marked decrease in patients’ BMIs in line with the increased in age at the time of 
diabetes diagnosis (Logue et al., 2011). 
 
5.6.5 Impact of sex 
Other observations include that metformin was prescribed more in females than in males, 
while SUs were prescribed more in males. These findings are consistent with previous 
results carried reported in the Netherlands, in a study that investigated the new revised 
guidelines for the treatment with hypoglycaemic agents between 1998 and 2003 (Lub et 
al., 2006). This might also be due to the fact that a number of females stopped taking SUs 
to avoid weight gain, particularly as a result of oedema, switching to metformin to aid 
glycaemic control and promote weight loss or remain neutral (Lub et al., 2006). The 
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current research suggested an association between sex type and anti-diabetic drugs 
prescribing, but there were other confounding factors that might explain this relationship, 
such as BMI. Obviously, women were heavier than men at the baseline, which may 
explain the higher rate of prescribing of weight-neutral anti-diabetic drugs. In conclusion, 
the current results were consistent with a previous study by Ewenighi et al. (2012), which 
found that only age and initial BMI could influence the prescribing of anti-diabetic drugs. 
 
5.6.6 Prescribing before and after release of the SIGN guidelines  
This research found no significant difference between the percentages of patients on 
weight-neutral, mixed and weight-gaining anti-diabetic medications, before and one year 
after the SIGN guidelines were released. The SIGN guidelines set out a clear treatment 
plan for patients with diabetes and obesity; aiming to encourage GPs to prescribe the 
appropriate anti-diabetic drugs for individuals with obesity to elevate the proportion of 
patients on weight-neutral drugs (SIGN 116, 2010). There was no improvement in the 
prescribing trend in weight-gaining drugs over the years from 2008 to 2014, which 
contradicts the current hypothesis. Therefore, the application of trend and regression tests 
was not considered to be appropriate. The slight increase in weight-gaining drugs 
prescribing over the years was not contrary to what might have been expected, as weight-
gaining prescriptions went up while BMIs also went up. Therefore, this might be 
explained by GPs’ habits or patients’ inability to control their blood glucose level. The 
percentage of patients on weight-gaining anti-diabetic drugs was slightly higher amongst 
those referred after one year after the SIGN guidelines were released (13.8%), compared 
with 11.6% before the release of the SIGN guidelines, despite recommendations for GPs 
to review patient history and the anti-diabetic prescribing patterns for patients before 
referring them to the GCWMS. Additionally, the recommendation is to try prescribing 
weight-neutral or mixed drugs for this group of patients; unless there are specific clinical 
indicators to the contrary. 
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5.7 Research strengths and limitations 
The main strength of this research is the large sample size, derived from one of the largest 
weight management services available, and providing objective measures of weight and 
height. To the best of our knowledge, this is the first study comparing the proportion of 
patients on anti-diabetic drugs before and after the SIGN guidelines were released. In 
addition, it is the first study to explore the prescribing patterns of anti-diabetic drugs for 
individuals with obesity and diabetes (the included participants had a BMI of ≥30 kg/m2). 
Conversely, much of the research to date has concentrated on prescribing patterns for 
patients with diabetes only (Kamrai & Sachdeva, 2010), describing trends for anti-
diabetic prescribing over time (Filion et al., 2009). Selection bias was minimal, with only 
1.8% of patients excluded (on account of their being on drug regimens that could not be 
classified into one of the groups). The prescribing information is likely to be accurate, as 
all the medication came through the SCI gateway. 
 
Conversely, one of the weaknesses of this study is potential information bias, as the drugs 
were categorised according to their effect on body weight alone, instead of looking at 
each group of drugs on an individual basis. Likewise, the results of the proportion of 
patients who were on weight-gaining drugs might have been affected by (group 3c), as 
some of the patients were prescribed insulin where they had uncontrolled glycaemia by 
oral hypoglycaemic agents. In addition, this study did not show the prescribing patterns 
for some drugs regimens as classified into three drugs categories. On the other hand, the 
classification of anti-diabetic drugs in this research was dependent on the SIGN 
guidelines and a good range of RCTs, which determined the effect of these drugs on body 
weight. Nevertheless, the SIGN guidelines were released in 2010, and a group of anti-
diabetic drugs (SGLT2 inhibitors) were subsequently approved for use in 2013. However, 
this group of drug was issued with new guidelines. This might therefore lead to the 
conclusion that there was strong evidence of a causal relationship in this classification.  
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5.8 Research implications 
This research confirms that half of individuals with type 2 diabetes referred to the 
GCWMS took weight neutral-anti-diabetic drugs, and around 12.7% were on weight-
gaining anti-diabetes medication. Metformin was the drug most prescribed for patients 
who are obese with type 2 diabetes, while SUs (group 3a) or SUs plus TZDs (group 3b) 
were the least prescribed drugs. The results of the research indicate that the prescribing 
practice for type 2 diabetes was broadly consistent with that recommended in the 
guidelines and that no significant improvements could be made. In contrast, after the 
SIGN guidelines were released, there was no change in the proportion of patients on 
weight-gaining anti-diabetic drugs. Whilst there might be good reasons why they were on 
them, such as uncontrolled blood glucose, it raises the question about whether it could be 
lower. Therefore, the SIGN guidelines for treating patients with obesity and type 2 
diabetes should be followed by GPs to ensure the prescription of weight-neutral or mixed 
anti-diabetic drugs for patients who are obese with type 2 diabetes. Due to the limitations 
in the evidence for the effects of anti-diabetic drugs in enhancing or inhibiting weight 
gain among participants who had joined the weight management programme, the effect of 
these drugs will be observed in the next chapter. Further implications will be discussed in 
chapter 7. 
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16 6.1 Chapter summary 
Many of the anti-diabetic agents used to target hyperglycaemia are associated with 
weight gain, which as explained in the previous chapter, creates an additional challenge 
when treating patients with obesity and type 2 diabetes. However, some anti-diabetic 
drug groups are known to cause weight neutral or in some cases cause weight loss. The 
objective of this research was to study the effect of baseline anti-diabetic drugs on weight 
change for participants enrolled in a lifestyle change programme at the GCWMS.  
 
An intervention cohort study was conducted using baseline anti-diabetic drugs data 
pertaining to a group of participants aged ≥18 years, of both sexes, with type 2 diabetes 
who had attended at least 2 sessions in the lifestyle phase of the GCWMS. Based on the 
BNF and Diabetes Update Guide to Meds & Kit, 2015, the anti-diabetic drugs prescribed 
were classified into three categories: weight-neutral, mixed and weight-gaining. Mean 
and percentage weight loss from the different anti-diabetic group and the different 
categories were reported and analysed using a t-test. In addition, the mean weight change 
of the total number of patients who attended the lifestyle phase, 5 kg and 5% weight loss 
were reported.  
 
Of the 998 eligible participants, 459 (46%), 412 (41.3%) and 127 (12.7%) individuals 
were on weight-neutral, mixed and weight-gaining anti-diabetic drugs, respectively. 
Patients taking the weight-gaining drugs had poorer outcomes compared with those on 
weight-neutral drugs. Mean weight changes for all patients on weight-gaining and 
weight-neutral anti-diabetic drugs was -2.5 kg (95% CI: -3.2 to -1.8 kg) and -3.3 kg (95% 
CI: -3.8 to -2.9 kg) (p =0.05), respectively. In terms of completion, patients on weight-
neutral drugs lost more weight than those on weight-gaining drugs; with mean weight 
changes of -4.9 kg (95% CI: -5.5 to -4.2 kg) and -3.3 kg (95% CI: -4.2 to -2.5 kg), 
respectively (p =0.005). In contrast, there was no significant difference between the two 
groups, in terms of mean percentage weight.  
 
In conclusion, patients on weight-neutral anti-diabetic drugs had a greater outcome 
compared with those on weight-gaining drugs. There may be good reasons to prescribe 
weight-gaining medications, however, weight gain could worsen blood glucose. It may be 
possible to improve weight loss by prescribing mixed or weight-neutral drugs instead.  
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6.2 Introduction 
In the past 20 years, new anti-diabetic drugs have been released and additional drugs have 
been developed to control blood glucose (Hollander, 2007). The mechanisms of these 
drugs might alter body weight by enhancing weight loss or promoting additional weight 
gain (Krentz, 2008). The majority of people diagnosed with type 2 diabetes are 
overweight or obese, and new groups of anti-diabetic drugs have recently been 
established for use in the management of type 2 diabetes associated with obesity (Krentz, 
2008). Although, it is a challenge to treat individuals with type 2 diabetes and obesity, 
due to some of the anti-diabetic agents, such as TZDs and SUs, being associated with 
weight gain (Kenkre et al., 2013), requesting an effective anti-diabetic drug capable of 
reducing body weight is the best approach to the successful treatment of individuals with 
type 2 diabetes and obesity (Solini, 2015; Pi-Sunyer, 2009). 
  
The majority of the literature reports that the currently used anti-diabetic drugs that may 
cause weight to remain neutral or cause weight loss are metformin, GLP-1, DPP-IV and 
SGLT2; while insulin, SUs and TZDs may cause weight gain. UKPDS suggested that 
SUs can cause 5 kg weight gain over a 10-year period of treatment (UKPDS, 1998); and 
another study reported that a 1-4 kg weight gain is associated with using SUs, before 
body weight steadies after six months (Krentz and Bailey, 2005). In addition, in the 
PROACTIVE trial, TZDs such as pioglitazone produced an average 3.6 kg weight gain 
over three years; whereas (Dormandy et al., 2005), according to the findings of the 
Diabetes Reduction Assessment with ramipril and rosiglitazone Medication (DREAM) 
trial, rosiglitazone yielded a 2.2 kg weight gain over a four-year period (Gerstein et al., 
2006). Likewise, in a 16-week study (with a small number of participants: n =14) that 
evaluated the effect of pioglitazone on glucose uptake, individuals apparently gained 
weight [3.0 ± 3.0 kg (p <0.001)] (Malone, 2005). 
 
The American Diabetes Association (ADA), and the European Society for the Study of 
Diabetes (EASD), have recommended that metformin should be used as a first-line 
treatment for patients with normal weight or those who are obese with type 2 diabetes, 
because it is not associated with weight gain and it may promote modest weight loss. In 
addition, the UKPDS found that participants with obesity and type 2 diabetes who 
received metformin gained less weight than those on SUs (UKPDS, 1998). GLP-1 is 
another anti-diabetic drug that can be offered to promote or neutralise weight loss. In a 
six-month study, it was found that exenatide produced significant weight loss (0.9 kg) 
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when prescribed to patients on both metformin and SUs, suggesting a possible 2.5 kg 
weight loss when added to metformin (Borna, 2007).  
 
Moreover, 27 RCTs show that GLP-1 was associated with significant weight reduction 
and a mean weight loss of -1.74 kg (95% CI: -3.11 to -0.48 kg) (Phung et al., 2010). A 
recent meta-analysis of 25 trials involving exenatide, administered twice daily or once 
weekly or liraglutide used for 20 weeks, showed there was a mean weight difference 
between the treatment group and control group of -2.9 kg (95% CI: -3.6 to -2.2 kg) 
(Kenkre et al., 2013). In patients with obesity and type 2 diabetes, DPP-IV inhibitors are 
an option for those who have failed to meet glycaemic targets with metformin alone, and 
they are neutral on body weight (Borna, 2007; Kenkre et al., 2013). A previous study of 
701 patients (24 weeks) suggested no weight difference between two groups of patients 
on metformin alone, versus metformin plus sitagliptin (Charbonnel et al., 2006). 
 
SGLT2 inhibitors have recently been approved for type 2 diabetes treatment, and are also 
associated with weight loss. A previous RCT of 24 weeks’ duration, with dapagliflozin 
2.5mg, 5 mg and 10 mg added to of metformin treatment, found a significant decrease in 
body weight in test subject (-2.2, -3.0 and -2.9 kg, respectively), compared with -0.9 kg in 
the control group (Bailey et al., 2010). A significant reduction in body weight was 
recorded in a 52-week study, in which empagliflozin was added to insulin treatment for 
patients who are obese with uncontrolled diabetes; the mean differences in empagliflozin 
10 mg and 25 mg versus placebo were -2.39 kg (95% CI: -3.40 to -1.39 kg; p <0.001) and 
-2.48 kg (95% CI: -3.48 to -1.47 kg; p <0.001) (Rosenstock et al., 2014). 
 
It was established in Chapter 5 (page 204) that there were differences in baseline weight 
associated with different prescribed anti-diabetic medications, and it was established in 
Chapter 3 (page 129) that baseline weight was a determinant of subsequent weight loss. 
Therefore, the aim of this research was to observe the effect when given anti-diabetic 
drugs from different categories (weight-neutral, mixed and weight-gaining oral 
hypoglycaemic agents) on body weight in individuals participating in the lifestyle change 
programme at the GCWMS. This research hypothesised that while the prescription of 
some anti-diabetic drugs might inhibit weight loss, some may actively enhance weight 
loss. Therefore, the research question posed was: are patients on weight-gaining anti-
diabetic medications less likely to lose weight in the GCWMS? 
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6.3 Materials and methods 
6.3.1 Study procedure 
This intervention cohort study analysed the effect of anti-diabetic medication known to 
promote or inhibit weight loss for patients with type 2 diabetes and referred to the 
GCWMS. The same methods as described in the previous chapter were followed; i.e. 
using the BNF to identify the anti-diabetic drugs prescribed to participants referred to the 
GCWMS. Anti-diabetic medications were classified into three categories according to 
their effect on body weight (Chapter 5, page 198-199):  
 
1. Weight neutral: 
 
        1a. Metformin only 
        1b. Metformin +DPP-IV +/OR GLP-1 +/OR SGL2 
 
2. Mixed: 
 
        2a. (SUs) AND (Metformin +/OR DPP-IV +/OR GLP-1 +/OR SGLT2) 
        2b. (TDZs + SUs) OR (TZDs) AND (Metformin +/OR DPP-IV +/OR GLP-1 +/OR         
SGLT2) 
 
3. Weight gaining: 
 
       3a. SUs only 
       3b. SUs + TDZs 
       3c. Any combination including insulin 
 
6.3.2 Inclusion and exclusion criteria 
Participants of both sexes with type 2 diabetes, aged ≥18 years and attending ≥2 sessions 
in the lifestyle phase were included. The reason for including only those who attended the 
lifestyle phase was to avoid any additional effects from the anti-obesity agents that might 
also be used in the phase 2 treatment of the GCWMS programme. The lifestyle phase 
included a combination of diet (600 kcal/day deficit diet), exercise, and behavioural 
changes over a 16-week period. Individuals not on oral hypoglycaemia drugs and patients 
on insulin only or any combination not prescribed above were excluded. 
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6.3.3 Statistical methods 
The results were reported as a number, percentage, mean weight change, confidence 
intervals, 5 kg and 5% weight loss for all patients (n =998) and for subgroups of 
individuals who had completed the lifestyle phase by attending (≥7 sessions) over 16 
weeks. These were applied to the three categories and each subgroup. Differences in 
mean weight change and mean percentage weight change were analysed using the t-test 
(between two groups) and ANOVA (more than two groups) for continuous data. The 
Bonferroni (pairwise) test was used to adjust for multiple comparisons. Statistical 
significant was defined as p <0.05, and all statistical analyses were performed using Stata 
version 12.1 (StataCorp, College Station, Texas). Finally, to minimise the effect of 
potential confounding factors, such as initial BMI, sex and age, a stratified analysis was 
used. 
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6.4 Results 
Of the 3,063 participants included in the previous chapter, 998 patients with type 2 
diabetes attended the lifestyle phase of the GCWMS, between 2008 and 2014, were 
included in the study. Further, 459 (46%), 412 (41.3%) and 127 (12.7%) patients were on 
weight-neutral, mixed and weight-gaining anti-diabetic drugs, and 49.5% of the 
participants were women, 40.5% were men and their mean age was 55.2 years. The mean 
BMIs and weights at baseline for individuals using weight-neutral, mixed and weight-
gaining drugs were 42.5, 41.4 and 40.6 kg/m2 and 116, 114.2 and 112.3 kg, respectively.  
 
6.4.1 The association between anti-diabetic drug groups prescribing and 
weight change 
Table 6-1 shows the mean weight change for patients on metformin only (weight-neutral, 
group 1a) was -3.3 kg (95% CI: -3.8 to –2.9 kg), and it was -2.5 kg (95% CI: -3.8 to -1.3 
kg) for those on group 1b (weight-neutral). On the other hand, the mean weight change 
for the 257 patients who were on mixed drugs (group 2a) was -3.4 kg (95% CI: -3.9 to -
2.9 kg) and 27% lost ≥5 kg. Similarly, 24.5% out of 155 patients in taking mixed drugs 
(group 2b) lost ≥5 kg with a mean weight change of -2.7 kg (95% CI: -3.4 to -2.1kg). The 
effects of SUs alone (weight-gaining, group 3a) on body weight found that 27.5% of the 
40 patients in this group lost ≥5 kg and the mean weight change was -2.3 kg (95% CI: -
3.9 to -0.7 kg); while there was a reduction of 2.9 kg (95% CI: -4.6 to -1.2 kg) in the body 
weight of 18 patients who took SUs + TZDs (weight gain, group 3b) and 27.5% lost ≥5 
kg. The results further show that the 69 patients who used insulin with oral 
hypoglycaemic drugs (weight gaining, group 3c) lost 2.5 kg (95% CI: -3.3 to -1.68 kg) 
and 24.5% achieved their target of 5 kg weight loss. In relation to the 5% weight loss, 
Table 6-1 shows 30% and 27.5% of all patients in groups 3a and 3b, respectively, 
achieved a 5% weight loss, and these percentages were higher than weight loss 
percentage for the other groups. 
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Group N % Mean weight change 
and 95% CI (kg) 
Lost ≥5 kg Lost≥5%  
1a. Metformin      
Completers (≥7 sessions) 226 53.5 -5.0 (-5.6 to -4.3) 106 (47%) 84 (37%) 
Non-completers (˂7 sessions) 196 46.4 -1.4 (-1.9 to -1.0) 17 (8.5%) 11(5.6%) 
Total (≥2 sessions) 423  -3.3 (-3.8 to -2.9) 123 (29%) 95 (22.5%) 
 
1b. Metformin +DPP-IV +/OR GLP-
1 +/OR SGL 
  
 
  
Completers (≥7 sessions) 22 61.1 -3.6 (-5.4 to -1.8) 7 (32%) 5 (22.5%) 
Non-completers (˂7 sessions) 14 38.8 -0.8 (-2.3 to 0.5) 1 (7%) 1 (7%) 
Total (≥2 sessions) 36 
 
-2.5 (-3.8 to -1.3) 8 (22%) 6 (16.5%) 
 
2a.  (SU) AND (Metformin +/OR 
DPP-IV +/OR GLP-1 +/OR SGLT2) 
 
   
  
Completers (≥7 sessions) 145 56.4 -4.6 (-5.2 to -4.0) 59 (40.5%) 56 (38.5%) 
Non-completers (˂7 sessions) 112 43.5 -2.0 (-2.6 to -1.3) 11 (10%) 10 (9%) 
Total (≥2 sessions) 257 
 
-3.4 (-3.9 to -2.9) 70 (27%) 66 (25.5%) 
 
2b. (TZD +/OR SU) AND 
(Metformin +/OR DPP-IV +/OR 
GLP-1 +/OR SGLT2) 
     
Completers (≥7 sessions) 91 59.7 -3.8 (-4.7 to -2.9) 29 (32%) 18 (45%) 
Non-completers (˂7 sessions) 64 40.3 -1.2 (-1.9 to -0.5) 4 (6.0%) 3 (5.0%) 
Total (≥2 sessions) 155 
 
-2.7 (-3.4 to -2.1) 38 (24.5%) 32 (20.5%) 
 
3a SU only 
 
  
   
Completers (≥7 sessions) 22 55 -3.9 (-6.1 to -1.6) 7 (32%) 8 (36.5%) 
Non-completers (˂7 sessions) 18 45 -0.3 (-2.6 to 1.8) 4 (22%) 4 (22%) 
Total (≥2 sessions) 40 
 
-2.3 (-3.9 to -0.7) 11 (27.5%) 12 (30%) 
 
3b. SU + TZD 
 
     
Completers (≥7 sessions) 13 72.2 -3.3 (-5.5 to -1.2) 4 (30.5%) 4 (30.5%) 
Non-completers (˂ 7 sessions) 5 27.7 -1.6 (-5.2 to 1.8) 1 (20%) 1 (20%) 
Total (≥2 sessions) 18  -2.9 (-4.6 to -1.2) 5 (27.5%) 5 (27.5%) 
 
3c.  Any combination including 
insulin 
     
Completers (≥7 sessions) 41 58.4 -3.1 (-4.1 to -2.1) 18 (34.5%) 14 (27%) 
Non-completers (˂7 sessions) 28 41.5 -1.6 (-3.0 to -0.1) 4 (11%) 4 (11%) 
Total (≥2 sessions) 69  -2.5 (-3.3 to -1.68) 22 (24.5%) 18 (20%) 
Table 6-1 Weight loss outcomes at the end of lifestyle phase for patients with diabetes on one  
of the seven groups of anti-diabetic drugs. 
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6.4.2 The association between anti-diabetic drug prescribing and weight 
change, by category 
6.4.2.1 Mean weight change and mean % weight loss 
Seven groups were combined into three drug categories depending on the effects reported 
on their body weights: weight-neutral, mixed and weight-gaining anti-diabetic drugs 
(Table 6-2). Patients on the weight-neutral drugs lost more weight than those on the 
weight-gaining drugs by the end of the lifestyle treatment phase (16 weeks); mean weight 
change was (-3.3 kg, 95% CI: -3.8 to -2.9 kg and -2.5 kg, 95% CI: -3.2 to -1.8 kg, p 
=0.05), respectively (Figure 6-1). The statistical test lies on the borderline, but shows a 
significant clinical difference. However, there was no statistically significant difference 
between the two categories in terms of the percentage weight change, as the p-value = 
0.17. There were no significant differences between the patients on weight-neutral drugs 
and those on mixed drugs in terms of mean weight change or percentage weight loss, as 
the total mean weight change in the mixed drugs category was -3.2 kg (95% CI: -3.5 to -
2.8 kg) and the mean percentage weight loss was -2.8% for both categories. The lowest 
mean percentage weight loss occurred in patients using weight-gaining anti-diabetic 
agents; the mean percentage weight loss was -2.3%, but this was not significantly 
different to that of patients in the other drug categories (Figure 6-2).  
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Figure 6-1 The mean weight change (kg) and the 95% confidence intervals at the 
end of lifestyle phase for all patients and completers on three different anti-
diabetic drug categories. 
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Figure 6-2 The percentage weight change (%) and 95% confidence intervals at the end 
of lifestyle phase for all patients and completers on three different anti-diabetic drug 
categories. 
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6.4.2.2 Target weight loss (5 kg and 5%) 
With regard to target weight loss, 28.5% of the individuals using weight-neutral drugs 
had lost ≥5 kg, whereas 26% and 26.5% of subjects on mixed and weight-gaining drugs 
lost ≥5 kg, respectively. In total, 24.5% of patients on weight-gaining anti-diabetic drugs 
lost 5% or more, while 22% and 23.5% of patients lost ≥5% when they took weight-
neutral and mixed drugs, respectively (as seen in Table 6-2, which presents weight losses 
of 5% or more). 
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Drugs categories N  (Total =998) % 
Mean weight 
change and 95% 
CI (kg) 
p-value 
(total) 
p-value 
(completers) 
Mean % weight 
change and 95% 
CI 
p-
value 
(total) 
p-value 
(completers) 
Lost ≥5 kg Lost ≥5%  
1- Weight-neutral 
drugs    
 
 
 
 
 
 
 
1&2 
0.73 
 
 
 
 
 
 
 
1&3 
0.05 
 
 
 
 
 
 
 
1&2 
0.14 
 
 
 
 
 
 
 
1&3 
0.005 
 
 
 
 
 
 
 
 
1&2 
0.98 
 
 
 
 
 
 
 
 1&3 
0.17 
 
 
 
 
 
 
 
1&2 
0.31 
 
 
 
 
 
 
 
        1&3 
0.06 
 
  
Completers (≥7 
sessions) 248 54.0 -4.9 (-5.5 to -4.2) -4.1 (-4.6 to -3.6)  113 (45.5%) 89 (36%) 
Non-completers 
(˂7 sessions) 211 46.0 -1.4 (-1.8 to -1.0) 
 18 (8.5%) 12(5.5%) 
Total (≥2 sessions) 459   -3.3 (-3.8 to -2.9) -2.8 (-3.1 to -2.5) 131 (28.5%) 101 (22%) 
2- Mixed drugs       
Completers (≥7 
sessions) 236 57.2 -4.3 (-4.8 to -3.8) 3.8 (-4.2 to -3.3) 93 (39.0%) 85 (36.0%) 
Non-completers 
(˂7 sessions) 176 42.7 -1.7 (-2.2 to 1.2) 
 15 (8.5%) 13 (7.0%) 
Total (≥2 sessions) 412 
 
   -3.2 (-3.5 to -2.8) -2.8 (-3.1 to -2.4) 108(26%) 98 (23.5%) 
3- Weight-gaining 
drugs 
 
   
  
 
Completers (≥7 
sessions) 76 59.8 -3.3 (-4.2 to -2.5) -3.2 (-4.0 to -2.4) 25 (33%) 22 (29%) 
Non-completers 
(˂7 sessions) 51 40.1 -1.1 (-2.2 to -0.9) 
 9 (17.5%) 9 (17.5%) 
Total (≥2 sessions) 127 
 
-2.5 (-3.2 to -1.8) -2.3 (-2.9 to -1.7) 34 (26.5%) 31(24.5%) 
Table 6-2 Weight loss outcomes for patients with type 2 diabetes receiving different categories of anti-diabetic drug. P-values were determined using 
t-test (p-value <0.05 considered statistically significant) (N: Number; CI: Confidence Interval). 
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6.4.2.3 Weight change outcomes for the completers 
Patients who completed the lifestyle phase of the programme by attending seven sessions 
or more, lost the most weight across all three groups. Patients on weight-neutral drugs and 
those who had completed the programme lost more weight than the patients on weight-
gaining drugs. The mean weight changes ranged from -4.9 kg (95% CI: -5.5 to -4.2 kg) and 
-3.3 kg (95% CI: -4.2 to -2.5 kg, p =0.005), respectively (Table 6-2). On the other hand, 
there was no significant difference between the two groups in terms of their percentage 
weight loss as a p-value =0.06; the mean percentage weight loss in the weight-neutral and 
weight-gaining groups was 4.1% and 3.2%, respectively. Overall, the mean percentage 
weight loss was not significantly different among the three different drug categories. 
Patients on mixed drugs lost -4.3 kg (95% CI: -4.8 to -3.8 kg), which is equivalent to 3.8% 
weight loss. Among the 248 patients with type 2 diabetes (on weight-neutral drugs) who 
completed the lifestyle phase, 113 (45.5%) lost at least 5 kg; meanwhile, of the 236 
patients on mixed drugs, 93 (39.0%) had lost 5 kg or more. Moreover, 25 (33%) patients 
on weight-gaining drugs (out of the 76 who completed the programme) lost at least 5 kg. 
Patients on weight-gaining drugs were less likely to lose ≥5% of their body weight, when 
compared with the other patients in different drug categories. 
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6.4.3 Weight loss outcomes for subgroups 
6.4.3.1 Sex 
The null hypothesis is that the weight changes associated with anti-diabetic prescribing 
would be no different in men and women. Overall, participants who were prescribed 
weight-gaining anti-diabetic drugs lost less weight than those on weight-neutral drugs. The 
mean weight loss in individuals on weight-gaining anti-diabetic drugs was -2.5 kg (95% 
CI: -3.2 to -1.8 kg), compared to -3.3 kg (95% CI: -3.8 to -2.9 kg) for weight-neutral drugs, 
and the p-value was 0.05, which indicates the difference was statistically significant (Table 
6-2). On the other hand, the difference between weight-neutral and mixed drugs was not 
statistically or clinically significant, as the mean difference was -0.1 kg and the 95% CI 
overlapped. Since men were more likely to be prescribed weight-gaining anti-diabetic 
drugs (Table 5-3) and to achieve target weight loss (Table 3-4), sex may have confounded 
the association between weight loss and anti-diabetic drug type. 
 
The mean weight change for men and women using weight-neutral drugs was -3.93 kg 
(95% CI: -4.7 to -3.0 kg) and -2.98 kg (95% CI: -3.4 to -2.5 kg) respectively; this 
difference was statistically significant (p =0.02) (Figure 6-3). However, there was no 
difference between men and women in terms of the use of mixed or weight-gaining anti-
diabetic drugs (Table 6-3). The results show that a higher proportion of men used mixed 
drugs (45.4%) compared with those used weight-neutral (35.4%) or weight-gaining 
(43.3%) drugs, but they lost less weight than those prescribed weight-neutral medications. 
The mean weight change in the weight-gaining group was -2.51 kg (95% CI: -3.7 to -1.2 
kg), compared with -3.93 kg (95% CI: -4.7 to -3.0 kg) and -3.32 kg (95% CI: -3.8 to -2.8 
kg) in the weight-neutral and mixed drug groups, respectively. 
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Figure 6-3 The mean weight change (kg) and the 95% confidence intervals 
at the end of the lifestyle phase in both sexes in three different anti-diabetic 
drug categories. 
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6.4.3.2 BMI 
The null hypothesis is that the weight changes associated with anti-diabetic prescribing are 
no different in heavier and lighter patients. Overall, there was a linear trend between 
weight loss and higher BMIs in each drug category, but this relationship was not 
significant and the CIs overlapped (Figure 6-4). In terms of initial BMI difference, those 
with BMI ≥50 kg/m2 on weight-neutral drugs lost more weight than patients with BMI 30-
34.9 kg/m2. The mean weight loss was -3.98 kg (95% CI: -5.0 to -2.9 kg) and -2.48 kg 
(95% CI: -3.2 to -1.6 kg) respectively (Table 6-3). However, the Bonferroni test shows that 
the difference between these two categories was not statistically significant (p =0.35). 
 
 
 
Figure 6-4 The mean weight change (kg) and the 95% confidence intervals at the end of 
the lifestyle phase, across different BMI categories of patients in three different anti-
diabetic drug categories. 
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6.4.3.3 Age 
The null hypothesis: the weight changes associated with anti-diabetic prescribing are no 
different in younger and older patients. When the overall results were split according to the 
age of the patients, some differences in weight changes in each of the three groups were 
observed, but the CIs overlapped (Figure 6-5). Generally, as older people were more likely 
to be prescribed weight-gaining anti-diabetic drugs (Table 5-2) and to achieve target 
weight loss (Table 3-4), age may confound the association between weight loss and drug 
type. However, no statistically significant difference was found across age categories in 
each drugs group. The p-values for weight-neutral, mixed and weight-gaining drugs were 
0.55, 0.44 and 0.55 respectively (Table 6-3). 
 
 
 
Figure 6-5 The mean weight change (kg) and the 95% confidence intervals at the end of 
the lifestyle phase, across different age categories of patients in three different anti-diabetic 
drug categories. 
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6.4.3.4 SIMD 
The null hypothesis: the weight changes associated with anti-diabetic prescribing are no 
different in people with different socioeconomic statuses. In general, whilst patients in the 
least deprived area were more likely to achieve their target weight loss (Table 3-4), socio-
economic status did not influence the prescribing of anti-diabetic drugs (Table 5-8). It 
might therefore be expected that SIMD may not have confounded the association between 
weight loss and drug type. Weight loss among those on weight-neutral, mixed or weight-
gaining anti-diabetic drugs did not vary by socio-economic circumstance.  
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 Weight-neutral drugs (n =459)  Mixed-drugs (n =412)  Weight-gaining drugs (n =127) 
 
 
  Category (n) 
 Mean weight 
change (kg) and 
(95% CI) 
(%) P Mean weight change (kg) and 
(95% CI) 
(%) P Mean weight change 
(kg) and (95% CI) 
(%)             P         
 
 
Male (404) 
Female (594) 
          -3.93 (-4.7 to -3.0) 
-2.98 (-3.4 to -2.5) 
35.4 
64.6 
0.02 -3.32 (-3.8 to -2.8) 
       -3.12 (-3.6 to -2.5)              
45.4 
54.6 
0.59 -2.51 (-3.7 to -1.2) 
-2.50 (-3.2 to -1.7)      
43.3 
56.7 
     0.98 
 
 
BMI 30-34.9 kg/m2 (179) 
BMI 35-39.9 kg/m2 (301) 
  
-2.48 (-3.2 to -1.6) 
-2.82 (-3.5 to -2.0) 
 -3.68 (-4.3 to -3.0) 
 
15.3 
26.4 
 
0.08 
 
-2.80 (-3.4 to -2.1) 
-2.83 (-3.3 to -2.3) 
 
17.2 
31.3 
 
0.27 
 
-2.86 (-3.9 to -1.7) 
-2.04 (-3.4 to -0.5) 
 
22.8 
30.7 
 
     0.84 
 
 
BMI 40-49.9 kg/m2 (414) 45.7  -3.5 (-4.2 to -2.8) 41.0  -2.61 (-3.8 to -1.4) 37.8  
 
BMI ≥50 kg/m2 (104)  -3.98 (-5.0 to -2.9) 12.6  -3.70 (-5.3 to -2.0) 10.4  -2.72 (-4.7 to -0.7) 8.7  
 
 
Age 18-29 years (24) 
  
-2.01 (-3.6 to -0.3) 
 
4.4 
  
-1.69 (-4.6 to 1.2) 
 
0.5 
  
-0.29 (-1.6 to 1.0) 
 
1.6 
 
 
 
30-39 years (78)  -2.66 (-3.7 to -1.6) 12.2 0.55 -1.72 (-2.8 to -0.6) 3.9 0.44 -3.98 (-6.9 to -0.9) 4.7       0.55 
 
40-49 years (186)  -3.54 (-4.4 to -2.6) 22.9  -2.79 (-3.5 to -2.0) 15.5  -2.31 (-3.8 to -0.8) 13.4  
 
50-59 years (330)  -3.64 (-4.4 to -2.8) 30.9  -3.13 (-3.7 to -2.4) 36.2  -2.45 (-3.8 to -1.0) 30.7  
 
60-69 years (289)  -3.2 (-4.1 to -2.3) 22.9  -3.48 (-4.1 to -2.8) 33.0  -3.02 (-4.2 to -1.8) 37.8  
 
≥70 years (91)  -3.00 (-4.6 to -1.4) 6.7  -3.75 (-5.2 to -2.2) 10.9  -1.20 (-2.7 to 0.3) 11.8  
 
 
SIMD: 1 (most deprived) (396)  
 
-2.92 (-3.5 to -2.2) 
 
41.9 
 
 
-3.04 (-3.6 to -2.4) 
 
38.2  
 
-2.71 (-3.6 to -1.7) 
 
37.8 
 
 
 
2 (202)  -3.28 (-4.0 to -2.5) 21.5 0.39 -2.78 (-3.5 to -1.9) 19.0 0.45 -1.86 (-3.6 to -0.7) 20.5       0.15 
 
3 (146)  -3.85 (-4.9 to -2.7) 14.0  -3.67 (-5.0 to -2.3) 14.6  -1.10 (-2.4 to 0.2) 17.3  
 
4 (124)  -3.05 (-4.5 to -1.5) 9.4  -3.1 (-4.0 to -2.2) 14.8  -3.48 (-5.2 to -1.0) 15.7  
 
5 (least deprived) (126)  -4.05 (-5.3 to -2.7) 13.2  -3.88 (-4.9 to -2.8) 13.4  -4.14 (-7.2 to -1.0) 8.7  
 
Table 6-3 Stratified analysis of weight loss with three different categories of anti-diabetic drugs at end of the lifestyle phase (n: number; CI: Confidence 
Interval). 
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6.5 Summary of the main findings  
• The mean initial BMI at baseline was higher in the weight-neutral drug group. 
• Patients on the weight-neutral anti-diabetic drugs lost more weight than the patients 
on weight-gaining drugs.  
• There was no significant difference in terms of percentage weight loss between the 
three different groups; this might be attributable to the differences in initial weight 
between the groups. 
• In terms of lifestyle programme completion, a higher proportion of patients on 
weight-neutral anti-diabetic medication achieved their target weight loss compared 
with the other groups. 
• In terms of lifestyle programme completion, mean weight loss was higher in those 
on metformin only, and lower in those on any combination, including insulin, 
followed by those on SUs + TZDs. 
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6.6 Discussion 
6.6.1 Weight loss outcomes 
Previous trials have reported the effect of anti-diabetic drugs on body weight when patients 
are being treated by controlling their blood glucose in their normal daily life. However, this 
is the first study to report the effects of these drugs on the body weight of individuals with 
diabetes when referred to a weight management programme for obesity treatment. In other 
words, this study has represented the effects of anti-diabetic drugs on weight change 
alongside lifestyle change. The lifestyle changes implemented included a 600 kcal deficit 
diet, exercise, and behavioural intervention. Overall, the patients on metformin or 
metformin and mixed anti-diabetic drugs lost more weight than the individuals on SUs, 
SUs + TZDs and any drugs combination including insulin.  
 
Those who used metformin with weight-neutral drugs (group 1b) lost less weight than 
those on metformin alone (group 1a), and the difference was statistically significant. The 
mean weight change was -2.5 kg (95% CI: -3.8 to -1.3 kg) and -3.3 kg (95% CI: -3.8 to -
2.9 kg). This might be because those on one medication are usually more adherent to their 
medication, hence not having had their medications increased, and are possibly also more 
adherent to diet and physical activity compared with those taking multiple drugs. 
Additionally, it may be because of the different duration of diabetes, as those who had type 
2 diabetes for a shorter period of time were perhaps more amenable to behaviour change 
than those who have lived with diabetes for several years without attempting weight loss.  
 
In terms of using drugs that may cause weight gain, there was no difference between group 
3a and group 3b in terms of ≥5 kg weight loss, as 27.5% of those in both groups lost at 
least 5 kg of their initial weight. In terms of the percentage weight change, there was no 
statistically significant difference between participants in the weight-neutral drugs category 
and those in the weight-gaining drugs category. This might be because the mean weight at 
the baseline was higher in the weight-neutral group compared with the weight-gaining 
group. 
 
However, due to the low number of patients in some of these groups, the drug groups were 
combined into three categories depending on their effect on body weight. To our 
knowledge, this is the first study to target patients with diabetes and obesity enrolled in a 
weight management programme. Due to the uniqueness of the study, it is hard to compare 
 248 
it with previous studies, because the data reported in previous studies were collected from 
general practices or specialised diabetes centre irrespective of BMI. 
 
6.6.2 Comparisons with other findings 
The results reported here on the effect of metformin, SUs and TZDs on body weight 
confirmed previous trial results, which showed that there was an association between using 
metformin, and stable or lower weight. Meanwhile, SUs and TZDs might cause weight 
gain in patients with diabetes. For instance, an earlier study (1-year duration) of 639 
individuals with type 2 diabetes showed groups of patients who received SUs plus TZDs 
gained an average of 2.8 kg compared with a reduction of 1 kg in metformin plus SUs 
group (Hanefeld et al., 2004). In addition, a four-year randomised study of 4,360 subjects 
with type 2 diabetes uncontrolled by lifestyle intervention and treated with metformin, 
rosiglitazone or glibenclamide showed individuals in the metformin group lost weight; 
however, a weight gain occurred in glibenclamide and rosiglitazone groups, but this was 
most significant in rosiglitazone group when compared with either of the other groups 
(Kahn et al., 2006). Moreover, a retrospective study (1-year duration) of 2,641 participants 
reported that patients on metformin had lost an average weight of -2.6 kg (95% CI: -2.5 to 
-2.9 kg), and those on SUs had gained 0.3 kg (95% CI: -0.2 to 0.8 kg); a result consistent 
with the current findings (Kostev et al., 2015). 
 
The reason for the effects of metformin on body weight is that it might influence body fat 
distribution in people with type 2 diabetes (Golay, 2008). A randomised study of 26 
weeks’ duration reported metformin significantly decreased visceral fat mass compared 
with placebo, whereas rosiglitazone did not (Hallsten et al., 2002). DPP-1V and GLP-1 in 
combination with metformin resulted in weight loss or weight remaining neutral, compared 
with SUs or TZDs; which agrees with the results of a previous study, irrespective of study 
duration (Phung et al., 2010). 
 
6.6.3 Lifestyle programme completion 
There was no significant variation in completion status between patients and drug 
category, as the percentage range for the three categories was from 54% to 59%. This 
research found that the total and completer patients who are diabetic on weight-neutral 
drugs lost more weight than the patients on weight-gaining anti-diabetic drugs, and there 
was no difference with those on mixed drugs. This might be because of the effects of these 
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drug categories on body weight or due to the effects of other factors, such as initial BMI or 
patient age. At baseline, this research showed that patients on weight-gaining drugs were 
older and weighed less than individuals on weight-neutral drugs. Findings reported in 
Chapter 3 and a study by Morrison et al. (2011) that evaluated the lifestyle phase of the 
GCWMS programme, showed that heavier and older people are more likely to lose their 
target weight. Generally, as the participants in the weight-neutral group were heavier and 
younger than the patients in the weight-gaining drugs group, it could be concluded that the 
main reason they lost more weight could be due to the effect of the drugs on body weight 
in addition to other factors.  
 
Earlier studies have reported that men and women vary in their behaviour and attitudes 
toward their diabetes. For instance, Nothwehr and Stump (2000) suggested that women 
were more likely to follow a diet to control blood glucose, but undertook less physical 
activity than men. However, the current results show that the relationship between anti-
diabetic drugs and weight change was not confounded by sex. Based on these results, men 
were the most represented in the mixed drugs group (45.4%). It might therefore be 
expected that this group would lose the most weight if the drugs themselves had no effect, 
and that the patients’ sex was entirely confounding the relationship. Another example was 
that as women accounted for the highest proportion of people in the weight-neutral drugs 
group (64.6%), this group might have been expected to lose lowest amount of weight. 
However, the lowest proportion of men was in the weight-neutral drugs group, and they 
lost the largest amount of weight. The null hypothesis can therefore be accepted, making it 
likely that the relationship between drug type and weight loss was not confounded by sex. 
 
A previous 26-week RCT compared the effect of liraglutide or rosiglitazone with 
glimepiride on weight change and glycaemic control in 1,041 participants. It reported that 
sex does not influence the effect of liraglutide on weight change, which is consistent with 
the current results (Marre et al., 2009). In addition, in a two-year follow up of the DiaRegis 
cohort study, Hartmann et al. (2015) found that the association between anti-diabetic drugs 
and weight change was not influenced by the sex or patient age. 
 
In terms of BMI factor, the results show that there was a strong linear relationship between 
weight loss and BMI, although this relationship was not statistically significant. These 
results are in agreement with Ji et al. (2013), who showed that baseline BMI had no effect 
on weight change in Chinese patients with type 2 diabetes who used metformin. In 
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addition, the results show that there was no statistically significant difference between the 
age categories in terms of mean weight change. Therefore, it might be possible to accept 
the null hypothesis; the results confirm that age and BMI did not confound the relationship 
between anti-diabetic drugs prescribing and weight loss. 
 
In terms of socio-economic status, a higher proportion of patients from the most affluent 
areas were on weight-neutral drugs (13.1%), compared to those on weight-gaining drugs 
(8.6%). However, they lost almost the same amount of weight -4.05 kg (95% CI: -5.3 to -
2.7 kg) and -4.14 kg (95% CI: -7.2 to -1.0 kg). It may thus be concluded that the 
association between weight change and drug type was not confounded by SIMD. 
 
6.6.4 Target weight loss 
In terms of achievement of target weight loss (≥5 kg) in the weight-gaining drug 
categories, there were modest differences in the percentages of patients losing 5 kg or 
more, and between the total number of patients and the completers, as the difference was 
just 6.5% compared with the other groups. This indicates that patients in this category 
gained some weight during the weight management programme; this might be a 
consequence of the effects of drugs such as SUs, TZDs and insulin. The majority of the 
patients in the mixed and weight-gaining drug categories who lost ≥5 kg, lost ≥5% of their 
body weight, compared with patients who used weight-neutral anti-diabetic drugs. This 
might be due to their higher initial weight and the BMI in the weight neutral-drugs group 
compared with the other groups. 
 
6.6.5 Recommendation 
Despite there are beneficial effects of weight loss on glycaemic control and reducing 
cardiovascular risk in people with diabetes, weight gain seems to be a barrier to controlling 
blood glucose, and is commonly associated with the use of some anti-diabetic drugs. This 
might cause patients to become discouraged from adhering to their treatment. Therefore, 
physicians should consider the weight effects of anti-diabetic drugs when managing 
patients with obesity and type 2 diabetes, so that they can offer them weight-neutral anti-
diabetic drugs that will supplement the patient’s need to embark upon a healthier lifestyle. 
In general, patients with obesity and diabetes have greater difficulty losing weight than 
people without diabetes (Wing et al., 1987), and many anti-diabetic drugs are associated 
with weight gain. Therefore, patients should be encouraged to enrol in a weight 
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management programme to achieve their glycaemic and weight targets, and attempts 
should be made to provide patients with alternative medications that are not associated 
with weight gain, or to reduce these agents without compromising glycaemic control. 
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6.7 Strengths and limitations 
A key strength of the present study was that it is the first research to observe the effects of 
anti-diabetic drugs on weight change among participants with type 2 diabetes referred to 
attend a lifestyle weight management programme. This intervention cohort study, which 
has quite a large sample size, reported the mean weight loss and the mean percentage 
weight loss, which provides a comprehensive data set and powerful results. Use of the 
GCWMS provided a good sample of individuals with diabetes from different 
demographics, all of whom were referred for obesity management. 
 
Notable limitations of the research include information bias, as each anti-diabetic drug 
category was classified into specific groups; and some anti-diabetic groups were not 
included. Therefore, this might have reduced the observed association. Another weakness 
of the study was that the data did not provide information regarding the patients’ duration 
of type 2 diabetes, or how long they had used other drugs to the study, both of which may 
influence or decrease the efficacy of some drug classes. Moreover, there was no 
information about the doses of anti-diabetic drugs prescribed to the patients. One source of 
weakness in this research, and one which could have affected the anti-diabetic drugs effect 
on weight change was the short duration of study, as outcomes were reported after the 
lifestyle phase (16 weeks). Therefore, a further study could be undertaken to assess the 
long-term effects of anti-diabetic medication on weight change. 
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6.8 Research implications  
In conclusion, due to the lack of evidence from other sources investigating the effect of 
anti-diabetic drugs on weight change among patients enrolled in a weight management 
programme, it is not possible to compare the results of this research with earlier empirical 
findings. The ADA recommended an anti-diabetic drug for type 2 diabetes with the ability 
to reduce hyperglycaemia, while the SIGN guidelines reported a clear treatment plan for 
patients with obesity and type 2 diabetes. Based on the above, and because many patients 
with type 2 diabetes are overweight or obese, there may be good reasons why GPs 
prescribed weight-gaining drugs. However, it may be possible to improve weight loss by 
optimising anti-diabetic drug prescribing. Further research, possibly of a qualitative nature, 
would be needed to determine whether there is scope to change anti-diabetic drug 
prescribing. Further analysis using multi-variable regression was considered, but it was 
found that a regression model cannot easily be fitted to change measures and there was no 
simple approach that could have been used to achieve this (Chiolero et al., 2013). In future 
investigations, it might be possible to test the association between weight loss and 
reductions in the doses of certain medications, such as the hypoglycaemic agents and anti-
hypertensive drugs. Further implications will be discussed in the following chapter. 
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              Chapter 7: Conclusion 
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7.1 Relationship between thesis chapters 
One of the risk factors for the development of diabetes mellitus is obesity. While weight 
loss can be achieved through lifestyles modifications, numerous RCTs have demonstrated 
that the additional use of orlistat, the only drug licensed in the UK specifically for the 
treatment of obesity, can increase this benefit. One such RCT was a two-year study 
supported by La Roche (O’Meara et al., 2001); others were considered in a HTA report. In 
2010, the SIGN guidelines recommended that the drug could be used in weight loss 
management as an adjunct to lifestyle interventions. The impact of orlistat on patients with 
obesity in terms of diabetic outcomes, including FPG and HbA1c, has been examined in 
medium- and small-scale research studies. A further example of the approved clinical use 
of orlistat is in the GCWMS, where the drug can be employed within the multidisciplinary 
weight management programme. Chapter 2 therefore comprised a systematic review of the 
impact of the use of orlistat in the management of patients who are overweight or obese in 
terms of their glycaemic values, along with a meta-analysis of the literature.  
 
In the United Kingdom, there are typically four tiers of weight management services 
programmes. Two of these are tier 2 services (lifestyle interventions) and tier 3 services 
(specialist weight management programmes). The NICE has identified four main gaps in 
the literature concerning these programmes (NICE, 2014). Firstly, there have been 
insufficient trials that directly compare different lifestyle weight management programmes 
in the United Kingdom. Secondly, small sample sizes and temporally restricted data 
collection points limit the usefulness of existing evidence. The third limitation is 
inadequate evidence regarding the relative efficacies of different interventions in terms of 
weight loss. Finally, the effectiveness of weight loss programmes varies according to 
socioeconomic group, gender and age; insufficient evidence exists regarding this. 
 
Based on the above, GCWMS referrals over the period from 2008 to 2014 were considered 
in Chapter 3, to investigate the impact on weight loss of lifestyle intervention (phase 1). 
The influence of diabetes status, age, the SIMD, initial BMI and sex were considered for 
this large sample size. Chapter 4 examined the efficacy of a range of interventions on 
weight loss, for example, LCD, FWL and orlistat (phase 2) for these patients.  
 
Finally, Chapter 3 demonstrated that there was a significant difference in terms of weight 
loss between patients with and without diabetes who were referred to the GCWMS. 
Additionally, a wide range of RCTs have reported that some anti-diabetic drugs might have 
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weight-neutral or weight-loss effect, whilst some may cause weight gain without any 
correlation with BMI. As the SIGN guidelines of 2010 set out a treatment plan for patients 
who are overweight or obese with type 2 diabetes, investigation of the commitment of GPs 
to prescribing hypoglycaemic agents prior to referral to weight management services was 
necessary. Therefore, in Chapter 5, the pattern of prescribing anti-diabetic drugs to patients 
referred to the GCWMS was studied. Following on from this, Chapter 6 described the 
impact of different classes of anti-diabetic drugs on weight loss.  
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7.2 Review of principal findings 
This thesis evaluated the effectiveness of GCWMS on obesity treatment, and reviewed the 
impact of the anti-obesity drug orlistat on glycaemic control in patients with obesity and 
type 2 diabetes. The prescribing patterns for anti-diabetic drugs were investigated and their 
effect on weight loss observed.  
 
Chapter 2 presented a systematic review and meta-analysis, demonstrating that a regime of 
orlistat 120 mg three times per day, in association with lifestyle intervention resulted in 
greater glycaemic control and significantly improved weight loss than was possible with 
lifestyle interventions alone. In the first three months of orlistat use, reductions were seen 
in FPG and HbA1c; moderate rises were also subsequently observed, despite weight loss 
continuing for up to one year. Neither weight loss nor glycaemic value were conclusively 
found to be affected by the combination of physical activity and a placebo, as insufficient 
studies using this regime were available.  
 
Fewer than half of the patients completing the lifestyle phase of the GCWMS in the cohort 
studies examined in Chapters 3 and 4 achieved a weight loss of 5 kg. It was found that 
those most likely to finish the programme and achieve the target weight loss were male, 
older, lived in more affluent areas, had higher BMIs, and without diabetes. Approximately 
50% of the participants had lost 5% or more of their initial weight, and approximately 55% 
had lost at least 5 kg by the end of phase 2. Those patients who performed well were 
selected to proceed to the FWL programme; approximately six out of seven of these 
achieved their target weight loss. While the patients using orlistat successfully lost weight, 
only 30% achieved their target weight loss. The intervention found to be least effective 
was LCD, with fewer than one-quarter of patients achieving their target losses.  
 
Approximately half the patients in the cross-sectional study described in Chapter 5 were 
prescribed weight-neutral anti-diabetic drugs. However, comparing 2008 and 2014, i.e. 
following the publication of the SIGN guidelines in 2010, there was no change in the 
pattern of prescribing drugs triggering a decrease in weight. The least frequently prescribed 
medication was SUs plus TZDs; the most commonly prescribed was metformin. 
Furthermore, the study revealed that other confounding factors might have influenced the 
prescription of anti-diabetic drugs; these were BMI at the outset and age.  
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Chapter 6 described an intervention cohort study. It was observed that, while not 
statistically significant, there was a clinically significant improvement in weight loss 
among the GCWMS patients on weight-neutral anti-diabetic medication compared to those 
on weight-gaining anti-diabetic drugs. However, there was no significant difference in 
terms of percentage weight loss. A potential reason for this is that the former patients’ 
initial weights were higher than those of the latter group. A total of 30.5% of patients 
completing the programme on the SUs plus TZDs regimen achieved their target weight 
loss; for the metformin group, this figure rose to nearly half of all patients (47%).  
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7.3 Strengths and limitations 
Each individual chapter of this thesis has discussed the strengths and limitations of the 
respective studies. Therefore, this section considers those associated with the overall 
methodology used throughout the research, which, as has been seen, comprised five studies 
– a systematic review and an associated meta-analysis, as well as a cross-sectional study 
and prospective cohort studies.  
 
The systematic review and meta-analysis were performed in accordance with the Cochrane 
methodology and reported according to PRISMA guidelines. The review included RCTs 
and assessed the impact of physical activity and of placebo, evaluating two forms of 
intervention. However, it only considered literature concerning patients who are 
overweight or obese with type 2 diabetes. Evidence of significant bias was assessed in 
accordance with the guidelines of the Cochrane Collaboration and no significant bias was 
found. Further use of the guidelines in terms of the I2 statistic investigated consistency in 
the studies’ results. This identified the statistic expressing the proportion of inconsistency 
(quantified as a percentage) that cannot be accounted for by random probability or 
sampling error alone (Higgins et al., 2003). Analysis using this parameter produces a 
readily quantifiable and interpretable measure of inconsistency, with an associated 
uncertainty level that is independent of sample size. The values of I2 can be interpreted 
across four broad ranges: ‘Considerable heterogeneity’ (I2 =75-100%), ‘Substantial 
heterogeneity’ (I2 =50-90%, ‘Moderate heterogeneity’ (I2 =30-60%) and ‘Might not be 
important’ (I2 =0-40%). The current results show a considerable heterogeneity between 
studies that reported the HbA1c and FPG outcomes. The overall I2 between the studies that 
reported the HbA1c and FPG outcomes was (100%, p =0.001 and 97.4%, p =0.001, 
respectively). In addition, there was substantial heterogeneity between the studies that 
reported the weight change (I2 =76.6%, p =0.001), except for the studies that reported the 
weight change after three months.  
 
Therefore, further research might be needed to examine the effect of orlistat on glycaemic 
control in real life for patients with obesity and type 2 diabetes. In the systematic review of 
RCTs, orlistat can result in adverse gastrointestinal reactions; as the participants in the 
research – both patients and study personnel – might have been influenced by the presence 
of such reactions, as they could have inferred whether or not a placebo had been 
administered.  
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There are a large number of factors that can influence the pattern of prescribing medication 
for patients with type 2 diabetes. This thesis is the first to investigate such a pattern for 
anti-diabetic medication used by patients referred to a weight management programme, 
and benefitted from the large sample size offered by the GCWMS. The thesis is also the 
first to observe the effect of the anti-diabetic drugs on weight loss. The resultant dataset 
incorporated patients from a wide range of socio-economic backgrounds and enabled 
impact of this programme to be examined with respect to patients’ age, BMI, SIMD and 
sex. While the research was stratified for many such potential confounding factors, residual 
ones remain possible in any observational studies of this nature.  
 
A range of sources of missing data resulted in some limitations in the study, which also 
reduced the variables available in the evaluation of the phase 3 maintenance phase. As this 
was a prospective study that included all patients referred to the GCWMS, it is likely that 
selection bias was almost certainly not present in the cross-sectional study. However, 
information bias may have been present as real-world clinical data were used. Attrition 
bias and information bias may have occurred in the cohort studies. Some patients did drop 
out of the GCWMS, but data explaining the reasons for this were not available. Inadequate 
data regarding the doses of anti-diabetic drugs used both before and after the lifestyle 
intervention programme prevented exploration of the impact of weight loss on the 
prescription of the dose of hypoglycaemic drugs.  
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7.4. Research in relation to other findings  
In this section, the results of the research as reported in the preceding chapters were 
highlighted and compared to other important research areas. 
 
In this research, the systematic review and meta-analysis of RCTs showed orlistat is an 
effective treatment for improving glycaemic control in people who are overweight or obese 
with type 2 diabetes, when used as an adjunct to lifestyle interventions. This is consistent 
with the results of the Cochrane review (Padwal et al., 2004), which reviewed patients both 
with and without diabetes. It also included an analysis of a subgroup of patients, reporting 
outcomes only for patients with diabetes. In that review of five studies, the mean HbA1c 
and FPG were -4.15 mmol/mol (95% CI: -6.44 to -1.96 mmol/mol) and -1.03 mmol/l (95% 
CI: -1.49 to -0.57 mmol/l) after one year. Three of these studies were included in the 
current review (Berne et al., 2005; Kelley et al., 2002; Miles et al., 2002), and the results 
reported were similar. The mean differences in HbA1c and FPG were –5.29 mmol/mol 
(95% CI: -7.31 to -3.27 mmol/mol) and -1.06 mmol/l (95% CI: -1.44 to -0.68 mmol/l) 
respectively.  
 
The respective mean differences in HbA1c and FPG between orlistat and the control group 
in another systematic review (Avenell et al., 2004) of six studies were -1.85 mmol/mol 
(95% CI: -2.62 to -1.09 mmol/mol) and -0.24 mmol/l (95% CI: -0.34 to 0.14 mmol/l). 
Therefore, the finding of this thesis that glycaemic control is promoted by orlistat is 
supported by these findings, although the review of Avenell et al. (2004) included only 
trials with follow-ups at one year and involving patients with and without type 2 diabetes.  
 
A systematic review in an HTA report (O’Meara et al., 2001) also investigated the effect 
of orlistat on weight loss, comparing the loss in a group prescribed orlistat with that in a 
control group. It reported that the trial groups achieved mean weight changes of -1.24 kg 
(95% CI: -2.6 to -0.1 kg), -3.41 kg and -2.9 kg (95% CI: -3.6 to -2.1 kg) after three months 
(two studies), six months (two studies) and one year (four studies) respectively. The 
research reported in this thesis also showed lower mean weight differences at 6 and 12 
months (the mean weight difference at 6 and 12 months was -2.23 kg (95% CI: -2.73 to -
1.74 kg) and -2.64 kg (95% CI: -3.09 to -2.19 kg) respectively; a potential reason for this 
might be the inclusion of participants both with and without diabetes. However, at three 
months, the thesis results showed greater weight changes (-1.73 kg (95% CI: -2.12 to -1.34 
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kg)) as the patients were using 120 mg of orlistat rather than the 50-60 mg prescribed in 
the review study.  
 
Similar results were found in the previous two studies evaluating the GCWMS (Morrison 
et al., 2011; Logue et al., 2014) and Chapters 3 and 4 of this thesis – that is, the lifestyle 
intervention of the NHS GCWMS led to effective weight loss, albeit for less than half of 
the patients completing the programme. The weight losses achieved were comparable with 
other NHS Tier 3 weight management programmes, such as SLiM (Brown et al., 2015) 
and the FWMS (Jennings et al., 2014). Similar commercial programmes, such as WMOR 
(Birnie et al., 2016), Slimming World, Rosemary Conley and Counterweight (The 
Counterweight Project Team, 2008) also produced similar results. However, 33% of 
patients on the Weight Watchers programme lost at least 5% of their initial weight (Ahern 
et al., 2011), compared to 25.5% of GCWMS patients, representing a higher success rate.  
 
Chapter 5 also showed consistency with previous studies. Patients with lower BMIs were 
more likely to be prescribed drugs associated with weight gain, such as TZDs or SUs, 
while patients with higher BMIs were more likely to be given weight-neutral drugs such as 
metformin. A previous study reported that for patients on SUs, the percentages with BMIs 
of <25, 25-<30, 30-<35 and ≥35 kg/m2 were 36.6%, 30.6%, 26.3% and 27.4% 
respectively; the corresponding proportions of patients prescribed metformin were 74.6%, 
83.5%, 84.5% and 86.9% (p-value <0.001) respectively (Hartmann et al., 2015). A 
previous study with a large (n =57,518) dataset reported that 90% of patients were 
prescribed metformin. This is consistent with this research, in which metformin was the 
most frequently prescribed anti-diabetic medication, while TZDs and SUs were the least 
frequently prescribed. According to primary care data in the United Kingdom, between 
2009 and 2013, 0.1% and 7.9% of patients were prescribed TZDs and SUs respectively 
(Sharma et al., 2016). This research was also in line with the results of a previous study, 
which found a connection between the prescribing of anti-diabetic medications and sex, 
initial BMI and age (Kamrai & Sachdeva, 2010).  
 
Chapter 6 described the first piece of research investigating the effect of anti-diabetic 
medication on weight change for patients with obesity who were referred to a weight 
management service. Therefore, any comparison with previous findings is difficult. 
However, the results were broadly in agreement with previous trials that determined that 
GLP-1, metformin and DDP-4 inhibitor were all associated with weight loss in type 2 
diabetics (Kostev et al., 2015; Phung et al., 2010). They also supported another review 
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study (Krentz and Bailey, 2005), systematic reviews and meta-analyses (Domecq et al., 
2015), which reported that SUs and TZDs were significantly associated with weight gain.  
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7.5 Recommendations 
7.5.1 Recommendations for healthcare professionals 
7.5.1.1 Referrals to weight management programmes 
As the worldwide incidence of obesity continues to increase, GPs are under increasing 
pressure to take a proactive lead in the prevention and treatment of the illness. Moreover, 
people with obesity appear increasingly willing to seek counselling for weight loss from 
GPs rather than from dieticians or other medical professionals (Tan et al., 2006). As this 
research highlighted a relatively low referral rate to the GCWMS, it is appropriate to make 
some recommendations for GPs.  
 
In order for GPs to lead obesity management, it is necessary to increase awareness of the 
influence their beliefs can have on practice. GPs should be encouraged to modify these 
beliefs where necessary in order to facilitate this. This should be considered during the 
education of GPs at medical school and during their residencies, in which a lack of obesity 
training has to date been associated with a lower incidence of discussion of exercise and 
diet with patients who are obese (Rurik et al., 2013). Therefore, there is a requirement for 
improved training and knowledge in the field of obesity during GPs’ education and 
training. Once qualified, they require access to better and more effective guidelines, wider 
referral options, improved tools for obesity screening and management and, importantly, 
greater coordination with other medical specialties. There may be some culture of 
discomfort surrounding the discussion of obesity. Overcoming this may be helped not only 
by improved training, as previously mentioned, but also by social and environmental 
changes. At a wider level, improved health policies, greater community involvement and a 
reorganization of healthcare structures and the demands placed on GPs should also be 
implemented.  
 
This research demonstrates that men are less likely to participate in weight loss 
programmes than women, a finding consistent with previous studies. This is, perhaps, 
surprising, given the increasing prevalence of male obesity in the United Kingdom and the 
acknowledged link between obesity and poor health (Gray et al., 2009). However, as little 
research has been carried out into men’s engagement and participation in weight loss 
programmes, this is a relatively poorly understood phenomenon. Therefore, it is important 
for GPs to be proactive in addressing the situation. In addition to an increased awareness of 
this particular aspect of the obesity problem, GPs must take responsibility for identifying 
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men with obesity and encourage them to enrol in weight management programmes. 
Initiatives that may help address the issue might include assisting with the initiation of 
programmes in appropriate locations, such as the workplace. Furthermore, men who are 
obese need to be actively motivated to reduce their weight. Increasing awareness of the 
health issues that may result from their high weight, particularly as they grow older, can 
lead to increased concern about potential serious conditions such as heart attacks, which 
may help encourage them to attend weight management services. 
 
7.5.1.2 Implementing guidelines on the prescription of anti-diabetic drugs 
Clinical guidelines are an important means of improving the quality of care. They are 
frequently developed and disseminated in healthcare systems across the world, but 
adherence varies greatly. There are many potential reasons for the variation in the degree 
to which different guidelines are followed in practice. Some examples are the means by 
which they are developed, the content of the recommendations, the type of problem being 
addressed and the body or organization disseminating the guidance (Grol and Grimshaw, 
2003). Barriers to adherence to guidelines reported in a previous study included a lack of 
awareness of their existence, a lack of agreement with or awareness of the content, or 
impediments related to patients or working environments (Casey, 2013). 
 
However, in terms of diabetes research and the resultant recommendations included in the 
guidelines for its treatment, changes are usually rapidly transferred to daily clinical 
practice. This is particularly true of drug treatments, as the major pharmaceutical 
companies are very proactive in promoting their products for use in hospitals, primary care 
settings and community pharmacies. Despite this, some GPs have continued to prescribe 
weight-gaining anti-diabetic medications for patients with obesity and type 2 diabetes even 
after the publication of the 2010 SIGN guidelines. This might be because some 
practitioners are not aware of the effect of these medications on weight-gain, while some 
of them may be aware of this effect but might be motivated by other reasons influencing 
their decisions, such as the cost of the drugs or GPs’ habits. In addition, it might be 
believed that these drugs reduce the risk of complications from diabetes, based on the 
UKPDS study that showed that a reduction in or increased control of blood glucose 
(HbA1c) reduces the risk of complications. However, most studies carried out subsequent 
to the UKPDS have actually simply looked at reducing blood glucose without looking at 
the outcomes, and assumed that they would be the same. The true reasons for GPs’ inertia 
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in terms of prescription might be determined through surveys, including those carried out 
online. 
 
It might be possible to change the practice of healthcare professionals using interventions 
that deemed to be consistently effective. Examples might include audit and feedback, 
various types of reminder systems (either computerised or manual), or participation in 
workshops, enabling them to discuss and engage in practice in order to reach consensus 
that treatment guidelines for a given clinical problem are appropriate. More traditional 
methods, such as educational meetings on diabetes, electronic publications or audio-visual 
educational material, may prove less effective (Bero et al., 1998). A previous systematic 
review by Jeffery et al. (2015) reviewed the evidence about the effective interventions that 
improve adherence to the CVD guidelines. It included 38 RCTs examining different 
interventions, such as education, audit and feedback, academic detailing, and other 
interventions. The authors concluded that, despite the small number of studies and their 
lower quality, many interventions show the potential to improve GPs’ adherence to the 
CVD guidelines. Educational intervention compared to usual care resulted in a statistically 
significant improvement in adherence to the guidelines; the mean difference was 0.58% 
(95% CI: 0.35 to 0.8). 
 
In summary, GPs must review patients’ anti-diabetic medication regimes prior to referral 
to the GCWMS. Doctors must aim to achieve familiarity with the latest guidelines on the 
pharmaceuticals available to them, including new drug groups and their potential effect on 
patients’ weight. 
 
Qualified pharmacists are increasingly involved in the prescription of medications for a 
limited range of indications. Broadly speaking, establishing wider, collaborative 
programmes for management of drug-therapy along these lines could be beneficial in the 
prescription of drugs to sufferers of chronic diseases or to patients with complicated drug 
regimes. Therefore, a further important means of improving the prescribing of anti-diabetic 
medication to patients with overweight or obesity would be to involve pharmacists, who 
could monitor the progress of patients’ care between visits to their doctors. The relevant 
expertise of pharmacists could enable them to manage the prescription of anti-diabetic 
medications and monitor the patient’s adherence to the prescribed regimen. For example, 
in the period between appointments to see their diabetes physician (which may be three or 
even six months), a patient could visit the pharmacist for routine monitoring. At these 
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visits, the pharmacist could measure the patient’s BMI and blood glucose levels and use 
these to determine whether any changes to their lifestyle, body weight, glucose control or 
drugs are required in order to change their glucose control and prevent any elevation in 
their BMI. The process might also incorporate remote disease management technology to 
enable interlink patients to have more frequent monitoring while reducing the number of 
pharmacist visits required. If the patients could upload their blood glucose meter readings 
electronically each week, their BMIs could be checked when attending the pharmacist 
appointment and decisions regarding the onward progress of their care made at that time.  
 
The outcomes of pharmacist interventions in the treatment of type 2 diabetes were 
identified by Pousinho et al. (2016) in a recent systematic review. The review included 36 
RCTs, involving 5,761 patients in total. It found that pharmacist interventions brought 
about more significant improvements in multiple outcomes than was achievable with usual 
care; for example, in terms of HbA1c, fasting blood glucose, blood pressure, lipid profile, 
and medication adherence. HbA1c was evaluated in 26 studies, of which 24 yielded a 
greater reduction in outcome. When the intervention group was compared with the control 
group, the difference between the groups ranged from -0.18% to -2.1%. When measuring 
BMI outcomes, 14 RCTs reported mean BMI fell between the baseline and final follow-up 
in case where there was pharmacist intervention. The variations reported between 
treatment and control groups ranged from +0.4 kg/m2 to -2.77 kg/m2. In eight studies, a 
greater improvement in medication adherence was observed in the intervention groups than 
in the control groups, but of these, only two reported a statistically significant difference. 
 
A further systematic review assessed the effect of pharmacists’ interventions on subjects 
suffering from chronic kidney disease (Salgado et al., 2012). A total of 37 studies were 
identified, including 4,743 patients with kidney problems. It was found that pharmacists 
recognised 2,683 drug-related problems in 1,209 participants. Pharmacists’ interventions 
reduced the incidence of end-stage renal failure in subjects with diabetic nephropathy (14.8 
versus 28.2 / 100 patients), and reduced mean systolic blood pressure from 175.8 mmHg to 
145.3 mmHg, p =0.02. Additionally, pharmacist interventions reduced the mean FPG in 
patients with chronic kidney disease from 11.6 mmol/l to 9.0 mmol/l, p =0.001. 
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7.5.2 Clinical implications and recommendations for the GCWMS 
The findings of this research demonstrated modest results for the GCWMS compared to 
Weight Watchers and other commercial weight management services. Therefore, several 
recommendations to improve the results further are offered.  
 
Accessibility 
It is important that the GCWMS programme be as accessible as possible to everyone for 
whom it would be of benefit. There is wide scope for facilitating this. A wide choice of 
appointment times, including evenings and early mornings to enable access for people at 
work during the day, would encourage them to complete the programme.  
 
Patients from the most deprived areas 
Patients from areas with the highest levels of socioeconomic deprivation must be 
encouraged to participate in the GCWMS programme; the provision of transport would 
assist with this. Educational classes in more deprived areas to provide people with clear 
and concise information about healthcare and the benefits of weight loss and the GCWMS 
would increase motivation.  
 
Physical activity 
More frequent physical activity sessions might improve the engagement of young people 
and men, motivating them to participate in and complete the programme. It should be 
noted that not all interventions will suit or be effective for all people. Successful 
participation not only requires motivation but also requires an appropriate intervention to 
be selected.  
 
Phase 2 
In phase 2, the overall outcomes of the programme might be improved by increasing the 
frequency of the sessions (for example, holding them on a fortnightly, rather than monthly, 
basis) and by contacting the patients each week. Overall effectiveness might be increased 
by raising the intensity of the phase 2 interventions and by targeting effective interventions 
at more specific populations. This is based on evidence that patients lost most of their 
weight during the lifestyle phase of nine sessions (fortnightly), compared with phase 2. 
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Multidisciplinary team 
Just as coordination with other specialties is a recommended course of action for GPs, it is 
recommended that the GCWMS should also work in conjunction with pharmacists and 
GPs to maximize the benefits of the service. Weight loss might be enhanced and the 
proportion of patients completing the programme increased by including these three groups 
on the management team. As well as the ability to supply medicine safely (and to identify 
suitable patients to whom it could be administered), pharmacists’ expert knowledge 
regarding drugs would enable the provision of information and advice about adverse side-
effects and interactions, as well as monitoring participants to maximise the drug’s efficacy. 
The physicians’ role might include working with dieticians to provide advice on healthy 
lifestyles, exercise and nutrition. Practice nurses may be a useful addition to the team as 
they can improve overall diabetes care by monitoring risk factors, ensuring attendance at 
screening, work with the GP to optimise medications and insure that individuals have the 
necessary education and skills to manage the condition. 
 
Orlistat 
Orlistat was shown in the systematic review and meta-analysis of RCTs to be of benefit for 
patients with type 2 diabetes, resulting in a clinically significant improvement in glycaemic 
control. For this purpose, it is an effective adjunct to lifestyle intervention and anti-diabetic 
drugs among patients who are obese and overweight with this form of diabetes. The review 
showed that there were statistically significant differences in absolute weight loss between 
treatment and control groups. As the mean difference between the groups was sometimes 
small, the clinical significance is uncertain, making this a decision for healthcare 
professionals involved in the treatment of patients with obesity. It is important to consider 
the possible adverse effects of orlistat when considering its use in patients’ treatments.  
 
Some differences were observed between the weight loss achieved through orlistat 
reported in the RCTs and its effect in the GCWMS. The GCWMS studies found weight 
loss to be lower than the figure derived from the systematic review and meta-analysis of 
the RCTs. In GCWMS, the mean weight loss at seven months was -2.93 kg (95% CI: -3.8 
to -2.0 kg); from the meta-analysis, the mean weight loss at three months was -3.67 kg 
(95% CI: -4.30 to -3.04 kg). Differences in selection criteria, programme setting and the 
intensity of support may have contributed to these differences. These differences are 
summarized in the table below: 
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Differences                    RCTs GCWMS 
Inclusion criteria       BMI ≥25 kg/m2 
      Participants with type 2 
diabetes 
          BMI ≥30 kg/m2 
          Participants with type 1 or 
type 2 diabetes 
 
Intervention 
      
      Orlistat + lifestyle change for 
3 months 
          
Lifestyle intervention for 4 
months, then orlistat for 3 
months 
 
Support 
    
     - Individual treatment 
     - Regular weight checks 
     - Contacting patients regularly 
by phone 
         
        - Group support 
        - Monthly weight checks 
        - Monthly session 
 
 
Table 7-1 Differences between using orlistat in RCTs and in real life weight management 
service. 
 
Using orlistat from the beginning of the lifestyle intervention might therefore improve 
weight loss in the GCWMS. This therefore highlights the need for a post-approval 
evaluation of the effectiveness of orlistat as delivered in a weight management programme 
centre or in routine primary care.   
  
Target weight loss definition 
The lifestyle treatment phase of GCWMS is clinically effective for patients completing the 
treatment programme. However, for patients with BMI ≥40 kg/m2, other risks might not be 
improved by a weight loss target of ≥5 kg, and this goal may be insufficient. Therefore, the 
weight loss target for the GCWMS might need to be reviewed and a higher target set. 
 
Medication prescribing 
This thesis has provided evidence to support the effect of anti-diabetic drugs on weight 
change. The results suggest that referral to lifestyle weight management with appropriate 
hypoglycaemic agents is a suitable course of action be considered for all patients who are 
obese with type 2 diabetes. These medications should be prescribed on an individualised 
basis, and the regimen should take into account the patient’s current BMI and weight 
profile.  
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7.5.3 Obesity prevention in Scotland 
Obesity is a growing problem and forecasts predict that it will continue to affect the health 
and economy of the population in the future. There is a clear link between the difference in 
a person’s intake of food and expenditure of energy and their weight change, as 
demonstrated through energy gap models. Excess energy intake is one of the driving 
factors of the increase in obesity.  
 
Scotland provides a good quality and different range of interventions for the treatment of 
obesity, but very much needs to take action on obesity prevention. Governments are the 
most important players in terms of reducing the obesity epidemic; the promotion and 
protection of public goods including public health – is one of their key responsibilities 
(Gortmaker et al., 2011). Therefore, it is critical for the government to monitor childhood 
and adult obesity, as well as the main aspects of the living environment that affect them 
and are affected by them. While the use of higher taxes might be effective at reducing 
obesity (for example, increasing the duty on alcohol and foods with a high caloric content 
to discourage consumers from purchasing them too frequently), there are arguably more 
positive measures that can be taken. One government department, the Food Standards 
Agency, is responsible for protecting public health with regard to food. It is important that 
they continue to work towards reducing obesity and to support the food and drink industry 
in this aim. The proportion of low-energy food and drinks must be increased at the expense 
of energy-dense alternatives, and products must continue to be altered to reduce portion 
sizes, salt and sugar content and saturated fat content. Clear product labelling enables 
consumers to choose healthier options. The government should play a role through its 
educational departments, working with the food industry to provide more nutritious meals 
to children. Schools themselves must also play their part, both through physical education 
and through measures such as teaching about healthy eating and reducing television 
viewing. 
 
Physical activity increases energy expenditure; increasing such activity is an effective 
intervention in helping to prevent obesity. Therefore, it is essential that each community 
has access to a suitable physical environment for children to enjoy a positive healthy 
lifestyle. Provision of facilities in the workplace and community to enable adults to 
exercise (for example, swimming, walking, running, cycling or jogging) would also be of 
benefit. Furthermore, obesity prevention is known to be strongly associated with 
sustainable food supply and poverty reduction, and taking measures to achieve these 
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objectives is likely to result in benefits in terms of reducing obesity (The Scottish 
Government, 2010). 
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7.5.4 Future Research 
This is the first research into the effect of anti-diabetic medication on weight loss in 
patients with diabetes who referred to weight management programmes. Indeed, research 
into the effectiveness of such weight management programmes themselves remains an 
emerging field in the United Kingdom. Therefore, it is expected that the studies presented 
in this thesis will provide a foundation for future research. Such research is required both 
to corroborate the findings of the thesis and to investigate the new questions that have 
arisen from the studies described in it. 
 
Two issues that emerged were that women and young people are less likely to achieve their 
target weight loss, while men are less likely than women to enrol in weight management 
programmes. Further research is required to investigate the potential reasons for these 
factors. There was a noticeable difference in the weight loss determined from the meta-
analysis of the RCTs and that seen at GCWMS; it is suggested that a further study should 
be carried out to confirm this. Furthermore, it is recommended that a direct comparison of 
the effect of orlistat on blood glucose control between RCTs should be made in a 
prospective study of real life data from the GCWMS. Further research into orlistat trials is 
also recommended to investigate the effect of physical activity and placebo on weight loss, 
HbA1c and FPG, as there is currently a lack of studies in this area. Moreover, if the 
GCWMS starts offering orlistat at the beginning of the lifestyle phase, further research in 
the form of a RCT into the use or non-use of orlistat in patients with type 2 diabetes at the 
start of the lifestyle interventions is recommended. 
 
As this research evaluated the effectiveness of two phases of the weight management 
programme (the lifestyle phase (four months) and phase 2 (three months)), a study 
investigating the maintenance phase would be beneficial. When combined with this work, 
such a study over a 12-months period would provide a comprehensive evaluation of the 
effectiveness of the GCWMS. It should be standardised rolling evaluation built into 
GCWMS with set reports so that the effect of any changes can be monitored in a timely 
fashion and acted upon. In addition, qualitative research or employing a questionnaire 
would be useful to assess the reasons for a higher dropout rate, and might help to improve 
the completion rate. This thesis represents one of the first analyses of the patterns of 
prescribing and subsequent effects of anti-diabetic drugs on weight change in patients 
referred to GCWMS. Combining the findings of Chapters 5 and 6 with the dataset and 
patients’ hospital records would provide a significant baseline dataset for a study into the 
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overall effectiveness of the programme. This would enable a study to be carried out to 
examine the effect of the doses of anti-diabetic drugs on weight loss in patients who have 
completed the entire programme. In addition, it would be interesting to study the 
association between weight loss and any changes in prescribed medications, as well as the 
effect of GCWMS on diabetes outcomes by conducting a cohort study. It would be 
valuable to conduct a piece of qualitative research, employing a survey or interviews, to 
consider the reasons why guidelines are not followed, since practitioners continue to 
prescribe weight-gaining anti-diabetic drugs for patients with obesity. 
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Appendix 1: Mean weight loss by the number of session attended 
at the lifestyle phase 
 
Number of 
session 
N 
(7,329) 
% Mean weight change and 
95% CI (kg) 
2 sessions 734 10.0 -0.54 (-0.6 to -0.3) 
3 sessions 664 9.1 -1.17 (-1.3 to -0.9) 
4 sessions 553 7.5 -1.57 (-1.8 to -1.3) 
5 sessions 540 7.4 -2.1 (-2.4 to -1.7) 
6 sessions 836 11.4 -3.06 (-3.3 to -2.8) 
7 sessions 1,326 18.1 -3.72 (-3.9 to -3.5) 
8 sessions 1,599 21.8 -5.23 (-5.4 to -5.0) 
9 sessions 1,077 14.7 -6.64 (-6.9 to -6.3) 
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